5/2007
‫התשס"ז‬/‫י"א‬
‫רשומות‬
ISRAEL STATE RECORDS
‫ט' באב התשס"ז‬
July 24, 2007
‫יומן הפטנטים והמדגמים‬
PATENTS AND DESIGNS JOURNAL
PATENTS
Applications filed
Applications accepted
Patents granted
Patents renewed
Patents not in force
Patents renewed for 20 years
Patents expired
Extension orders renewed
Notices
Changes in particulars entered
in register
Corrigenda
Country codes
Indices of applications accepted
DESIGNS
Designs registered
Designs renewed
Designs void
‫עמוד‬
Page
1756
1898
2112
2113
2115
2116
2117
2118
2119
‫פטנטים‬
2123
2124
2125
i
‫בקשות שהוגשו‬
‫בקשות שקובלו‬
‫פטנטים שניתנו‬
‫פטנטים שחודשו‬
‫פטנטים שתוקפם פקעו‬
‫פטנטים שחודשו לעשרים שנה‬
‫פטנטים שפג תוקפם‬
‫צווי הארכה שחודשו‬
‫הודעות‬
‫שינויים בפרטים רשומים‬
‫בפנקס‬
‫תיקוני טעויות‬
‫קודים למדינות‬
‫מפתחות לבקשות שקובלו‬
2127
2141
2142
‫מדגמים‬
‫מדגמים שנרשמו‬
‫מדגמים שחודשו‬
‫מדגמים שבוטלו‬
‫ידיעות כלליות‬
:‫ וכו' בענייני פטנטים ומדגמים יש לשלוח אל‬,‫ מסמכים‬,‫מכתבים‬
‫ ירושלים‬,4 ‫ רח' הסדנא‬,‫רשם הפטנטים והמדגמים‬
‫ ירושלים והיא פתוחה לציבור בימי חול‬,‫ תלפיות‬,4 ‫לשכת הפטנטים נמצאת ברח' הסדנא‬
.12:30 -‫ ו‬8:30 ‫שאינם ערבי שבת או מועד בין השעות‬
‫ שקלים בעד כל‬2.50 ‫לשכת הפטנטים מספקת תצלומים של פירוטים ושרטוטים במחיר של‬
.‫עמוד או חלק ממנו‬
'‫אג רות ללשכת הפטנטים מתקבלות אך ורק על ידי תשלום לחשבון הלשכה בבנק הדואר מס‬
‫ יש להציג קבלת בנק הדואר ללשכה יחד עם הבקשה לפעולה שעבורה האגרה‬. 0-24145-2
.‫שולמה‬
GENERAL INFORMATION
Letters, documents, etc. concerning Patents and Designs should be addressed to:
The Commissioner of Patents and Designs, 4 Hasadnah St., Jerusalem
The Patent Office is located at 4 Hasadnah St., Talpiot, Jerusalem and is open to the public on
weekdays, except on Fridays or on the eves of holydays, from 08:30 to 12:30 hrs.
The Patent Office supplies photocopies of specifications and drawings at the rate of NIS 2.50
per page or part thereof.
Fees to the Patent Office can be accepted only by payment to the Postal Bank Account of the
Office, No. 0-24145-2. The receipt of the Postal Bank must be presented to the office together
with the application for the action for which the fee has been paid.
Copyright by the State of Israel. No
Extracts may be published except with the
permission of the Patent Office.
‫זכות היוצרים בתקצירים אלה שמורה‬
‫ אין להעתיק מת‬,‫למדינת ישראל‬
‫קצירים‬
.‫אלה אלא ברשות לשכת הפטנטים‬
Price per single issue (incl. VAT) : NIS 96.
.₪ 96 ).‫מ‬.‫ע‬.‫ לכל חוברת בודדת (כולל מ‬:‫מחיר‬
Annual subscription (incl. VAT):
NIS 1,152.
Available at the Distribution Service of
Government Publications, 29 B-Street,
Hakirya, Tel-Aviv.
July 24, 2007– ‫ט' באב התשס"ז‬
.₪ 1,152 ).‫מ‬.‫ע‬.‫דמי חתימה לשנה (כולל מ‬
:‫אפשר להשיג אצל‬
'‫ רחוב ב‬,‫שרות ההפצה של פרסומי הממשלה‬
.‫אביב‬-‫ תל‬,‫ הקריה‬,29 '‫מס‬
1754
NOTICE UNDER SECTION 16 OF THE
PATENTS LAW, 5727-1967
In the following there are listed new
Applications complying with the
Provisions of rule 32(a) of the Patent
Regulations, 5728-1968
Particulars of the applications are
given in the following order:
Number and date of application
And the first four symbols of the
International Classification
Title of invention
(as proposed by applicant)
Applicant
Priority right: Convention country –
Number and date of
Foreign application
‫ לחוק הפטנטים‬16 ‫הודעה לפי סעיף‬
1967 - ‫תשכ"ז‬
‫להלן רשימת בקשות חדשות‬
‫הממלאות אחר הדרישות שנקבעו‬
,‫(א) לתקנות הפטנטים‬32 ‫בתקנה‬
:1968–‫תשכ"ח‬
‫פרטי הבקשות מובאים לפי‬
:‫סדר זה‬
‫מספר הבקשה – ותאריך הגשתה‬
‫וארבעה הסמנים הראשונים של‬
‫הסיווג הבינלאומי‬
‫שם האמצאה (כפי שהוצע ע"י‬
)‫המבקש‬
‫המבקש‬
– ‫ מדינת האיגוד‬:‫דין קדימה‬
‫תאריך ומספר‬
‫בקשת החוץ‬
International Application Number
‫מספר בקשה בינלאומית‬
International Publication Number
‫מס' פרסום בינלאומי‬
1755
July 24, 2007– ‫ט' באב התשס"ז‬
24/02/2004
160549
SIGNAL QUALITY MONITORING
SYSTEM
AELIS PHOTONICS (ISRAEL) LTD
WO
PCT/IL03/00646 06/08/2003
14/03/2004
160858
A PROCESS FOR THE PREPARTION
OF NANOPARTICULATE
COMPOSITIONS AND COMPOSITION
OBTAINED THEREFROM
MAKHTESHIM CHEMICAL WORKS
LTD.
23/03/2004
161035
169384
169696
DEVICE FOR FILTERING BLOOD IN A
VESSEL WITH HELICAL ELEMENTS
CORDIS CORPORATION
US
10/896481
22/07/2004
10/896571
22/07/2004
US
July 24, 2007– ‫ט' באב התשס"ז‬
‫אליס פוטוניקס (ישראל) בע"מ‬
A01N
‫תהליך להכנה של תכשיר הדברה ננוח‬
‫חלקיקי והרכב המתקבל מהתהליך‬
‫מכתשים מפעלים כימיים בע"מ‬
G06F
C01G
‫תהליך להכנת חלקיקי ננו של תחמוצת‬
‫ברזל‬
A METHOD FOR PRODUCING IRON
OXIDE NANO PARTICLES
JOMA INTERNATIONAL AS
14/07/2005
‫מערכת לניתור איכות אותות‬
‫ייצוב המצגת במסכים של מחשבים‬
‫ומכשור טלביזיוני‬
‫יוסף טרנר‬
STABILITING SCREEN DISPLAY OF
COMPUTERS AND TV SETS
JOSEF TURNER
23/06/2005
H04L
A61M
‫מכשיר לסינון דם בכלי בעל אלמנטים‬
‫הליקליים‬
1756
20/07/2005
169783
‫אריזה לכוס נישואים‬
‫אפרים גולשבסקי‬
WEDDING GLASS HOUSING
EPHRAIM GOLSHEVSKY
17/11/2005
172020
172480
METHOD FOR AUTOMATIC
DETECTION AND CLASSIFICATION
OF OBJECTS AND PATTERNS IB LOW
RESOLUTION ENVIRONMENTS
SHAI NISSIM
01/05/2006
175339
FLAME RETARDANT COMPOSITION
BROMINE COMPOUNDS LTD.
04/05/2006
COMPOSITION AND METHODS OF
PREPARATION OF A DIAGNOSTIC
DELIVERY SYSTEM CONTAINING
HYDROPHILIC X-RAY CONTRAST
AGENTS
DR. LEONID LURYA
1757
E04C
‫התקן לבנין‬
‫אלון קוה‬
BUILDING DEVICE
ALON KAVE
08/12/2005
A47G
175403
G06T
‫שיטה לגילוי וסיווג אוטומטיים של‬
‫אובייקטים ודוגמאות בתוך סביבה של‬
‫רזולוציה נמוכה‬
‫שי ניסים‬
C08G
‫הרכב מעכב בעירה‬
‫תרכובות ברום בע"מ‬
A61K
‫הרכב ושיטות להכנת מערכת העברה‬
‫דיאגנוסטית המכילה חומרי ניגוד‬
X ‫הידרופיליים לקרני‬
‫ד"ר ליאוניד לוריה‬
July 24, 2007– ‫ט' באב התשס"ז‬
16/05/2006
175679
‫התקן‬
‫פלסן סאסא בע"מ‬
DEVICE
PLASAN SASA LTD.
18/08/2005
180929
THE USE OF N-ARYL
DIAZASPIRACYCLIC COMPOUNDS
IN THE TREATMENT OF ADDICTION
TARGACEPT, INC.
US
60/603479
20/08/2004
PCT/US/2005/029371
WO/2006/023630
03/08/2005
180931
180966
COMPOSITIONS AND METHODS FOR
SMOKING CESSATION
MODUS BIOLOGICAL MEMBRANES
LTD.
US
60/591261
27/07/2004
60/659095
08/03/2005
US
PCT/IL/2005/000789
WO/2006/011140
July 24, 2007– ‫ט' באב התשס"ז‬
C07D
‫–אריל‬N ‫השימוש בתרכובות‬
‫דיאזאספיראציקליות לטיפול בהתמכרות‬
MEDICAMENTS FOR TREATING
CHRONIC RESPIRATORY DISEASE
ARGENTA DISCOVERY LIMITED
GB
0417481.9
05/08/2004
PCT/GB/2005/003039
WO/2006/013359
25/07/2005
B64D
C07D
‫תרופה לטיפול במחלת נשימה כרונית‬
C07F
‫תכשירים ושיטות להפסקת עישון‬
‫מודוס מימברנות ביולוגיות בע"מ‬
1758
08/03/2007
181809
A BRACKET AND METHOD FOR
PREPARATION OF SAME
ARIE KROOL ENGINES LTD.
15/09/2005
‫תומך ושיטה לייצורו‬
‫מנועי אריה קרול בע"מ‬
181914
USE OF TELLURIUM, COMPOUNDS
FOR INHIBITION OF INTERLEUKINCONVERTING ENZYME
BIOMAS LTD.
US
60/610660
17/09/2004
PCT/IL/2005/000990
WO/2006/030438
30/06/2006
METHOD AND APPARATUS FOR
CONTINUOUS SAMPLING OF INK
AND PROOFING PRINT FOR A
PRINTING PRESS
YOAV SALOMON
1759
C07F
‫חומרים המכילים טלור ושימוש בהם‬
CONVERTING–INTERLEUKIN ‫לעיכוב‬
ENZYME
‫ביומאס בע"מ‬
181996
EFFICIENT PARTITIONING OF
CONTROL AND DATA FIELDS
QUALCOMM INCORPORATED
US
60/737688
16/11/2005
11/449218
07/06/2006
US
PCT/US/2006/025932
WO/2006/012447
19/03/2007
F16M
G06J
‫חלוקה יעילה של שדות שליטה ונתונים‬
182005
B41J
‫שיטה ומכשיר להתאמת גוונים רציפה של‬
‫דיו והגהת צבע לדפוס‬
‫סולי וואנו‬
July 24, 2007– ‫ט' באב התשס"ז‬
02/11/2005
182006
METHOD AND SYSTEM FOR SPATIOTEMPORAL VIDEO WARPING
YISSUM RESEARCH DEVELOPMENT
COMPANY OF THE HEBREW
UNIVERSITY OF JERUSALEM
US
60/624896
05/11/2004
60/644371
18/01/2005
US
60/692595
22/06/2005
US
PCT/IL/2005/001150
WO/2006/048875
30/09/2005
‫שיטה ומערכת לעריכת וידיאו בזמן–מרחב‬
182007
METHOD FOR EX-VIVO PURGING IN
AUTOLOGOUS TRANSPLANTATION
APOXIS S.A.
US
60/615084
01/10/2004
PCT/EP/2005/054950
WO/2006/037762
03/10/2005
182008
PULMONARY ADMINISTRATION OF
AN ANTITHROMBOTIC COMPOUND
N.V. ORGANON
EP
04104897.6 06/10/2004
PCT/EP/2005/054973
WO/2006/037771
16/09/2005
182009
INHIBITORS OF THE INTERACTION
BETWEEN MDM2 AND P53
JANSSEN PHARMACEUTICA N.V.
EP
04077630.4 22/09/2004
60/613902
28/09/2004
US
PCT/EP/2005/054604
WO/2006/032631
July 24, 2007– ‫ט' באב התשס"ז‬
H04N
‫יישום חברה לפיתוח המחקר של‬
‫האוניברסיטה העברית בירושלים‬
C12N
‫שיטה לטיהור חוץ גופי של השתלה‬
‫עצמית‬
A61K
‫מתן ריאתי של תרכובת נוגדת פקקת‬
C07D
MDM 2 ‫מעכבים של האינטראקציה בין‬
P 53–‫ל‬
1760
15/09/2005
182010
HETEROARYL COMPOUNDS FOR USE
AS BETAMIMETICS IN THE
TREATMENT OF RESPIRATORY
DISEASES
BOEHRINGER INGELHEIM
INTERNATIONAL GMBH
DE
102004045648.8 21/09/2004
PCT/EP/2005/054595
WO/2006/032627
03/10/2005
182011
TREATMENT SCREENING METHODS
HOLLIS-EDEN PHARMACEUTICALS,
INC.
US
60/615307
01/10/2004
60/628252
15/11/2004
US
PCT/US/2005/035786
WO/2007/030124
21/09/2005
182012
MONOCLONAL ANTIBODIES TO
PROGASTRIN
RECEPTOR BIOLOGIX, INC.
US
60/612224
22/09/2004
PCT/IB/2005/002793
WO/2006/032980
1761
C07D
‫תרכובות הטרואריל לשיוש כחומרים‬
‫בטאמימטיים לטיפול במחלות בדרכי‬
‫הנשימה‬
A61K
‫טיפול בשיטות סריקה‬
G01N
‫נוגדנים חד–שבטיים לפרוגאסטרין‬
July 24, 2007– ‫ט' באב התשס"ז‬
29/09/2005
182013
A METHOD AND DEVICE FOR
QUESTIONING A PLURALITY OF
COMPUTERIZED DEVICE
‫שיטה והתקן לשאילתה של מספר‬
‫התקנים ממוחשבים‬
‫ י מולכו‬,‫ שמרון‬:‫פרומיסק בע"מ אצל‬
‫פרסקי‬
PROMISEC LTD
IL
164402
60/672050
US
60/672072
US
60/672045
US
60/672046
US
11/226451
US
PCT/IL/2005/001047
WO/2006/038210
G06F
04/10/2004
18/04/2005
18/04/2005
18/04/2005
18/04/2005
15/09/2005
15/03/2005
182014
METHOD FOR DETECTING A
MANTLE DIAPIR TONGUE
LOCATION
VLADIMIR NIKOLAEVICH LARIN
RU
2004130955 22/10/2004
PCT/RU/2005/000114
WO/2006/043852
19/03/2007
‫שיטה לזיהוי מיקום מעטפת שן קודחת‬
182015
182017
ELECTRONIC DEVICE AND ITS
USAGE IN THE BIO-RESONANCE
FUNCTIONAL MEDICINE
TOMESCU, ION
RO
200400806
21/09/2004
200500718
17/08/2005
RO
PCT/RO/2005/000012
WO/2006/033587
July 24, 2007– ‫ט' באב התשס"ז‬
A47D
‫לוח נרות זיכרון‬
‫ישראל הרשקוביץ‬
MEMORIAL CANDLE BOARD
ZOHAR PELED
15/09/2005
G01V
A61N
–‫מתקן אלקטרוני והשימוש בו ברפואה ביו‬
‫רזוננסית תפקודית‬
1762
19/03/2007
182018
B65H
BEARING JOURNAL FOR
ATTACHMENT
HANS GEORG HAGLEITNER
EP
06024601.4 28/11/2006
19/03/2007
‫הכוונת תיעוד עבור סיפוח‬
182019
G07B
REAL-TIME PARKING PAYMENT
MONITORING SYSTEM
QUICK PARK LTD
20/10/2005
‫מערכת לניתור תשלום חנייה‬
‫קוויק פארק בע"מ‬
182020
A61K
PHARMACEUTICAL COMPOSITION
COMPRISING DICLOFENAC
NOVARTIS AG
US
60/620706
21/10/2004
PCT/US/2005/038090
WO/2006/047365
22/09/2005
‫תכשיר רוקחות המכיל דיקלופנק‬
182021
COMPOUNDS, COMPOSITIONS
CONTAINING THEM, PREPARATIONS
THEREOF AND USES THEREOF
ASTRAZENECA AB
GB
PCT/GB2004/004124 24/09/2004
GB
PCT/GB2004/004112 24/09/2004
0500183-9
24/01/2005
SE
PCT/SE/2005/001405
WO/2006/033633
1763
C07D
,‫ תכשירים המכילים אותן‬,‫תרכובות‬
‫הכנותן ושימושן‬
July 24, 2007– ‫ט' באב התשס"ז‬
19/03/2007
182022
CASSETTE HAVING ELASTOMERIC
CLAMPING RIBS
ALCON. INC.
US
11/391757
29/03/2006
19/03/2007
20/09/2005
PEPTIDE CYCLISATION
LONZA AG
EP
04022310.9
05014954.1
EP
PCT/EP/2005/010133
WO/2006/032457
‫מארז בעל צלעות מהדקות אלסטומריות‬
182023
SURGICAL SYSTEM HAVING A
CASSETTE WITH AN ACOUSTIC
COUPLING
ALCON. INC.
US
11/391748
29/03/2006
A61B
A61B
‫מערכת כירורגית הכוללת מארז עם קשר‬
‫קולי‬
182024
C07K
‫יצירת טבעת פפטידית‬
20/09/2004
11/07/2005
21/09/2005
182025
COMPOUNDS FOR INFLAMMATION
AND IMMUNE-RELATED USES
SYNTA PHARMACEUTICALS, CORP.
US
60/611913
21/09/2004
PCT/US/2005/033980
WO/2006/034402
July 24, 2007– ‫ט' באב התשס"ז‬
C07D
‫תרכובות לדיכוי מערכת החיסון ולמניעת‬
‫תופעות דלקתיות‬
1764
15/09/2005
182027
PHARMACEUTICAL COMPOSITION
COMPRISING TEMOZOLOMIDE ESTER
TIAN JIN TASLY GROUP CO. LTD.
CN
200410072056.4 22/09/2004
PCT/CN/2005/001477
WO/2006/032190
19/03/2007
182029
A METHOD AND SYSTEM FOR
EMAIL AND PIM
SYNCHRONIZATION AND UPDATING
EMOZE LTD
09/11/2001
182030
CYANOPYRROLIDINE DERIVATIVES
TAISHO PHARMACEUTICAL CO.,
LTD.
2000JP
10/11/2000
344036
2001-215766 16/07/2001
JP
PCT/JP/2001/009818
WO/2002/038541
12/09/2005
182031
A METHOD OF SUPPORTING
OPERATION OF SLEEP MODE IN A
WIDEBAND RADIO ACCESS SYSTEM
LG ELECTRONICS INC.
10-2004KR
30/09/2004
0078044
10-200404/11/2004
KR
0089252
C07D
‫הרכב פרמצבטי הכולל אסטר‬
‫טמוזולומיד‬
G06F
‫שיטה ומערכת לסינכרון ועדכון דואר‬
‫אלקטרוני ו–פים‬
‫אמוז בע"מ‬
C07D
‫תולדות ציאנופירולידין‬
H04Q
‫שיטה לתמיכת הפעלה של מצב רדום‬
‫במערכת גישת רדיו פס–רחב‬
PCT/KR/2005/003001
WO/2006/036047
1765
July 24, 2007– ‫ט' באב התשס"ז‬
30/09/2004
182032
G01R
PRE-ALIGNMENT OUTSIDE AN
ANTENNA MEASUREMENT RANGE
TELEFONAKTIEBOLAGET LM
ERICSSON (PUBL)
‫קדם–כיוון משושה מחוץ לתחום מדידה‬
PCT/SE/2004/001402
WO/2006/036094
28/09/2005
182033
METHOD FOR UPDATING A TABLE
OF CORRESPONDENCE BETWEEN A
LOGICAL ADDRESS AND AN
IDENTIFICATION NUMBER
NAGRAVISION S.A.
EP
04104784.6 30/09/2004
PCT/EP/2005/054896
WO/2006/035054
21/09/2005
H04L
‫שיטה לעידכון טבלת התאמה בין כתובת‬
‫לוגית ומספר זיהוי‬
182034
SUBSTITUTED CHROMAN DERIVATIVES,
MEDICAMENTS AND USE IN THERAPY
NOVOGEN RESEARCH PTY LTD.
US
60/611300
21/09/2004
AU
PCT/AU2004/01619 19/11/2004
2005201855
03/05/2005
AU
PCT/AU/2005/001435
WO/2006/032085
July 24, 2007– ‫ט' באב התשס"ז‬
C07D
‫ תרופות‬,‫תולדות כרומן מומחת‬
‫ושימוש בטיפול‬
1766
20/09/2005
182035
IN VIVO INCORPORATION OF
ALKYNYL AMINO ACIDS INTO
PROTEINS IN EUBACTERIA
THE SCRIPPS RESEARCH INSTITUTE
US
60/612220
21/09/2004
60/630876
24/11/2004
US
60/634151
07/12/2004
US
PCT/US/2005/033784
WO/2006/034332
14/09/2005
‫הכללה בגוף החי של חומצות אמינו‬
‫אלקיניליות לתוך חלבונים של יובקטריות‬
182037
METHOD OF GENERATING
VERIFICATION DATA
KONINKLIJKE PHILIPS
ELECTRONICS N.V.
EP
04104579.0 22/09/2004
PCT/IB/2005/053007
WO/2006/033048
04/10/2005
182039
MICROPATTERNED PLATE WITH
MICRO-PALLETS FOR
ADDRESSABLE BIOCHEMICAL
ANALYSIS
THE REGENTS OF THE UNIVERSITY
OF CALIFORNIA
US
60/615882
04/10/2004
PCT/US/2005/035860
WO/2006/041938
1767
C12Q
G11B
‫שיטה ליצור מידע מאומת‬
C12Q
‫לוח בעל דגם מזערי ועם בליטות זעירות‬
‫לאנליזה ביוכימית ניתנת לאיתור‬
July 24, 2007– ‫ט' באב התשס"ז‬
20/01/2005
182040
PROCESS FOR GOOD PACKAGING,
NAMELY FOOD STUFFS, PACKAGING
AND KITS FOR THEIR REALIZATION
STELLIFERI & ITAVEX SPA
IT
RM2004A000472 01/10/2004
PCT/IT/2005/000029
WO/2006/038238
20/03/2007
‫ במיוחד דברי‬,‫תהליך לאריזה יעילה‬
‫ אריזות וערכות לביצוע התהליך‬,‫אוכל‬
182041
G06F
‫ארכיטקטורת מחשב עבור התקן‬
‫אלקטרוני המספקת מערכת קבצים‬
‫מאובטחת‬
COMPUTER ARCHITECTURE FOR AN
ELECTRONIC DEVICE PROVIDING A
SECURE FILE SYSTEM
HARRIS CORPORATION
US
11/387342
B65D
23/03/2006
21/09/2005
182042
CHROMAN DERIVATIVES, MEDICAMENTS
AND USE IN THERAPY
NOVOGEN RESEARCH PTY LTD.
US
60/611299
21/09/2004
2004-315009
29/10/2004
JP
2004906363
05/11/2004
AU
AU
PCT/AU2004/01619 19/11/2004
2005201855
03/05/2005
AU
60/676934
03/05/2005
US
PCT/AU/2005/001436
WO/2006/032086
20/03/2007
182043
COMPUTER ARCHITECTURE FOR A
HANDHELD ELECTRONIC DEVICE
WITH A SHARED HUMAN MACHINE
INTERFACE
HARRIS CORPORATION
US
11/385063
21/03/2006
July 24, 2007– ‫ט' באב התשס"ז‬
C07D
‫ תרופות ושימוש בהן‬,‫תולדות כרומן‬
‫בטיפול‬
G06F
‫ארכיטקטורת מחשב עבור התקן‬
‫אלקטרוני נישא ביד עם ממשק משותף‬
‫אדם–מכונה‬
1768
20/09/2005
182044
H04M
SYSTEM AND METHOD FOR
STRUCTURING INFORMATION
TALKFLOW SYSTEMS, LLC
US
10/945428
21/09/2004
PCT/US/2005/033501
WO/2006/034204
30/09/2005
‫מערכת ושיטה לעיצוב מידע‬
182045
‫מכשיר הדמיה בעל כושר הפרדה גבוה‬
‫המכיל גביש מוליך למחצה‬
SEMICONDUCTOR CRYSTAL HIGH
RESOLUTION IMAGER
STANFORD UNIVERSITY
US
60/614799
30/09/2004
PCT/US/2005/035203
WO/2006/039494
20/09/2005
G01T
182046
C07D
PROCESS FOR THE PREPARATION OF 4-{4-[({[4-CHLORO-3(TRIFLUOROMETHYL]PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}N- METHYLPYRIDINE-2- CARBOXAMIDE
BAYER HEALTHCARE AG
EP
04023131.8
29/09/2004
PCT/EP/2005/010118
WO/2006/034796
–3–‫–כלורו‬4[{([ –4{–4 ‫תהליך להכנת‬
–}‫(טריפלואורומתיל)פניל]אמינו}קרבוניל)אמינו]פנוקסי‬
‫– קרבוקסאמיד‬2–‫– מתילפירידין‬N
14/10/2005
182047
INDAZOLES, BENZISOXAZOLES AND
BENZISOTHIAZOLES AND THEIR
USE AS ESTROGENIC AGENTS
C07D
‫ בנזאיזוקסזולים‬,‫אינדזולים‬
‫ובנזאיזותיאזולים ושימוש בהם כגורמים‬
‫אסטרוגניים‬
LABORATOIRE THERAMEX
EP
04292439.9 14/10/2004
PCT/EP/2005/055262
WO/2006/040351
1769
July 24, 2007– ‫ט' באב התשס"ז‬
23/09/2005
182048
METHOD OF TREATING
ORGANOPHOSPHOROUS POISONING
UNIVERSITY OF MARYLAND,
BALTIMORE
US
60/613121
24/09/2004
PCT/US/2005/033789
WO/2006/036686
20/03/2007
‫שיטה לטיפול בהרעלת זרחנים אורגניים‬
182052
182053
182054
NOVEL BIS-AZAINDOLE
DERIVATIVES, PREPARATION AND
PHARMACEUTICAL USE THEREOF
AS KINASE INHIBITORS
AVENTIS PHARMA S.A.
FR
0410386
01/10/2004
PCT/FR/2005/002410
WO/2006/037875
July 24, 2007– ‫ט' באב התשס"ז‬
H04M
‫מכשיר אלקטרוני בעל שלוש שכבות‬
‫ניידות‬
ELECTRONIC DEVICE WITH THREE
MOVABLE LAYERS
QUALCOMM INCORPORATED
US
10/945576
20/09/2004
PCT/US/2005/033734
WO/2006/034309
29/09/2005
A47J
‫מסחטת מיצים‬
‫רונן מסאמי‬
A JUICER
RONEN MASAMI
20/09/2005
C08K
C07D
‫ הכנתן‬,‫תולדות חדשות של ביס–אזאינדול‬
‫ושימושים תרופתיים שלהם כמעכבי‬
‫קינאזות‬
1770
06/10/2005
182055
AGENT FOR PROPHYLAXIS OR
TREATMENT OF METABOLIC
SYNDROME
TAKEDA PHARMACEUTICAL
COMPANY LIMITED
2004JP
07/10/2004
294889
2005-125373 22/04/2005
JP
PCT/JP/2005/018823
WO/2006/038722
22/03/2005
‫חומר למניעת סינדרום מטבולי או לטיפול‬
‫בו‬
182056
ADDITIONAL IMPROVEMENTS IN POWDER
COMPACTION AND ENROBING
BIOPROGRESS TECHNOLOGY LIMITED
GB
PCT/GB2004/004097 24/09/2004
PCT/GB/2005/001077
WO/2006/032828
29/09/2005
182057
RELEASABLE SECURING
APPARATUS AND METHOD OF
USING SAME
STUDIO MODERNA SA
US
10/956669
01/10/2004
PCT/EP/2005/054926
WO/2006/037752
15/09/2005
1771
C07D
182058
A61J
‫שיפורים נוספים בדחיסת אבקה‬
‫ומעטפת‬
B62K
‫התקן אבטוח הניתן לשחרור ושיטה‬
‫לשימוש בו‬
C07D
July 24, 2007– ‫ט' באב התשס"ז‬
PROCESS FOR PREPARING
ZIPRASIDONE
MEDICHEM, S.A.
ES
P200402315 29/09/2004
PCT/EP/2005/054588
WO/2006/034964
12/04/2000
182059
INTERLEAVER AND
DEINTERLEAVER FOR USE IN A
DIVERSITY TRANSMISSION
COMMUNICATION SYSTEM
QUALCOMM INCORPORATED
US
09/293527
15/04/1999
PCT/US/2000/009794
WO/2000/064073
22/09/2005
182060
POLYCATIONIC POLYMER
COATINGS FOR IMMOBILIZING
BIOLOGICAL SAMPLES
TRIPATH IMAGING, INC.
US
60/612391
23/09/2004
PCT/US/2005/033938
WO/2006/034385
26/09/2005
182061
METHODS AND COMPOSITIONS FOR
TREATING FLAVIVIRUSES,
PESTIVIRUSES AND HEPACIVIRUS
IDENIX (CAYMAN) LIMITED
US
60/613085
24/09/2004
PCT/US/2005/034786
WO/2006/037028
July 24, 2007– ‫ט' באב התשס"ז‬
‫תהליך להכנת זיפראסידון‬
H04B
‫מדרג לסרוגין ומבטל דירוג לסרוגין‬
‫במערכת תקשורת מרובת תמסורת‬
G01N
‫ציפויים פולימריים פוליקטיוניים לקיבוע‬
‫דגימות ביולוגיות‬
C07H
,‫שיטות והרכבים לטיפול בפלביווירוסים‬
‫ והפאסיווירוס‬,‫פסטיווירוסים‬
1772
22/09/2005
182062
METHODS AND COMPUTER
PROGRAM PRODUCTS FOR
ANALYSIS AND OPTIMIZATION OF
MARKER CANDIDATES FOR
CANCER PROGNOSIS
TRIPATH IMAGING, INC.
US
60/611965
22/09/2004
60/612073
22/09/2004
US
PCT/US/2005/033931
WO/2006/036726
18/01/2006
22/09/2005
H01L
,‫שיטה לכוונון של התקן אופטי לתאורה‬
‫התקן אופטי‬
‫ ושיטת חשיפה‬,‫ מערכת חשיפה‬,‫לתאורה‬
182065
ANTENNA FOR WIRELESS KVM,
AND HOUSING THEREFOR
AVOCENT CALIFORNIA
CORPORATION
US
10/948307
24/09/2004
PCT/US/2005/034327
WO/2006/036855
1773
‫שיטות ומוצרי תוכנת מחשב לאנליזה‬
‫ואופטימיזציה של מועמדי סמן לפרוגנוזה‬
‫של סרטן‬
182064
METHOD OF ADJUSTING LIGHTING
OPTICAL DEVICE, LIGHTING
OPTICAL DEVICE, EXPOSURE
SYSTEM AND EXPOSURE METHOD
NIKON CORPORATION
2005JP
21/01/2005
013576
2005-120709 19/04/2005
JP
PCT/JP/2006/300584
WO/2006/077849
G06F
H01Q
‫ אלחוטי ובית עבורה‬KVM ‫אנטנה עבור‬
July 24, 2007– ‫ט' באב התשס"ז‬
29/07/2005
182066
NOVEL HETEROCYCLIC NF-K?
INHIBITORS
4SC AG
EP
04022363.8 20/09/2004
60/612794
27/09/2004
US
PCT/EP/2005/008261
WO/2006/032322
13/10/2005
‫ הטרוציקליים חדשים‬K?–NF ‫מעכבי‬
182067
PROCESS FOR PREPARING
TELMISARTAN
TEVA PHARMACEUTICAL
INDUSTRIES LTD.
US
60/619563
15/10/2004
PCT/US/2005/037001
WO/2006/044648
18/10/2005
July 24, 2007– ‫ט' באב התשס"ז‬
C07D
‫שיטה להכנת טלמיסרטן‬
‫טבע תעשיות פרמצבטיות בע"מ‬
182068
PROCESS FOR PREPARING
AMORPHOUS ATORVASTATIN
HEMI-CALCIUM BY DISSOLVING
THE SALT IN AN ORGANIC SOLVENT
WHICH IS A MIXTURE OF AN
ALCOHOL AND A KETONE AND/OR
AN ESTER AND REMOVING THE
SOLVENT
TEVA PHARMACEUTICAL
INDUSTRIES LTD.
US
60/620022
18/10/2004
PCT/US/2005/037751
WO/2006/045018
C07D
C07D
‫תהליך להכנת אטורבסטטין המי–קלציום‬
‫אמורפי על ידי המסת המלח בממס אורגני‬
‫או‬/‫שהוא תערובת של אלכוהול וקטון ו‬
‫אסטר והוצאת הסולבנט‬
‫טבע תעשיות פרמצבטיות בע"מ‬
1774
28/09/2005
182069
A61K
‫תחליבים עם כמות קטנה של שמן‬
‫להזרקת טקסוידים ותרופות אחרות בלתי‬
‫מסיסות‬
LOW OIL EMULSION COMPOSITIONS
FOR DELIVERING TAXOIDS AND
OTHER INSOLUBLE DRUGS
SD PHARMACEUTICALS, INC.
US
10/952243
28/09/2004
PCT/US/2005/034971
WO/2006/037089
23/09/1999
182070
‫סקריטאז השייך למחלת אלצהיימר‬
ALZHEIMER'S DISEASE SECRETASE
PHARMACIA & UPJOHN COMPANY
LLC
US
60/101594
24/09/1998
PCT/US/1999/020881
WO/2000/017369
23/09/2005
182071
CONTAINER SEAL FOR THE STORAGE
OF DANGEROUS LIQUID MATERIAL
IMPRESS GROUP BV
DE
102004046677.7 24/09/2004
102004049225.5
08/10/2004
DE
PCT/DE/2005/001691
WO/2006/032264
10/09/2005
182072
CAP FOR DRUG DELIVERY DEVICES
TERUMO CORPORATION
EP
04022880.1 24/09/2004
PCT/EP/2005/009739
WO/2006/032385
1775
C12Q
B65D
‫אטם למיכל אכסון חומר נוזלי מסוכן‬
A61M
‫פקק להתקנים להעברת תרופה‬
July 24, 2007– ‫ט' באב התשס"ז‬
14/09/2005
182073
DRIVE MECHANISM FOR A DRUG
DELIVERY DEVICE
SANOFI-AVENTIS DEUTSCHLAND
GMBH
EP
04023630.9 04/10/2004
PCT/EP/2005/009839
WO/2006/037434
14/09/2005
‫מנגנון הנעה להתקן לשחרור תרופה‬
182074
182076
IN VIVO DEVICE FOR ASSISTING
AND IMPROVING DIASTOLIC
VENTRICULAR FUNCTION
CORASSIST CARDIOVASCULAR LTD.
US
60/611711
22/09/2004
PCT/IL/2005/001014
WO/2006/033107
25/09/2005
July 24, 2007– ‫ט' באב התשס"ז‬
G11C
‫מתקן לסיוע ושיפור תפקוד חדרי דיאסטולי‬
‫בגוף חי‬
182077
IMPROVED LITHIUM CELL AND
METHOD OF FORMING SAME
TADIRAN BATTERIES LTD.
US
10/950485
28/09/2004
PCT/IL/2005/001021
WO/2006/035426
A61M
‫מנגנון מציג מנה עבור התקן לשחרור‬
‫תרופה‬
DOSE DISPLAY MECHANISM FOR A
DRUG DELIVERY DEVICE
TERUMO CORPORATION
EP
04023628.3 04/10/2004
PCT/EP/2005/009840
WO/2006/037435
22/09/2005
A61M
‫קוראסיסט קרדיווסקולר בע"מ‬
H01M
‫תא ליתיום משופר ושיטה להכנתו‬
‫תדיראן סוללות בע"מ‬
1776
20/03/2007
182078
SYSTEM FOR ATTACHING A
CUTTING MEMBER TO A CUTTER
ISCAR LTD.
21/03/2007
‫מערכת לחיבור אלמנט חיתוך לכלי חיתוך‬
‫ישקר בע"מ‬
182079
THE TECHNIQUE OF PROCESSING A
SIGNAL AND CONTINUOUS NOISE
MIXTURE FOR OVERCOMING THE
SENSITIVITY THRESHOLD AND
IMPROVING THE PROTECTION
FROM EXTERNAL INTERFERENCES
OF THE ELECTROMAGNETIC
OSCILLATIONS RECEIVER
BUNIN GENNADI
21/03/2007
182080
G09G
‫יצחק בר יונה‬
182081
B60N
‫התקן תליה לרכב‬
‫פלסן סאסא בע"מ‬
182082
POLYMER ELECTROLYTE
MEMBRANE FUEL CELL STACK
PEMERY CORP.
US
60/614476
01/10/2004
PCT/US/2005/035356
WO/2006/039583
1777
‫גנאדי בונין‬
‫צג עדשות שרוחבן משתנה‬
SUSPENSION FOR A VEHICLE
PLASAN SASA LTD.
03/10/2005
G01S
‫טכניקת עיבוד תערובת אות ורעש מתמשך‬
‫להתגברות על סף הרגישות של המקלט‬
‫ושיפור הגנתו של מקלט תנודות‬
‫אלקטרומגנטיות בפני הפרעות חיצוניות‬
LENTICULAR DISPLAY UNIT WITH
VARIABLE PITCH
ITZHAK BAR YONA
21/03/2007
B23B
H01M
‫צבר תאי דלק בעלי קרום אלקטרוליטים‬
‫פולימרי‬
July 24, 2007– ‫ט' באב התשס"ז‬
10/11/2005
182083
RECOMBINANT NEWCASTLE
DISEASE VIRUS
BAYER SCHERING PHARMA AG
EP
04090432.8 12/11/2004
PCT/EP/2005/012186
WO/2006/050984
21/03/2007
21/03/2007
July 24, 2007– ‫ט' באב התשס"ז‬
G06F
‫ארכיטקטורת מחשב למתקן אלקטרוני‬
‫ למערכת תיקים מסוג‬SLS ‫המספק גישת‬
‫ עם טעינה בטוחה והגנה על זיכרון‬MLS
‫ביצוע תוכניות‬
182087
TYPE I INTERFERON BLOCKING
AGENTS FOR PREVENTION AND
TREATMENT OF PSORIASIS
UNIVERSITAT ZURICH
EP
04405628.1 07/10/2004
PCT/CH/2005/000566
WO/2006/037247
G06F
‫ארכיטקטורת מחשב למתקן אלקטרוני‬
‫המספק גישה מאובטחת מרמה בודדה עד‬
‫למערכת תיקים מאובטחת רב–שלבית‬
182085
COMPUTER ARCHITECTURE FOR AN
ELECTRONIC DEVICE PROVIDING
SLS ACCESS TO MLS FILE SYSTEM
WITH TRUSTED LOADING AND
PROTECTION OF PROGRAM
EXECUTION MEMORY
HARRIS CORPORATION
US
11/387744
23/03/2006
30/09/2005
‫וירוס רקומביננטי של מחלת ניוקאסל‬
182084
COMPUTER ARCHITECTURE FOR AN
ELECTRONIC DEVICE PROVIDING
SINGLE-LEVEL SECURE ACCESS TO
MULTI-LEVEL SECURE FILE SYSTEM
HARRIS CORPORATION
US
11/387991
23/03/2006
A61K
A61K
‫ למניעה‬I ‫גורמים חוסמי אינטרפרון מסוג‬
‫וטיפול בפסוריאזיס‬
1778
28/09/2005
182088
‫תומכנים לכלי דם קטנים‬
SMALL VESSEL STENT DESIGNS
CARDIOMIND, INC.
US
60/619437
14/10/2004
PCT/US/2005/034929
WO/2006/044147
23/08/2005
182089
PROCEDURE FOR OBTAINING
WATER FROM A MASS OF
ATMOSPHERIC AIR AND A MACHINE
FOR OBTAINING WATER BY
CONDENSING THE HUMIDITY IN A
MASS OF AIR
ERMAKOV, ALEXANDER
ES
P200402290 24/09/2004
ES
P200402739 15/11/2004
ES
P200402740 15/11/2004
PCT/ES/2005/000471
WO/2006/040370
14/10/2005
1779
E03B
‫הליך לקבלת מים ממסה של אוויר‬
‫אטמוספרי ומכונה עבור קבלת מים‬
‫באמצעות ריכוז לחות במסה של אויר‬
182090
2,6-SUBSTITUTED-4MONOSUBSTITUTEDAMINOPYRIMIDINE AS PROSTAGLANDIN
D2 RECEPTOR ANTAGONISTS
AVENTIS PHARMACEUTICALS INC.
US
60/619272
15/10/2004
PCT/US/2005/037148
WO/2006/044732
A61F
C07D
–‫–אמינו‬4 ,‫–מותמר‬2 ,6 ‫פירימידין‬
D2 ‫מונומותמר כאנטאגוניסטים לרצפטור‬
‫פרוסטאגלנדני‬
July 24, 2007– ‫ט' באב התשס"ז‬
30/09/2005
182092
‫ממסות‬/‫תערובות פעילות שטח‬
SURFACTANT/SOLVENT MIXTURES
BAYER CROPSCIENCE GMBH
DE
102004049608.0 12/10/2004
PCT/EP/2005/010560
WO/2006/040022
05/10/2005
182093
3,6-SUBSTITUTED 5-ARYLAMINO-1HPYRIDINE-2-ONE DERIVATIVES AND
RELATED COMPOUNDS AS POLY(ADPRIBOSE)POLYMERASE (PARP)
INHIBITORS IN THE TREATMENT OF
TISSUE DAMAGE OR DISEASE CAUSED
BY NECROSIS OR APOPTOSIS
SANOFI-AVENTIS DEUTSCHLAND
GMBH
DE
102004050196.3 15/10/2004
PCT/EP/2005/010697
WO/2006/042638
07/10/2005
182094
July 24, 2007– ‫ט' באב התשס"ז‬
C07D
‫נגזרות קווינאזולין‬
182095
PROCESS FOR MAKING PHENOXY
BENZAMIDE COMPOUNDS
ASTRAZENECA AB
GB
0423042.1
16/10/2004
0502963.2
12/02/2005
GB
PCT/GB/2005/003882
WO/2006/040527
C07D
–‫–ארילאמינו‬5 ‫ של נגזרות‬3 ,6 ‫התמרות‬
‫–און ותרכבות משויכות‬2–‫ –פירידין‬H 1
‫ –ריבוז)פולימראז‬ADP(‫כמעקבי פולי‬
‫ ) בטיפול בפגיעות רקמה או‬PARP(
‫מחלות הנגרמות מנמק או אפופטוזיס‬
QUINAZOLINE DERIVATIVES
ASTRAZENECA AB
EP
04292417.5 12/10/2004
PCT/GB/2005/003846
WO/2006/040520
11/10/2005
C07C
C07C
‫תהליך להכנת תרכובות פנוקסי בנזאמיד‬
1780
21/10/2005
182096
METHODS FOR PREPARING
INDAZOLE COMPOUNDS
PFIZER INC
US
60/624575
02/11/2004
PCT/IB/2005/003300
WO/2006/048745
25/10/2005
‫שיטות להכנת תרכובות אינדאזול‬
182097
CALCULATING AND ADJUSTING
THE PERCEIVED LOUDNESS AND/OR
THE PERCEIVED SPECTRAL
BALANCE OF AN AUDIO SIGNAL
DOLBY LABORATORIES LICENSING
CORPORATION
US
60/622458
26/10/2004
60/638607
21/12/2004
US
PCT/US/2005/038579
WO/2006/047600
28/09/2005
1781
H03G
‫שערוך והתאמה של עוצמת הרעש‬
‫או האיזון הספקטרלי הנתפס‬/‫הנתפס ו‬
‫של אות אודיו‬
182098
HANDOFF SUPPORTS FOR
NETWORKS HAVING DIFFERENT
LINK ESTABLISHMENT PROTOCOLS
QUALCOMM INCORPORATED
US
60/614215
28/09/2004
11/233676
22/09/2005
US
PCT/US/2005/035284
WO/2006/037128
C07D
H04L
‫תמיכת מעבר שיחות בין ערוצים לרשתות‬
‫בעלות פרוטוקולי יסוד שונים‬
July 24, 2007– ‫ט' באב התשס"ז‬
23/09/2005
182099
PIPERIDINYLAMINO-THIENO[2,3-D]
PYRIMIDINE COMPOUNDS
EPIX DELAWARE, INC.
US
10/947995
23/09/2004
11/075565
08/03/2005
US
PCT/US/2005/034862
WO/2006/034511
21/03/2007
]D –3 ,2[ ‫תרכובות פיפרידינילאמינו–תיאנו‬
‫פירימידין‬
182100
CUTTING INSERT FOR A MILLING
CUTTER
TAEGUTEC INDIA LTD
21/09/2005
B23B
‫שימת חיתוך לכלי כרסום‬
‫טגוטק הודו בע"מ‬
182102
INDOLE ACETIC ACIDS EXHIBITING
CRTH2 RECEPTOR ANTAGONISM
AND USES THEREOF
ATHERSYS, INC.
US
60/611316
PCT/US/2005/034029
WO/2006/034419
C07D
C07D
‫חומצות אינדול אצטיות המציגות‬
‫אנטגוניזם‬
‫ ושימושיהן‬CRTH 2 ‫לקולטני‬
21/09/2004
21/09/2005
182103
BENZIMIDAZOLE ACETIC ACIDS
EXHIBITING
CRTH2 RECEPTOR ANTAGONISM
AND USES THEREOF
ATHERSYS, INC.
US
60/611296
21/09/2004
PCT/US/2005/034028
WO/2006/034418
July 24, 2007– ‫ט' באב התשס"ז‬
C07D
‫חומצות בנזאימידזול אצטיות המציגות‬
‫ ושימושיהן‬CRTH 2 ‫אנטגוניזם לרצפטור‬
1782
16/09/2005
182104
APPARATUS FOR ALTERING THE
BODY TEMPERATURE OF A PATIENT
LIFE RECOVERY SYSTEMS HD, LLC
US
10/948918
24/09/2004
PCT/US/2005/033044
WO/2006/036585
23/09/2005
182105
USE OF MEMANTINE FOR THE
PREPARATION OF A MEDICAMENT
FOR THE TREATMENT OF
CHILDHOOD BEHAVIORAL
DISORDERS
MERZ PHARMA GMBH & CO. KGAA
US
60/612600
23/09/2004
PCT/US/2005/034199
WO/2006/034465
16/09/2005
182106
APPARATUS FOR ALTERING THE
BODY TEMPERATURE OF A PATIENT
LIFE RECOVERY SYSTEMS HD, LLC
US
10/950152
24/09/2004
PCT/US/2005/033302
WO/2006/036612
23/09/2005
GENOMIC ASSAY
INGENEUS INC
US
60/612670
PCT/IB/2005/053162
WO/2006/033088
1783
182107
A61F
‫מכשיר לשינוי טמפרטורת הגוף בחולה‬
C07D
‫שימוש בממנטין בהכנת תרופה לטיפול‬
‫בהפרעות התנהגותיות של ילדות‬
A61F
‫מכשיר לשינוי טמפרטורת הגוף בחולה‬
C12Q
‫בדיקת גנום‬
24/09/2004
July 24, 2007– ‫ט' באב התשס"ז‬
21/09/2004
182108
PRESSURE VESSEL DOOR SEAL
MECHANISM
NAMES OF INVENTORS
B01J
‫מנגנון אטימת דלת של כלי–לחץ‬
PCT/US/2004/031007
WO/2006/041439
21/09/2004
182109
B01J
‫תמך מיסב כדורי‬
ROTARY BEARING SUPPORT
NAMES OF INVENTORS
PCT/US/2004/030961
WO/2006/041437
11/10/2005
182110
P13 KINASE GAMMA INHIBITORS
FOR THE TREATMENT OF ANEMIA
APPLIED RESEARCH SYSTEMS ARS
HOLDING N.V.
EP
04104997.4 12/10/2004
PCT/EP/2005/055156
WO/2006/040318
22/09/2005
July 24, 2007– ‫ט' באב התשס"ז‬
‫ קינאז גמא לטיפול באנמיה‬P13 ‫מעכבי‬
182112
USE OF TGF-? ANTAGONISTS OF
LIMIT NEPHROTOXICITY OF
IMMUNOSUPPRESSIVE AGENTS
THE MCW RESEARCH FOUNDATION,
INC.
US
60/612187
22/09/2004
PCT/US/2005/033942
WO/2006/036729
C07D
A61K
TGF–? ‫שימוש באנטגוניסטים של‬
‫להגבלת רעילות כליתית של גורם מדכאי‬
‫חיסון‬
1784
22/03/2007
182113
‫מערכת חלבונים ומוצרי מזון הכוללים‬
‫אותה‬
PROTEIN SYSTEM AND FOOD
PRODUCTS INCLUDING SAME
KRAFT FOODS HOLDINGS, INC.
US
11/278210
31/03/2006
19/09/2005
182114
MAGNESIUM REMOVAL FROM
MAGNESIUM REDUCED METAL
POWDERS
H.C. STARCK INC.
US
10/953163
29/09/2004
PCT/US/2005/033291
WO/2006/039126
29/09/2005
182115
182117
STENT
VERYAN MEDICAL LIMITED
GB
0421085.2
22/09/2004
PCT/GB/2005/003665
WO/2006/032902
1785
B22F
‫הסרת מגנזיום מאבקות מתכת המכילות‬
‫כמות מחוזרת של מגנזיום‬
STEROID ANALOGS AND
CHARACTERIZATION AND
TREATMENT METHODS
HOLLIS-EDEN PHARMACEUTICALS,
INC.
US
60/614869
29/09/2004
PCT/US/2005/035020
WO/2006/110172
22/09/2005
C07K
A61K
‫אנלוגים של סטרואידים אפיון ושיטות‬
‫טיפול‬
A61F
‫סטנט‬
July 24, 2007– ‫ט' באב התשס"ז‬
02/02/2000
182118
‫גלאי רב משתמשים עבור מספר גורמי‬
‫התפשטות‬
MULTIUSER DETECTOR FOR
VARIABLE SPREADING FACTORS
INTERDIGITAL TECHNOLOGY
CORPORATION
US
60/154985
21/09/1999
PCT/US/2000/002621
WO/2001/022610
14/09/2000
182119
JOINT DETECTION OF MULTIPLE
USER SIGNALS IN A WIRELESS
COMMUNICATION SYSTEM
INTERDIGITAL TECHNOLOGY
CORPORATION
US
60/153801
14/09/1999
PCT/US/2000/025241
WO/2001/020801
22/03/2007
182120
F24F
‫שיטה טכנולוגיה ומכשיר לקירור ומיזוג‬
‫אוויר סולארי‬
‫איתן בר‬
182121
PYRIMIDINE DERIVATIVES,
PROCESSES FOR THE PREPARATION
THEREOF AND PHARMACEUTICAL
COMPOSITIONS CONTAININGTHE
SAME
REDDY US THERAPEUTICS, INC.
US
60/612374
23/09/2004
PCT/US/2005/034243
WO/2006/034473
July 24, 2007– ‫ט' באב התשס"ז‬
H04B
‫זיהוי משותף של אותות משתמש מרובים‬
‫במערכת תקשורת אלחוטית‬
METHOD, TECHNOLOGY AND
APPARATUS FOR SOLAR COOLING
AND AIR CONDITIONING
ETAN BAR
23/09/2005
H04B
C07D
‫ תהליכים להכנתן‬,‫תולדות פירימידין‬
‫ותכשירי רוקחות המכילים אותן‬
1786
22/03/2007
182122
READING ASSISTANT FOR TORAH
SCROLLS
MAX MOSKOWITZ
22/03/2007
‫עזר לקריאת ספרי תורה‬
182123
182124
PHARMACEUTICAL COMPOSITIONS
CONTAINING (-)-(S)-2,8-DIMETHYL3-METHYLENE-1-OXA-8AZASPIRO[4,5]DECANE AND SALTS
THEREOF
ASTELLAS PHARMA INC.
2004JP
05/10/2004
292611
PCT/JP/2005/018310
WO/2006/038596
26/10/2005
C07D
–S)–8,2(–)–( ‫תכשירי רוקחות המכילים‬
–8–‫–אוקסא‬1–‫–מתילין‬3–‫דימתיל‬
‫]דקאן ומלחיו‬5,4[‫אזאספירו‬
182125
OPTICALLY ACTIVE 4,4-DISUBSTITUTED OXAZOLIDINE
DERIVATIVES AND PROCESSES FOR
THE PREPARATION THEREOF
SANKYO COMPANY LIMITED
2004JP
28/10/2004
313183
PCT/JP/2005/019678
WO/2006/046595
1787
E05B
‫מחוון מצב נעילה‬
‫לוקשור בע"מ‬
LOCK STATUS INDICATOR
LOCKSURE LTD.
04/10/2005
A47F
C07D
‫תולדות אוקסאזולידין המותמרות פעמיים‬
‫ עם פעילות אופטית ושיטות‬4 ‫בעמדה‬
‫להכנתן‬
July 24, 2007– ‫ט' באב התשס"ז‬
04/10/2005
182126
COMPOSITIONS CONTAINING 5PHENOXYALKOXYPSORALEN
DERIVATIVES
THE REGENTS OF THE UNIVERSITY
OF CALIFORNIA
US
10/958997
04/10/2004
PCT/US/2005/035572
WO/2006/041800
12/01/2006
22/03/2007
–5 ‫תכשירים המכילים תולדות‬
‫פנוקסיאלקוקסיפסוראלן‬
182127
MICROCAPSULES AND EMULSIONS
CONTAINING LOW BLOOM
GELATINE AND METHODS FOR THE
PREPARATION THEREOF
OCEAN NUTRITION CANADA LTD
US
11/040820
21/01/2005
11/227961
15/09/2005
US
PCT/IB/2006/001214
WO/2006/085227
182128
A23L
‫תיון‬
‫רננה שוורץ‬
182129
AJUSTABLE COVER FOR A BUTTON
YAEL BOUHADANA
July 24, 2007– ‫ט' באב התשס"ז‬
B01J
‫כמוסותי מיקרו ותחליבים במכילים גלטין‬
‫עם מספר בלום נמוך ושיטות להכנתם‬
TEA BAG
TAL YESHUA
22/03/2007
C07D
A47G
‫כיסוי מתכוונן לכפתור‬
‫יעל בוהדנה‬
1788
22/03/2007
182130
‫סיכת ראש מיוחדת עבור כיפה‬
‫שניידר יוסף‬
SPECIAL HAIR CLIP FOR YARMULKE
SHNAIDER YOSEF
17/09/2005
182131
A PRACTICAL, COST-EFFECTIVE
SYNTHESIS OF
CHLOROMETHYLATED 1,4BENZOQUINONES
ZYMES, LLC
EP
04022718.3 23/09/2004
PCT/EP/2005/010057
WO/2006/032425
22/09/2005
182132
182133
METHOD AND SYSTEM FOR
ADJUSTING A POSITION OF AN
OBJECT
RAYTHEON COMPANY
US
10/951044
24/09/2004
PCT/US/2005/033804
WO/2006/135422
1789
C07C
–4,1–‫סינתזה מעשית וזולה של כלורומתיל‬
‫בנזוקווינונים‬
AN IMPROVED ARTICULATION
SECTION
MEDIGUS LTD.
IL
164260
23/09/2004
PCT/IL/2005/001016
WO/2006/033109
20/09/2005
A44B
A61B
‫מקטע מפרקי משופר‬
‫מדיגוס בע"מ‬
F16M
‫שיטה ומערכת להתאמת מיקום של‬
‫אוביקט‬
July 24, 2007– ‫ט' באב התשס"ז‬
27/09/2005
182134
PROCESS FOR PRODUCTION OF 2CHLORO-4-NITROIMIDAZOLE
OTSUKA PHARMACEUTICAL CO.,
LTD.
2004JP
27/09/2004
278974
PCT/JP/2005/018230
WO/2006/035960
22/09/2005
‫–ניטרואימידזול‬4–‫–כלורו‬2 ‫תהליך ליצירת‬
182135
LIQUID ALLERGY VACCINE
FORMULATION FOR ORMUCOSAL
ADMINISTRATION
ALK-ABELLO A/S
DK
PA200401468 27/09/2004
60/613892
27/09/2004
US
PCT/DK/2005/000601
WO/2006/034707
10/09/2005
July 24, 2007– ‫ט' באב התשס"ז‬
A61K
‫תכשיר חיסון נוזלי לאלרגיה למתן‬
‫אורומוקסלי‬
182136
NOVEL PYRIMIDINE DERIVATIVES
AND THEIR USE AS PPAR-ALPHA
MODULATORS
BAYER HEALTHCARE AG
DE
102004046623.8
PCT/EP/2005/009734
WO/2006/032384
C07D
C07D
‫תולדות חדשות של פירימידין ושימוה‬
‫בהן‬
ALPHA – PPAR ‫כמאפננות‬
25/09/2004
1790
28/09/2005
182137
ADDITIVE FOR LIQUID OR
LIQUIFIED HYDROCARBON FUELED
DIRECT FIRED BURNERS, OPEN
FLAMES AND RELATED PROCESSES
ENVIROFUELS, L.L.C.
US
60/613699
28/09/2004
PCT/US/2005/034988
WO/2006/037094
14/10/2005
23/09/2005
‫ להבות פתוחות ותהליכים‬,‫תוסף למבערים‬
‫ המוצתים באופן ישיר ומתודלקים‬,‫קשורים‬
‫בהידרוקרבון נוזלי‬
182138
LENTICULAR AUTOSTEREOSCOPIC
DISPLAY AND METHOD AND
ASSOCIATED AUTOSTEREOSCOPIC
IMAGE SYNTHESIZING METHOD
ARTISTIC IMAGES
FR
0411018
18/10/2004
PCT/FR/2005/002562
WO/2006/042953
SEA BAG
1791
H04N
‫שיטה ומתקן תצוגה דמוי עדשה המקנה‬
‫ראייה תלת מימדית עצמית ושיטה לעבוד‬
‫תמונה של ראייה תלת מימדית עצמית‬
182139
MODIFIED Fc MOLECULES
AMGEN INC.
US
60/612680
24/09/2004
PCT/US/2005/034273
WO/2006/036834
22/03/2007
C10L
182140
C07K
‫ מותאמות‬Fc ‫מולקולות‬
B65B
‫תיק ים‬
July 24, 2007– ‫ט' באב התשס"ז‬
22/09/2005
182141
METER REGISTER HAVING AN
ENCODER
ARAD MEASURING TECHNOLOGIES
LTD.
US
60/612339
23/09/2004
60/674423
25/04/2005
US
11/228031
15/09/2005
US
PCT/IL/2005/001010
WO/2006/033106
18/07/2000
182142
METHOD AND APPARATUS FOR
CONTROLLING TRANSMISSION
GATED COMMUNICATION SYSTEM
QUALCOMM INCORPORATED
US
03/360139
23/07/1999
PCT/US/2000/019600
WO/2001/008324
27/09/2005
182143
CULTIVATION OF PRIMATE
EMBRYONIC STEM CELLS
WICELL RESEARCH INSTITUTE, INC
US
10/952096
28/09/2004
11/078737
11/03/2005
US
PCT/US/2005/034510
WO/2006/036925
July 24, 2007– ‫ט' באב התשס"ז‬
G01D
‫מד רושם עם מקודד‬
‫ארד טכנולוגיות מדידה בע"מ‬
H04B
‫שיטה והתקן לבקרת מערכת תקשורת‬
‫בעלת שערי שידור‬
C12N
‫גידול של תאי גזע עובריים פרימטיים‬
‫בתרבית‬
1792
30/09/2005
182144
‫צורה מנתית של איבופרופן המשוחרר‬
‫באופן מותאם‬
MODIFIED RELEASE IBUPROFEN
DOSAGE FORM
SCOLR PHARMA, INC.
US
60/614932
30/09/2004
60/689631
10/06/2005
US
11/238802
29/09/2005
US
PCT/US/2005/035630
WO/2006/039692
23/09/2005
182145
20-CYCLOALKYL,26,27ALKYL/HALOALKYL VITAMIN D3
COMPOUNDS AND METHODS OF
USE THEROF
BIOXELL, S.P.A.
US
60/612732
24/09/2004
PCT/US/2005/034213
WO/2006/036813
07/12/2004
1793
C07D
–27 ,26,‫–ציקלואלקיל‬20 ‫תרכובות‬
‫הלואלקיל‬/‫אלקיל‬
‫ ושיטות לשימושיהן‬D3 ‫ויטמין‬
182146
METHOD AND SYSTEM FOR
MODIFYING A USED
HYDROCARBON FLUID TO CREATE
A CYLINDER OIL
A.P. MOLLER-MAERSK A/S
EP
04388064.0 24/09/2004
PCT/DK/2004/000846
WO/2006/032271
A61K
C10M
‫שיטה ומערכת להפיכת נוזל הידרוקרבוני‬
‫לשמן צילינדר‬
July 24, 2007– ‫ט' באב התשס"ז‬
27/09/2005
182147
EFFICIENT SYNTHESIS OF 4,5DIHYDRO-PYRAZOLO[3,4-C]PYRID-2ONES
BRISTOL-MYERS SQUIBB COMPANY
US
60/613754
28/09/2004
60/637623
20/12/2004
US
11/235647
26/09/2005
US
PCT/US/2005/034511
WO/2006/036926
27/09/2005
182148
CRYSTALLINE FORMS OF A
PYRAZOLO '3,4-C! PYRIDINE
FACTOR XA INHIBITOR
BRISTOL-MYERS SQUIBB COMPANY
US
60/613656
28/09/2004
11/235519
26/09/2005
US
PCT/US/2005/034512
WO/2006/036927
19/09/2005
182149
SULFONAMIDE COMPOUNDS
JANSSEN PHARMACEUTICA N.V.
US
60/612720
24/09/2004
PCT/US/2005/033692
WO/2006/036670
22/09/2005
182150
COOLING METHODS AND
APPARATUS
TROX UK LIMITED
GB
0421232.0
23/09/2004
PCT/GB/2005/003648
WO/2006/032888
July 24, 2007– ‫ט' באב התשס"ז‬
C07D
–‫–דיהידרו‬5,4 ‫סינטזה יעילה של‬
‫–אונים‬2–‫]פיריד‬C–4,3[‫פירזולו‬
C07D
!C–4,3' ‫צורות גבישיות של פיראזולו‬
Xa ‫פירידין מעכב לפקטור‬
C07D
‫תרכובות סולפונמיד‬
G06F
‫מכשיר ושיטות לצינון‬
1794
23/09/2004
182151
A61B
‫מכשיר לדגימת רקמות‬
SAMPLER
PANTARHEI BIOSCIENCE B.V.
PCT/NL/2004/000658
WO/2006/033569
27/09/2005
182153
CLOSTRIDIAL NEUROTOXINS FOR
USE IN TISSUE HEALING
MERZ PHARMA GMBH & CO. KGAA
US
60/613392
27/09/2004
PCT/GB/2005/003728
WO/2006/035225
25/03/2007
‫נוירוטוקסינים של קלוסטרידיאל לשימוש‬
‫בריפוי רקמה‬
182154
DNA TRACEABILITY SYSTEM,
LONG-TERM DNA BANKING AND
GENOTYPING BY MULTIPLEXING OF
SNP MARKERS
THE VOLCANI CENTER-THE STATE
OF ISRAEL, MINISTRY OF
AGRICULTURE, AGRICULTURAL
RESEARCH ORGANIZATION
25/03/2007
ANASTOMOSIS SUTURING DEVICE
AND METHODS THEREOF
SADE HOCHSTADTER DAN
1795
A61K
182155
C12N
‫ אגירה‬,‫מערכת נעקבות מבוססות דנ"א‬
‫ושימור לטווח ארוך של דנ"א וקביעת‬
‫תבנית גנטית על ידי ריבוב של סמנים‬
‫בעלי שונות בנוקלאוטיד יחיד‬
‫ משרד‬,‫ מדינת ישראל‬,‫מכון וולקני‬
‫ מנהל המחקר החקלאי‬,‫החקלאות‬
A61B
‫מכשיר ושיטת תפירת אנסטומוזה‬
‫עופר יוספוביץ‬
July 24, 2007– ‫ט' באב התשס"ז‬
25/03/2007
182156
AN AUTOMATED PRODUCTION LINE
FOR MANUFACTURING WAX
PATTERNS FOR THE INVESTMENT
CASTING PROCESS
MICHAEL RACINE
04/10/2005
182157
A COUNTERION EXCHANGE
PROCESS FOR PEPTIDES
NOVETIDE, LTD.
US
60/616010
04/10/2004
60/630528
22/11/2004
US
PCT/US/2005/035868
WO/2006/041945
25/03/2007
182158
USING A WEB CAMERA ON A PC FOR
DIAGNOSIS AND TREATMENT OF
MENTAL DISORDERS
DAVID WEXELMAN
25/03/2007
182159
182161
STABLE TABLET FORMULATION OF
TETRAHYDROBIOPTERIN
BIOMARIN PHARMACEUTICAL INC.
US
60/629189
17/11/2004
PCT/US/2005/041252
WO/2006/055511
July 24, 2007– ‫ט' באב התשס"ז‬
‫קו ייצור אוטומטי לייצור שעוות בשביל‬
‫תהליך יציקה בשעווה נעלמת‬
‫מיכאל רסין‬
C07K
‫תהליך החלפת יון נגדי עבור פפטידים‬
A61M
‫סטימולאציה בדרך הראיה על ידי צילום‬
‫אינטרנט במחשב עבור אבחנה ורפואה‬
‫למחלת נפש‬
‫דוד וקסלמן‬
B29C
‫מכשיר המחבר שיניים‬
‫לפטין יפים‬
COGGED CLUTCH DEVICE
LAPATIN OLGA
16/11/2005
B65G
A61K
‫פורמולציה גלולה יציבה של‬
‫טטראהידרוביופטרין‬
1796
28/09/2005
182162
‫שיטה לאומדן הגבהה ומערכת רדאר‬
‫המשתמשת בשיטה זו‬
ELEVATION ESTIMATION METHOD
AND RADAR APPARATUS USING IT
THALES NEDERLAND B.V.
NL
1027151
30/09/2004
PCT/EP/2005/054870
WO/2006/035041
28/09/2005
182163
A METHOD FOR FINDING THE
LOCATION OF A MOBILE TERMINAL
IN A CELLULAR RADIO SYSTEM
QUALCOMM INCORPORATED
US
10/954847
29/09/2004
PCT/US/2005/035084
WO/2006/039434
28/09/2005
05/10/2005
H04L
CDMA ‫מכשיר ושיטה לזיהוי חוזרים לזמן‬
‫פסבדולייט‬
182165
HIGH FLUX AND LOW FOULING
FILTRATION MEDIA
H04Q
‫שיטה לאיתור מיקום מסוף נייד במערכת‬
‫רדיו סלולרית‬
182164
APPARATUS AND METHOD FOR
CDMA TIME PSEUDOLITE FOR
REPEATER IDENTIFICATION
QUALCOMM INCORPORATED
US
10/955274
29/09/2004
PCT/US/2005/035085
WO/2006/039435
G01S
B01D
‫מדיה לסינון עם זרימה עם זרימה גבוהה‬
‫וסתימה נמוכה‬
THE RESEARCH FOUNDATION OF
STATE UNIVERSITY OF NEW YORK
US
60/616592
06/10/2004
60/633987
07/12/2004
US
PCT/US/2005/035738
WO/2007/001405
1797
July 24, 2007– ‫ט' באב התשס"ז‬
23/09/2005
182166
BUSINESS PROCESS MANAGEMENT
SYSTEM AND METHOD
DATA QUALITY SOLUTIONS LLC
US
60/612615
24/09/2004
11/141710
01/06/2005
US
PCT/US/2005/033918
WO/2006/036720
25/03/2007
182167
REMOTE CONTROL BRAKING
SYSTEM
ZIV MAGUZ
25/03/2007
ENERGY PRODUCTION
DAVID COHEN
July 24, 2007– ‫ט' באב התשס"ז‬
B62H
‫זיו מגוז‬
182169
A61K
‫תכשיר דיאודורנט הפעיל לזמן ארוך‬
‫חלאבין תעשיות בע"מ‬
182170
CMP COMPOSITION WITH A
POLYMER ADDITIVE FOR POLISHING
NOBLE METALS
CABOT MICROELECTRONICS
CORPORATION
US
US10/963108 12/10/2004
PCT/US/2005/036577
WO/2006/044417
25/03/2007
‫שיטה ומערכת לניהול עיבוד עסקי‬
‫מערכת בלימה בשלט רחוק‬
LONG ACTING DEODORANT
COMPOSITION
HLAVIN INDUSTRIES LTD.
11/10/2005
G06F
182171
C09G
‫הרכב לליטוש כימי–מכני עם תוסף‬
‫פולימר לליטוש מתכות אצילות‬
F03B
‫ייצור אנרגיה‬
‫דוד כהן‬
1798
25/03/2007
182172
SYNTHETIC DERIVATIVES OF BETA
GLYCOLIPIDS AND COMPOSITIONS
THEREOF FOR THE TREATMENT OF
PATHOLOGIC DISORDERS
HADASIT MEDICAL RESEARCH
SERVICES & DEVELOPMENT LTD
27/09/2005
,‫נגזרות מלאכותיות של בתא–גליקוליפידים‬
‫תכשירים המכילים אותם ושיטות לטיפול‬
‫בהפרעות פתולוגיות‬
‫הדסית שרותי מחקר רפואי ופיתוח בע"מ‬
182173
SHEET METAL LID FOR A
BEVERAGE CAN, PROVIDED WITH A
LARGE PERFORATION
BALL PACKAGING EUROPE GMBH
EP
04104724.2 28/09/2004
PCT/EP/2005/054858
WO/2006/035033
22/09/2005
182174
TARGET PROPERTY MAPS FOR
SURVEILLANCE SYSTEMS
OBJECTVIDEO INC.
US
10/948785
24/09/2004
PCT/US/2005/034201
WO/2006/036805
25/09/2005
182175
APPARATUS AND METHOD FOR
FUSION AND PRESENTATION OF
VOLUMETRIC DATA AND
ANGIOGRAPHIC DATA
PAIEON INC.
US
10/949155
24/09/2004
PCT/IL/2005/001024
WO/2006/033113
1799
C07H
B65D
,‫כיסוי משטח ממתכת פחית משקה‬
‫המסופקת יחד עם חירור גדול‬
H04N
‫מפות מוכוונות מטרה למערכות פיקוח‬
A61B
‫התקן ושיטה למיזוג וייצוג מידע נפחי‬
‫ואנג'יוגרפי‬
July 24, 2007– ‫ט' באב התשס"ז‬
27/09/2005
182177
PROCESS FOR PREPARING 4,5DIHYDRO-PYRAZOLO [3,4-C] PYRID2-ONES
BRISTOL-MYERS SQUIBB COMPANY
US
60/613938
28/09/2004
60/688999
09/06/2005
US
11/235510
26/09/2005
US
PCT/US/2005/034548
WO/2007/001385
27/09/2005
07/10/2005
H04L
‫מערכות ושיטה לשוטטות אחר שם מארח‬
‫ וירטואליות‬IP ‫וירטואלי וניהול כתובות‬
182179
ANALOGS OF ShK TOXIN AND
PHARMACEUTICAL COMPOSITIONS
CONTAINING THE SAME
THE REGENTS OF THE UNIVERSITY
OF CALIFORNIA
US
60/617395
07/10/2004
PCT/US/2005/036234
WO/2006/042151
July 24, 2007– ‫ט' באב התשס"ז‬
]C–4,3[‫–דיהידרו–פירזולו‬5,4 ‫שיטה להכנת‬
‫–אונים‬2–‫פיריד‬
182178
SYSTEMS AND METHOD FOR
VIRTUAL HOST NAME ROAMING
AND MANAGING VIRTUAL IP
ADDRESSES
CITRIX SYSTEMS, INC.
US
10/711583
27/09/2004
10/711591
27/09/2004
US
PCT/US/2005/034507
WO/2006/036923
C07D
A61K
‫ ותכשירי‬ShK ‫אנאלוגים של טוקסין‬
‫רוקחות המכילים אותם‬
1800
26/09/2005
182180
2H-1,3-BENZOXAZIN-4(3H)-ONE
DERIVATIVES AND
PHARMACEUTICAL COMPOSITIONS
CONTAINING THE SAME
PORTOLA PHARMACEUTICALS, INC.
US
60/614564
29/09/2004
PCT/US/2005/034246
WO/2006/039212
30/09/2005
–)H3( 4–‫– בנזאוקסאזין‬H 2– 1, 3 ‫תולדות‬
‫און ותכשירי רוקחות המכילים אותן‬
182181
POLYMERS OF BROMOSTYRENE
AND PROCESSES FOR THE
PREPARATION THEREOF
CHEMTURA CORPORATION
US
60/615132
30/09/2004
PCT/US/2005/035384
WO/2006/039602
05/10/2005
1801
C08F
‫פולימרים של ברומוסטירין ותהליכים‬
‫להכנתם‬
182182
A NUCLEIC ACID MOLECULE
ENCODING AN A ?-ANTIBODY
CHAIN AND METHODS AND
COMPOSITIONS FOR IMPROVING
RECOMBINANT PROTEIN
PRODUCTION
WYETH
US
60/616474
05/10/2004
PCT/US/2005/035854
WO/2006/041934
C07D
C07K
‫מולקולה חומצת גרעין המקודדת שרשרת‬
‫ ושיטות ותכשירים לשיפור הכנת‬A ? ‫נוגדן‬
‫חלבון ריקומביננטי‬
July 24, 2007– ‫ט' באב התשס"ז‬
16/09/2005
182183
A HEAVY HYDROCARBON
AROMATICS CONVERSION
CATALYST COMPOSITION,
PROCESSES FOR THE PREPARATION
THEREOF AND UTILIZING THE
SAME
EXXONMOBIL CHEMICAL PATENTS
INC.
US
10/982487
05/11/2004
PCT/US/2005/033658
WO/2006/052324
20/09/2005
28/09/2005
G21G
‫שיטה ומערכת ליצור רדיואיזוטופים‬
‫ורדיואיזוטופים הנוצרים באמצעות שיטה זו‬
182185
A BACTERIAL ATP SYNTHASE
BINDING DOMAIN
JANSSEN PHARMACEUTICA N.V.
EP
04104720.0 28/09/2004
60/620500
20/10/2004
US
PCT/EP/2005/054893
WO/2006/035051
July 24, 2007– ‫ט' באב התשס"ז‬
‫תכשיר מזרז להפיכת פחמימנים ארומטיים‬
‫ תהליכים להכנתו ולשימוש‬,‫כבדים לקלים‬
‫בו‬
182184
METHOD AND SYSTEM FOR
PRODUCTION OF RADIOISOTOPES
AND RADIOISOTOPES PRODUCED
THEREBY
SOREQ NUCLEAR RESEARCH
CENTER ISRAEL ATOMIC ENERGY
COMMISSION
US
60/613511
28/09/2004
PCT/IL/2005/001004
WO/2006/035424
B01J
‫המרכז למחקר גרעיני נחל שורק הועדה‬
‫לאנרגיה אטומית‬
C07K
‫ סינתאז חיידקי‬ATP ‫אתר קשור של‬
1802
18/10/2005
182186
SOLUBLE ZCYTOR21, ANTIZCYTOR21 ANTIBODIES AND
BINDING PARTNERS AND METHODS
OF USING IN INFLAMMATION
ZymoGenetics INC.
US
60/619651
18/10/2004
60/622207
25/10/2004
US
PCT/US/2005/037332
WO/2006/044840
06/10/2005
182187
METHOD AND SYSTEM FOR
ULTRASOUND TISSUE TREATMENT
GUIDED THERAPY SYSTEMS, L.L.C
US
60/616752
06/10/2004
60/616755
06/10/2004
US
60/617203
07/10/2004
US
60/617295
07/10/2004
US
PCT/US/2005/036377
WO/2006/042201
06/10/2005
182188
METHOD AND SYSTEM FOR
CONTROLLED THERMAL
TREATMENT OF HUMAN
SUPERFICAL TISSUE
GUIDED THERAPY SYSTEMS, L.L.C
US
60/616754
06/10/2004
PCT/US/2005/036269
WO/2006/042168
1803
C07K
21 ‫ נוגדים נוגדי‬,‫ מסיסים‬ZCYTOR 21
‫ וגורמים נקשרים ושיטות‬ZCYTOR
‫לשימוש בהם בדלת‬
A61N
‫שיטה ומערכת לטיפול אולטרא סאונד‬
‫ברקמה‬
A61N
‫שיטה ומערכת לטיפול חומני מבוקר של‬
‫רקמה אנושית שטחית‬
July 24, 2007– ‫ט' באב התשס"ז‬
06/10/2005
182189
METHOD AND SYSTEM FOR
NONINVASIVE COSMETIC
ENHANCEMENT
GUIDED THERAPY SYSTEMS, L.L.C
US
60/616355
06/10/2004
60/616753
06/10/2004
US
60/617338
07/10/2004
US
60/616294
07/10/2004
US
PCT/US/2005/036253
WO/2006/042163
26/09/2005
‫שיטה ומערכת להגברה קוסמטית לא‬
‫פולשנית‬
182190
182191
182192
SYSTEM AND METHOD FOR
PROVIDING AIR TO A COMPRESSOR
OF AN AIRCRAFT AUXILIARY GAS
TURBINE ENGINE
GENERAL ELECTRIC COMPANY
US
11/398108
05/04/2006
July 24, 2007– ‫ט' באב התשס"ז‬
A47L
‫מנפק אבקה‬
‫אילת תלם‬
A POWDER DISPENSER
AYELET TELEM
26/03/2007
E05B
‫מנעול וחותם לקונטיינר‬
CONTAINER LOCK AND SEAL
E-LOCK TECHNOLOGIES LTD.
US
60/613512
28/09/2004
PCT/IL/2005/001025
WO/2006/035428
26/03/2007
A61B
F02C
‫מערכת ושיטה לאספקת אוויר למדחס של‬
‫מנוע עזר גז טורבינה לכלי טייס‬
1804
26/03/2007
182193
METHOD FOR THE MONOBLOC
SIZING FOR TEMPERING CASINGS
AND DEVICE FOR IMPLEMENTING
THE METHOD
SNECMA
FR
0651039
27/03/2006
17/10/2005
‫שיטה לקביעת מידות גוף חד–חלקי עבור‬
‫בית הרפיה והתקן ליישום השיטה‬
182194
SURFACE ACOUSTIC WAVE GAS
SENSOR WITH SENSITIVE GETTER
LAYER AND PROCESS FOR ITS
MANUFACTURE
SAES GETTERS S.P.A.
IT
MI2004A002017 22/10/2004
PCT/IT/2005/000605
WO/2006/043299
26/03/2007
182195
B23B
‫כלי לחיתוך‬
‫ פטנטים בע"מ‬.‫ ג'י‬.‫ אר‬.‫ג'י‬
182196
METHOD FOR MEASURING
POSITION OF MASK SURFACE IN
HEIGHT DIRECTION, EXPOSURE
APPARATUS AND EXPOSURE
METHOD
NIKON CORPORATION
2004JP
22/12/2004
370393
PCT/JP/2005/023996
WO/2006/068288
1805
G01N
‫חיישן גז משטח גל–אקוסטי עם שכבת‬
‫גטר רגישה ותהליך ליצורו‬
CUTTER TOOL
G.R.G. PATENTS LTD
21/12/2005
B22F
H01L
‫שיטה למדידת מיקומו של משטח של‬
‫ מכשור חשיפה ושיטת‬,‫מיסוך בכיוון גובה‬
‫חשיפה‬
July 24, 2007– ‫ט' באב התשס"ז‬
27/12/2005
182197
LASER PLASMA EUV LIGHT
SOURCE, TARGET MEMBER,
PRODUCTION METHOD FOR TARGET
MEMBER, TARGET SUPPLYING
METHOD, AND EUV EXPOSURE
SYSTEM
NIKON CORPORATION
2005JP
12/01/2005
005425
PCT/JP/2005/024221
WO/2006/075535
26/09/2005
‫ גוף‬,EUV ‫מקור תאורת פלאזמה לייזר‬
‫ שיטה‬,‫ שיטת ייצור לגוף מטרה‬,‫מטרה‬
EUV ‫ ומערכת חשיפה‬,‫לאספקת מטרה‬
182199
THREAD SYSTEM FOR INSTALLING IN
DRINKING WATER SYSTEMS AND
OTHER LIQUID-GUIDING SYSTEMS
DETLEF MILITZ
DE
202004015240.1
PCT/DE/2005/001730
WO/2006/034701
23/09/2005
C02F
‫מערכת בורג להתקנה במערכות מי‬
‫שתיה ומערכות לאספקה של נוזלים‬
‫אחרים‬
27/09/2004
182200
RF GROUND SWITCH FOR PLASMA
PROCESSING SYSTEM
LAM RESEARCH CORPORATION
US
10/953229
29/09/2004
PCT/US/2005/034073
WO/2006/039193
July 24, 2007– ‫ט' באב התשס"ז‬
H01L
C23F
‫ עבור תהליך עיבוד‬RF ‫מתג הארקה‬
‫פלאזמאי‬
1806
06/10/2005
182202
CUPREDOXIN DERIVED TRANSPORT
AGENTS AND METHODS OF USE
THEREOF
TOHRU YAMADA
US
60/616782
07/10/2004
60/680500
13/05/2005
US
60/700297
19/07/2005
US
PCT/US/2005/035758
WO/2006/088508
18/10/2005
C07K
‫גורמי העברה ממוצא קופרדוקסין ושיטות‬
‫שימוש בהם‬
182203
C07D
THIADIAZOLE COMPOUNDS AND
METHODS OF USE
AMGEN, INC.
US
60/619010
18/10/2004
PCT/US/2005/037374
WO/2006/044860
11/01/2001
‫תרכובות תיאדיאזול ושיטות שימוש‬
182204
METHOD AND SYSTEM FOR
PROVIDING A CUSTOMIZED MEDIA
LIST
INDIVIDUAL NETWORK, LLC
US
09/487120
19/01/2000
PCT/US/2001/001115
WO/2001/054403
10/09/2005
‫שיטה ומערכת לאספקת רשימת מדיה‬
‫המתואמת למשתמש‬
182205
PEELABLE, CHILD-RESISTANT
PACKAGE FOR FILM-SHAPED DRUG
FORMS
LTS LOHMANN THERAPIE-SYSTEME
AG
DE
102004047447.8 30/09/2004
PCT/EP/2005/009746
WO/2006/037424
1807
H04N
B65D
,‫ ברת קילוף‬,‫אריזה עמידה בפני ילדים‬
‫לתרופות בצורת פילם‬
July 24, 2007– ‫ט' באב התשס"ז‬
10/08/2005
182206
‫מערכת של עדשות בגלגלי העין‬
INTRAOCULAR LENS SYSTEM
ALCON, INC.
US
10/955111
30/09/2004
PCT/US/2005/028389
WO/2006/038982
26/03/2007
182207
SYSTEM AND METHOD FOR USER
SELECTABLE RELEASE MODALITY
FOR A SURGICAL CASSETTE
ALCON, INC.
US
11/394896
31/03/2006
27/09/2005
26/03/2007
July 24, 2007– ‫ט' באב התשס"ז‬
G08C
‫שיטה ומכשיר לניהול והפקה של מוזיקה‬
‫או מעבר–קול מרוחק‬
182210
SURGICAL CASSETTE WITH
COMPLIANT CLAMPING ZONE
ALCON, INC.
US
11/391859
29/03/2006
A61B
‫שיטה ומערכת לבחירת אופן שחרור של‬
‫קסטת ניתוחים‬
182208
METHOD AND APPARATUS FOR
REMOTE VOICE-OVER OR MUSIC
PRODUCTION AND MANAGEMENT
SOUNDSTREAK, INC.
US
60/613572
27/09/2004
PCT/US/2005/034850
WO/2006/037053
A61F
A61B
‫קלטת כירורגית עם אזור תפיסה תואם‬
1808
10/10/2005
182211
PROCESS FOR PREPARING PURINE
COMPOUNDS
PFIZER PRODUCTS, INC.
US
60/621559
22/10/2004
PCT/IB/2005/003255
WO/2006/043175
21/09/2005
12/09/2005
CORNEAL BIOMETRY
POSITIVE EYE-D LTD
AU
2004905635
60/685484
US
PCT/AU/2005/001386
WO/2006/034527
26/09/2005
C07D
HSD1–B11 ‫נגזרות של אינדזולון כמעכבי‬
182213
A61B
‫ביומטריה של קרנית‬
29/09/2004
31/05/2005
182214
DIBENZODIAEPINONE ANALOGUES,
PROCESSES FOR THEIR
PRODUCTION AND THEIR USE AS
PHARMACEUTICALS
ECOPIA BIOSCIENCES INC.
US
10/951436
27/09/2004
60/625653
08/11/2004
US
60/647381
28/01/2005
US
2,497,031
11/02/2005
CA
60/701472
22/07/2005
US
PCT/CA/2005/001467
WO/2006/034574
1809
‫תהליך להכנה של תרכובות פורין‬
182212
INDAZOLONE DERIVATIVES AS 11BHSD1 INHIBITORS
F. HOFFMANN-LA ROCHE AG
EP
04104753.1 29/09/2004
PCT/EP/2005/010175
WO/2006/034804
C07D
C07D
‫ תהליכים‬,‫אנלוגים של דיבנזודיאזיפינון‬
‫ליצירתם ושימושם כתכשירי רוקחות‬
July 24, 2007– ‫ט' באב התשס"ז‬
28/03/2007
182257
BODY AWARENESS EXERCISE
DEVICE
HULLAHALA FUN DEVELOPMENTS
LTD.
28/03/2007
‫מכשיר לתרגול תחושת גוף‬
‫הולהלה פיתוח שעשועים בע"מ‬
182258
A BEATING HEART SHAPED
BALOON
HULLAHALA FUN DEVELOPMENTS
LTD.
28/03/2007
30/09/2005
‫הולהלה פיתוח שעשועים בע"מ‬
182260
182261
THERAPEUTIC AGENTS WITH
DECREASED TOXICITY
GENENTECH, INC.
US
60/616507
05/10/2004
60/641534
05/01/2005
US
PCT/US/2005/033952
WO/2006/041641
July 24, 2007– ‫ט' באב התשס"ז‬
A63F
‫משחק מוחצן של קלפים או אבני משחק‬
METHODS OF TREATING CD30
POSITIVE LYMPHOMAS
MEDAREX, INC.
US
60/615284
01/10/2004
PCT/US/2005/035477
WO/2006/039644
22/09/2005
A63H
‫בלון אלסטי פועם בדמות לב‬
182259
EXRTOVERTED GAME OF TILES OR
CARDS
HULLAHALA FUN DEVELOPMENTS
LTD.
A63B
‫הולהלה פיתוח שעשועים בע"מ‬
A61K
30–‫שיטות לטיפול בלימפומות חיוביות ל‬
CD
A61K
‫גורמים טיפוליים עם רעילות מופחתת‬
1810
13/10/2005
182262
SELF-FIXATING SCAFFOLDS
MEDTRONIC, INC.
US
60/618425
13/10/2004
PCT/US/2005/037430
WO/2006/044890
13/10/2005
182263
CELLULAR AND GENETIC
INTERVENTION TO TREAT
VENTRICULAR TACHYCARDIA
MEDTRONIC, INC.
US
60/618423
13/10/2004
PCT/US/2005/036923
WO/2006/044589
21/10/2005
182264
MECHANICAL LOCKING OF FLOOR
PANELS WITH A FLEXIBLE TONGUE
VALINGE INNOVATION AB
EP
04025167.0 22/10/2004
PCT/SE/2005/001586
WO/2006/043893
20/10/2005
182266
PESTICIDAL MIXTURES
BASF AKTIENGESELLSCHAFT
US
60/621121
22/10/2004
PCT/EP/2005/011280
WO/2006/045522
1811
A61N
‫פיגומים בעלי קיבוע עצמי‬
A61F
‫התערבות תאית וגנטית לטיפול‬
‫בטכיקרדיה‬
E04F
‫נעילה מכנית של לוחות רצפה עם לשון‬
‫גמישה‬
C07D
‫תערובות קוטלות מזיקים‬
July 24, 2007– ‫ט' באב התשס"ז‬
28/10/2005
182267
NOVEL ANTHRANILAMIDE
PYRIDINUREAS AS VASCULAR
ENDOTHELIAL GROWTH FACTOR
(VEGF) RECEPTOR KINASE
IMHIBITORS
SCHERING AKTIENGESELLSCHAFT
EP
04090418.7 03/11/2004
PCT/EP/2005/011708
WO/2006/048248
16/12/2005
‫אנתראנילאמיד פירידינאוריאות כמעכבי‬
‫קולטן קינאז של גורם גדילה אנדותלי של‬
‫כלי דם‬
182268
NOVEL NAPHTHYL SUBSTITUTED
AZABICYCLO DERIVATIVES AND
THEIR USE AS MONOAMINE
NEUROTRANSMITTER RE-UPTAKE
INHIBITORS
NEUROSEARCH A/S
DK
PA200401984 22/12/2004
60/637735
22/12/2004
US
PCT/EP/2005/056846
WO/2006/067090
04/10/2005
182269
SOLID PHASE PEPTIDE SYTHESIS
F. HOFFMANN-LA ROCHE AG
EP
04104994.1 12/10/2004
PCT/EP/2005/010654
WO/2006/040037
July 24, 2007– ‫ט' באב התשס"ז‬
C07D
C07D
‫תולדות של אזאביציקלו מותמרות‬
‫בנפתיל ושימוש בהן כמעכבי לקיחה‬
‫מחדש של מעביר–אות–עצבי מונואמיני‬
C07K
‫סינטזת פפטידים במצב מוצק‬
1812
07/12/2005
182270
A NEW PROCESS FOR THE
PREPARATION OF PHENOLIC
HYDROXY -SUBSTITUTED
COMPOUNDS
RICHTER GEDEON VEGYESZETI
GYAR RT.
HU
P0402530
08/12/2004
11/11/2005
HU
P0501044
PCT/HU/2005/000128
WO/2006/061666
30/11/2005
12/05/2000
A01H
‫צמח אבטיח מרובה ענפים ושיטה ליצורו‬
182272
NOVEL INTERLEUKIN-1 AND
TUMOR NECROSIS FACTOR-?
MODULATORS, SYNTHESES OF SAID
MODULATORS AND METHODS OF
USING SAID MODULATORS
THE REGENTS OF THE UNIVERSITY
OF CALIFORNIA
US
60/134295
14/05/1999
60/186853
03/03/2000
US
PCT/US/2000/013202
WO/2000/073253
1813
‫תהליך חדש להכנת תרכובות מותמרות‬
‫בהדרוקסי פנול‬
182271
MULTIBRANCHING WATERMELON
PLANT AND METHOD OF
PRODUCING
HARRIS MORAN SEED COMPANY
US
10/999650
30/11/2004
PCT/US/2005/043193
WO/2006/060425
C07C
C07C
–‫–וגורמי נמק רקמיים‬1 ‫מווסתי אינטרלוקיו‬
‫ הכנת מווסתים אלו ושיטות של שימוש‬, ?
‫בהם‬
July 24, 2007– ‫ט' באב התשס"ז‬
28/03/2007
182273
A DEVICE FOR REMOVABLY FITTING
TO PRAMS CARRYCOT SEATS AND
CARRYCOTS BEING PROVIDED WITH
AN ARTICULATED HANDLE
JANE, S.A.
ES
ES200600853U 12/04/2006
09/07/2003
15/10/2004
‫התקן עבור מתאם שניתן להסרה‬
‫לעגלות תינוק למושבי סלסלת תינוק‬
‫וססלת תינוק עם ידית גרירה‬
182275
METHOD AND APPARATUS FOR
CONVEYING REPORTS FOR SMS
MESSAGES IN WIRELESS
COMMUNICATION SYSTEMS
QUALCOMM INCORPORATED
US
10/192049
09/07/2002
PCT/US/2003/021600
WO/2004/006596
182276
July 24, 2007– ‫ט' באב התשס"ז‬
H04B
‫שיטה והתקן לאיתות משופר של אור‬
‫אזהרה‬
182277
METHOD AND INTERMEDIATES FOR
THE PREPARATION OF
DERIVATIVES OF N-(1BENZHYDRYL-AZETIDIN-3-YL)-NPHENYL-METHYLSULPHONAMIDE
AVENTIS PHARMA S.A.
FR
0410845
14/10/2004
PCT/FR/2005/002489
WO/2006/040464
H04Q
‫שיטה ומתקן למשלוח דוחות עבור הודאות‬
‫ במערכות תקשורת אלחוטיות‬SMS
ENHANCED BEACON SIGNALING
METHOD AND APPARATUS
QUALCOMM FLARION
TECHNOLOGIES, INC.
US
10/965011
14/10/2004
PCT/US/2004/034191
WO/2006/043939
10/10/2005
A47D
C07D
N ‫שיטה וחומרי ביניים להכנת תולדות של‬
–‫–פניל‬N–)‫–איל‬3–‫(–– בנזהידרולאזטידין‬1
‫מתילסולפונאמיד‬
1814
14/10/2005
182278
METHODS AND APPARATUS FOR
DETERMINING, COMMUNICATING
AND USING INFORMATION WHICH
CAN BE USED FOR INTERFERENCE
CONTROL PURPOSES
QUALCOMM FLARION
TECHNOLOGIES, INC.
US
60/618773
14/10/2004
PCT/US/2005/037115
WO/2006/044718
19/10/2005
‫ להתקשרות‬,‫שיטות והתקנים להחלטה‬
‫ולשימוש במידע אשר יכול להיות לשימוש‬
‫עבור מטרות בקרת שליטה‬
182279
ANGIOPOIETIN-2-SPECIFIC BINDING
AGENTS
AMGEN INC.
US
60/620161
19/10/2004
10/982440
04/11/2004
US
PCT/US/2005/037911
WO/2006/045049
07/10/2005
182282
ENGINE ROOM IN A SEALABLE
CONTAINER
STIDD SYSTEMS, INC.
US
10/960523
07/10/2004
PCT/US/2005/036422
WO/2006/137907
25/09/2005
182283
USE OF COAL ASH FOR THE SAFE
DISPOSAL OF MINERAL WASTE
ORGYR TECHNOLOGIES LTD.
US
10/950589
28/09/2004
PCT/IL/2005/001023
WO/2006/035427
1815
H04B
C07K
2–‫גורמי קישור ספציפיים לאנג'יופויאטין‬
F02B
‫חדר מנועים בתוך מכל בר–אטימה‬
C03B
‫שימוש באפר פחם לנטרול פסולת‬
‫מניראלית‬
‫אורגיר טכנולוגיות בע"מ‬
July 24, 2007– ‫ט' באב התשס"ז‬
29/03/2007
182285
A MULTI PURPOSE EXERCISE AND
REHABILITATION DEVICE
DANIEL ORGAL
10/08/2005
‫מכשיר כושר ושיקום רב שימושי‬
‫דניאל אורגל‬
182286
METHOD AND APPARATUS FOR
PROVIDING AUTHORIZED REMOTE
ACCESS TO APPLICATION SESSIONS
CITRIX SYSTEMS, INC.
US
10/711731
30/09/2004
PCT/US/2005/028605
WO/2006/038985
29/03/2007
182288
RECIPROCALLY AND LINEARLY
ACTUATED OSTEOTOME
BERREBY RICHARD
09/10/2005
H04L
‫שיטה והתקן לנתינת הרשאת גישה‬
‫מרוחקת לזמני עבודת יישום‬
A61B
‫איזמל עצמות המונע באופן ישר והפיך‬
‫ריצ'רד ברבי‬
182290
ACCOMMODATING INTRAOCULAR
LENS (AIOL), AND AIOL
ASSEMBLIES INCLUDING SAME
NULENS LTD.
US
60/617738
13/10/2004
PCT/IL/2005/001069
WO/2006/040759
July 24, 2007– ‫ט' באב התשס"ז‬
A63B
A61F
,)AIOL( ‫עדשה מסתגלת תוך עינית‬
‫) הכוללת אותם‬AIOL( ‫מערכות‬
‫ניולנס בע"מ‬
1816
06/10/2005
182291
CLOSURE FOR A CONTAINER
WEST PHARMACEUTICAL
SERVICES, INC.
US
60/616809
07/10/2004
PCT/US/2005/035902
WO/2006/041965
29/03/2007
182292
DEVICE FOR TREATING FRUIT
MATERIEL POUR
L'ARBORICULTURE FRUITIERE
FR
06.02988
05/04/2006
29/03/2007
182293
DEVICE FOR SEPARATING THE
STALKS OF FRUIT, GROUPED
TOGETHER IN CLUSTERS, FROM
ONE ANOTHER
MATERIEL POUR
L'ARBORICULTURE FRUITIERE
FR
06.02989
05/04/2006
17/10/2005
182294
METHODS AND COMPOSITIONS FOR
COMBINATORIAL-BASED
PRODUCTION OF MULTIVALENT
RECOMBINANT ANTIGENS
NEUGENESIS CORPORATION
US
60/619364
15/10/2004
PCT/US/2005/037249
WO/2006/044796
1817
B32B
‫מכסה עבור מיכל‬
A01N
‫מכשיר לטיפול בפירות‬
A23N
‫מכשיר להפרדת גבעולי פרי המקובצים‬
‫באשכול אחד מהשני‬
A61K
‫שיטות ותרכובות ליצור מבוסס‬
‫קומבינטוריקה של אנטיגנים‬
‫רקומביננטיים רב ערכיים‬
July 24, 2007– ‫ט' באב התשס"ז‬
26/09/2005
182295
PRIMER FOR DETECTION OF
CYTOCHROME P450 HYDROXYLASE
SPECIFIC TO POLYENE
HANSON BIOTECH CO, LTD
10-2004KR
04/10/2004
0078613
PCT/KR/2005/003185
WO/2006/080648
06/10/2005
INJECTION DEVICE
NOVO NORDISK A/S
EP
04388068.1
PCT/EP/2005/055068
WO/2006/040296
182296
C12Q
P450 ‫פריימר לאיתור ציטוכרים‬
‫הידרוקסילאז מיוחד לפוליאן‬
A61M
‫התקן הזרקה‬
11/10/2004
13/10/2005
182298
4-HYDROXY TAMOXIFEN GEL
FORMULATIONS
LABORATOIRES BESINS
INTERNATIONAL
EP
04292447.2 14/10/2004
60/638359
23/12/2004
US
PCT/EP/2005/011654
WO/2006/040196
28/09/2005
182299
COPOLYMER AND TOP COATING
COMPOSITION
JSR CORPORATION
2004JP
30/09/2004
287724
2005-130557 27/04/2005
JP
PCT/JP/2005/017790
WO/2006/035790
July 24, 2007– ‫ט' באב התשס"ז‬
A61K
‫–הידרוקסי טאמוקסיפן‬4 ‫הרכבי ג'ל של‬
C08F
‫קופולימר ותכשיר ציפוי עליון‬
1818
27/03/2007
182301
METHOD AND APPARATUS FOR
SQUELCH GATING A RECEIVING
SIGNAL
ROHDE & SCHWARZ GMBH & CO.
KG
06 007
EP
07/04/2006
405.1
145.8 000 07 04/01/2007
EP
04/10/2005
18/08/2005
H01P
‫מערכי סינון ומערכות תקשורת המבוססות‬
‫עליהם‬
182303
A METHOD FOR PROTECTING
IMPLANTABLE SENSORS AND
PROTECTED IMPLANTABLE
SENSORS
ZULI HOLDINGS LTD.
US
10/952360
27/09/2004
PCT/IB/2005/002588
WO/2006/035275
1819
‫שיטה והתקן למיתוג על ידי השתקה של‬
‫סיגנל נקלט‬
182302
FILTER ASSEMBLIES AND
COMMUNICATION SYSTEMS BASED
THEREON
HUBER + SUHNER AG
EP
04023918.8 07/10/2004
PCT/EP/2005/054990
WO/2006/037781
H04B
A61B
‫שיטה להגנת חיישנים הניתנים להשתלה‬
‫וחיישנים מוגנים הניתנים להשתלה‬
‫זולי החזקות בע"מ‬
July 24, 2007– ‫ט' באב התשס"ז‬
22/09/2005
182304
BENZOXAZINE AND QUINOXALINE
DERIVATIVES AND USES
F. HOFFMANN-LA ROCHE AG
US
60/614705
30/09/2004
60/630608
24/11/2004
US
PCT/EP/2005/010238
WO/2006/037481
07/10/2005
‫נגזרות של בנזוקסזין וקוינוקסלין ושימושים‬
182305
DIAMINOALKANE ASPARTIC
PROTEASE INHIBITORS
VITAE PHARMACEUTICALS, INC.
US
60/616770
07/10/2004
PCT/US/2005/036230
WO/2006/042150
01/10/2004
C07D
C07D
‫מעכבי דיאמינואלקאן אספריק פרוטאז‬
182306
APPARATUS AND METHOD FOR
PREPARING AND DELIVERING A
BEVERAGE WITH THE USE OF A
RAW MATTER CONTAINED IN A
CARTRIDGE
HAUSBRANDT TRIESTE 1892 SPA
A47J
‫מערכת ושיטה להכנה והובלה של משקה‬
‫על ידי שימוש בחומר גלם הנמצא בתוך‬
‫מחסנית‬
PCT/IT/2004/000541
WO/2006/038227
10/09/2005
182309
NON-RECLOSABLE PACKAGING FOR
PRODUCTS PREJUDICIAL TO HEALTH,
AS WELL AS PROCESS FOR ITS
PRODUCTION
LTS LOHMANN THERAPIE-SYSTEME
AG
DE
102004047445.1 30/09/2004
PCT/EP/2005/009748
WO/2006/037425
July 24, 2007– ‫ט' באב התשס"ז‬
B65D
‫אריזה שאינה ניתנת לסגירה מחודשת‬
‫למוצרים המסוכנים לבריאות ותהליך‬
‫לייצורה‬
1820
26/09/2005
182310
ALKIL-PYRIDINES AS 11-BETA
INHIBITORS FOR DIABETES
F. HOFFMANN-LA ROCHE AG
EP
04104856.2 04/10/2004
PCT/EP/2005/010372
WO/2006/037501
29/03/2007
‫–בטא לסוכרת‬11 ‫אלקיל–פירידינים כמעכבי‬
182311
FLUIDIC CASSETTE DETECTION
MECHANISM
ALCON, INC.
US
60/787970
31/03/2006
07/10/2005
182312
1821
C07C
‫תרכובות אמיטרז‬
182313
COMPOUNDS FOR MYOCARDIAL
PERFUSION IMAGING
BRISTOL-MYERS SQUIBB PHARMA
COMPANY
US
60/619678
18/10/2004
PCT/US/2005/036275
WO/2006/044280
G08B
‫מנגנון איתור המבוסס על קלטת זורמית‬
AMITRAZ COMPOSITIONS
WYETH
US
60/616995
08/10/2004
60/683646
23/05/2005
US
PCT/US/2005/036121
WO/2006/042099
11/10/2005
C07D
H01L
‫תרכובות להדמיית פרפוזיה של שריר הלב‬
July 24, 2007– ‫ט' באב התשס"ז‬
06/10/2005
182314
1,2,4-TRIAZOLYLAMINOARYL
(HETEROARYL) SULFONAMIDE
DERIVATIVES
JANSSEN PHARMACEUTICA N.V.
US
60/617119
08/10/2004
PCT/US/2005/036396
WO/2006/042215
30/09/2005
13/10/2005
‫– טריאזולילאמינואריל‬4,2,1 ‫נגזרות של‬
‫(הטרואריל) סולפונאמיד‬
182315
3-ETHER AND 3-THIOETHER
SUBSTITUTED CYCLOSPORIN
DERIVATIVES FOR THE TREATMENT
AND PREVENTION OF HEPATITIS C
INFECTION
SCYNEXIS, INC.
US
60/615152
01/10/2004
60/707626
11/08/2005
US
PCT/US/2005/035533
WO/2006/039668
182316
182317
CGRP RECEPTOR ANTAGONISTS
MERCK & CO. INC.
US
60/618451
13/10/2004
60/683837
24/05/2005
US
PCT/US/2005/036763
WO/2006/044504
July 24, 2007– ‫ט' באב התשס"ז‬
A61K
–3–‫–אתר ו‬3 ‫נגזרות ציקלוספורין מותמרות‬
‫תיואתר לטיפול ומניעת זיהום בהפאטיטיס‬
C
N-BENZENESULFONYL
SUBSTITUTED ANILINO-PYRIMIDINE
ANALOGS
WYETH
US
60/617668
13/10/2004
PCT/US/2005/036674
WO/2006/044457
12/10/2005
C07D
C07D
‫אנלוגים של אנילינו–פירימידין מותמרים‬
‫–בנזנסולפוניל‬N
C07D
CGRP–‫אנטגוניסטים לרצפטור ל‬
1822
29/09/2005
182319
DEVICE AND METHOD FOR
TREATING WEIGHT DISORDERS
DUOCURE, INC.
US
60/614421
PCT/IL/2005/001053
WO/2006/035446
28/09/2005
‫מכשיר ושיטה לטיפול בהפרעות משקל‬
‫כגון השמנת יתר‬
‫דוקיור אינק‬
30/09/2004
182320
COLLAGEN PRODUCING PLANTS
AND METHODS OF GENERATING
AND USING SAME
COLLPLANT LTD
US
60/613719
29/09/2004
PCT/IL/2005/001045
WO/2006/035442
29/09/2005
182321
COMPOSITION FOR IMPROVING
EFFICIENCY OF DRUG DELIVERY
THE MEDICAL RESEARCH FUND AT
THE TEL-AVIV SOURASKY MEDICAL
CENTER
US
60/613720
29/09/2004
60/613721
29/09/2004
US
60/623878
02/11/2004
US
60/677813
05/05/2005
US
60/677827
05/05/2005
US
PCT/IL/2005/001049
WO/2006/035444
1823
A61B
C12N
,‫ שיטות להפקתם‬,‫צמחים מייצרי קולאגן‬
‫ושימושם‬
‫קולפלנט בע"מ‬
A61M
‫תכשיר לשיפור יעילות אספקת תרופה‬
‫תשתית ושירותים‬, ‫מחקרים‬-‫תל השומר‬
‫רפואיים בע"מ‬
July 24, 2007– ‫ט' באב התשס"ז‬
29/09/2005
182322
MONITORING OF CONVECTION
ENHANCED DRUG DELIVERY
THE MEDICAL RESEARCH FUND AT
THE TEL-AVIV SOURASKY MEDICAL
CENTER
US
60/613720
29/09/2004
60/613721
29/09/2004
US
60/623878
02/11/2004
US
60/677827
05/05/2005
US
60/677813
05/05/2005
US
PCT/IL/2005/001048
WO/2006/035443
17/09/2002
29/03/2007
‫ניטור אספקת תרופה בהסעה מוגברת‬
‫תשתית ושירותים‬, ‫מחקרים‬-‫תל השומר‬
‫רפואיים בע"מ‬
182324
METHOD FOR THE PREPARATION OF
A MEAT SUBSTITUTE PRODUCT,
MEAT SUBSTITUTE PRODUCT
OBTAINED WITH THE METHOD AND
READY TO CONSUME MEAT
SUBSTITUTE PRODUCT
NUG NAHRUNG-UND
GENUSSMITTEL
VERTRIEBSGESELLSCHAFT MBH
NL
1019816
22/01/2002
PCT/NL/2002/000594
WO/2003/061400
A23J
‫ מוצר‬,‫שיטה להכנת מוצר תחליף לבשר‬
‫תחליף לבשר אשר הוכן לפי השיטה ומוצר‬
‫תחליף לבשר מוכן לאכילה‬
182325
MULTI-PURPOSE AND FULLY
AUTOMATIC FILTER HOUSING (FOR
FILTERING AND CLEANING AND
DISINFECTION OF FILTERS)
A46B
B01D
‫בית מסנן רב תכליתי ובעל אוטומציה‬
)‫מלאה (לסינון וכן לניקוי וחיטוי מסננים‬
‫דיב תלחמי‬
July 24, 2007– ‫ט' באב התשס"ז‬
1824
06/10/2005
182326
APPARATUS AND METHOD OF
MANUFACTURING SOLAR CELLS
MIDSUMMER AB
SE
0402432-9
08/10/2004
PCT/SE/2005/001476
WO/2006/038875
17/10/2005
182327
SHEET PRODUCT FOR THERMAL
PRINTING AND FOR MAGNETIC
RECORDING
ARJO WIGGINS LIMITED
GB
0423107.2
18/10/2004
PCT/GB/2005/004003
WO/2006/043044
24/10/2005
182328
METHOD FOR READING MAGNETIC
DATA
ARJO WIGGINS LIMITED
GB
0423676.6
25/10/2004
PCT/GB/2005/004099
WO/2006/046016
29/03/2007
PRECISION FLUID FLOW
REGULATOR AND METHOD FOR
FLOW REGULATION
BORIS NUDELMAN
1825
182329
H01L
‫מכשיר ושיטה ליצור תאים סולריים‬
B41M
‫מוצר יריעה להדפסה תרמית ולהקלטה‬
‫מגנטית‬
G11B
‫שיטה לקריאת נתונים מגנטיים‬
B05B
‫וסת זרימת נוזלים מדויקת ושיטה לויסות‬
‫זרימה‬
‫בוריס נודלמן‬
July 24, 2007– ‫ט' באב התשס"ז‬
12/10/2005
182330
IMPROVED ADENOVIRAL VECTORS
AND USES THEREOF
CRUCELL HOLLAND B.V.
EP
04105005.5 13/10/2004
60/618469
13/10/2004
US
60/697724
08/07/2005
US
PCT/EP/2005/055183
WO/2006/040330
30/09/2005
29/03/2007
‫וקטורי אדנווירוס משופרים ושימושים בהם‬
182331
PMMOV RESISTANT CAPSICUM
PLANTS
DE RUITER SEEDS R & D B.V.
EP
04077744.3 01/10/2004
04077768.2
06/10/2004
EP
PCT/NL/2005/000707
WO/2006/038794
182332
July 24, 2007– ‫ט' באב התשס"ז‬
A61B
‫מערכת ושיטה להערכת מצבו של חולה‬
‫גיוון אימג'ינג בע"מ‬
182333
RELIABILITY CENTERED
MAINTENANCE SYSTEM AND
METHOD
NANCY REGAN
US
60/615058
01/10/2004
PCT/US/2005/035393
WO/2006/039609
A01H
‫עמידות צמחי פלפל לווירוס כתמי הפלפל‬
) PMMoV(
SYSTEM AND METHOD FOR
ASSESSING A PATIENT CONDITION
GIVEN IMAGING LTD.
US
60/787696
31/03/2006
03/10/2005
C12N
G06F
‫מערכת ושיטה לתחזוקה מרוכזת מהימנות‬
1826
22/09/2005
182334
C25B
SYNTHESIS OF HYDROGEN
PEROXIDE
UOP LLC
US
10/955442
30/09/2004
PCT/US/2005/034354
WO/2006/039228
28/10/2005
‫סינטזה של מי חמצן‬
182335
C07D
NICOTINAMIIDE PYRIDINUREAS AS
VASCULAR ENDOTHELIAL GROWTH
FACTOR (VEGF) RECEPTOR KINASE
INHIBITORS
SCHERING AKTIENGESELLSCHAFT
EP
04090420.3 03/11/2004
PCT/EP/2005/011709
WO/2006/048249
‫ניקוטינאמיד פירידינאוריאות כמעכבי‬
‫קולטן קינאז של גורם גדילה אנדותלי בכלי‬
‫דם‬
07/10/2005
182336
SINGLE DOMAIN ANTIBODIES AGAINST
TNFR1 AND METHODS OF USE THEREFOR
DOMANTIS LIMITED
GB
PCT/GB2004/04253 08/10/2004
10/985847
10/11/2004
US
PCT/GB/2005/003873
WO/2006/038027
05/10/2005
182337
METHOD AND COMPOSITION FOR
ENHANCING ANTI-ANGIOGENIC
THERAPY
TILTAN PHARMA LTD.
US
60/616348
06/10/2004
PCT/IB/2005/004069
WO/2006/056889
1827
A61K
TNFR1 ‫נוגדנים חד–תחומיים כנגד‬
‫ושיטות לשימוש בהם‬
A61K
‫שיטה ותכשיר להגבת טפול רפואי נוגד‬
‫היווצרות כלי דם‬
‫תילתן פרמה בע"מ‬
July 24, 2007– ‫ט' באב התשס"ז‬
30/09/2005
182339
HCV NS3-NS4A PROTEASE
INHIBITION
VERTEX PHARMACEUTICALS
INCORPORATED
US
60/615412
01/10/2004
PCT/US/2005/035191
WO/2006/039488
19/10/2005
182340
METHOD FOR THE ISOLATION OF
HAPTOGLOBIN
NHS BLOOD AND TRANSPLANT
GB
0423196.5
19/10/2004
PCT/GB/2005/004037
WO/2006/043062
03/08/2000
182341
METHOD FOR MODIFYING ROOT
GROWTH
E.I. DUPONT DE NEMOURS AND
COMPANY
US
09/369798
06/08/1999
PCT/US/2000/021145
WO/2001/010193
07/10/2005
182342
VASOACTIVE INTESTINAL
POLYPEPTIDE PHARMACEUTICALS
FORBES MEDI-TECH (RESEARCH)
INC.
US
60/617500
08/10/2004
PCT/US/2005/036235
WO/2006/042152
July 24, 2007– ‫ט' באב התשס"ז‬
A61K
HCV ‫ מ‬NS4A–NS3 ‫עיכוב של פרוטאז‬
C07K
‫שיטה לבודד הפטוגלובין‬
A01G
‫שיטה להסגלת גידול שורש‬
A61K
‫תכשירים פרמצבטיים של פוליפפטידיים‬
‫מעיים בעלי פעילות ואזואקטיבית‬
1828
01/04/2007
182343
CUTTING INSERT AND TOOL FOR
MILLING AND RAMPING AT HIGH
FEED RATES
ISCAR LTD.
01/04/2007
‫שימה וכלי עבור כרסום בקדמות גבוהות‬
‫ישקר בע"מ‬
182345
182346
MEDICAL TREATMENT SYSTEM
COMPRISING OF MULTIPLE LIGHT
EMITTING LAMPS PACKED
TOGETHER
OREN AHARON
01/04/2007
A61N
‫מכשיר רפואי המבוסס על מספר מקורות‬
‫אור ארוזים ופועמים יחדיו‬
‫אורן אהרון‬
182347
METHOD AND SYSTEM FOR
PREVENTING UNDESIRED GROWTH
OF PLANT ROOTS
HAIM LERNER
1829
G09F
‫שיטה ומערכת להנפקת פרסומות שאינן‬
‫היצף‬
‫שראל מוקה‬
A METHOD AND SYSTEM FOR
ISSUING NON-SPAM ADS
SHAHAR RUBIN
01/04/2007
B23C
A01G
‫שיטה ומערכת למניעת גידול בלתי רצוי‬
‫של שורשי צמח‬
‫חיים לרנר‬
July 24, 2007– ‫ט' באב התשס"ז‬
01/04/2007
182348
B65B
‫מחזיק מיכלים‬
‫רוני ארז לוי‬
CONTAINER HOLDERS
RONNY EREZ LEVY
07/10/2005
182349
DRILLING DEVICE FOR DRILLING
CONTACT HOLES FOR ASSEMBLING
CONTACT SURFACES OF MULTILAYER
CIRCUIT BOARDS
COMET GMBH
DE
102004049439.8 08/10/2004
PCT/EP/2005/010823
WO/2006/040088
04/10/2005
182350
MESSAGE TRANSMISSION IN
WIRELESS ACCESS SYSTEM
LG ELECTRONICS INC.
10-2004KR
04/10/2004
0078858
10-200517/01/2005
KR
0004248
H05K
‫מקדחה לקידוח חור מגע להרכבת‬
‫משטחי מגע של לוחות מעגל מודפסים‬
‫רב–שכבתיים‬
H04L
‫שידור מסר במערכת גישה אלחוטית‬
PCT/KR/2005/003268
WO/2006/038781
July 24, 2007– ‫ט' באב התשס"ז‬
1830
05/10/2005
182351
STEPPED CANNULA
THE REGENTS OF THE UNIVERSITY
OF CALIFORNIA
US
60/616238
05/10/2004
60/641551
04/01/2005
US
PCT/US/2005/036110
WO/2006/042090
26/10/2005
182352
THE USE OF ET-743 IN THE
PREPARATION OF A MEDICAMENT
FOR TREATING CANCER AND
MEDICAL KITS CONTAINING ET-743
PHARMA MAR, S.A.U.
US
60/622163
26/10/2004
PCT/GB/2005/050189
WO/2006/046080
05/10/2005
182355
THROMBIN RECEPTOR
ANTAGONISTS
SCHERING CORPORATION
US
60/617514
08/10/2004
PCT/US/2005/035745
WO/2006/041872
1831
A61B
‫אבוב מדורג‬
A61K
‫ להכנת תורפה‬ET– 743 ‫השימוש ב‬
‫לטיפול בסרטן וערכות רפואית המכילות‬
ET – 743
C07D
‫אנטגוניסטים לרצפטור של תרומבין‬
July 24, 2007– ‫ט' באב התשס"ז‬
05/10/2005
182356
NOVEL CYCLIC AND ACYCLIC
PROPENONES AND THEIR USE IN
THE PREPARATION OF
MEDICAMENTS FOR TREATING CNS
DISORDERS
MERZ PHARMA GMBH & CO. KGAA
US
60/616193
05/10/2004
60/656426
24/02/2005
US
60/707239
11/08/2005
US
PCT/GB/2005/003817
WO/2006/037996
13/10/2005
‫פרופנונים ציקלים ולא ציקלים ושימושם‬
CNS ‫בהכנת תרופות לטיפול בהפרעות‬
182357
182358
SYNTHETIC PEPTIDES WHICH
REDUCE OR ELIMINATE BAGS
FORMED UNDER THE LOWER RIM
OF THE EYES AND USE THEREOF IN
COSMETIC OR
DERMOPHARMACEUTICAL
COMPOSITIONS
LIPOTEC S.A.
ES
P200402364 05/10/2004
PCT/ES/2005/000514
WO/2006/040374
July 24, 2007– ‫ט' באב התשס"ז‬
A61K
‫דחף נגד מלריה‬/‫תכשירי חיסון ראשוני‬
MALARIA PRIME/BOOST VACCINES
THE GOVERNMENT OF THE UNITED
STATES, AS REPRESENTED BY THE
SECRETARY OF THE ARMY, ON
BEHALF OF THE WALTER REED
ARMY INSTITUTE OF RESEARCH
US
60/619056
14/10/2004
04105035.2
14/10/2004
EP
PCT/EP/2005/055209
WO/2006/040334
22/09/2005
C07C
C07K
‫פפטידים סינטטים המפחיתים או מסלקים‬
‫שקיות הנוצרות מתחת לעיניים והשימוש‬
‫שלהם בתרכובות קוסמטיות או תרכובות‬
‫רוקחות לטיפול בעור‬
1832
13/10/2005
182359
C07D
QUINOXALINES AS B RaF
INHIBITORS
ASTRAZENECA AB
US
60/619373
15/10/2004
PCT/GB/2005/003953
WO/2006/040568
01/04/2007
RaF B ‫קווינוקסאלינים כמעכבי‬
182361
PLAY SYSTEM FOR CHILDREN,
INCLUDING PLAYMAT AND
PLAYPIECES
GILI LITMAN
‫ערכת משחק לילדים הכוללת שטיח‬
‫פעילות וחלקי משחק‬
‫גילי ליטמן‬
03/10/2005
182362
USE OF [D-MEALA]3-[ETVAL]4CYCLOSPORIN FOR THE TREATMENT OF
HEPATITIS C INFECTION AND
PHARMACEUTICAL COMPOSITION
COMPRISING SAID [D-MEALA]3[ETVAL]4-CYCLOSPORIN
DEBIOPHARM S.A.
IB
PCT/IB2004/003205 01/10/2004
PCT/IB/2005/002940
WO/2006/038088
02/10/2005
182363
USE OF A DEVELOPING NONSYNGENEIC GRAFT
YEDA RESEARCH AND
DEVELOPMENT CO. LTD
US
60/614968
04/10/2004
165425
28/11/2004
IL
PCT/IL/2005/001059
WO/2006/038211
1833
A63B
A61K
D–[MEALA]3– ‫תכשירים המכילים‬
[ETVAL]–4–CYCLOSPORIN
‫ושימוש בהם לטיפול בצהבת נגיפית‬
C ‫מסוג הפטיטיס‬
A61K
‫שימוש בשתל לא סינגנאי מאיבר מתפתח‬
‫ידע חברה למחקר ופיתוח בע"מ‬
July 24, 2007– ‫ט' באב התשס"ז‬
06/10/2005
182364
‫תכשירים קוטלי פטריות‬
FUNGICIDAL COMPOSITIONS
SYNGENTA PARTICIPATIONS AG
GB
0422400.2
08/10/2004
PCT/EP/2005/010757
WO/2006/037634
05/10/2005
182365
5-SULFONYL-1-PIPERIDINYL
SUBSTITUTED INDOLE
DERIVATIVES AS 5-HT6 RECEPTOR
ANTAGONISTS FOR THE
TREATMENT OF CNS DISORDERS
GLAXO GROUP LIMITED
GB
0422263.4
07/10/2004
PCT/GB/2005/003835
WO/2006/038006
06/10/2004
A01N
C07D
–5 –‫נגזרות של אינדול המותמרות ב‬
‫–פיפרידיניל כאנטגוניסטים של‬1–‫סולפוניל‬
‫ לטיפול בבעיות במערכת‬HT6–5 ‫רצפטורי‬
‫העצבים המרכזית‬
182366
A61L
‫מכשיר להשתלת עצם‬
BONE IMPLANT DEVICE
BAYCO TECH LIMITED
PCT/IB/2004/003260
WO/2006/038056
01/04/2007
METHOD FOR COMPRESSING
ELEVATION MAPS
ARIEL-UNIVERSITY RESEARCH
July 24, 2007– ‫ט' באב התשס"ז‬
182367
G06T
‫שיטה לדחיסת מפות גבהים‬
‫חברה אוניברסיטאית למחקר‬-‫אריאל‬
‫ופיתוח בע"מ‬
1834
01/04/2007
182369
CAR PASSENGERS' SEAT WHICH IS
CONVERTIBLE TO OPERATE WITH A
TRANSVERSALLY SLIDABLE BABY
SEAT SYSTEM
PESACH GIDON
21/09/2005
‫כיסא לנוסעים במכונית הניתן להמרה‬
‫לצורך פעולה עם מערכת כיסא לתינוק‬
‫המאפשרת הזזה רוחבית‬
‫פסח גדעון‬
182370
DISTRIBUTION UNIT OF A
TELECOMMUNICATIONS SYSTEM AND
WIRE GUIDE ELEMENT FOR A
DISTRIBUTION UNIT
CCS TECHNOLOGY, INC.
DE
202004015829.9 12/10/2004
202005000133.3
05/01/2005
DE
PCT/EP/2005/010170
WO/2006/039984
01/04/2007
182371
1835
G02B
‫דוגמאות של עצמים מוליכים על מצע‬
‫ושיטות להכנתן‬
182373
NO CARB TABLETOP SWEETENERS
SUBSTITUTE
MCNEIL NUTRITIONALS, LLC
US
10/957940
04/10/2004
PCT/US/2005/034454
WO/2006/041668
H04Q
‫יחידת חלוקה של מערכת תקשורת‬
‫ומוליך עבור יחידת חלוקה‬
PATTERNS OF CONDUCTIVE
OBJECTS ON A SUBSTRATE AND
METHOD OF PRODUCING THEREOF
HANITA COATINGS R.C.A. LTD
US
60/788728
04/04/2006
23/09/2005
B60N
A23L
‫תחליפי המתקה שולחניים ללא פחמימות‬
July 24, 2007– ‫ט' באב התשס"ז‬
24/07/2006
182375
PHARMACEUTICAL COMPOSITIONS
COMPRISING LEVETIRACETAM AND
PROCESS FOR THEIR PREPARATION
UCB PHARMA S.A.
EP
05016189.2 26/07/2005
05016945.7
04/08/2005
EP
PCT/EP/2006/007260
WO/2007/012439
31/01/2005
182376
CONTINUOUS EXTRUSION PROCESS
FOR PRODUCING GRAFTED
POLYMERS
ORREX PLASTICS COMPANY, LLC.
OF
US
60/617548
11/10/2004
PCT/CA/2005/000119
WO/2006/039774
17/10/2005
182377
PARTS MARKING SYSTEM AND
METHOD
THE FORCE, INC.
US
60/619489
15/10/2004
60/727003
15/10/2005
US
PCT/US/2005/037666
WO/2007/046801
10/03/2005
182378
HOUSE, MORE PARTICULARLY AN
EMERGENCY HOUSE
RUDI OMER COOPMAN
BE
2004/0491
06/10/2004
PCT/BE/2005/000034
WO/2006/037192
July 24, 2007– ‫ט' באב התשס"ז‬
A61K
‫תכשירי רוקחות המכילים לוויטיראצטם‬
‫ותהליך להכנתם‬
B29C
‫תהליך שיחול רציף ליצירת פולימרים‬
‫מותכים‬
G06F
‫מערכת ושיטה לסימון חלקים‬
E04H
‫ במיוחד בית למקרי חירום‬,‫בית‬
1836
09/11/2005
182379
NEAR LIQUIDUS INJECTION
MOLDING PROCESS
HUSKY INJECTION MOLDING
SYSTEMS LTD.
US
10/985879
10/11/2004
PCT/CA/2005/001707
WO/2006/050599
30/09/2005
06/10/2005
‫תהליך עיצוב בהזרקה של דמוי נוזלים‬
182380
UNIFIED ANALOG INPUT FRONT
END APPARATUS AND METHOD
SMITHS AEROSPACE LLC
US
10/954485
01/10/2004
PCT/US/2005/035483
WO/2006/039649
182381
1837
F41G
‫מטען הרג לכלי נשק‬
‫התעשייה האוירית לישראל בע"מ‬
182383
DOUBLE HYBRID SYSTEM BASED
ON GENE SILENCING BY
TRANSCRIPTIONAL INTERFERENCE
Aventis Pharma S.A
FR
0411372
25/10/2004
PCT/FR/2005/002646
WO/2006/045941
H03G
‫התקן ושיטה לקלט אנלוגי עבור משתמש‬
‫קצה‬
KILL PAYLOAD OF A WEAPON
ISRAEL AEROSPACE INDUSTRIES
LTD.
IL
164414
05/10/2004
PCT/IL/2005/001065
WO/2006/038215
24/10/2005
B22D
G01N
‫ המבוססת על‬,‫מערכת כפולת היבריד‬
‫השתקה גנית באמצעות הפרעת תיעתוק‬
July 24, 2007– ‫ט' באב התשס"ז‬
31/10/2005
182384
‫ עם‬FCC ‫ בתהליכי‬NOX ‫חיזור פליטות‬
‫שריפה מלאה‬
REDUCTION OF NOX EMISSIONS IN
FULL BURN FCC PROCESSES
W.R. GRACE & CO. CONN
US
60/624492
02/11/2004
PCT/US/2005/039093
WO/2006/050168
17/10/2005
182385
PYRIDINE DERIVATIVES AND THE
PREPARATION AND THE
THERAPEUTIC USE THEREOF
SANOFI-AVENTIS
FR
0411030
18/10/2004
PCT/FR/2005/002566
WO/2006/042955
11/10/2005
29/09/2005
July 24, 2007– ‫ט' באב התשס"ז‬
C12P
H ‫ייצור מימן באמצעות ביטוי הטרולוגי של‬
‫ בכלמידומונאס‬II ‫( דהידרוגנאז סוג‬P) NAD
182387
VEHICLES AND CONTROL SYSTEMS
THEREOF WITH ADJUSTABLE
STEERING AXES
AIRTRAX, INC.
US
10/953072
30/09/2004
PCT/US/2005/035032
WO/2006/037104
C07D
‫תולדות פירידין הכנתן ושימושן הרפואי‬
182386
PRODUCING HYDROGEN BY
HETEROLOGOUS EXPRESSION OF A
TYPE II NAD (P) H DEHYDROGENASE
IN CHLAMYDOMONAS
COMMISSARIAT A L'ENERGIE
ATOMIQUE
FR
0410715
11/10/2004
PCT/FR/2005/002511
WO/2006/040471
C10G
B62D
‫כלי רכב ומערכות בקרה בשל כך בעלי‬
‫צירי היגוי מתכווננים‬
1838
10/04/2007
182388
ALARM SYSTEM FOR MAINTAINING
SAFE DISTANCE BETWEEN MOTOR
VEHCLES
YEHOSHUA RAHAMIM LEVI
10/04/2007
‫מערכת התראה על אי שמירת מרחק‬
‫בטיחותי בין כלי רכב‬
‫ישועה רחמים לוי‬
182389
METHOD OF AIR PURIFICATION
FROM DUST AND ELECTROSTATIC
FILTER
YEFIM RISKIN
10/04/2007
07/10/2005
1839
‫יפים ריסקין‬
H04N
‫ שיטה והתקן להצגת אותות וידאו‬,‫מערכת‬
182393
AN APPARATUS FOR AND METHOD
OF SAMPLING AND COLLECTING
POWDERS FLOWING IN A GAS
STREAM
SDC MATERIALS, LLC
US
60/617586
08/10/2004
PCT/US/2005/036147
WO/2006/042109
B03C
‫שיטה לטיגור אוויר מאבק ופילטר‬
‫אלקטרומטטי‬
182391
SYSTEM, METHOD AND DEVICE FOR
PRESENTING VIDEO SIGNALS
C-NARIO
B60Q
‫נאריו‬-‫סי‬
G01N
‫התקן ושיטה לדגימה ואיסוף אבקות‬
‫הזורמות בזרם גז‬
July 24, 2007– ‫ט' באב התשס"ז‬
29/09/2005
TRACK ASSEMBLY FOR
SUPPORTING FABRICS
MILTON A. MORRIS
US
60/617977
11/096560
US
PCT/US/2005/035178
WO/2006/041722
182394
E06B
‫מיכלל נתיב לתמיכת אריגים‬
11/10/2004
01/04/2005
26/08/2005
182395
A METHOD OF FORMING A
DESICCATING PART
MULTISORB TECHNOLOGIES, INC.
US
10/963350
12/10/2004
PCT/US/2005/030470
WO/2006/044034
07/10/2005
‫שיטה ליצור חלק מייבש‬
182396
SEMISYNTHESIS PROCESS FOR THE
PREPARATION OF 10-DEACETYL-NDEBENZOYL-PACLITAXEL
INDENA S.P.A.
US
60/616840
08/10/2004
04425752.5
08/10/2004
EP
05007888.0
11/04/2005
EP
PCT/EP/2005/010822
WO/2006/037653
05/10/2005
C07D
–‫– דיאצטיל‬10 ‫תהליך חצי–סינטטי להכנת‬
‫–דיבנזואיל–פקליטקסל‬N
182397
THIAZOLYL-DIHYDRO INDAZOLES
BOEHRINGER INGELHEIM
INTERNATIONAL GMBH
DE
102004048877.0 07/10/2004
102005005813.2
09/02/2005
DE
05107230.4
05/08/2005
EP
PCT/EP/2005/055021
WO/2006/040281
July 24, 2007– ‫ט' באב התשס"ז‬
C08K
C07D
‫אינדאזולים דיהידרו–תיאזוליל‬
1840
05/10/2005
PI3 KINASES
BOEHRINGER INGELHEIM
INTERNATIONAL GMBH
DE
102004048877.0
102005005813.2
DE
PCT/EP/2005/055015
WO/2006/040279
31/10/2005
182398
PI3 ‫קינאזות‬
07/10/2004
09/02/2005
182399
ANTHRANILAMIDE PYRIDINUREAS
AS VEGF RECEPTOR KINASE
INHIBITORS
SCHERING AKTIENGESELLSCHAFT
EP
04090419.5 03/11/2004
PCT/EP/2005/011712
WO/2006/048251
04/10/2005
182401
SURFACE POLYMERISATION
PROCESS AND POLYMER PRODUCT
USING RAFT AGENT
THE UNIVERSITY OF SYDNEY
AU
2004905729 04/10/2004
2005903366
24/06/2005
AU
PCT/AU/2005/001512
WO/2006/037161
1841
C07D
C07D
‫אתרנילאמיד פירידינואוריאה כמעכבי‬
VEGF ‫קולטן קינאז‬
C08F
‫תהליך לפולימריזציית פני שטח ותוצר‬
RAFT ‫פולימרי המשתמש בגורם‬
July 24, 2007– ‫ט' באב התשס"ז‬
06/10/2005
182402
DISPENSING DEVICE, STORAGE
DEVICE AND METHOD FOR
DISPENSING POWDER
BOEHRINGER INGELHEIM
INTERNATIONAL GMBH
GB
0422106.5
06/10/2004
0425289.6
17/11/2004
GB
0427552.5
15/12/2004
GB
0509108.7
04/05/2005
GB
PCT/EP/2005/010768
WO/2006/037636
06/10/2005
182404
MUTATED AMYLOID PROTEIN
HIROSHI MORI
2004JP
06/10/2004
294292
PCT/JP/2005/018896
WO/2006/038729
05/10/2005
182405
MOULDABLE BIODEGRADABLE
POLYMER
PLANTIC TECHNOLOGIES LIMITED
AU
2004905695 05/10/2004
PCT/AU/2005/001507
WO/2006/037157
July 24, 2007– ‫ט' באב התשס"ז‬
A61M
‫ מכשיר לאיחסון ושיטה‬,‫מכשיר לניפוק‬
‫לניפוק אבקה‬
C12N
‫חלבון אמילואידי שעבר מוטציה‬
C08L
‫פולימר הניתן לעיצוב ולפירוק ביולוגי‬
1842
07/10/2005
182408
STIMULATION OF PROLIFERATION
OF PLURIPOTENTIAL STEM CELLS
THROUGH ADMINISTRATION OF
PREGNANCY ASSOCIATED
COMPOUNDS
STEM CELL THERAPEUTICS CORP
US
60/616204
07/10/2004
60/661255
10/03/2005
US
PCT/CA/2005/001540
WO/2006/037233
15/12/2005
‫המרצת שגשוג של תאי גזע בעלי‬
‫פוטנציאל שגשוג באמצעות מתן תרכובות‬
‫הקשורות להריון‬
182409
METHOD FOR THE PRODUCTION OF
CONCRETE BLOCKS OR CONCRETE
SLABS
METTEN, STEIN+DESIGN GMBH & CO.
KG
EP
102004062656.1 24/12/2004
PCT/EP/2005/013492
WO/2006/069636
06/10/2005
182410
METHOD OF FORMATION OF THE
SHAPE-RETENTIVE AGGREGATES
OF GEL PARTICLES AND THEIR USES
ULURU INC.
US
10/960461
06/10/2004
PCT/US/2005/035905
WO/2006/041967
10/04/2007
182411
METHODS FOR MAKING IMPROVED
TEXTURE CEREAL BARS
KRAFT FOODS HOLDINGS, INC.
US
11/279165
10/04/2006
1843
A61K
B28B
‫שיטה לייצור לבני בטון או פרוסות בטון‬
A61K
‫שיטה להכנה של אגרגטים שומרי–צורה‬
‫של חלקיקי ג'ל והשימוש בה‬
A23L
‫שיטות להכנת חטיפי דגן בעלי מרקם‬
‫משופר‬
July 24, 2007– ‫ט' באב התשס"ז‬
19/10/2005
182412
COMPLEX CONTAINING
MEQUITAZINE, A CYCLODEXTRIN
AND AN INTERACTION AGENT
PIERRE FABRE MEDICAMENT
FR
0411202
21/10/2004
PCT/EP/2005/055388
WO/2006/042857
28/10/2005
10/04/2007
‫ ציקלודקסטרין‬,‫תצמיד המכיל מקוויטאזין‬
‫וגורם תגובה‬
182413
CONTAINMENT PENS FOR FINFISH
AQUACULTURE
OCEAN FARM TECHNOLOGIES, INC.
US
10/976641
29/10/2004
60/671861
14/04/2005
US
PCT/US/2005/039536
WO/2006/050386
182414
182415
PHARMACEUTICAL COMPOSITIONS
COMPRISING CB1 CANNABINOID
RECEPTOR ANTAGONISTS AND
POTASSIUM CHANNEL OPENERS
FOR THE TREATMENT OF DIABETES
MELLITUS TYPE I, OBESITY AND
RELATED CONDITIONS
SOLVAY PHARMACEUTICALS GMBH
US
60/621077
25/10/2004
04105265.5
25/10/2004
EP
60/651625
11/02/2005
US
PCT/EP/2005/055534
WO/2006/045799
July 24, 2007– ‫ט' באב התשס"ז‬
A01K
‫מכלאות המכילות תנאי גידול לדגי סנפיר‬
EXPANDABLE MODULAR RACK
DESIGN
NORTHROP GRUMMAN
CORPORATION
US
11/429892
08/05/2006
25/10/2005
A61K
B25B
‫עיצוב מתלה מודולרי הניתן להרחבה‬
C12Q
‫תכשירי רוקחות המכילים אנטגוניסטים‬
‫ קאנאבינואיד ופותחי‬CB1 ‫של קולטן‬
‫תעלות אשלגן לטיפול בסכרת‬
‫ השמנת יתר ומצבים דומים‬,1 ‫מטיפוס‬
1844
18/10/2005
182416
‫קרום חוסם‬
BARRIER FILM
PLANTIC TECHNOLOGIES LIMITED
AU
2004905987 18/10/2004
PCT/AU/2005/001605
WO/2006/042364
18/10/2005
182417
MITOTIC KINESIN INHIBITORS AND
METHODS OF USE THEREOF
ARRAY BIOPHARMA INC.
US
60/620048
19/10/2004
11/252232
17/10/2005
US
PCT/US/2005/037305
WO/2006/044825
19/10/2005
19/10/2005
1845
C07D
‫ ושיטות‬CRF ‫אנטגוניסטים של הרצפטור‬
‫הקשורות אליהם‬
182421
PROCESS FOR THE PREPARATION
OF PYRAZOLES
SYNGENTA PARTICIPATIONS AG
CH
1750/04
21/10/2004
PCT/EP/2005/011232
WO/2006/045504
C07D
‫מעכבי מיטוטיק קינאסין ושיטות לשימוש‬
‫בהם‬
182420
CRF RECEPTOR ANTAGONISTS AND
METHODS RELATING THERETO
SB PHARMCO PUERTO RICO INC.
US
60/620060
19/10/2004
0519957.5
30/09/2005
GB
PCT/US/2005/037576
WO/2006/044958
C08L
C07D
‫תהליך להכנת פיראזולים‬
July 24, 2007– ‫ט' באב התשס"ז‬
13/10/2005
182422
‫חומרים הנקשרים לחלבוני פריון ושיטות‬
‫לשימוש‬
PRION PROTEIN BINDING
MATERIALS AND METHODS OF USE
PATHOGEN REMOVAL AND
DIAGNOSTIC TECHNOLOGIES INC.
US
10/962670
13/10/2004
PCT/US/2005/036676
WO/2006/044459
04/10/2005
182423
DISUBSTITUTED
PYRAZOLOBENZODIAZEPINES
USEFUL AS INHIBITORS FOR CDK2
AND ANGIOGESIS, AND FOR THE
TREATMENT OF BREAST, COLON,
LUNG AND PROSTATE CANCER
F. HOFFMANN-LA ROCHE AG
US
60/618174
13/10/2004
PCT/EP/2005/010653
WO/2006/040036
26/10/2005
July 24, 2007– ‫ט' באב התשס"ז‬
C07D
‫פירזולובנזודיאזפינים די–מותמרים‬
‫ וליצירת‬CDK2–‫המשמשים כמעכבים ל‬
,‫ המעי הגס‬,‫ ולטיפול בסרטן השד‬,‫כלי דם‬
‫הריאות וסרטן הערמונית‬
182424
NOVEL SULPHONAMIDE
DERIVATIVES AS GLUCOCORTICOID
RECEPTOR MODULATORS FOR THE
TREATMENT OF INFLAMMATORY
DISEASES
ASTRAZENECA AB
SE
0402635-7
29/10/2004
PCT/SE/2005/001608
WO/2006/046914
A61K
C07D
‫נגזרות חדשות של סולפונמיד כמאפנני‬
‫קולטן גלוקורטיקואידי לטיפול במחלות‬
‫דלקתיות‬
1846
19/10/2005
182425
APPARATUS FOR DISTRIBUTING IN A
THIN LAYER A MIX BASED ON
AGGLOMERATE STONE OR CERAMIC
MATERIAL
TONCELLI, LUCA
IT
TV2004A000118 20/10/2004
PCT/EP/2005/055376
WO/2006/045728
25/10/2005
05/11/2001
1847
C07D
‫תרכובות ביציקליות מותמרות בסולפוניל‬
PPAR ‫כמאפננים של‬
182428
INDOLYLMALEIMIDE DERIVATIVES
AS PROTEIN KINASE C INHIBITORS
NOVARTIS AG
US
60/246400
60/283705
US
PCT/EP/2001/012785
WO/2002/038561
‫מכשיר לפיזור שכבה דקה של תערובת‬
‫המבוססת על גושי אבן או קרמיקה‬
182427
SULFONYL-SUBSTITUTED BICYCLIC
COMPOUNDS AS MODULATORS OF
PPAR
KALYPSYS, INC.
US
60/623252
29/10/2004
60/679813
11/05/2005
US
PCT/US/2005/038418
WO/2006/055187
B28B
C07D
‫נגזרות של אינדוליל מלאיאימיד כמעכבים‬
‫של‬
C ‫פרוטאין–קינאז‬
07/11/2000
13/04/2001
July 24, 2007– ‫ט' באב התשס"ז‬
14/10/2005
182429
ARYLSULFONYLMETHYL OR
ARYLSULFONAMIDE SUBSTITUTED
AROMATIC COMPOUNDS SUITABLE
FOR TREATING DISORDERS THAT
RESPOND TO MODULATION OF THE
DOPAMINE D3 RECEPTOR
ABBOTT GMBH & CO. KG
US
60/618776
14/10/2004
60/711942
26/08/2005
US
PCT/EP/2005/011091
WO/2006/040178
14/10/2005
‫תרכובות ארומטיות מותמרות‬
‫ארילסולפונילמתיל או ארילסולפונאמיד‬
‫המתאימות לטיפול בהפרעות שמגיבות‬
D3 ‫לויסות רצפטור דופאמין‬
182430
6-AMINO(AZA)INDANE COMPOUNDS
SUITABLE FOR TREATING
DISORDERS THAT RESPOND TO
MODULATION OF THE DOPAMINE
D3 RECEPTOR
ABBOTT GMBH & CO. KG
US
60/618743
14/10/2004
PCT/EP/2005/011090
WO/2006/040177
14/10/2005
July 24, 2007– ‫ט' באב התשס"ז‬
C07C
‫–אמינו(אזא)אינדן המתאימות‬6 ‫תרכובות‬
‫לטיפול בהפרעות שמגיבות לוויסות‬
D3 ‫רצפטור הדופאמין‬
182431
HETEROCYCLIC COMPOUNDS
SUITABLE FOR TREATING
DISORDERS THAT RESPOND TO
MODULATION OF THE DOPAMINE
D3 RECEPTOR
ABBOTT GMBH & CO. KG
US
60/618878
14/10/2004
PCT/EP/2005/011106
WO/2006/040182
C07D
C07D
‫תרכובות הטרוציקליות המתאימות לטיפול‬
‫בהפרעות המגיבות למודולציה של‬
D3 ‫רצפטור הדופאמין‬
1848
10/04/2007
182433
AN IMPROVED UNDERDRAIN
SYSTEM
RG DELAWARE, INC.
US
11/400330
10/04/2006
14/10/2005
182434
4PHENYLSULFONAMIDOPIPERIDINES
AS CALCIUM CHANNEL BLOCKERS
EURO-CELTIQUE S.A.
US
60/618419
14/10/2004
60/694972
30/06/2005
US
PCT/EP/2005/011105
WO/2006/040181
06/10/2005
182435
METHOD AND APPARATUS FOR
COUPLING COMPONENTS
KAMATICS CORPORATION
US
10/963209
11/10/2004
PCT/US/2005/036397
WO/2006/042216
06/10/2005
182436
THIENOPYRIDINONE COMPOUNDS
AND METHODS OF TREATMENT
EPIX DELAWARE, INC.
US
10/960769
07/10/2004
PCT/US/2005/035935
WO/2006/041985
1849
E02B
‫מערכת ניקוז תחתי משופרת‬
C07D
‫–פנילסולפונאמידופיפרידינים כחוסמי‬4
‫תעלת סידן‬
F16D
‫שיטה ומערכת לחיבור רכיבים‬
C07D
‫תרכובות תינופירידינון ושיטות טיפול‬
July 24, 2007– ‫ט' באב התשס"ז‬
20/09/2005
182437
METHOD AND APPARATUS FOR
ASSIGNING USERS TO USE ARQINTERLACES IN A WIRELESS
CELLULAR COMMUNICATION
SYSTEM
QUALCOMM INCORPORATED
US
10/960312
06/10/2004
PCT/US/2005/033742
WO/2006/041628
04/10/2005
‫שיטה והתקן להקצאת משתמשים‬
‫ במערכת‬ARQ–INTERLACES ‫לשימוש‬
‫תקשורית סלולרית אלחוטית‬
182438
ENHANCED BLOCK
ACKNOWLEDGEMENT
QUALCOMM INCORPORATED
US
60/616335
05/10/2004
PCT/US/2005/035771
WO/2006/041891
08/10/2004
H04L
‫אישור חסימה מוגבר‬
182439
NOVEL INTERMEDIATES USEFUL
FOR THE PREPARATION OF
ARIPIPRAZOLE AND METHODS FOR
THE PREPARATION OF THE NOVEL
INTERMEDIATES AND
ARIPIPRAZOLE
SUVEN LIFE SCIENCES LIMITED
H04L
C07D
‫תוצרי ביניים השימושיים בהכנת‬
‫אריפיפרזול ושיטות להכנת תוצרי הביניים‬
‫החדשים ואריפיפרזול‬
PCT/IN/2004/000316
WO/2006/038220
July 24, 2007– ‫ט' באב התשס"ז‬
1850
04/10/2005
182440
SUBTYPE-MATCHED INACTIVATED
WHOLE VIRUS VACCINES FOR
TREATING PATIENTS WITH HIV
INFECTION
BIOVAXIM LIMITED
US
60/615729
04/10/2004
11/243094
04/04/2005
US
PCT/IB/2005/003384
WO/2006/038124
04/10/2005
03/10/2005
C12N
‫זיהוי ובידוד תאים מולטיפוטנטיים מרקמה‬
‫מזנכימלית בלתי–אוסטיאוכונדאלית‬
182442
METHODS AND COMPOSITIONS FOR
CONCENTRATING SECRETED
RECOMBINANT PROTEIN
NEW ENGLAND BIOLABS, INC.
US
60/616420
06/10/2004
60/692470
14/06/2005
US
PCT/US/2005/035697
WO/2006/041849
1851
–‫תרכיבי חיסון מנגיפים שלמים בלתי‬
‫פעילים מותאמי תת–סוג לטיפול בחולים‬
HIV–‫הנגועים ב‬
182441
IDENTIFICATION AND ISOLATION
OF MULTIPOTENT CELLS FROM
NON-OSTEOCHONDRAL
MESENCHYMAL TISSUE
UNIVERSIDAD AUTONOMA DE
MADRID
ES
200402355
04/10/2004
PCT/EP/2005/010811
WO/2006/037649
C12N
C12N
‫שיטות והרכבים לריכוז חלבון רקומביננטי‬
‫מופרש‬
July 24, 2007– ‫ט' באב התשס"ז‬
26/07/2005
182444
NOVEL DIPEPTIDYL PEPTIDASE IV
INHIBITORS, PHARMACEUTICAL
COMPOSITIONS CONTAINING THEM,
AND PROCESS FOR THEIR
PREPARATION
GLENMARK PHARMACEUTICALS S.A.
US
60/618102
12/10/2004
IN
MUM/2004/1096 14/10/2004
60/635266
10/12/2004
US
IN
MUM/2004/1332 14/12/2004
PCT/IB/2005/002204
WO/2006/040625
12/10/2005
01/02/2005
182446
STACKABLE, FOLDING MULTI-UNIT
WASHSTAND
SERDA, JOAN MIGUEL
ES
P200402634 02/11/2004
PCT/ES/2005/000040
WO/2006/051126
July 24, 2007– ‫ט' באב התשס"ז‬
,‫ חדשים‬IV ‫מעכבי דיפפטידיל פפטידאז‬
,‫הרכבים פרמצבטיים המכילים אותם‬
‫ושיטה להכנתם‬
182445
PROCESS FOR THE PREPARATION OF
N-(3,5-DICHLOROPYRID-4-YL)4DIFLUOROMETHOXY-8METHANESULFONA MIDODIBENZO[B,D]FURAN-1-CABOXAMIDE
GLENMARK PHARMACEUTICALS S.A.
US
60/618474
13/10/2004
IN
MUM/2004/1099 14/10/2004
60/621981
21/10/2004
US
PCT/IB/2005/003035
WO/2006/040652
C07D
C07C
–4–‫–דיכלורופיריד‬N–(5,3 ‫שיטה להכנת‬
8–‫דיפלואורומתיל‬4–)‫איל‬
–‫ פוראן‬D,B[[ ‫מתאנסולפונאמידו–דיבנזו‬
‫–קרבוקסאמיד‬1
A47K
‫כיור רב–יחידתי מתקפל ונערם‬
‫חואן מיגל סרדה‬
1852
10/04/2007
182447
‫התקן להוצאת פלסטרים‬
‫אהוד רטנר‬
ADHESIVE BANDAGE DISPENSER
EHUD RATTNER
10/04/2007
182450
PROTECTIVE DEVICE AND
PROTECTIVE MEASURE FOR A RADAR
SYSTEM
OERLIKON-CONTRAVES AG
DE
102006017107.1 10/04/2006
11/10/2005
FILTER CARTRIDGE
BRITA GMBH
10 2004 049
DE
876.8
PCT/EP/2005/010915
WO/2006/040121
16/10/2005
F41H
‫התקן הגנה וסידורי הגנה למערכת‬
‫ראדאר‬
182451
A47J
‫מחסנית סינון‬
13/10/2004
182452
COMPUTATIONAL SOLUTION OF
AND BUILDING OF THREE
DIMENSIONAL VIRTUAL MODELS
FROM AERIAL PHOTOGRAPHS
OFEK AERIAL PHOTOGRAPHY
INTERNATIONAL LTD
US
60/618578
15/10/2004
60/659084
08/05/2005
US
PCT/IL/2005/001095
WO/2006/040775
1853
A61F
H04N
‫פתרון חישובי ובניה של מודלים וירטואלים‬
‫תלת–מימדיים מתוך תצלומי אויר‬
‫אופק תצלומי אויר אינטרנשיונל בע"מ‬
July 24, 2007– ‫ט' באב התשס"ז‬
19/10/2005
182453
VACCINES AGAINST JAPANESE
ENCEPHALITIS VIRUS AND WEST
NILE VIRUS
ACAMBIS INC.
US
60/620466
20/10/2004
60/620948
21/10/2004
US
60/674415
24/04/2005
US
60/674546
25/04/2005
US
60/718923
19/09/2005
US
PCT/US/2005/037369
WO/2006/044857
11/10/2005
‫תרכיבי חיסון נגד נגיף דלקת המוח היפני‬
‫ונגיף הנילוס המערבי‬
182454
LABELLING AND SEQUENCING OF
NUCLEIC ACIDS
INTERASEQ GENETICS LIMITED
GB
0422551.2
11/10/2004
PCT/GB/2005/003921
WO/2006/040549
07/10/2005
182455
BILAYER TABLET
BOEHRINGER INGELHEIM
INTERNATIONAL GMBH
EP
04024239.8 12/10/2004
PCT/EP/2005/010812
WO/2006/040085
July 24, 2007– ‫ט' באב התשס"ז‬
A61K
C12Q
‫תיוג וריצוף חומצות גרעין‬
H01R
‫טבליה דו שכבתית‬
1854
13/10/2005
182459
COMPOUNDS FOR NONSENSE
SUPPRESSION, AND METHODS FOR
THEIR USE
PTC THERAPEUTICS, INC
US
60/617653
13/10/2004
60/617670
13/10/2004
US
60/617633
13/10/2004
US
60/617634
13/10/2004
US
60/617655
13/10/2004
US
60/624170
03/11/2004
US
PCT/US/2005/036673
WO/2006/044456
18/11/2005
18/10/2005
C07K
BH 3 ‫ של חלבון‬BH 3 ‫חלבון המכיל אתר‬
182463
METHOD AND APPARATUS FOR
SUPPORTING AND CLAMPING A
SUBSTRATE
SPEEDLINE TECHNOLOGIES, INC.
US
10/967450
18/10/2004
PCT/US/2005/037199
WO/2006/044767
1855
‫ ושיטות‬,‫תרכובות לדיכוי רצף פסק‬
‫לשימוש בהן‬
182460
FUSION PROTEIN COMPRISING A
BH3 -DOMAIN OF A BH3-ONLY
PROTEIN
XIGEN S.A.
EP
04028278.2 29/11/2004
PCT/EP/2005/012389
WO/2006/056370
F28G
B41F
‫שיטה והתקן לתמיכה ותפיסה של‬
‫סובסטרט‬
July 24, 2007– ‫ט' באב התשס"ז‬
11/04/2007
182465
‫אתחול משולב וסימולטני של‬
‫פלאטפורמות‬
SIMULTANEOUS DUAL BOOTING OF
PLATFORMS
HARRIS CORPORATION
US
11/408834
20/04/2006
13/10/2005
182466
PHARMACEUTICAL COMPOSITION
COMPRISING MICROCAPSULES OF
STATINS SUSPENDED IN ALKYL
ESTERS OF POLYUNSATURATED
FATTY ACIDS (PUFA)
GP PHARM S.A.
ES
P200402492 19/10/2004
PCT/ES/2005/000542
WO/2006/045865
14/10/2005
182467
182468
A METHOD AND A KIT FOR SHAPING
A PORTION OF A WOODY PLANT
INTO A DESIRED FORM
EZEKIEL GOLAN
US
10/963689
14/10/2004
PCT/IL/2005/001051
WO/2006/040756
July 24, 2007– ‫ט' באב התשס"ז‬
A61K
‫תרכובות פארמצאוטיות המכילות‬
‫מיקרוקפסולות של סטטינים המותלים‬
‫באסתרים אלקיליים של חומצות שומן רב‬
) PUFA( ‫בלתי רוויות‬
REMOTE SENSOR AND IN-SITU
SENSOR SYSTEM FOR IMPROVED
DETECTION OF CHEMICALS IN THE
ATMOSPHERE AND RELATED
METHOD THEREOF
UNIVERSITY OF VIRGINIA PATENT
FOUNDATION
US
60/619259
15/10/2004
PCT/US/2005/037030
WO/2006/137913
29/09/2005
G06F
D21H
‫חיישן רחוק ומערכת חישה מקומית‬
‫לחישה משופרת של כימיקלים‬
‫באטמוספרה ושיטה קשורה‬
A01G
‫שיטה וערכה לעיצוב צמח עצני על פי‬
‫צורה מבוקשת‬
‫חזי גולן‬
1856
01/11/2005
182469
COMBINATION COMPRISING ZD6474
AND AN ANTIANDROGEN
ASTRAZENECA AB
GB
0424339.0
03/11/2004
PCT/GB/2005/004220
WO/2006/048633
12/10/2005
‫ ואנטי–אנדרוגן‬ZD6474‫שילוב הכולל‬
182471
LOG-LIKELIHOOD ESTIMATION
BASED ON CHANNEL ESTIMATION
ERRORS DUE TO GUARD SUBBANDS
A61K
H04L
‫הערכה לוגית קרובה לוודאי המבוססת על‬
‫טעויות הערכת ערוץ הודות לשמירת פס‬
‫המשנה‬
QUALCOMM INCORPORATED
US
60/618345
12/10/2004
11/248975
11/10/2005
US
PCT/US/2005/037077
WO/2006/042326
14/10/2005
182472
FERMENTATIVE PRODUCTION OF
MANNITOL
THE UNITED STATES OF AMERICA,
AS REPRESENTED BY THE
SECRETARY OF AGRICULTURE
US
60/619488
15/10/2004
PCT/US/2005/036947
WO/2006/044608
19/10/2005
182473
CATALYZED DECOMPOSING FOAM
FOR ENCAPSULATING SPACEBASED KINECTIC OBJECTS
RAYTHEON COMPANY
US
10/969724
20/10/2004
PCT/US/2005/037586
WO/2007/001419
1857
C12P
‫ייצור תוסס של מניטול‬
B64G
‫קצף מפריד ומזרז לשם עטיפת חפצים‬
‫המתעופפים בחלל‬
July 24, 2007– ‫ט' באב התשס"ז‬
12/10/2005
182474
PROCESS FOR FORMING
AMORPHOUS ATORVASTATIN
WARNER-LAMBERT COMPANY LLC
US
60/623086
28/10/2004
PCT/IB/2005/003173
WO/2006/046109
20/04/2006
‫תהליך להכנת אטורוסטטין אימורפי‬
182475
A CHARGING NETWORK, CHARGING
AGENT APPARATUS AS WELL AND THE
CHARGING METHOD THEREOF
HUAWEI TECHNOLOGIES CO, LTD.
CN
200510066099.6204 20/04/2005
PCT/CN/2006/000745
WO/2006/111095
20/10/2005
182476
STABLE METAL/CONDUCTIVE
POLYMER COMPOSITE COLLOIDS
AND METHODS FOR MAKING AND
USING THE SAME
ENGLEBIENNE & ASSOCIATES
US
60/621258
21/10/2004
PCT/US/2005/038099
WO/2006/047371
12/10/2005
H04L
‫ התקן לחיוב כמו גם‬,‫רשת חיוב‬
‫שיטה לחיוב‬
C12Q
‫מוליך פולימרי יציב מורכב‬/‫ציפוי מתכתי‬
‫מקולואיד ושיטות לעשייה ושימוש בהם‬
182477
TELEMETRICALLY CONTROLLED
BAND FOR REGULATING
FUNCTIONING OF A BODY ORGAN
OR DUCT, AND METHODS OF
MAKING, IMPLANTATION AND USE
ENDOART SA
US
10/962939
12/10/2004
PCT/IB/2005/003024
WO/2006/040647
July 24, 2007– ‫ט' באב התשס"ז‬
A61K
A61F
‫רצועה נשלטת מרחוק להסדרת הפעילות‬
,‫ ושיטה לייצר‬,‫של איבר גוף או של צינור‬
‫השתלה ושימוש‬
1858
13/10/2005
182478
A61M
‫התקן ושיטה בריאטרי‬
BARIATRIC DEVICE AND METHOD
BFKW, LLC.
US
60/619308
15/10/2004
60/632147
01/12/2004
US
60/636845
15/12/2004
US
60/711310
25/08/2005
US
PCT/US/2005/036991
WO/2006/044640
10/10/2005
182479
REACTOR AND METHOD FOR
SYNTHESISING VINYL ACETATE IN
THE GASEOUS PHASE
UHDE GMBH
DE
102004050585.3 15/10/2004
PCT/EP/2005/010883
WO/2006/042659
12/10/2005
11/10/2005
A61K
‫תכשירי פקטור גדילה הנגזר מטסיות דם‬
‫ושיטות לשימוש בהם‬
182481
FILTER CARTRIDGE AND SEAT
ELEMENT FOR A FILTER CARTRIDGE
BRITA GMBH
DE
102004049877.6 13/10/2004
PCT/EP/2005/010914
WO/2006/040120
1859
‫ריאקטור ושיטה לסינתזה של ויניל‬
‫אצטט בפזה הגזית‬
182480
PLATELET-DERIVED GROWTH
FACTOR COMPOSITIONS AND
METHODS OF USE THEREOF
BIOMIMETIC THERAPEUTICS, INC.
US
10/965319
14/10/2004
11/159533
23/06/2005
US
PCT/US/2005/036447
WO/2006/044334
B01J
A47J
‫מחסנית סינון ותושבת למחסנית סינון‬
July 24, 2007– ‫ט' באב התשס"ז‬
07/10/2005
182482
ELECTRIC MOTOR-DRIVEN WATER
CRAFT, WHICH IS COOLED BY THE
SURROUNDING WATER
ROTINOR GMBH
DE
102004049615.3 12/10/2004
PCT/EP/2005/010798
WO/2006/040078
16/04/2007
182558
DRAINAGE SYSTEM CONVERTIBLE
TO WATER COLUM CONTROL (WET)
OR VACUUM REGULATOR CONTROL
(DRY)
BIOMETRIX LTD
15/09/2005
182559
IMPROVED LIQUIFIER
ZUMEX, MAQUINAS Y ELEMENTOS,
S.A.
ES
200402487
22/10/2004
PCT/ES/2005/000499
WO/2006/045864
July 24, 2007– ‫ט' באב התשס"ז‬
B63H
‫כלי שיט מונע חשמלית המקורר על ידי‬
‫המים הסובבים‬
A61M
‫מערכת ניקוז בית חזה המאפשרת ויסות‬
‫ואקום ע"י עמודת מים או ע"י וסת ואקום‬
‫ללא שימוש במים‬
‫ביומטריקס בע"מ‬
A47J
‫התקן משופר לייצור נוזלים‬
1860
18/10/2005
182560
A METHOD FOR TRANSMITTING
FEEDBACK INFORMATION IN AN
OFDMA MOBILE COMMUNICATION
SYSTEM
LG ELECTRONICS INC.
10-2004KR
18/10/2004
0083048
10-200403/11/2004
KR
0089029
10-200427/12/2004
KR
0112927
10-200505/01/2005
KR
0000930
H04B
‫שיטה לשידור מידע משוב במערכת‬
OFDMA ‫תיקשורת ניידת‬
PCT/KR/2005/003469
WO/2006/043773
16/04/2007
182561
EXERCISE DEVICE FOR STOMACH
MUSCLES
HAIM HAZAN
21/10/2005
‫התקן להתעמלות שרירי הבטן‬
‫חיים חזן‬
182562
IMPROVED VIRAL PURIFICATION
METHODS
ONCOLYTICS BIOTECH INC.
US
60/621257
22/10/2004
PCT/CA/2005/001617
WO/2006/042414
03/11/2005
182563
NANOPARTICULATE COMPOSITIONS
OF TUBULIN INHIBITOR
BAXTER INTERNATIONAL INC.
US
60/626036
08/11/2004
60/642878
11/01/2005
US
PCT/US/2005/039922
WO/2006/052712
1861
A63B
C12N
‫שיטות משופרות לניקוי וירוסים‬
A61K
‫תכשירים מחלקיקים זעירים של מעכבי‬
‫טובולין‬
July 24, 2007– ‫ט' באב התשס"ז‬
17/10/2005
182564
A REINFORCED ABSORBABLE
MULTILAYERED HEMOSTATIC
WOUND DRESSING AND METHOD
OF MAKING
OMRIX BIOPHARMACEUTICALS INC.
US
60/620539
20/10/2004
60/696258
01/07/2005
US
PCT/US/2005/037407
WO/2006/044882
17/10/2005
182565
HEMOSTAT
OMRIX BIOPHARMACEUTICALS INC.
US
60/620539
20/10/2004
60/696258
01/07/2005
US
PCT/US/2005/037403
WO/2006/044879
17/10/2005
182566
A REINFORCED ABSORBABLE
MULTILAYERED FABRIC FOR USE IN
MEDICAL DEVICES AND METHOD
OF MANUFACTURE
ETHICON, INC.
US
60/620624
20/10/2004
PCT/US/2005/037406
WO/2006/044881
July 24, 2007– ‫ט' באב התשס"ז‬
A61L
‫ רב–שכבתית‬,‫ סופגת‬,‫חבישה מחוזקת‬
‫והמוסטטית לפצע ושיטה ליצורה‬
A61L
‫המוסטאט‬
A61L
‫אריג מחוזק סופג רב שכבתי לשימוש‬
‫בהתקנים רפואיים ושיטה ליצורו‬
1862
07/10/2005
182567
OPHTHALMIC DISPLAY
COMPRISING AN OPHTHALMIC
LENS AND OPTICAL IMAGE
ESSILOR INTERNATIONAL
(COMPAGNIE GENERALE
D'OPTIQUE)
FR
0452541
05/11/2004
PCT/FR/2005/050829
WO/2006/048564
16/04/2007
‫תצוגה עינית המכילה עדשות עיניות ודמות‬
‫אופטית‬
182568
THE METHOD AND APPARATUS FOR
PROCESSING OF DEHYDRATED
SLUDGE
MAIN TREND LTD.
14/11/2005
12/11/2004
1863
‫מיין טרנד בע"מ‬
C07D
,5–)‫–איל‬3–‫ –פיראזול‬H 2(–7 ‫תולדות של‬
‫–דיהידרוקסי–חומצה הפטנואית כמעכבי‬3
‫ רידוקטאז לטיפול בליפידמיה‬HMG CO
182570
ELECTROACOUSTIC METHOD AND
DEVICE FOR STIMULATION OF
MASS TRANSFER PROCESSES FOR
ENHANCED WELL RECOVERY
KLAMATH FALLS, INC.
US
10/986677
11/11/2004
PCT/US/2004/037702
WO/2006/052258
C02F
‫שיטה ומכשיר לעיבוד של רפש יבש‬
182569
7-(2H-PYRAZOL-3-YL)-3, 5DIHYROXY-HEPTANOIC ACID
DERIVATIVES AS HMG CO-A
REDUCTASE INHIBITORS FOR THE
TREATMENT OF LIPIDEMIA
WARNER LAMBERT COMPANY LLC.
US
60/630481
23/11/2004
PCT/IB/2005/003461
WO/2006/056845
G02B
E21B
‫שיטה אלקטרואקוסטית ומיכשור לזירוז‬
‫של העברה המונית של תהליכים עבור‬
‫התאוששות טובה‬
July 24, 2007– ‫ט' באב התשס"ז‬
29/11/2005
182571
SYSTEM AND METHOD OF
GENERATING A RINGING
MAGNETIC PULSE FOR THE
TREATMENT OF FLOWING LIQUIDS
CLEARWATER SYSTEMS
CORPORATION
US
60/634959
10/12/2004
11/192452
27/07/2005
US
PCT/US/2005/043282
WO/2006/062784
20/10/2005
09/11/2005
‫מערכת ושיטה ליצירת פעימת מגנטית‬
‫טבעתית לטיפול בנוזלים זורמים‬
182572
REPAIR OF NUCLEIC ACIDS FOR
IMPROVED AMPLIFICATION
NEW ENGLAND BIOLABS, INC.
US
60/620896
21/10/2004
60/646728
24/01/2005
US
60/673925
21/04/2005
US
PCT/US/2005/038281
WO/2006/047461
182573
182575
ON-RESIN PEPTIDE CYCLIZATION
LONZA AG
EP
04024813.0 19/10/2004
05008979.6
25/04/2005
EP
PCT/EP/2005/011182
WO/2006/045483
July 24, 2007– ‫ט' באב התשס"ז‬
C12Q
‫תיקון חומצות גרעין לשיפור אמפליפיקציה‬
HYDROXYBENZOATE SALTS OF
METANICOTINE COMPOUNDS
TARGACEPT, INC.
US
60/626751
10/11/2004
PCT/US/2005/040650
WO/2006/053082
18/10/2005
C02F
C07D
‫מלחי הידרוקסיבנזואט של תרכובות‬
‫מתאניקוטין‬
C07K
‫ציקליזציה של פפטיד על–שרף‬
1864
16/04/2007
182577
B41J
METHOD AND SYSTEM FOR
CLEANING PRINT-HEADS OF INKJET
PRINTERS
SIMON BIELER
16/10/2005
‫שיטה ומערכת לניקוי ראשי הדפסה‬
‫למדפסות דיו‬
‫שמעון בילר‬
182578
‫מערכת עזר לניווט לשימוש בשטחים‬
‫עירוניים‬
‫ אופטרוניקס בע"מ‬.‫אף‬.‫די‬.‫או‬
AN AUXILLIARY NAVIGATION
SYSTEM FOR USE IN URBAN AREAS
O.D.F. OPTRONICS LTD.
IL
164650
18/10/2004
PCT/IL/2005/001093
WO/2006/043270
16/04/2007
G06K
182579
PROCESS FOR FINDING THE MOST
PROMINENT GROUP OF VERTICES IN
COMPLEX NETWORKS
BEN GURION UNIVERSITY OF THE
NEGEV RESEARCH AND
DEVELOPMENT AUTHORITY
21/10/2005
G06F
‫תהליך למציאת קבוצת הקודקודים היותר‬
‫חשובה ברשתות מורכבות‬
‫ הרשות‬,‫גוריון בנגב‬-‫אוניברסיטת בן‬
‫למחקר ופיתוח‬
182580
C07D
POLYMORPHIC FORMS OF 6-[2(METHYLCARBAMOYL)PHENYLSULFANYL]3-E-[2-(PYRIDIN-2-YL) ETHENYL]INDAZOLE
– 2[–6 ‫צורות פולימורפיות של‬
–]‫(מתילכרבמואיל)פנילסולפאניל‬
)‫–יל‬2–‫–(פירידינ‬E– [ 2–3
‫אתניל]אינדזול‬
PFIZER INC.
US
60/624665
PCT/IB/2005/003312
WO/2006/048751
1865
02/11/2004
July 24, 2007– ‫ט' באב התשס"ז‬
27/10/2005
182581
PROCESSES FOR PREPARING
GLATIRAMER
SANDOZ AG
US
60/623346
29/10/2004
60/651372
09/02/2005
US
60/651535
09/02/2005
US
60/723901
05/10/2005
US
PCT/US/2005/039003
WO/2006/050122
31/05/2001
‫תהליכים להכנת גלטיראמר‬
182582
PROCESS FOR THE PREPARATION
OF CYCLOPROPYL CARBOXYLIC
ACID ESTERS AND DERIVATIVES
ASTRAZENECA AB
GB
0013487.4
02/06/2000
0002101-4
06/06/2000
SE
PCT/SE/2001/001240
WO/2001/092200
24/10/2005
11/10/2005
July 24, 2007– ‫ט' באב התשס"ז‬
C07D
–‫–מתוקסימתיל‬4 ‫תרכובות ונגזרות של‬
‫–קרבוקסיליק אסיד כמעכבים‬2–‫פירולידין‬
C ‫של וירוס הפטיטיס‬
182585
IMIDAZO-BENZODIAZEPINE
DERIVATIVES
F. HOFFMANN-LA ROCHE AG
EP
04105169.9 20/10/2004
PCT/EP/2005/010908
WO/2006/045430
C07C
‫תהליך להכנת אסטרים של חומצה‬
‫ציקלופרופיל קרבוקסילית ונגזרות‬
182583
4-METHOXYMETHYL-PYRROLIDINE2-CARBOXYLIC ACID COMPOUNDS
AND DERIVATIVES THEREOF AS
HEPATITIS C VIRUS INHIBITORS
GLAXO GROUP LIMITED
GB
0423673.3
25/10/2004
PCT/EP/2005/011532
WO/2006/045613
C08G
C07D
‫נגזרות של אימידזו–בנזודיאזפין‬
1866
20/10/2005
182586
XANTHINE DERIVATIVES WITH
HM74A RECEPTOR ACTIVITY
SMITHKLINE BEECHAM
CORPORATION
GB
0423568.5
22/10/2004
0427079.9
10/12/2004
GB
PCT/EP/2005/011376
WO/2006/045565
18/10/2004
A ‫נגזרות קסנתין עם פעילות של רצפטור‬
74 HM
182588
METHOD AND SYSTEM FOR
SENDING ELECTRONICS MAIL OVER
A NETWORK
EBUZON B.V.
NL
1027274
18/10/2004
PCT/NL/2005/000749
WO/2006/043807
27/10/2005
182589
PROCESS FOR THE DE-ENRICHMENT
OF ENANTIOMERICALLY ENRICHED
SUBSTRATES
AVECIA PHARMACEUTICALS
LIMITED
GB
04240008
29/10/2004
PCT/GB/2005/004179
WO/2006/046062
1867
C07D
H04L
‫מערכת ושיטה למשלוח דואר אלקטרוני‬
‫ברשת‬
C07B
‫תהליך לסילוק העשרה של מצעים‬
‫מועשרים אננטיומרית‬
July 24, 2007– ‫ט' באב התשס"ז‬
27/10/2005
182590
CATALYST COMPOSITIONS AND
THEIR USE IN THE DE-ENRICHMENT
OF ENANTIOMERICALLY ENRICHED
SUBSTRATES
AVECIA PHARMACEUTICALS
LIMITED
GB
0424002.4
29/10/2004
0507960.3
20/04/2005
GB
PCT/GB/2005/004176
WO/2006/046059
16/04/2007
‫תרכובות קטליטיות ושימוש שלהן בסילוק‬
‫העשרה של מצעים מועשרים אננטיומרית‬
182592
DISPENSER FOR DISPENSING
PREDETERMINED DOSAGE OF
FLOWABLE MATTER
GLIK YEHUDA
18/10/2005
‫יהודה גליק‬
182593
A47K
‫מיכל‬
182594
3-TRIAZOLYPHENYL SULFIDE
DERIVATIVE AND
INSECTICIDE/ACARICIDE/NEMATICIDE
CONTAINING THE SAME AS ACTIVE
INGREDIENT
KUMIAI CHEMICAL INDUSTRY CO., LTD.
JP
2004-305251 20/10/2004
PCT/JP/2005/019315
WO/2006/043635
July 24, 2007– ‫ט' באב התשס"ז‬
B01D
‫התקן מנפק כמות מדידה של חומר ניגר‬
A CONTAINER
PHOENIX PRODUCT DEVELOPMENT
LTD
GB
0423515.6
22/10/2004
0509289.5
06/05/2005
GB
PCT/GB/2005/003996
WO/2006/043042
20/10/2005
C07B
C07D
‫–טריאזוליפניל סולפיד‬3 ‫תולדה של‬
‫וחומר הדברת‬
‫נמטיסייד‬/‫אקאריסייד‬/‫חרקים‬
‫המכילים אותה כרכיב פעיל‬
1868
17/04/2007
182599
‫סכיני גילוח‬
‫ישועה רחמים לוי‬
SHAVIN KNIFES
YEHOSHUA RAHAMIM LEVI
19/10/2005
182600
3-ARYLAMINO PYRIDINE
DERIVATIVES, THEIR PREPARATION
AND USE
APPLIED RESEARCH SYSTEMS ARS
HOLDING N.V.
EP
04024967.4 20/10/2004
PCT/EP/2005/011257
WO/2006/045514
27/10/2005
1869
A61K
‫שימוש בפרוטאז או מעכב פרוטאז לייצור‬
‫תרופות‬
‫ידע חברה למחקר ופיתוח בע"מ‬
182602
SERUM FREE CELL CULTURE
MEDIUM FOR MAMMALIAN CELLS
ARES TRADING S.A.
EP
04105451.1 02/11/2004
60/624885
04/11/2004
US
PCT/EP/2005/055637
WO/2006/108455
C07D
‫ הכנתן‬,‫–ארילאמינו פירידין‬3 ‫תולדות‬
‫והשימוש בהן‬
182601
THE USE OF A PROTEASE OR A
PROTEASE INHIBITOR FOR THE
MANUFACTURE OF MEDICAMENTS
YEDA RESEARCH AND
DEVELOPMENT CO. LTD
IL
164942
31/10/2004
PCT/IL/2005/001121
WO/2006/048862
28/10/2005
B26B
C12N
‫מדיום תאי תרבית ללא סרום לתאי יונקים‬
July 24, 2007– ‫ט' באב התשס"ז‬
17/04/2007
182603
PROTEIN SKIMMER HAVING FOAM
COLLECTION CUP WITH
INSPECTION WINDOW
RED SEA FISH PHARM LTD.
17/04/2007
‫מקפה חלבונים כולל ספל לאיסוף קצף‬
‫עם חלון בקרה‬
‫רד סי פיש פארם בע"מ‬
182604
182605
FLUID CONTROL DEVICE WITH
MANUALLY DEPRESSED ACTUATOR
MEDIMOP MEDICAL PROJECTS LTD.
17/04/2007
July 24, 2007– ‫ט' באב התשס"ז‬
A61J
‫התקן לבקרת נוזלים עם מפעיל לחוץ ידני‬
‫מדימופ פרויקטים רפואיים בע"מ‬
182606
A MEDICAL GUIDE WIRE, AN
ASSEMBLY BODY OF THE SAME
MEDICAL GUIDE WIRE AND
MICROCATHETER, AN ASSEMBLY
BODY OF THE SAME MEDICAL
GUIDE WIRE, A BALOON CATHETER
AND A GUIDING CATHETER
ASAHI INTECC CO., LTD.
JP2006JP
03/07/2006
183925
G02B
‫עדשה תוך עינית מסתגלת עם טבעת‬
‫אחורנית‬
‫ניולנס בע"מ‬
ACCOMMODATING INTRAOCULAR
LENS WITH POSTERIOR RING
NULENS LTD.
17/04/2007
B03D
A61B
‫ התקן לחיבור כבל‬,‫כבל הנחייה רפואי‬
‫ התקן‬,‫ההנחייה הרפואי עם מיקרו–קתטר‬
‫לחיבור כבל ההנחייה הרפואי עם קתטר‬
‫בלון וקתטר הנחייה‬
1870
21/10/2005
182607
‫מערכת אספקת גז מווסתת‬
REGULATED GAS SUPPLY SYSTEM
FATS INC.
US
10/970668
21/10/2004
PCT/US/2005/037813
WO/2006/047246
24/02/2005
182608
ORALLY EFFECTIVE CANNABINOID
ANALOGS
PHARMOS LIMITED
US
60/620716
22/10/2004
PCT/IL/2005/000231
WO/2006/043260
18/10/2005
182609
182610
TETRACYCLIC INDOLE
DERIVATIVES AS ANTIVIRAL
AGENTS
ISTITUTO DI RICERCHE DI
BIOLOGIA MOLECOLARE P.
ANGELETTI SPA
GB
0423767.3
26/10/2004
0512519.0
21/06/2005
GB
PCT/GB/2005/004127
WO/2006/046030
1871
C07C
‫אנלוגים של קנבינואידים פעילים דרך הפה‬
YEAST-BASED THERAPEUTIC FOR
CHRONIC HEPATITIS C INFECTION
GLOBEIMMUNE, INC.
US
60/620158
18/10/2004
PCT/US/2005/037499
WO/2006/044923
25/10/2005
G05D
‫פארמוס בע"מ‬
C12Q
‫תכשיר רפואי מבוסס שמרים לזיהום‬
‫ כרוני‬C ‫צהבת‬
C07D
‫נגזרות אינדול טטרהציקליות כגורמים‬
‫אנטיויראליים‬
July 24, 2007– ‫ט' באב התשס"ז‬
28/10/2005
182612
BUCCODENTAL HYGIENE
APPARATUS AND DISPOSABLE UNIT
JOSEPH OHAYON
FR
0411556
28/10/2004
PCT/FR/2005/002713
WO/2006/045966
20/10/2005
182613
DIAL-DOWN MECHANISM FOR
WIND-UP PEN
NOVO NORDISK A/S
EP
04077900.1 21/10/2004
PCT/EP/2005/011285
WO/2006/045526
25/10/2005
182614
PHARMACEUTICAL COMPOUNDS
PIRAMED LIMITED
GB
0423653.5
25/10/2004
PCT/GB/2005/004129
WO/2006/046031
25/10/2005
182615
PHARMACEUTICAL COMPOUNDS
PIRAMED LIMITED
GB
0423653.5
25/10/2004
PCT/GB/2005/004137
WO/2006/046035
July 24, 2007– ‫ט' באב התשס"ז‬
A61C
‫התקן דנטלי הגיינה של הלחי ויחידה‬
‫לשימוש חד–פעמי‬
A61M
‫מנגנון למחזיק דמוי–עט הניתן להעלאה‬
‫והורדה של הכמות המוזרקת המדודה‬
C07D
‫תרכובות רוקחיות‬
C07D
‫תרכובות רוקחיות‬
1872
20/10/2005
182616
‫התקן להזרקה עם קפיץ פיתול ותצוגה‬
‫מסתובבת‬
INJECTION DEVICE WITH TORSION
SPRING AND ROTATABLE DISPLAY
NOVO NORDISK A/S
EP
04077899.5 21/10/2004
PCT/EP/2005/011287
WO/2006/045528
17/04/2007
182617
INFRARED THERMOMETER AND
PROBE COVER THEREFOR
COVIDIEN AG
US
11/379743
21/04/2006
02/11/2005
A61M
A61B
‫מדחום אינפרא אדום וכיסוי לחיישן שלו‬
182618
METHODS AND COMPOSITIONS FOR
TREATING CHRONIC LYMPHOCYTIC
LEUKEMIA
CONFORMA THERAPEUTICS
CORPORATION
US
60/624638
02/11/2004
PCT/US/2005/039816
WO/2006/050457
22/10/2005
‫שיטות ותרכובות לטיפול בלאוקמיה‬
‫כרונית לימפוציטית‬
182619
ANTIMICROBIAL ACTIVE INGREDIENTCONTAINING SILICONE ELASTOMERS
BAYER INNOVATION GMBH
DE
102004054040.3 05/11/2004
PCT/EP/2005/011365
WO/2006/050806
1873
A01N
A61L
‫אלסטומרים מסיליקון המכילים חומר‬
‫פעיל אנטי–מיקרוביאלי‬
July 24, 2007– ‫ט' באב התשס"ז‬
10/05/2005
182620
DISPLAY FOR PUBLIC USE
ANDRAZ OGOREVC
PSI
03/11/2004
200400298
PCT/SI/2005/000012
WO/2006/049586
04/11/2005
182621
MODULATORS OF RETINOLRETINOL BINDING PROTEIN (RBP)TRANSTHYRETIN (TTR) COMPLEX
FORMATION
SIRION THERAPEUTICS, INC.
US
60/625532
04/11/2004
60/629695
19/11/2004
US
60/660904
11/03/2005
US
60/672405
18/04/2005
US
PCT/US/2005/040236
WO/2006/052860
03/11/2005
182622
HEAVY CHAIN AND DOMAIN
ANTIBODIES
UNILEVER PLC
EP
04078212.0 25/11/2004
04078211.2
25/11/2004
EP
PCT/EP/2005/011805
WO/2006/056306
July 24, 2007– ‫ט' באב התשס"ז‬
G09F
‫תצוגה לשימוש ציבורי‬
A61K
‫וסתים של יצירת קומפלקס חלבון קושר‬
‫רטינול–רטינול‬
) TTR( ‫ ) וטרנסטירטין‬RBP(
A61K
‫נוגדני שרשרת כבדה ותחום יחיד‬
1874
03/11/2005
182623
IMPROVED METHOD OF
MANUFACTURING AN ALLOYED
FILM AND APPARATUS FOR THE
METHOD
OLE-BENDT RASMUSSEN
GB
0424355.6
03/11/2004
PCT/EP/2005/012184
WO/2006/048335
17/10/2005
182624
2-AMIDO-4 PHENYLTHIAZOLE
DERIVATIVES, THE PREPARATION
AND THE THERAPEUTIC USE
THEREOF
SANOFI-AVENTIS
FR
0411083
19/10/2004
PCT/FR/2005/002565
WO/2006/042954
18/10/2005
182625
USER EQUIPMENT CELLULAR
IDENTIFICATION
QUALCOMM INCORPORATED
US
60/620458
19/10/2004
11/244485
05/10/2005
US
PCT/US/2005/037902
WO/2006/045046
21/10/2005
182626
METHODS FOR REFOLDING OF
RECOMBINANT ANTIBODIES
AMGEN, INC.
US
60/621295
22/10/2004
60/701762
22/07/2005
US
PCT/US/2005/038045
WO/2006/047340
1875
B29C
‫שיטה משופרת לייצור פילם מסוגסג‬
‫ומכשיר עבור השיטה‬
C07D
,‫–פנילתיאזול‬4–‫–אמידו‬2 ‫תולדות של‬
‫ והשימוש ברפואי בהן‬,‫הכנתן‬
H04L
‫זיהוי סלולרי לציוד המשתמש‬
C12P
‫שיטה לקיפול חוזר של נוגדנים‬
‫ריקומבננטים‬
July 24, 2007– ‫ט' באב התשס"ז‬
18/11/2005
182627
NETWORK ACCELERATOR FOR
CONTROLLED LONG DELAY LINKS
VIASAT, INC.
US
60/629817
19/11/2004
11/282359
17/11/2005
US
PCT/US/2005/042244
WO/2006/055944
18/11/2005
‫מאיץ לרשת עבור קישורים מבוקרים עם‬
‫עיכוב ארוך‬
182628
ANTHRANILAMIDE INSECTICIDES
E.I. DU PONT DE NEMOURS AND
COMPANY
US
60/629120
18/11/2004
60/689414
10/06/2005
US
PCT/US/2005/042196
WO/2006/055922
03/11/2005
182629
INSECT REPELLENT COMPOSITIONS
COMPRISING
DIHYDRONEPETALACTONE, AN
ALCOHOL, AND AN ESTER
E.I. DU PONT DE NEMOURS AND
COMPANY
US
60/624579
03/11/2004
PCT/US/2005/040146
WO/2006/050519
18/04/2007
182631
PERSONALIZED TRAVEL
INFORMATION SYSTEM & METHOD
ITRAVEL LTD
July 24, 2007– ‫ט' באב התשס"ז‬
G06F
C07D
‫חומרי הדברה אנתרנלאמידיים‬
A01N
‫תכשירים דוחי חרקים המכילים‬
‫ כוהל ואסטר‬,‫דיהידרונפטלקטון‬
G09F
‫מערכת ושיטה לאינפורמציה תיירותית‬
‫מכוונת‬
‫אייטרוול בע"מ‬
1876
26/10/2005
182632
BENZENE DERIVATIVES HAVING AT
LEAST 2 SUBSTITUENTS AND
PHARMACEUTICAL COMPOSITIONS
CONTAINING THE SAME
DAIICHI SANKYO COMPANY
LIMITED
2004JP
27/10/2004
311821
2005-187686 28/06/2005
JP
PCT/JP/2005/019676
WO/2006/046593
21/10/2005
01/11/2005
A61K
‫ליפוזומים הכוללים גרעין רדיואקטיבי וגורם‬
‫ציטוטוקסי לרפואה‬
182635
ORAL SOLID DOSAGE FORMS
CONTAINING A LOW DOSE OF
ESTRADIOL
BAYER SCHERING PHARMA AG
EP
04078014.0 02/11/2004
PCT/EP/2005/011726
WO/2006/048261
1877
‫תולדות בנזין עם לפחות שני מתמירים‬
‫ותכשירי רוקחות המכילים אותן‬
182634
LIPOSOMES ENCLOSING A
RADIONUCLIDE AND A CYTOTOXIC
AGENT FOR COMBINATION
THERAPY
ALGETA AS
GB
0423565.1
22/10/2004
PCT/GB/2005/004074
WO/2006/043083
C07C
A61K
‫צורות מתן פומי מוצקות המכילות מינון‬
‫נמוך של אסטראדיאול‬
July 24, 2007– ‫ט' באב התשס"ז‬
25/10/2005
182636
PROCESS FOR PREPARING A
LYOPHILISED MATERIAL
GLAXOSMITHKLINE BIOLOGICALS
S.A.
GB
0423861.4
27/10/2004
0501651.4
26/01/2005
GB
PCT/EP/2005/011623
WO/2006/045625
21/10/2005
‫תהליך להכנת חומר מיובש בהקפאה‬
182637
TRANSDERMAL DELIVERY
SYSTEMS
DURECT CORPORATION
US
60/621123
21/10/2004
PCT/US/2005/038086
WO/2006/047362
02/12/2004
182638
July 24, 2007– ‫ט' באב התשס"ז‬
C07J
‫תהליך לאסטריפיקציה של חומצה‬
‫קרבותיאוטית‬
182640
GLUCURONIDE METABOLITES AND
EPIMERS THEREOF OF TIGECYCLINE
WYETH
US
60/625121
05/11/2004
PCT/US/2005/039944
WO/2006/052717
A61K
‫מערכות למתן דרך העור‬
PROCESS FOR THE ESTERIFICATION
OF A CARBOTHIOIC ACID
HOVIONE INTER LTD.
PT
103,202
19/10/2004
PCT/GB/2004/005052
WO/2006/043015
03/11/2005
F26B
C07J
‫מטבוליטים גלוקורונידים ואפימרים שלהם‬
‫של טיגציקלין‬
1878
17/10/2005
182641
PYRIMIDINE DERIVATIVE FUSED
WITH NONAROMATIC RING
ASTELLAS PHARMA INC.
2004JP
20/10/2004
305374
PCT/JP/2005/019000
WO/2006/043490
24/10/2005
‫תולדות פירימידין דחוסה עם טבעת שאינה‬
‫ארומטית‬
182642
INDOLINE COMPOUND AND
PROCESS FOR PRODUCING THE
SAME
KISSEI PHARMACEUTICAL CO., LTD.
2004JP
27/10/2004
313040
PCT/JP/2005/019478
WO/2006/046499
12/11/2004
C07D
‫תרכובת אינדולין ותהליך ליצורה‬
182643
NOVEL COMPOSITION AND
METHODS FOR THE TREATMENT OF
IMMUNE RELATED DISEASES
GENENTECH, INC.
C07D
C07K
‫תכשירים חדשים ושיטות לטיפול במחלות‬
‫הקשורות למערכת החיסון‬
PCT/US/2004/037612
WO/2006/054961
1879
July 24, 2007– ‫ט' באב התשס"ז‬
04/11/2005
182644
COMPOSITIONS AND METHODS FOR
TREATMENT OF PROTEIN
MISFOLDING AND PROTEIN
AGGREGATION DISEASES
UNIVERSITY OF WASHINGTON
US
60/625364
04/11/2004
60/724961
07/10/2005
US
PCT/US/2005/040161
WO/2006/052821
19/10/2005
29/11/2005
‫תכשירים ושיטות לטיפול במחלות‬
‫הנובעות מקיפול לא נכון של חלבונים‬
‫והצטברות חלבונים‬
182645
USE OF A2A ADENOSINE RECEPTOR
AGONISTS
CV THERAPEUTICS, INC.
US
60/620577
20/10/2004
PCT/US/2005/037368
WO/2006/044856
182646
182647
AN ORAL PREPARATION HAVING
IMPROVED BIOAVAILABILITY
DONG WHA PHARM. IND. CO, LTD
10-2004KR
23/11/2004
0096390
PCT/KR/2005/003950
WO/2006/057507
July 24, 2007– ‫ט' באב התשס"ז‬
A61K
‫ אדנולין‬A 2A ‫שימוש באגוניסט של קולטן‬
SELF-DRILLING HOLLOW WALL
ANCHOR
MECHANICAL PLASTICS CORP.
US
11/001945
02/12/2004
PCT/US/2005/043943
WO/2006/060776
22/11/2005
A61K
F16B
‫עוגן קיר חלול עם קידוח עצמי‬
A61K
‫תכשיר אורלי בעל זמינות ביולוגית‬
1880
17/10/2005
182648
BLISTER FOR INHALERS
BOEHRINGER INGELHEIM
INTERNATIONAL GMBH
EP
04025038.3 21/10/2004
PCT/EP/2005/055313
WO/2006/045715
03/01/2002
182649
WATER SPRINKLER HEAD WITH
INTEGRAL OFF-ON WATER FLOW
CONTROL VALVE AND ADAPTIVE
FITTINGS THEREFOR
THEODORE SIRKIN
US
09/755793
05/01/2001
10/027335
19/12/2001
US
24/10/2005
182650
LOADABLE POLYMERIC PARTICLES
FOR THERAPEUTIC AND/OR
DIAGNOSTIC APPLICATIONS AND
METHODS OF PREPARING AND
USING THE SAME
POLYZENIX GMBH
US
60/621729
25/10/2004
60/684307
24/05/2005
US
PCT/IB/2005/004007
WO/2006/046155
14/10/2005
182651
ROLLING SCALP INVIGORATOR
ANDERSON, D.C.
US
60/619871
19/10/2004
11/037953
18/01/2005
US
PCT/US/2005/036743
WO/2006/044493
1881
A61M
‫בועה למשאף‬
B05B
‫ עם‬,‫מכלול ראש מתז מים ומתאמים‬
‫שסתום הפעל–הפסק אינטגרלי‬
A61K
‫חלקיקים פולימריים ניתנים להעמסה‬
‫או אבחנתיים‬/‫עבור יישומים רפואיים ו‬
‫ושיטות להכנתם ולשימוש בהם‬
A61H
‫ממריץ מתגלגל לקרקפת‬
July 24, 2007– ‫ט' באב התשס"ז‬
21/10/2005
182652
NITROBENZINDOLES AND THEIR
USE IN CANCER THERAPY
AUCKLAND UNISERVICES LIMITED
NZ
536107
22/10/2004
PCT/NZ/2005/000278
WO/2006/043839
05/10/2005
‫ניטרובנזינדולים ושימושם בטיפול בסרטן‬
182653
ANTI-SNORING COMPOSITION
PERSEE MEDICA
FR
0411153
20/10/2004
PCT/FR/2005/002444
WO/2006/042926
01/11/2004
C07D
182654
EFFICIENT AND SECURE RENEWAL
OF ENTITLEMENTS
NDS LIMITED
A61K
‫תכשיר נגד נחירות‬
H04N
‫חידוש הרשאות בצורה מובטחת ויעילה‬
PCT/IL/2004/000998
WO/2006/048856
13/02/2006
182655
IMPROVED PHTHALONITRILE
COMPOSITES
RAYTHEON COMPANY
US
60/652501
11/02/2005
PCT/US/2006/004975
WO/2006/086758
July 24, 2007– ‫ט' באב התשס"ז‬
C08G
‫פתלוניטריל מרוכבים משופרים‬
1882
15/07/2004
182656
METHOD FOR TRANSMISSION
POWER CONTROL BASED ON
EVALUATION OF A REVERSE
ACTIVITY BIT AND DATA FLOW
SPECIFIC UPWARD/DOWNWARD
RAMPING FUNCTIONS, AND
CORRESPONDING WIRELESS
ACCESS TERMINAL
QUALCOMM INCORPORATED
US
60/487648
15/07/2003
60/493782
06/08/2003
US
60/527081
03/12/2003
US
10/890719
13/07/2004
US
PCT/US/2004/022901
WO/2005/011212
22/04/2007
‫שיטה לבקרת הספק שידור עפ"י שערוך‬
‫של סיבית פעילות בערוץ החוזר ופונקציות‬
,‫עליה וירידה הספציפיות לזרימת המידע‬
‫וכן מסוף אלחוטי מתאים‬
182707
182710
TREATMENT OR PREVENTION OF
HEMORRHAGIC VIRAL INFECTIONS
WITH IMMUNOMODULATOR
COMPOUNDS
SCICLONE PHARMACEUTICALS,
INC.
US
60/622022
27/10/2004
PCT/US/2005/038834
WO/2006/047702
1883
G06Q
‫מדיד לשיפוע‬
‫רפי שגב‬
INCLINATION GAUGE
RAFI SEGEV
27/10/2005
H04L
G09F
‫טיפול או מניעה של דלקות ויראליות‬
‫מדממות עם תרכובות אימונומודולריות‬
July 24, 2007– ‫ט' באב התשס"ז‬
24/10/2005
182711
METHOD AND COMPOSITION FOR
IDENTIFICATION
PETERS SETH ALARIC
ZA
2004/8583
22/10/2004
PCT/IB/2005/003158
WO/2006/043167
21/10/2005
21/10/2005
‫שיטה ותכשיר לזיהוי‬
182712
(BIPHENYL) CARBOXYLIC ACIDS
AND DERIVATIVES THEREOF
CELLZOME AG
EP
04025003.7 21/10/2004
04026125.7
04/11/2004
EP
60/642100
10/01/2005
US
PCT/EP/2005/011349
WO/2006/045554
182714
182715
DUFFY ANTIGEN RECEPTOR FOR
CHEMOKINES AND USE HEREOF
THE NEW YORK BLOOD CENTER,
INC.
US
60/620993
21/10/2004
PCT/US/2005/037803
WO/2006/047242
July 24, 2007– ‫ט' באב התשס"ז‬
C07C
‫חומצות (ביפניל) קרבוקסיליות ותולדותיהן‬
IMPLIED ACKNOW LEDGEMENT
DATA TRANSPORT PROTOCOL FOR
A MULTI-STATION NETWORK
IWICS INC.
US
60/620908
21/10/2004
PCT/IB/2005/003141
WO/2006/043161
20/10/2005
C07C
H04L
‫פרוטוקול לאישור מרומז להעברת מידע‬
‫עבור מערכת תקשורת רבת–תחנות‬
A61K
DUFFY ‫קולטן לאנטיגן מטיפוס‬
‫לכמוקינים ושימוש בו‬
1884
08/11/2005
182716
FSH ‫שיטה לניקוי‬
METHOD FOR PURIFYING FSH
ARES TRADING S.A.
EP
04105639.1 09/11/2004
60/628717
17/11/2004
US
PCT/EP/2005/055815
WO/2006/051070
15/11/2005
182719
METHOD AND APPARATUS FOR
TRANSMITTING AND RECEIVING
DOWNLINK CONTROL
INFORMATION IN A MOBILE
COMMUNICATION SYSTEM
SUPPORTING UPLINK PACKET DATA
SERVICE
SAMSUNG ELECTRONICS CO., LTD.
10-2004KR
15/11/2004
0093283
10-200416/11/2004
KR
0093743
C07K
H04B
‫שיטה ומכשיר לשידור וקליטת אותות‬
‫בקרה בערוץ המסורת לוויני יורד‬
‫) במערכת קשר ניידת‬DOWNLINK(
‫התומכים בשירות חבילות מידע בתמסורת‬
)UPLINK( ‫לווינית עולה‬
PCT/KR/2005/003864
WO/2006/052118
31/10/2005
182721
SERVICE PROCESSOR GATEWAY
SYSTEM AND APPLIANCE
AVOCENT FREMONT CORP.
US
10/976728
29/10/2004
PCT/US/2005/039411
WO/2006/050336
24/10/2005
1885
182722
H04L
‫מערכת ומכשיר שער למעבד שירות‬
C12N
July 24, 2007– ‫ט' באב התשס"ז‬
TOMATO PLANTS HAVING HIGHER
LEVELS OF RESISTANCE TO
BOTRYTIS
DE RUITER SEEDS R & D B.V.
EP
04077931.6 25/10/2004
PCT/NL/2005/000762
WO/2006/046861
20/10/2005
182723
COATED CUTTING INSERT AND
MANUFACTURING METHOD
THEREOF
SUMITOMO ELECTRIC HARDMETAL
CORP.
2004JP
29/10/2004
316611
PCT/JP/2005/019287
WO/2006/046462
24/10/2005
182724
SURFACE-COATED CUTTING TOOL
SUMITOMO ELECTRIC HARDMETAL
CORP.
2004JP
29/10/2004
316338
PCT/JP/2005/019476
WO/2006/046498
26/10/2005
182725
METHOD AND DEVICE FOR
DETERMINATION OF ROLL ANGLE
BAE SYSTEMS BOFORS AB
SE
0402611-8
28/10/2004
PCT/SE/2005/001600
WO/2006/046912
July 24, 2007– ‫ט' באב התשס"ז‬
‫שתילי עגבנייה בעלי רמות גבוהות של‬
‫עמידות לבוטריטיס‬
B23B
‫כלי חיתוך מצופה ושיטה לייצורו‬
B23B
‫כלי חיתוך בעל ציפוי פני השטח‬
F41G
‫שיטה והתקן לקביעת זוית גלגול‬
1886
07/11/2005
182726
5-HETEROARYL THIAZOLES AND
THEIR USE AS P13K INHIBITORS
ASTRAZENECA AB
SE
0402735-5
09/11/2004
PCT/GB/2005/004268
WO/2006/051270
17/11/2005
182727
AMIDE COMPOUND
TAKEDA PHARMACEUTICAL
COMPANY LIMITED
2004JP
18/11/2004
334748
2005-226950 04/08/2005
JP
PCT/JP/2005/021136
WO/2006/054652
25/10/2005
182728
SUSTITUTED TETRACYCLINE
COMPOUNDS
PARATEK PHARMACEUTICALS, INC.
US
60/622027
25/10/2004
60/622749
27/10/2004
US
PCT/US/2005/039014
WO/2006/047756
19/10/2005
1887
182729
C07D
‫–הטרואריל והשימוש בהם‬5 ‫תיאזולים‬
P13K ‫כמעכבי‬
C07D
‫תרכובת אמיד‬
C07C
‫תרכובות טטרהציקלין מותמרות‬
H04J
July 24, 2007– ‫ט' באב התשס"ז‬
METHOD AND APPARATUS FOR
MANAGING END-TO-END VOICE
OVER INTERNET PROTOCOL MEDIA
LATENCY
QUALCOMM INCORPORATED
US
10/969496
20/10/2004
PCT/US/2005/037510
WO/2006/044930
20/10/2005
‫שיטה והתקן לניהול פרוטוקול אינטרנט‬
‫לשידור קול מקצה לקצה עם זמן אחזור‬
‫של אמצעי תקשורת‬
182731
POWER-EFFICIENT DATA
RECEPTION IN A COMMUNICATION
SYSTEM WITH PACKET VARIABLE
DELAY
QUALCOMM INCORPORATED
US
10/969155
20/10/2004
PCT/US/2005/038108
WO/2006/045100
20/10/2005
‫ניצול יעיל של כוח עבור קליטת נתונים‬
‫במערכת תקשורת עם שיהוי משתנה‬
182732
MULTIPLE FREQUENCY BAND
OPERATION IN WIRELESS
NETWORKS
QUALCOMM INCORPORATED
US
60/620488
20/10/2004
PCT/US/2005/038079
WO/2006/045097
24/10/2005
25/10/2005
July 24, 2007– ‫ט' באב התשס"ז‬
H04L
‫רצועת פעולה בעלת תדרים מרובים‬
‫ברשת אלחוטית‬
182733
METHOD AND APPARATUS FOR
PERFORMING AN ATOMIC
SEMAPHORE OPERATION
QUALCOMM INCORPORATED
US
10/971740
22/10/2004
PCT/US/2005/038516
WO/2006/047570
H04L
G06F
‫שיטה והתקן לביצוע הליך אטומי סמפורי‬
182734
C07C
1888
‫–אמינוטטרהציקלינים ושיטות שימוש‬4
‫בהם‬
4-AMINOTETRACYCLINES AND
METHODS OF USE THEREOF
PARATEK PHARMACEUTICALS, INC.
US
60/622027
25/10/2004
60/673827
21/04/2005
US
PCT/US/2005/038733
WO/2006/047671
15/12/2005
182738
–H8–8–‫–הטרואריל‬3 ‫אננטיומרים של‬
‫–אן ושימוש‬2–‫)אוקט‬1.2.3(‫אזאביציקלו‬
‫בהם כמעכבי לקיחה מחדש של מעביר‬
‫אות עצבי מונואמינו‬
ENANTIOMERS OF 3-HETEROARYL8H-8-AZABICYCLO(3.2.1)OCT-2-ENE
AND THEIR USE AS MONOAMINE
NEUROTRANSMITTER RE-UPTAKE
INHIBITORS
NEUROSEARCH A/S
DK
PA200401950 17/12/2004
60/636869
20/12/2004
US
DK
PA200500506 08/04/2005
60/669887
11/04/2005
US
PCT/EP/2005/056801
WO/2006/064031
22/10/2005
182739
ACYLATEDNONADEPSIPEPTIDES USED
AS LYSOBACTIN DERIVATIVES
AICURIS GMBH & CO.KG
DE
102004053407.1 05/11/2004
PCT/EP/2005/011363
WO/2006/048139
18/11/2005
182740
FLUORIDATION PROCESS
GE HEALTHCARE LIMITED
GB
0425501.4
19/11/2004
PCT/GB/2005/004451
WO/2006/054098
04/04/2003
1889
C07D
182742
C07K
‫נונאדפסי פפטידים אציליים המשמשים‬
‫כתולדות ליזובקטין‬
C07H
‫תהליך פלואורידציה‬
A61K
July 24, 2007– ‫ט' באב התשס"ז‬
A STORAGE STABLE
PHARMACEUTICAL PREPARATION
COMPRISING OXYCODONE OR A
PHARMACEUTICALLY ACCEPTABLE
SALT THEREOF AND NALOXONE OR
A PHARMACEUTICALLY
ACCEPTABLE SALT THEREOF
EURO - CELTIQUE S.A.
DE
10215131.8 05/04/2002
10215067.2
05/04/2002
DE
PCT/EP/2003/003540
WO/2003/084520
21/06/1999
‫איחסון קבוע של תכשירי רוקחות‬
‫המכילים אוקסיקודון או באמצעות תרופות‬
‫מלח מזה ונאלוקסון או באמצעות תרופות‬
‫מלח קבילות מזה‬
182744
EPOTHILONE DERIVATIVES AND
THEIR SYNTHESIS AND USE
THE SCRIPPS RESEARCH INSTITUTE
US
09/102602
22/06/1998
PCT/EP/1999/004287
WO/1999/067252
27/10/2005
182745
A HIGHLY POROUS, FASTDISINTEGRATING SOLID DOSAGE
FORM AND ITS WAY OF
MANUFACTURING COMPRISING
THE PREPARATION OF A PODWER
AND A FREEZEDRYING STEP
PANTEC AG
EP
04105381.0 28/10/2004
PCT/EP/2005/055591
WO/2006/045830
02/11/2005
July 24, 2007– ‫ט' באב התשס"ז‬
182747
C07D
‫נגזרות של אפוטילון הסינתזה שלהם‬
‫ושימושיהם‬
A61K
‫קפסולה מוצקה נקבובית ביותר‬
‫המתפוררת במהירות ודרך להכנתה‬
– ‫המורכבת מהכנת האבקה ומהקפאת‬
‫ייבושה‬
A61K
1890
REVERSE MICELLES BASED ON
PHYTOSTEROLS AND
ACYLGLYCEROLS AND
THERAPEUTIC USES THEREOF
DENDERAH PHARMA SA
EP
04025991.3 02/11/2004
PCT/IB/2005/003592
WO/2006/048772
28/10/2005
182749
VWFA AND/OR ANT_IG DOMAIN
CONTAINING PROTEINS
ARES TRADING SA
GB
0423974.5
28/10/2004
PCT/GB/2005/004191
WO/2006/046072
26/10/2005
182750
ADAPTER, LID AND CONNECTOR
FOR OSTOMY BAGS
OSTOMYCURE AS
EP
04077965.4 27/10/2004
PCT/IB/2005/053504
WO/2006/046210
26/10/2005
182751
S-ALKYL-SULPHENYL PROTECTION
GROUPS IN SOLID-PHASE
SYNTHESIS
LONZA LIMITED
EP
04025395.7 26/10/2004
PCT/EP/2005/011476
WO/2006/045603
1891
‫מיצלות הפוכות המבוססות על‬
‫פיטוסטרולים ואצילגליצרולים ושימושים‬
‫ריפויים שלהן‬
C07K
‫או‬/‫ ו‬VWFA ‫חלבונים המכילים אתרי‬
ANT_IG
A61F
‫ מכסה ומחבר עבור שקיות‬,‫מתאם‬
‫אוסטומי‬
C07K
‫–אלקיל–סולפניל‬S ‫קבוצות מגנות של‬
‫בסינטזת פאזה מוצקה‬
July 24, 2007– ‫ט' באב התשס"ז‬
25/10/2005
182752
SALTS OF ISOPHOSPHORAMIDE
MUSTARD AND ANALOGS THEREOF
AS ANTI-TUMOR AGENTS
DEKK-TEC INC
US
60/622087
25/10/2004
60/672707
18/04/2005
US
PCT/US/2005/038523
WO/2006/047575
18/10/2005
18/10/2005
B44F
‫שיטה לייצור אוטומטי של אובייקטים‬
‫תלת–מימדיים ומצעים ארוגים מאובייקטים‬
‫דו–מימדיים או אובייקטים תלת–מימדיים‬
182754
METHOD FOR THE PRODUCTION OF
A SUBSTRATE HAVING A
HOLOGRAPHIC APPEARANCE
2089275 ONTARIO LTD.
US
60/621669
26/10/2004
60/624547
04/11/2004
US
60/654937
23/02/2005
US
60/654941
23/02/2005
US
60/654938
23/02/2005
US
PCT/CA/2005/001577
WO/2006/045177
July 24, 2007– ‫ט' באב התשס"ז‬
‫מלחים של חרדל של איזופוספוראמיד‬
‫ואנלוגים שלהם כחומרים נגד גידולים‬
182753
METHOD FOR THE AUTOMATED
PRODUCTION OF THREEDIMENSIONAL OBJECTS AND
TEXTURED SUBSTRATES FROM
TWO-DIMENSIONAL OR THREEDIMENSIONAL OBJECTS
2089275 ONTARIO LTD.
US
60/621669
26/10/2004
60/624547
04/11/2004
US
60/654936
23/02/2005
US
60/654941
23/02/2005
US
60/654938
23/02/2005
US
60/654937
23/02/2005
US
PCT/CA/2005/001579
WO/2006/045178
C07F
G03H
‫שיטה לייצור של מצע בעל מראה‬
‫הולוגרפי‬
1892
04/11/2005
182755
METABOLITES OF CERTAIN
[1,4]DIAZEPINO
[6,7,1-IJ]QUINOLINE DERIVATIVES
AND METHODS OF PREPARATION
AND USE THEREOF
WYETH
US
60/625335
05/11/2004
PCT/US/2005/040289
WO/2006/052886
02/11/2005
182756
REVERSE MICELLE COMPOSITION
FOR DELIVERY OF METAL CATIONS
COMPRISING A DIGLYCERIDE AND
A PHYTOSTEROL AND METHOD OF
PREPARATION
MEDESIS PHARMA S.A.
EP
04025987.1 02/11/2004
PCT/IB/2005/003605
WO/2006/048773
18/10/2005
182757
MOBILE OR STATIONARY
MODULAR SELF-CONTAINED
DEHYDRATION TOILET,
DEHYDRATION ENGINE, AND GRAY
WATER RECOVERY SYSTEM
LUMBERT STEVEN
US
10/904234
29/10/2004
PCT/US/2005/037334
WO/2006/049856
1893
C07D
‫מטבוליטים של תולדות של קרטין‬
‫] קווינולין ושיטות‬IJ–6,7,1[‫]דיאזפינו‬1,4[
‫להכנתן ושימוש בהם‬
A61K
‫תרכובת של מיצלות הפוכות למסירת‬
‫ המכילים דיגליצרידים‬,‫קטיוני מתכת‬
‫ופיטוסטרול ושיטה להכנתה‬
C02F
‫ נייד או נייח‬,‫ מודולרי‬,‫מתקן שרותים יבש‬
‫ מנוע ייבוש ומערכת‬,‫בעל מיכל עצמי‬
‫הבראה למים אפורים‬
July 24, 2007– ‫ט' באב התשס"ז‬
20/10/2005
182758
OPTICAL CORRELATION
APPARATUS AND METHOD
INSTRO PRECISION LTD.
GB
0424432.3
04/11/2004
PCT/GB/2005/004051
WO/2006/048604
05/11/2004
182759
G01S
‫מכשיר ושיטה למתאם אופטי‬
H01M
‫דלקים מוצקים לתאי דלק‬
SOLID FUELS FOR FUEL CELLS
UOP LLC
PCT/US/2004/037099
WO/2006/052243
09/11/2005
182760
CONJUGATE MOLECULE
COMPOUNDS WITH ENHANCED
CELL UPTAKE ACTIVITY
XIGEN S.A.
EP
04026934.2 12/11/2004
PCT/EP/2005/011991
WO/2006/050930
26/10/2005
182761
IDENTIFICATION OF JAK2
MUTATION IN POLYCYTHEMIA
VERA
UNIVERSITE PARIS SUD XI
FR
0411480
27/10/2004
PCT/EP/2005/055586
WO/2006/045827
July 24, 2007– ‫ט' באב התשס"ז‬
A61K
‫תרכובת מולקולות מאוחדות בעלות‬
‫פעילות ספיגה תאית מוגברת‬
C12N
VERA –‫ ב‬JAK2–‫זיהוי מוטציה ב‬
POLYCYTHEMIA
1894
21/10/2005
182763
THROMBOPOIETIN ACTIVITY
MODULATING COMPOUNDS AND
METHODS
LIGAND PHARMACEUTICALS INC.
US
60/621879
25/10/2004
60/675001
25/04/2005
US
PCT/US/2005/038055
WO/2006/047344
01/11/2005
02/11/2005
A61K
‫שיטה לטיפול בהשמנת יתר ובמחלות ובאי‬
‫סדרים הקשורים להשמנת יתר‬
182765
PYRIDAZINE COMPOUNDS,
COMPOSITIONS AND METHODS
UNIVERSITE' LOUIS PASTEUR DE
STRASBOURG OF
US
60/624346
02/11/2004
60/723090
03/10/2005
US
60/723124
03/10/2005
US
PCT/US/2005/039541
WO/2006/050389
1895
‫תרכובות ושיטות לוויסות פעילות‬
‫תרומבופויטין‬
182764
METHODS FOR TREATING OBESITY
AND OBESITY RELATED DISEASES
AND DISORDERS
AMYLIN PHARMACEUTICALS, INC.
US
60/624357
01/11/2004
PCT/US/2005/039686
WO/2006/052608
C07D
C07D
‫ תכשירים ושיטות‬,‫תרכובות פירידאזין‬
July 24, 2007– ‫ט' באב התשס"ז‬
16/11/2005
182768
DRUG COMBINATION COMPRISING
A SELECTIVE SEROTONIN
REUPTAKE INHIBITOR AND
GLUCOCORTICOID RECEPTOR
ANTAGONIST FOR THE TREATMENT
OF DEPRESSION
N.V. ORGANON
EP
04257199.2 19/11/2004
PCT/EP/2005/056023
WO/2006/053884
03/11/2005
‫צירוף תרופתי המכיל מעכב בררני של‬
‫טעינה מחדש של סרטונין ואנטגוניסט של‬
‫קולטן גלוקוקורטיקואיד לטיפול בדיכאון‬
182769
HUMIDITY CONTROL DEVICE
MULTISORB TECHNOLOGIES, INC.
US
10/984080
09/11/2004
PCT/US/2005/039999
WO/2006/052748
26/10/2005
182771
A THYMUS-SPECIFIC PROTEIN
IMMUNE SYSTEM KEY LTD
US
60/621086
25/10/2004
PCT/IL/2005/001113
WO/2006/046239
24/01/2005
MEDICAL CONNECTOR
JR. ROWAN P. SMITH
US
10/971906
PCT/US/2005/002259
WO/2006/046961
A61K
182772
C08K
‫התקן לבקרת לחות‬
C07K
‫חלבון תימוס מסויים‬
IMMUNE SYSTEM KEY LTD
A61M
‫מחבר רפואי‬
25/10/2004
July 24, 2007– ‫ט' באב התשס"ז‬
1896
NOTICE UNDER SECTION 26 OF THE
PATENTS LAW, 5727-1967
The applications, particulars of which are set
out below, have been accepted pursuant to
Section 17 of the Patents Law. Any person
wishing to oppose the grant of a patent on any
of the applications published here, may,
within three months from the date of this
journal, give to the Commissioner of Patents
notice under Section 30 of the Patents Law, in
the manner prescribed in regulations 57 et seq
of the Patents Regulations, 5728-1968
Particulars of the applications, where
applicable, are given in the following order:
[11] [21] Number of application
[54] Title of invention
[22] Application date
[31] [32] [33] Number and date of foreign
application – convention country.
*[51] Int.Cl.
[61] Application for patent of addition
[62] Divisional application
[71] Applicant
[72] Inventor
[87] International Publication Number
[74] Address for service
[57] Abridgement of invention (in the
language in which the specification is drawn
up)
*Note: As from Patents and Designs Journal
No.1/06, patent applications are classified
according to the Eighth Edition of the
International Patent Classification (2006)
1897
- ‫ לחוק הפטנטים תשכ"ז‬26 ‫הודעה לפי סעיף‬
1976
‫הבקשות שפרטיהן מתפרסמים להלן קובלו‬
‫ כל המעונין‬.‫ לחוק הפטנטים‬17 ‫לפי סעיף‬
‫להתנגד למתן פטנט על פי בקשה מהבקשות‬
‫ תוך שלושה חדשים‬,‫המתפרסמות רשאי‬
‫ להגיש לרשם הפטנטים‬,‫מתאריך יומן זה‬
‫ לחוק‬30 ‫הודעת התנגדות לפי סעיף‬
‫ ואילך‬57 ‫הפטנטים בדרך הקבועה בתקנה‬
.1968 – ‫ תשכ"ח‬,‫לתקנות הפטנטים‬
‫פרטי הבקשות במידה ויישימים מובאים לפי‬
:‫סדר זה‬
‫מספר הבקשה‬
‫שם האמצאה‬
‫תאריך הבקשה‬
‫מספר ותאריך של בקשות החוץ – מדינת‬
‫האגוד‬
‫*סיווג בינלאומי – מהדורה שביעית‬
‫בקשה לפטנט מוסף‬
‫בקשת חלוקה‬
‫המבקש‬
‫הממציא‬
‫מס' פרסום של בקשה הבינלאומית‬
‫מען למסירת מסמכים‬
)‫תקציר האמצאה (בשפה בה ערוך הפירוט‬
'‫ החל מיומן הפטנטים והמדגמים מס‬:‫*הערה‬
‫ ניתן ציון לבקשות פטנטים הסיווג לפי‬1/06
‫המהדורה השמינית של הסיווג הבינלאומי‬
)2006 ‫של פטנטים (משנה‬
July 24, 2007– ‫ט' באב התשס"ז‬
]11[]21[
114668
‫ליגנד של קינאז טרנסממברנלי של גידול‬
,‫ תכשירים המכילים אותו‬,)Htk( ‫כבד‬
‫מולקולות של חומצות גרעין המקודדות‬
‫ וקטורים הכוללים מולקולות‬,‫ליגנדים כאלה‬
‫ תאי מאכסן‬,‫של חומצות גרעין כאלה‬
‫ שיטה להכנת‬,‫הכוללים וקטורים כאלה‬
‫ליגנד כזה והשימוש בו להכנת תרופה‬
Htk ‫וכתרופה לשפעול רצפטור‬
]54[
HEPATOMA TRANSMEMBRANE
KINASE (HTK) LIGAND,
COMPOSITIONS COMPRISING
THE SAME, NUCLEIC ACID
MOLECULES ENCODING SUCH
LIGANDS, HOST CELLS
COMPRISING SUCH VECTORS, A
METHOD FOR PREPARATION OF
SUCH LIGAND AND USE
THEREOF IN PREPARATION OF
A MEDICAMENT AND AS A
MEDICAMENT FOR ACTIVATING
HTK RECEPTOR
]22[
]31[
]51[
]71[
]74[
19.07.1995
08/277722
]32[ 20.07.1994
]33[ US
Int. Cl.8 A61K 038/17, C07K 014/47, C12N 015/12
GENENTECH, INC., U.S.A.
S. HOROWITZ & CO.,
,'‫ הורוביץ ושות‬.‫ש‬
ZION HOUSE,
‫ תל‬,41-45 ‫ שדרות רוטשילד‬,‫בית ציון‬
41-45 ROTHSCHILD BLVD.,
‫אביב‬
TEL AVIV 65784
[57] An isolated protein molecule which
induces phosphorylation of the hepatoma
transmembrane kinase (Htk) receptor and
binds to the Htk receptor, and comprises
an amino acid sequence selected from the
group consisting of:
(a) amino acids 25-333 of the amino acid
sequence shown in figure 2 (SEQ ID
NO:4);
(b) the naturally occurring amino acid
sequence for a mature Htk ligand from an
animal species other than those sequences
of (a);
(c) allelic variants of the sequences (a) or
(b) that phosphorylate and bind the Htk
receptor; and
(d) the sequences of (a), (b), (c) having a
single conservative amino acid substitution
as defined in Table 1 that phosphorylate
and bind the Htk receptor, the figures and
tables as shown in the specification.
__________
July 24, 2007– ‫ט' באב התשס"ז‬
1898
]11[]21[
122991
‫ ושימושיהם‬P53 ‫וריאנטים של חלבון‬
‫הרפואיים‬
]54[
P53 PROTEIN VARIANTS AND
THERAPEUTICAL USES
THEREOF
]22[
]31[
]51[
17.07.1996
95/08729
]32[ 19.07.1995
]33[ FR
Int. Cl.8 A61K 038/16, 048/00, A61P 035/00, C07K 014/035, 014/82, 019/00, C12N
015/09, 015/12, 015/62, 015/86
AVENTIS PHARMA S.A, FRANCE
LUZZATTO & LUZZATTO,
,‫לוצאטו את לוצאטו‬
INDUSTRIAL PARK, OMER,
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
P.O.B. 5352,
BEER-SHEVA 84152
]71[
]74[
[57] Variant of p53 protein in which a part
of the oligomerisation domain as well as
all of the regulation domain are deleted
and replaced by an artificial leucine zipper
characterized in that the deletion of the Cterminal part is made from the residue 326
or from the residue 337 and further
characterized in that all or part of the
transactivation domain is deleted and
replaced by the viral protein 16 of the
herpes simplex virus (VP16)
transactivation domain.
__________
1899
July 24, 2007– ‫ט' באב התשס"ז‬
]11[]21[
123201
‫) קאמפטותצין המותמרים‬S)20 ‫תולדות‬
‫ הכנתן ותכשירי‬,‫ והמסיסים במים‬5 ‫בעמדה‬
‫רוקחות המכילים אותן‬
]54[
WATER SOLUBLE 5SUBSTITUTED 20(S)CAMPTOTHECIN DERIVATIVES,
THEIR PREPARATION AND
PHARMACEUTICAL
COMPOSITIONS CONTAINING
THE SAME
]22[
]31[
22.04.1997
08/655259
]32[ 05.06.1996
]33[ US
08/655258
05.06.1996
US
08/771391
19.12.1996
US
Int. Cl.8 A61K 031/395, A61P 035/00, C07D 491/00, 491/22
REDDY-CHEMINOR, INC., U.S.A.
DR. REDDY'S LABORATORIES
LIMITED, INDIA
WO/1997/046563
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.,
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
]51[
]71[
]87[
]74[
[57] A compound of the formula
or its pharmaceutically acceptable salts,
wherein R1, R2, R3 and R4 independently
represent hydrogen or represent a group
selected from hydroxy, (C1-C6) alkoxy,
substituted amino wherein the amino group
is mono or disubstituted and the
substituents are selected from (C1-C6) alkyl
or halo (C1-C6) alkyl; (C1-C6) alkyl or
substituted (C1-C6) alkyl wherein the
substituents are selected from hydroxy,
(C1-C6) alkoxy, halo (C1-C6) alkyl, cyano,
nitro, amino, or (C1-C6) alkylamino; R1,
R2, R3 and R4 are not all the same except
July 24, 2007– ‫ט' באב התשס"ז‬
where all of R1, R2, R3 and R4 are
hydrogen; R5 represents hydrogen or (C1C6) alkyl; and R6 represents hydrogen, (C1C6) alkyl, benzyl where the phenyl group
may be unsubstituted or mono, di or tri
substituted with substituents selected from
halogen, (C1-C6) alkoxy, cyano, nitro, (C1C6) alkyl, amino, or substituted amino
wherein the amino group is mono or
disubstituted with (C1-C6) alkyl groups;
substituted benzoyl wherein the
substituents are selected from (C1-C6)
alkyl, halo (C1-C6) alkyl, halogen, (C1-C6)
1900
alkoxy, cyano, nitro, amino, or (C1-C6)
alkylamino; substituted (C1-C6) alkyl,
wherein the substituents are selected from
halogen, hydroxy, (C1-C6) alkoxy,
phenoxy, or amino in which the amino
group can be unsubstituted, mono or
disubstituted wherein the substituents are
selected from hydroxy or (C1-C6) alkyl,
when the amino group is disubstituted the
substituents are independent or combined
together to form a ring having 5 or 6 ring
atoms the ring atoms being carbon,
nitrogen, and optionally oxygen atoms; or
a heterocyclic ring having 5 to 7 carbon
atoms and one or two nitrogen atoms, with
a proviso that
(i) when R1 is methoxy, R6 is not hydrogen
or unsubstituted (C1-C6) alkyl group;
(ii) when R2 is hydroxyl, (C1-C6) alkoxy,
alkylamino, R6 is not hydrogen or
unsubstituted (C1-C6) alkyl group;
(iii) when R5 is (C1-C6) alkyl, R6 is not
hydrogen or unsubstituted (C1-C6) alkyl
group;
(iv) when R1 through R5 represent
hydrogen, R6 is not hydrogen or
unsubstituted (C1-C6) alkyl.
__________
]11[]21[
123248
HCV NS3 ‫תכשירים המכילים מקטע של‬
‫הליקז‬
]54[
COMPOSITIONS COMPRISING
AN HCV NS3 HELICASE
FRAGMENT
]22[
]31[
]51[
12.09.1996
08/529169
]32[ 15.09.1995
]33[ US
Int. Cl.8 A61K 038/43, 048/00, C07K 014/18, 019/00, C12N 009/14, 015/51, 015/55,
015/62, G01N 033/50
CHIRON CORPORATION, U.S.A.
WO/1997/012043
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
]71[
]87[
]74[
[57] Composition comprising an HCV
NS3 helicase fragment having the same
amino acid sequence as shown in SEQ ID
NO:2 or having, when optimally aligned,
The applications for division
from this application have
not yet been published
at least 70% homology with the amino acid
sequence shown in SEQ ID NO:2 and
having essentially the same biological
activity.
,171901,171900,171896
‫בקשות חלוקה מבקשה זו‬
.‫שטרם פורסמו‬
___________
1901
July 24, 2007– ‫ט' באב התשס"ז‬
]11[]21[
]54[
OSTEOTOME FOR
RHINOPLASTY
]22[
]51[
]71[
]74[
03.05.1998
Int. Cl.8 A61B 001/00, 017/16
EFRON ROZAN
EFRON ROZAN,
MOSHE KOL 8 APP.16
TEL AVIV 69626
124301
‫אוסטאוטום לרינופלסטי‬
‫ אביב‬- ‫ תל‬,‫אפרון רוזן‬
,‫אפרון רוזן‬
‫ אביב‬- ‫ תל‬,8/16‫רחוב משה קול‬
[57] An osteotome for rhinoplasty
comprising a handle (1), a carrying part (2)
linked rigidly with the handle and two
cutting elements (3) secured on the
carrying part, each of them being bounded
by the inner surface and outer surface
which cross each other and form a cutting
edge (6) at the point of intersection, in
which case, both cutting elements present
each other their inner surfaces, are located
symmetrically relative to each other and
have a gap in between for the nasal
septum.
__________
July 24, 2007– ‫ט' באב התשס"ז‬
1902
]11[]21[
126835
‫נוגדנים לקולטן של אינטרפרון‬
ALPHA/BETA
]54[
ANTIBODIES AGAINST
INTERFERON ALPHA/BETA
RECEPTOR
]22[
]31[
]51[
29.04.1997
118096
]32[ 01.05.1996
]33[ IL
Int. Cl.8 A61K 039/395, A61P 037/02, 043/00, C07K 016/28, C12N 005/10, 005/12,
015/13, 015/63, G01N 033/53, 033/577
YEDA RESEARCH AND
‫ רחובות‬,‫ידע חברה למחקר ופיתוח בע"מ‬
DEVELOPMENT CO. LTD.
WO/1997/041229
INTERLAB LTD.,
,‫אינטר לאב בע"מ‬
KIRYAT WEIZMANN
‫ נס ציונה‬,‫קרית ויצמן‬
NES ZIONA 76110
]71[
]87[
]74[
[57] An antibody wherein said antibody
binds to the IFN α/β receptor or its
IFNAB-BPI and IFNAB-BPII soluble
forms and said antibody selectively blocks
the biological activity of IFN- α.
__________
]11[]21[
127162
‫מולקולות הקשורות עם פגיעה בכליות‬
]54[
KIDNEY INJURY RELATED
MOLECULES
]22[
]31[
23.05.1997
60/018228
]32[ 24.05.1996
]33[ US
60/023442
23.08.1996
US
Int. Cl.8 A61K 038/17, 039/395, 048/00, 051/10, A61P 013/12, C07K 014/435,
014/47, 016/18, 019/00, C12N 005/10, 005/12, 015/12, 015/63
BIOGEN IDEC MA INC., U.S.A.
THE GENERAL HOSPITAL
CORPORATION, U.S.A.
WO/1997/044460
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.,
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
]51[
]71[
]87[
]74[
[57] A polypeptide comprising an amino
acid sequence that is at least 90% identical
to the sequence of SEQ ID NO:3, SEQ ID
NO:5 or SEQ ID NO:7, and which is a
kidney injury molecule (KIM), said KIM
being a cell surface protein selectively
expressed in post-ischemic mammalian
kidney tissue.
__________
1903
July 24, 2007– ‫ט' באב התשס"ז‬
]11[]21[
128407
‫ליגאנד הקשור בגורם נמק של גידול‬
]54[
TUMOR NECROSIS FACTOR
RELATED LIGAND
]22[
]31[
07.08.1997
023541
]32[ 07.08.1996
]33[ US
028515
18.10.1996
US
040820
18.03.1997
US
Int. Cl.8 A61K 038/19, 039/395, 048/00, A61P 035/00, 037/00, 043/00, C07K
014/525, 016/24, C12N 001/15, 001/19, 001/21, 005/10, 015/12, 015/28, 015/63
BIOGEN IDEC MA INC., U.S.A.
THE FACULTY OF MEDICINE OF
THE UNIVERSITY OF GENEVA,
SWITZERLAND
WO/1998/005783
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.,
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
]51[
]71[
]87[
]74[
[57] A DNA sequence selected from the
group consisting of:
(a) a DNA sequence comprising a
nucleotide sequence shown in SEQ ID
NO:1 or 3;
(b) a DNA sequence which encodes a
polypeptide having the amino acid
sequence shown in SEQ ID NO:2 or 4;
(c) a DNA sequence which encodes a
fragment of the polypeptide of (b), wherein
said fragment has the capability of
regulating cell death;
(d) a DNA sequence which is 60%
homologous to the DNA sequence of (a)
and which encodes a polypeptide which is
capable of regulating cell death;
(e) a DNA sequence being degenerate to a
DNA sequence of any one of (a) to (c); and
(f) a DNA sequence encoding a soluble
form of the polypeptide encoded by the
DNA sequence of any one of (a) or (e)
which retains the capability of regulating
cell death; or the complementary strand
thereof.
_________
July 24, 2007– ‫ט' באב התשס"ז‬
1904
]11[]21[
128691
‫תולדות באנזאמידין המותמרות על ידי‬
‫חומצת אמינו טבעתית ותולדות חומצלה‬
‫הידרוקסית טבעתית ושימושם נגד קרישה‬
]54[
BENZAMIDINE DERIVATIVES
SUBSTITUTED BY CYCLIC
AMINO ACID AND CYCLIC
HYDROXY ACID DERIVATIVES
AND THEIR USE AS ANTICOAGULANTS
]22[
]31[
11.09.1997
08/713066
]32[ 12.09.1996
]33[ US
08/920319
27.08.1997
US
Int. Cl.8 A61K 031/00, 031/395, A61P 007/00, C07C 043/263, 211/43, 217/54,
229/52, 275/28, 279/18, 323/07, C07D 213/64, 251/26, 401/12, 403/12
SCHERING
AKTIENGESELLSCHAFT,
GERMANY
WO/1998/011094
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.,
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
]51[
]71[
]87[
]74[
[57] A compound of the formulae:
1905
July 24, 2007– ‫ט' באב התשס"ז‬
wherein: A is –C(R8) = or –N=;
Z1 and Z2 are independently –O-, -N(R9)-,
-S-, -S(O)-, -S(O)2-, or –OCH2-;
R1 and R4 are each independently
hydrogen, halo, alkyl, nitro –OR9, C(O)OR9, -C(O)N(R9)R10, -N(R9)R10, N(R9)C(O)R9 or N(H)S(O)2R12;
R2 is –C(NH)NH2 –C(NH)N(H)OR9, C(NH)N(H)C(O)OR12, C(NH)N(H)C(O)R9, -C(NH)N(H)S(O)2R12
or –C(NH)N(H)C(O)N(H)R9;
R3 is hydrogen, halo, alkyl, haloalkyl,
nitro, ureido, guanidine, -OR9, C(NH)NH2, -C(NH)N(H)OR9, C(O)N(R9)R10, -R11-C(O)N(R9)R10, CH(OH)C(O)N(R9)R10, -N(R9)R10, R11N(R9)R10, -C(O)OR9, -R11-C(O)OR9, N(R9)C(O)R9, (1,2)-tetrahydropyrimidinyl
(optionally substituted by alkyl), (1,2)imidazolyl (optionally substituted by
alkyl), or (1,2)-imidazolinyl (optionally
substituted by alkyl);
R5 and R6 are independently hydrogen,
halo, alkyl, haloalkyl, nitro, N-(R9)R10, C(O)OR9, -C(O)N(R9)R10, C(O)N(R9)CH2C(O)N(R9)R10, N(R9)C(O)N(R9)R10, -N(R9)C(O)R10, or –
N(R9)S(O)2R12;
R7 is –N(R9)-(C(R9)(R10))n-R13 (where n is
0 to 4), -O-(C(R9)(R10))n-R13 (where n is o
to 4), or –N(R14)R15;
R8 is hydrogen, alkyl or halo;
each R9 and R10 is independently
hydrogen, alkyl, aryl (optionally
substituted by halo, alkyl, hydroxy, alkoxy,
aralkoxy, amino, dialkylamino,
monoalkylamino, nitro, carboxy,
alkoxycarbonyl, aminocarbonyl,
monoalkylaminocarbonyl, or
dialkylaminocarbonyl), or aralkyl
(optionally substituted by halo, alkyl, aryl,
hydroxy, alkoxy, aralkyl, amino,
dialkylamino, monoalkylamino, nitro,
carboxy, alkoxycarbonyl, aminocarbonyl,
monoalkylaminocarbonyl, or
dialkylaminocarbonyl);
July 24, 2007– ‫ט' באב התשס"ז‬
R11 is a straight or branched alkylene
chain;
R12 is alkyl, aryl (optionally substituted by
halo, alkyl, hydroxy, alkoxy, aralkoxy,
amino, dialkylamino, monoalkylamino,
nitro, carboxy, alkoxycarbonyl,
aminocarbonyl, monoalkylaminocarbonyl,
or dialkylaminocarbonyl), or aralkyl
(optionally substituted by halo, alkyl, aryl,
hydroxy, alkoxy, aralkyl, amino,
dialkylamino, monoalkylamino, nitro,
carboxy, alkoxcyarbonyl, aminocarbonyl,
monoalkylaminocarbonyl, or
dialkylaminocarbonyl);
R13 is a mono- bi- or tri-cyclic carbocyclic
ring system containing from 3 to 15 carbon
atoms which may be partially or fully
saturated or aromatic, wherein the carbon
atoms may be optionally oxidized and
wherein the carbocyclic ring system is
substituted by –C(R9)(R10))m-R16 (where m
is 0 to 4), and is optionally substituted by
alkyl, aryl, aralkyl, alkoxy, aryloxy,
aralkoxy, halo, haloalkyl, haloalkoxy,
hydroxy, -N(R9)R10, -C(O)OR9, or –
C(O)N(R9)R10;
Or R13 is a mono-, bi- or tri-cyclic
heterocyclic ring system containing from 3
to 15 ring members including carbon and 1
to 4 hetero atoms selected from nitrogen,
oxygen and sulfur atoms, wherein the
carbon, nitrogen and sulfur atoms may be
optionally oxidized and wherein the
heterocyclic ring system may be partially
or fully saturated or aromatic and is
substituted by –(C(R9)(R10))m-R16 (where
m is 0 to 4), and is optionally substituted
by alkyl, aryl, aralkyl, alkoxy, aryloxy,
aralkoxy, halo, haloalkyl, haloalkoxy,
hydroxy, -N(R9)R10, -C(O)OR9, or –
C(O)N(R9)R10;
R14 and R15, together with the nitrogen
atom, form a mono- bi- or tri-cyclic
heterocyclic ring system containing from 3
to 15 ring members including carbon and 1
to 3 additional hetero atoms selected from
1906
nitrogen, oxygen and sulfur atoms,
wherein the carbon, nitrogen, or sulfur
atoms may be optionally oxidized and
wherein the heterocyclic ring system may
be partially or fully saturated or aromatic
and is substituted by –C(R9)(R10)m-R16
(where m is 0 to 4), and is optionally
substituted by alkyl, aryl, aralkyl, alkoxy,
aryloxy, aralkoxy, halo, haloalkyl,
haloalkoxy, hydroxy, -N(R9)R10, C(O)OR9, or –C(O)N(R9)R10; and
R16 is –C(O)OR9 or –C(O)N(R9)R10;
provided that when R7 is –N(R9)(C(R9)(R10)n-R13 (where n is 0), R13 can
not be phenyl, naphthyl or piperidinyl
substituted by –C(O)OR9; when R7 is –O(C(R9)(R10))n-R13 (where n is 0), R13 can
not be phenyl, naphthyl, piperidinyl or
pyrrolidinyl substituted by –C(O)OR9; and
when R7 is –N(R14)R15, R14 and R15,
together with the nitrogen atom, can not be
piperazinyl or piperidinyl substituted by –
C(O)OR9;
as a single stereoisomer or a mixture
thereof; or a pharmaceutically acceptable
salt thereof.
_________
]11[]21[
128765
‫תכשירי רוקחות המכילים איזופלאבונים‬
]54[
PHARMACEUTICAL
COMPOSITIONS CONTAINING
ISOFLAVONES
]22[
]31[
]51[
29.08.1997
PO2039
]32[ 30.08.1996
]33[ AU
Int. Cl.8 A61K 000/833000 000/840000 031/12, 031/16, 031/215, 031/353, 031/404,
031/473, A61P 001/00, 009/00, 013/00, 015/00, 017/10, 017/14, 019/00, 025/00,
025/28, 029/00, 035/00, C07C 049/24, 049/82, 069/035, 069/30, 229/00, 235/12,
C07D 209/08, 209/32, 311/38, 471/06
NOVOGEN RESEARCH PTY LTD.,
AUSTRALIA
WO/1998/008503
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
]71[
]87[
]74[
[57] Use of a compound for the
manufacture of a medicament for the
treatment, amelioration, defence against,
and/or prevention of menopausal
syndrome including hot flushes, anxiety
and depression, mood swings, night
sweats, headaches, and urinary
incontinence; osteoporosis; premenstrual
syndrome including fluid retention and
cyclical mastalgia, and dysmenorrhoea;
Reynaud's Syndrome; Reynaud's
1907
Phenomenon; Buergers Disease; coronary
artery spasm; migraine headaches;
hypertension; benign prostatic
hypertrophy; breast cancer; uterine cancer;
ovarian cancer; testicular cancer; large
bowel cancer; endometrial cancer;
prostatic cancer; uterine cancer;
atherosclerosis; Alzheimers disease;
inflammatory diseases including
inflammatory bowel disease, ulcerative
colitis, and Crohns disease; rheumatic
July 24, 2007– ‫ט' באב התשס"ז‬
diseases including rheumatoid arthritis;
acne; baldness including male pattern
baldness (alopecia hereditaria); psoriasis
and/or diseases associated with oxidant
stress including cancer, myocardial
infarction, stroke, arthirits, sunlight
induced skin damage or cataracts
whereby the compound is selected from
the group consisting of
R1 is H, or RACO where RA is C1-10 alkyl
or an amino acid,
R8 is CORD where RD is H, OH, C1-10 alkyl
or an amino acid,
R9 is CO2RC or CORE where RC is C1-10
alkyl and RE is H, C1-10 alkyl or an amino
acid, R10 is CORc or CORcORE where RC
and RE are as previously defined,
R11 is H or OH,
R12 is H, COOH, CO2RC where RC and is
as previously defined, or CONHRE where
RE is as previously defined,
R13 is H or RB where RB is an amino acid
or CORA where RA is as previously
defined,
R14 is H, or CORA where RA is as
previously defined,
R15 is CORA where RA is as previously
defined,
R16 is H, CORB or CO2RC where RB and
RC are as previously defined,
R17 is H or hydroxy C1-10 alkyl,
R18 is H or C1-10 alkyl, and "----"
represents either a single bond or a double
bond;
provided that where the use is a use for the
manufacture of a medicament for the
treatment or prophylaxis of menopausal
syndrome or premenstrual tension
syndrome compounds of the formulae
July 24, 2007– ‫ט' באב התשס"ז‬
1908
where R2 is OH; or where the compound is
are specifically excluded; and provided
that where the use is a use for the
manufacture of a medicament for the
treatment of a form of cancer, autoimmune
diseases including rheumatoid arthritis or
osteoporosis compounds of the formula
where R2 is OH, and R4 is CO2H or
CO2CH2CH3 are specifically excluded.
The applications for division
from this application have
not yet been published
,181059
‫בקשות חלוקה מבקשה זו‬
.‫שטרם פורסמו‬
________
1909
July 24, 2007– ‫ט' באב התשס"ז‬
]11[]21[
130123
‫הביטוי‬, LAG–3 ‫מוטנטים של החלבון‬
‫ השימוש בהם ושיטה לייצורם‬,‫שלהם‬
]54[
MUTANTS OF THE LAG-3
PROTEIN, THEIR EXPRESSION
AND USE AND METHOD FOR
THEIR PRODUCTION
]22[
]31[
]51[
25.11.1997
96/14608
]32[ 28.11.1996
]33[ FR
Int. Cl.8 A61K 038/17, 045/00, 051/00, A61P 035/00, 037/02, 037/06, C07K
014/435, 014/705, 019/00, C12N 001/21, 005/10, 015/12, 015/62, 015/63
INSTITUT GUSTAVE ROUSSY,
FRANCE
INSTITUT NATIONAL DE LA
SANTE ET DE LA RECHERCHE
MEDICALE (INSERM), FRANCE
APPLIED RESEARCH SYSTEMS
ARS HOLDING N.V.,
NETHERLANDS ANTILLES
WO/1998/023741
REINHOLD COHN AND
,‫ריינהולד כהן ושותפיו‬
PARTNERS,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]71[
]87[
]74[
[57] Purified polypeptide corresponding to
a mutated form of the soluble LAG-3
protein or of one of its fragments
comprising the extracellular domain D1
and D2, consisting in an amino acid
substitution at one of the positions selected
from the group consisting of:
position 30 where aspartic acid is replaced
by alanine (D30A),
position 56 where histidine is replaced by
alanine (H56A),
position 77 where tyrosine is replaced by
phenylalanine (Y77F),
position 88 where arginine is replaced by
alanine (R88A),
position 103 where arginine is replaced by
alanine (R103A),
position 109 where aspartic acid is
replaced by glutamic acid (D109E),
position 115 where arginine is replaced by
alanine (R115A);
or a deletion of the region between
position 54 (P) and position 66(A).
_________
]11[]21[
July 24, 2007– ‫ט' באב התשס"ז‬
130405
1910
]54[
USE OF COMPLEXES BETWEEN
CATIONIC LIPOSOMES AND
POLYDEOXYRIBONUCLEOTIDES
FOR PREPARATION OF
MEDICAMENTS
]22[
]51[
]71[
]74[
10.06.1999
Int. Cl.8 A61K 009/127, 031/00, 047/48
GENTIUM SPA, ITALY
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
[57] Complexes formed by cationic
liposomes and by
polydeoxyribonucleotides having a
molecular weight in the range 7,00060,000 Da, preferably 10,000-60,000 Da,
‫שימוש בקומפלכסים הנוצרים בין‬
‫ליפוזומים קטיונים‬
‫ופולידאוקסיריבונוקליאוטידים להכנת‬
‫תרופות‬
,‫ריינהולד כהן ושותפיו‬
‫ תל‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
‫אביב‬
obtainable by depolymerization of nucleic
acids, wherein the
polydeoxyribonucleotides are located on
the outer surface of the liposome, for use
as a medicament.
_________
]11[]21[
]54[
OPTICAL RESONATORS WITH
DISCONTINUOUS PHASE
ELEMENTS
]22[
]31[
]51[
]71[
29.04.1998
120754
]32[ 01.05.1997
Int. Cl.8 H01S 003/08
YEDA RESEARCH AND
DEVELOPMENT CO. LTD.
WO/1998/050986
IP – PARTNERSHIP,
P.O.BOX 669
RAANANA 43350
]87[
]74[
[57] An optical resonator comprising
reflector elements (20, 23) and at least one
static discontinuous phase element (86)
disposed between said reflector elements,
said at least one discontinuous phase
element having planar regions (90) and at
least one sharp discontinuity defining a
boundary (95) between said planar regions,
said at least one discontinuous phase
element being aligned such that said planar
regions introduce a discontinuous phase
1911
132455
‫מהודים אופטיים עם אלמנטים של פאזה‬
‫לא מתמשכת‬
]33[
IL
‫ רחובות‬,‫ידע חברה למחקר ופיתוח בע"מ‬
,‫הנרי סיני‬
‫ רעננה‬,669 .‫ד‬.‫ ת‬,
change to separate regions of field
distributions in at least one desired mode
propagating in said resonator, such that
said separate regions of said field
distributions of said at least one desired
mode, after traversing said element, are
generally in phase, and said at least one
sharp discontinuity being operative to
produce a change in the phase of at least
one undesired mode of said resonator, and
being disposed at a location corresponding
July 24, 2007– ‫ט' באב התשס"ז‬
to an area of significant intensity of said at
least one undesired mode, whereby the
divergence of said at least one undesired
mode is greater than the divergence
naturally arising from the cavity of said at
least one desired mode and propagation of
said at least one undesired mode is
suppressed.
__________
]11[]21[
132666
‫תכשירי רוקחות פיטואסטרוגניים‬
]54[
PHYTOESTROGENIC
PHARMACEUTICAL
PREPARATIONS
]22[
]51[
]71[
01.11.1999
Int. Cl.8 A61K 003/600000 045/00, 045/06, C07D 311/02
MIGAL GALILEE
‫ ראש פינה‬,‫מיג"ל מרכז ידע גליל עליון‬
TECHNOLOGICAL CENTER
LUZZATTO & LUZZATTO,
,‫לוצאטו את לוצאטו‬
INDUSTRIAL PARK, OMER,
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
P.O.B. 5352,
BEER-SHEVA 84152
]74[
[57] Phytoestrogenic pharmaceutical
composition comprising as active
July 24, 2007– ‫ט' באב התשס"ז‬
ingredient at least one isoflavan having
estrogen-like activity, optionally also
1912
‫‪carrier, adjuvant, excipient or diluent.‬‬
‫‪comprising a pharmaceutically acceptable‬‬
‫__________‬
‫‪132700‬‬
‫חוט מאריך בעל שקע ותקע מאובטחים‬
‫יראל יאירוב‪ ,‬ירושלים‬
‫יראל יאירוב‪,‬‬
‫רח' שבתאי הנגבי ‪ ,75\19‬ירושלים‬
‫[‪ ]57‬מערכת לאבטחה של מחבר זכר‪-‬נקבה‪,‬‬
‫המערכת כוללת‪:‬‬
‫(א) שני מעטים חיצוניים (‪ )1,2‬דמויי קונוס חלול‪,‬‬
‫כל אחד מיועד להכלה של חלק זכרי או חלק‬
‫נקבי‪ ,‬כל מעטה חיצוני כולל‪ :‬שתי קליפות (‪)4‬ת‬
‫כל אחת מהווה מחצית מעטפת קונוס‬
‫המתחברות זו לזו‪ ,‬כל קליפה כוללת בשוליה‪,‬‬
‫סמוך לאזור החיבור עם הקליפה השניה‪ ,‬שני‬
‫מבנים דמויי כנף (‪ ,)12‬כך שבחיבור הקליפות זו‬
‫לזו‪ ,‬המבנים דמויי הכנף מתחברים ויוצרים‬
‫משני צידי הקונוס החלול – שני חללים מאורכים‬
‫[‪]11[]21‬‬
‫‪EXTENSION CORD WITH‬‬
‫‪FASTENED PLUG AND SOCKET‬‬
‫[‪]54‬‬
‫‪02.11.1999‬‬
‫‪Int. Cl.8 H01R 004/00‬‬
‫‪YAREL YAIROV‬‬
‫‪YAREL YAIROV,‬‬
‫‪SHABTAY HANEGBI ST 75/19‬‬
‫‪JERUSALEM‬‬
‫[‪]22‬‬
‫[‪]51‬‬
‫[‪]71‬‬
‫[‪]74‬‬
‫(‪12‬א); בדופן הפנימית של המבנים דמויי הכנף‪,‬‬
‫לאורך השוליים נמצאות מגרעות ארוכות;‬
‫(ב) שתי שיני אבטחה (‪ )16‬נפרדות הכוללות‪:‬‬
‫מבנה מאורך שקצה אחד שלו מיועד לאחיזה‬
‫באחד מהחללים המאורכים הנוצרים מחיבור‬
‫שני מבנים דמויי כנף‪ ,‬והקצה השני של שן‬
‫האבטחה כולל בליטה (‪ )14‬המתאימה למגרעת‬
‫במבנה דמוי הכנף; כך שבזמן ששני מעטים‬
‫חיצוניים דמויי קונוס מתחברים זה לזה‪ ,‬שתי‬
‫שיני אבטחה מצמידות את החללים המאורכים‬
‫שנוצרו ע"י המבנים דמויי הכנף בקירבה אלו‬
‫לאלו‪.‬‬
‫________‬
‫‪133195‬‬
‫ט' באב התשס"ז –‪July 24, 2007‬‬
‫[‪]11[]21‬‬
‫‪1913‬‬
‫אצילאנלידים שאינם סטרואידים‬
‫המותמרים בקבוצת (הטרו) ציקליות עם‬
‫פעילות מעורבת של גאסטגן ואנדרוגן‬
‫ותהליכים להכנתם‬
]54[
NONSTEROIDAL (HETERO)
CYCLICALLY SUBSTITUTED
ACYLANILIDES WITH MIXED
GESTAGEN AND ANDROGEN
ACTIVITY AND PROCESSES FOR
THEIR PRODUCTION
]22[
]31[
]51[
02.06.1998
197 23 722.3 ]32[ 30.05.1997
]33[ DE
Int. Cl.8 A61K 031/16, 031/365, 031/38, 031/41, 031/50, 031/535, A61P 005/26,
005/34, C07C 235/26, C07D 237/32, 249/18, 265/02, 271/12, 285/10, 307/00, 307/88,
311/76, 333/72
SCHERING
AKTIENGESELLSCHAFT,
GERMANY
WO/1998/054159
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.,
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
]71[
]87[
]74[
[57] Compounds of the formula
where R1 and R2 are the same or different
and are each a hydrogen atom, a C1-C5alkyl group or a halogen atom, or else,
together with the carbon atom of the chain,
are a ring having a total of 3-7 members,
R3 is a C1-C5-alkyl group or a partly or
fully fluorinated C1-C5-alkyl group,
A is a mono- or bicyclic, carbocyclic or
heterocyclic, aromatic ring which is
optionally substituted by one or more
radicals selected from halogen atoms, C1C5-alkyl groups, C2-C5-alkenyl groups, CR5=CR6R7 where R5, R6 and R7 are the
same or different and are each
independently hydrogen atoms or C1-C5alkyl groups, hydroxyl groups, hydroxyl
July 24, 2007– ‫ט' באב התשס"ז‬
groups which bear a C1-C10-acyl group, a
C3-C10-carbalkoxyalkyl group, a C2-C5cyanoalkyl group, a C3-C10 unsubstituted
or substituted allyl group, a C3-C10
unsubstituted or substituted propargyl
group, a C2-C5-alkoxyalkyl group or a C1C5-alkyl group substituted fully or partly
by fluorine atoms, or is selected from the
cyano or nitro group, C1-C5-alkoxy groups,
C1-C5-alkylthio groups, mono- or
disubstituted C1-C10 amino groups or
partly or fully fluorinated C1-C5-alkyl
groups,
B is a carbonyl or a CH2 group and
Ar is a ring system selected from the group
of the subformulae
1914
where the X3a, X4, X6, X7 radicals (in the
subformula 2), the X4, X6, X7 radicals (in
the subformulae 3 and 4), the X3a, X3b, X4,
X6, X7 radicals (in the subformulae 5, 6
and 7) or the Y4, Y5, Y7, Y8 radicals (in the
subformulae 8, 9, 10 and 11) are the same
or different and are selected from
hydrogen atoms, C1-C5-alkyl groups which
may additionally contain a hydroxyl group
optionally etherified with a C1-C5-alkyl
group or esterified with a C1-C5-alkanoyl
group, partly or fully fluorinated C1-C5alkyl groups, C2-C5-alkenyl groups, CR5=CR6R7 where R5, R6 and R7 are each
as defined above, alkynyl groups -C≡CR5
where R5 is as defined above,
the X3a and X3b radicals, together with the
carbon atoms of the benzofused ring
system 5, 6 or 7, may also form a ring
having a total of 3-7 members, and
additionally the X4, X6, X7 radicals (in the
subformulae 2, 3, 4, 5, 6 and 7) or the Y4,
Y5, Y7, Y8 radicals (in the subformulae 8,
9, 10 and 11) are selected from halogen
atoms, hydroxyl groups, C1-C5-alkoxy
groups or C1-C5-alkanoyl groups, and also,
in the case that B is a CH2 group, the
physiologically tolerated salts of the
compounds of the general formula I with
acids.
________
1915
July 24, 2007– ‫ט' באב התשס"ז‬
]11[]21[
133686
,‫אנלוגים של גליקופרוטאין הורמונים‬
‫הכנתם והשימוש בהם‬
]54[
GLYCOPROTEIN HORMONE
ANALOGS, THEIR PREPARATION
AND THEIR USE
]22[
]31[
]51[
]71[
25.06.1998
60/050784
]32[ 25.06.1997
]33[ US
Int. Cl.8 A61K 038/22, 038/24, C07K 014/575, 014/59, C12N 015/16
APPLIED RESEARCH SYSTEMS
ARS HOLDING N.V.,
NETHERLANDS ANTILLES
WO/1998/058957
INTERPHARM LABORATORIES
,‫אינטרפארם מעבדות בע"מ‬
LTD.,
,‫ פארק לתעשיות עתירות ידע‬,‫קרית ויצמן‬
KIRYAT WEIZMANN
‫ציונה‬-‫נס‬
NES ZIONA 76110
]87[
]74[
[57] An analog of glycoprotein hormone,
wherein said glycoprotein hormone is
selected from the group consisting of
human chronic gonadotropin (hCG),
human luteinizing hormone (hLH), human
folicile stimulating hormone (hFSH),
human thyroid stimulating hormone
(hTSH) and functional muteins thereof,
wherein functional muteins are modified
forms of the glycoprotein hormones,
wherein the modifications do not create
inter-subunit disulphide bonds, and
wherein at least 80% of the functional
biological activity of the original hormone
is retained, having an α- subunit and a β-
subunit, wherein the amino acid sequences
of said glycoprotein hormone subunit are
modified so as to create an intersubunit
disulfide bond between an α- subunit
cysteine and a β-subunit cysteine, which
cysteines are disposed within two residues
of native cysteine residue positions of said
glycoprotein hormone and not outside of
the outermost cysteine units of the
corresponding native subunit, for improved
stability, said analog retaining at least 25%
of the affinity of the corresponding
hormone for its native glycoprotein
hormone receptor.
__________
]11[]21[
July 24, 2007– ‫ט' באב התשס"ז‬
133799
1916
‫מקדימים עצבים מגבילי גדילה‬
]54[
LINEAGE-RESTRICTED
NEURONAL PRECURSORS
]22[
]31[
03.07.1998
08/909435
]32[ 04.07.1997
]33[ US
09/109858
02.07.1998
US
Int. Cl.8 A61K 048/00, C12N 005/06, 005/08
UNIVERSITY OF UTAH RESEARCH
FOUNDATION, U.S.A.
WO/1999/001159
SANFORD T.COLB & CO.,
,'‫ קולב ושות‬.‫סנפורד ט‬
P.O.B. 2273,
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
REHOVOT
]51[
]71[
]87[
]74[
[57] A method of isolating a pure
population of mammalian CNS neuronrestricted precursor cells comprising the
steps of:
(a) isolating a population of mammalian
multipotent CNS stem cells capable of
generating both neurons and glia;
(b) incubating the multipotent CNS stem
cells in a medium configured for inducing
said cells to begin differentiating;
(c) removing A2B5 + cells from the
differentiating cells via specific antibody
capture with an antibody that specifically
recognizes A2B5;
(d) purifying from the differentiating cells
a subpopulation of cells expressing
embryonic neural cell adhesion molecule;
and
(e) incubating the purified subpopulation
of cells in a medium configured for
supporting adherent growth thereof,
wherein the cells are derived from (i)
spinal cords of approximately 13.5 day
embryos of rats or equivalent embryonic
stages of other mammals, or (ii) cells
equivalent to (i) developed by proliferation
and differentiation from early embryonic
spinal cord tissue or embryonic stem cells,
and wherein the isolated cells are capable
of self-renewal in the presence of FGF.
_________
]11[]21[
1917
134371
July 24, 2007– ‫ט' באב התשס"ז‬
]54[
‫תכשיר לבקרת ריבוי ומוות של תאים‬
COMPOSITION FOR
REGULATING CELL
PROLIFERATION AND CELL
DEATH
]22[
]31[
05.08.1998
60/054777
]32[ 05.08.1997
]33[ US
60/075067
18.02.1998
US
60/075111
18.02.1998
US
60/086317
21.05.1998
US
]51[ Int. Cl.8 A61K 048/00, C12N 015/19, 015/31
]71[ BIONICHE LIFE SCIENCES INC.,
CANADA
]87[ WO/1999/007383
]74[ EITAN, PEARL, LATZER AND
,‫ לצר וכהן צדק‬,‫ פרל‬,‫איתן‬
COHEN ZEDEK,
‫ הרצליה‬,12688 .‫ד‬.‫ ת‬, 7 ‫רחוב שנקר‬
P.O.B. 12688,
HERZLIYA 46733
[57] A composition comprising:
(b) a pharmaceutically acceptable carrier,
(a) Mycobacterium phlei-DNA (M-DNA),
wherein the M-DNA has anti-cancer
and
activity.
The applications for division
from this application have
not yet been published
,180924
‫בקשות חלוקה מבקשה זו‬
.‫שטרם פורסמו‬
____________
]11[]21[
July 24, 2007– ‫ט' באב התשס"ז‬
134494
1918
–13 ‫תהליכים להכנת נגזרות‬
‫דאוקסיאנטראציקלין ותכשירים רפואיים‬
‫המכילים אותן‬
]54[
PROCESSES FOR PREPARING 13DEOXYANTHRACYCLINE
DERIVATIVES AND
PHARMACEUTICAL
COMPOSITIONS CONTAINING
THEM
]22[
]31[
]51[
]71[
13.08.1998
08/910218
]32[ 13.08.1997
]33[ US
Int. Cl.8 A61K 031/704, A61P 035/00, C07H 015/252, C12P 019/56
GEM PHARMACEUTICALS, INC.,
U.S.A.
WO/1999/008687
EITAN, PEARL, LATZER AND
,‫ לצר וכהן צדק‬,‫ פרל‬,‫איתן‬
COHEN ZEDEK,
‫ הרצליה‬,12688 .‫ד‬.‫ ת‬, 7 ‫רחוב שנקר‬
P.O.B. 12688,
HERZLIYA 46733
]87[
]74[
[57] A pharmaceutical composition for
treating a mammalian host in need of an
anticancer treatment, comprising an
effective anticancer amount without
limitation on total cumulative dosage of at
least one compound of the formula
wherein R1 is H or OH: R2 is H, OH, or
OMe; R3 is H or OH: R4 is H or OH: and
R5 is a carbohydrate or substituted
carbohydrate, and wherein the total
cumulative dosage is at least 825 mg/m2.
__________
]11[]21[
1919
134926
July 24, 2007– ‫ט' באב התשס"ז‬
]54[
VACUUM PLASMA PROCESSOR
HAVING COIL WITH ADDED
CONDUCTING SEGMENTS TO
ITS PERIPHERAL PART
]22[
]31[
]51[
]71[
16.09.1998
08/931504
]32[ 16.09.1997
Int. Cl.8 H01J 037/00
LAM RESEARCH CORPORATION,
U.S.A.
WO/1999/014784
WOLFF, BREGMAN AND GOLLER,
19B KEREN HAYESOD ST.,
P.O.B. 1352,
JERUSALEM 91013
]87[
]74[
[57] A vacuum plasma processor for
treating a workpiece with a plasma
comprising a vacuum chamber where the
workpiece is adapted to be located, the
chamber having an inlet for introducing
into the chamber a gas which can be
converted into the plasma for treating the
workpiece, a coil (100) positioned to
couple an RF field to the gas for exciting
the gas to the plasma state, the RF field
derived from a main part of the coil
interacting with an electromagnetic shield,
the electromagnetic shield substantially
confining the coil RF field to structure
associated with the processor and
interacting with the RF field derived from
the main coil part in such a manner as to
tend to reduce (a) the RF field derived
from the main coil part in a part of the
July 24, 2007– ‫ט' באב התשס"ז‬
‫מעבד פלסמה בואקום בעל סליל עם‬
‫קטעים מוליכים שהוספו להיקפו‬
]33[
US
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
plasma generally aligned with a peripheral
portion of the main coil part and (b)
plasma flux density in the part of the
plasma generally aligned with the main
coil part peripheral portion relative to flux
density of a portion of the plasma
generally inside the part of the plasma
generally aligned with the main coil part
peripheral portion, the main coil part
peripheral portion including an additional
coil structure (161-168) for supplying an
additional amount of RF field to the
portion of the plasma generally aligned
with the main coil part peripheral portion,
the additional amount of RF field supplied
increasing the plasma flux density in the
part of the plasma generally aligned with
the main coil part peripheral portion.
1920
_________
]11[]21[
135520
-8-‫בנז(ו)איל‬-8-‫מותמרות‬-N ‫תולדות‬
,‫מטאנמין‬-3- ‫]אוקטן‬1.2.3[ ‫אזאביציקלו‬
‫ותכשירים פרמצבטיים המכילים אותן‬
]54[
N-SUBSTITUTED 8-BENZ(O)YL-8AZABICYCLO [3.2.1.] OCTANE-3METHANAMINE DERIVATIVES,
THEIR PREPARATION AND
PHARMACEUTICAL
COMPOSITIONS CONTAINING
THEM
]22[
]31[
07.10.1998
97/12580
]32[ 09.10.1997
]33[ FR
97/12583
09.10.1997
FR
Int. Cl.8 A61K 031/46, A61P 025/00, C07D 451/02
SANOFI AVENTIS, FRANCE
WO/1999/019325
SANFORD T.COLB & CO.,
,'‫ קולב ושות‬.‫סנפורד ט‬
P.O.B. 2273,
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
REHOVOT
]51[
]71[
]87[
]74[
[57] Compound in the form of a pure
geometrical isomer or a mixture of such
isomers of the formula
1921
July 24, 2007– ‫ט' באב התשס"ז‬
in which U represents (A) either a 2, 3dihydro-1H-inden-2-yl group of the
formula
or (B) a heterocylic group of the formula
in which V represents a hydrogen or
halogen atom, a (C1-C3) alkyl group or one
or two (C1-C3) alkoxy groups, W and X
each represent, respectively, either two
oxygen atoms, or an oxygen atom and a
CH2 group, or a CH2 group and an oxygen
atom, or an oxygen atom and a CO group,
n represents the number 0 or 1,
R represents either a propyl group when U
represents a 2,3-dihydro-1H-inden-2-yl
group of general formula (A) or a
hydrogen atom or a (C1-C3) alkyl group
when U represents a heterocyclic group of
general formula (B),
Y represents one or more atoms or groups
chosen from the following: hydrogen,
halogen, (C1-C3) alkyl and (C1-C3) alkoxy,
and Z represents two hydrogen atoms or an
oxygen atom.
__________
]11[]21[
136544
‫תרבות אנושית של נוגדני עכבר‬
]54[
HUMANIZATION OF MURINE
ANTIBODY
]22[
]31[
]51[
]71[
04.12.1998
08/986016
]32[ 05.12.1997
]33[ US
Int. Cl.8 C12P 021/08, C40B 004/01000
THE SCRIPPS RESEARCH
INSTITUTE, U.S.A.
WO/1999/029888
SANFORD T.COLB & CO.,
,'‫ קולב ושות‬.‫סנפורד ט‬
P.O.B. 2273,
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
REHOVOT
]87[
]74[
July 24, 2007– ‫ט' באב התשס"ז‬
1922
[57] A method of producing a humanized
mouse monoclonal antibody which
consists of the steps:
(a) constructing a first human antibody
heavy or light chain library consisting of
antibody heavy chains or antibody light
chains in which each chain in the first
human antibody light or heavy chain
library has three complementarity
determining region (CDR) loops in which
the complementarity determining region
three (CDR3) loop in each light or heavy
chain has the amino acid sequence of a
corresponding mouse antibody heavy or
light chain CDR3 loop and is flanked by
unaltered human framework residues;
(b) constructing a second human antibody
heavy or light chain library consisting of
antibody heavy chains or antibody light
chains, in which each chain in the second
human antibody heavy or light chain
library has three complementarity
determining region (CDR) loops in which
the complementarity determining region
three (CDR3) loop in each light or heavy
chain has the amino acid sequence of a
corresponding mouse antibody heavy or
light chain CDR3 loop and is flanked by
unaltered human framework residues;
wherein the chains of said second human
antibody heavy or light chain library are
the complementary heavy or light chain of
said first human antibody heavy or light
chain library chains, such that one library
is a light chain library and the other library
is a heavy chain library;
(c) creating a library of heavy and light
chain pairs by combining chains from said
first human antibody heavy or light chain
library of step (a) with a complementary
chain from an antibody which binds a
preselected antigen forming a library of
heavy and light chain pairs;
(d) isolating antigen binding chains of step
(a) by selecting from the library of step (c),
a heavy and light chain pair which binds to
said preselected antigen, isolating from the
antigen binding heavy and light chain pair,
the antigen binding chains of step (a);
(e) creating a humanized pair library by
combining isolated antigen binding chains
of step (d), with chains of said library of
step (b), so that a first isolated chain of
step (d), together with a complementary
second chain in said library of step (b)
combine to form a heavy and light chain
humanized pair library;
(f) selecting from the humanized pair
library of step (e) a humanized heavy and
light chain pair that binds to said
preselected antigen; and
(g) combining two of said selected
humanized heavy and light chain pair of
step (f) to form a whole antibody; wherein
said humanized mouse monoclonal
antibody binds the same antigen as the
mouse monoclonal antibody.
__________
]11[]21[
1923
136566
July 24, 2007– ‫ט' באב התשס"ז‬
]54[
METHOD FOR TRANSFER
ALIGNMENT OF AN INERTIAL
MEASUREMENT UNIT IN THE
PRESENCE OF UNKNOWN
AIRCRAFT MEASUREMENTS
DELAYS
]22[
]51[
]71[
05.06.2000
Int. Cl.8 F41G 007/36
RAFAEL-ARMAMENT
DEVELOPMENT AUTHORITY
LTD.
JOSEPH BEN-YAAKOV, JACOB
REINER
DR. MARK FRIEDMAN LTD.,
MOSHE AVIV TOWER, 54TH
FLOOR
7 JABOTINSKY STREET
52520
RAMAT GAN
]72[
]74[
[57] A method for velocity match transfer
alignment between a carrier vehicle and a
carried vehicle comprised of:
(a) repeatedly measuring a velocity
difference between the carrier vehicle and
the carried vehicle;
(b) subsequent to each said measurement,
updating a state vector that include a
predicted value of said velocity difference;
(c) between said measurements,
propagating said state vector forward in
time; and
(d) moving the carrier vehicle and the
carried vehicle along a trajectory that
July 24, 2007– ‫ט' באב התשס"ז‬
‫שיטה לכיוונון של יחידת מדידה אינרציאלית‬
‫בנוכחות עיכובי מדידות מטוסים בלתי‬
‫ידועים‬
,‫רשות לפיתוח אמצעי לחימה בע"מ‬-‫רפא"ל‬
‫חיפה‬
‫ יעקב ריינר‬,‫יוסף בן יעקב‬
,‫ד"ר מרק פרידמן בע"מ‬
,77 ‫ ז'בוטינסקי‬54 ‫ קומה‬,‫מגדל משה אביב‬
‫ גן‬-‫רמת‬
includes a first segment, a second segment
and a third segment, said moving along
said first segment being effected at a first
substantially constant velocity, said
moving along second segment including an
acceleration, said moving along said third
segment being effected at a second
substantially constant velocity different
from said first velocity, said measuring,
said updating, and said propagating being
effected during said moving along said
first and third segments, only said
propagating being effected while moving
along said second segment.
1924
__________
]11[]21[
136767
‫שימוש באוריאות פניליות והטרוציקליות‬
RAF ‫מותמרות ליצור תרופות לעיכוב‬
‫קינאז ומספר תרכובות חדשות כאלה‬
]54[
USE OF SUBSTITUED PHENYL
AND HETEROCYCLIC UREAS
FOR THE MANUFACTURE OF
MEDICAMENTS FOR THE
INHIBITION OF RAF KINASE
AND SOME SUCH NEW
COMPOUNDS
]22[
]31[
]51[
22.12.1998
08/996343
]32[ 22.12.1997
]33[ US
Int. Cl.8 A61K 031/33, A61P 035/00, C07D 231/38, 257/06, 261/14, 263/38, 271/10,
277/38, 285/12, 307/66, 333/36, 401/12, 403/12, 409/12, 413/12, 417/12
BAYER PHARMACEUTICALS
CORPORATION, U.S.A.
WO/1999/032106
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
]71[
]87[
]74[
[57] Use of a compound of the formula
1925
July 24, 2007– ‫ט' באב התשס"ז‬
wherein B is phenyl, pyridinyl,
pyrimidinyl, pyrazinyl, pyridazinyl,
naphthyl, quinolinyl, isoquinolinyl,
phthalimidinyl, furyl, pyrrolyl, imidazolyl,
pyrazolyl, oxazolyl, isoxazolyl, thiazolyl,
isothiazolyl, benzofuryl, benzothienyl,
indolyl, benzopyrazolyl, benzoxazolyl,
benzisoxazolyl, benzothiazolyl or
benzisothiazolyl, substituted by one or
more substituents independently selected
from the group consisting of halogen, up to
per-halosubstitution, and Xn, wherein n is
0-3 and each X is independently selected
from the group consisting of –CN, -CO2R5,
-C(O)NR5R5', -C(O)R5, -NO2, -OR5, -SR5,
-NR5R5'-NR5C(O)OR5', -NR5C(O)R5', C1C10 alkyl, C2-C10 alkenyl, C1-C10 alkoxy,
C3-C10 cycloalkyl, C6-C14 aryl, C3-C13
heteroaryl, up to per halo-substituted C1C10 alkyl, up to per halo-substituted C2-C10
alkenyl, up to per halo-substituted C1-C10
alkoxy, up to per halo-substituted C3-C10
cycloalkyl and –Y-Ar;
wherein R5 and R5' are independently
selected from H, C1-C10 alkyl, C2-C10
alkenyl, C3-C10 cycloalkyl, up to perhalosubstituted C1-C10 alkyl, up to per-
halosubstituted C2-C10 alkenyl and up to
per-halosubstituted C3-C10 cycloalkyl,
wherein Y is –O-, -S-, -N(R5)-, -(CH2)m-, C(O)-, -CH(OH)-, (CH2)mO-,
NR5C(O)NR5 NR5'-, NR5C(O)-, C(O)NR5-, (CH2)mS-, -(CH2)mN(R5)-, O(CH2)m-, -CHXa, -CXa2-, -S-(CH2)m- and
–N(R5)(CH2)m-,
m=1-3, and Xa is halogen; and
Ar is a 5-10 member aromatic structure
containing 0-4 members of the group
consiting of nitrogen, oxygen and sulfur
optionally substituted by halogen up to
per-halosubstitution and optionally
substituted by Zn1, wherein n1 is 0 to 3 and
each Z is independently selected from the
group consisting of –CN, =O, -CO2R5, C(O)NR5R5', -C(O)-NR5, -NO2, -OR5, SR5, -NR5R5', -NR5C(O)OR5', -C(O)R5, NR5C(O)R5', -SO2R5, SO2NR5R5', C1-C10
alkyl, C1-C10 alkoxy, C3-C10 cycloalkyl, up
to per halo-substituted C1-C10 alkyl; and up
to per halo substituted C3-C10 cycloalkyl,
and
A is a heteroaryl moiety selected from the
group consisting of
wherein R1 is selected from the group
consisting of halogen, C3-C10 alkyl, C3-C10
cycloalkyl, C1-C13 heteroaryl, C6-C14 aryl,
C7-24 alkaryl, up to per-halosubstituted C1C10 alkyl, up to per-halosubstituted C3-C10
cycloalkyl, up to per-halosubstituted C1-
C13 heteroaryl, up to per-halosubstitued
C6-14 aryl, and up to per-halosubstituted C714 alkaryl;
R2 is selected from the group consisting of
H, -C(O)R4, -C(O)NR3R3', C1-C10 alkyl,
C3-C10 cycloalkyl, C7-C24 alkaryl, C4-C23
July 24, 2007– ‫ט' באב התשס"ז‬
1926
alkheteroaryl, substituted C1-C10 alkyl,
substituted C3-C10 cycloalkyl, substituted
C7-C24 alkaryl and substituted C4-C23
alkheteroaryl,
where if R2 is a substituted group, it is
substituted by one or more substituents
independently selected from the group
consisting of –CN, -CO2R4, -C(O)-NR3R3',
-NO2, -OR4, -SR4, and halogen up to perhalosubstitution, wherein R3 and R3' are
independently selected from the group
consisting of H, -OR4, -SR4, -NR4R4', C(O)R4, -CO2R4, -C(O)NR4R4', C1-C10
alkyl, C3-C10 cycloalkyl, C6-C14 aryl, C3C13 heteroaryl up to per halosubstituted C1C10 alkyl, up to per-halosubstituted C3-C10
cycloalkyl, and up to per-halosubstituted,
C6-C14 aryl or C3-C13 heteroaryl; and
wherein R4 and R4' are independently
selected from the group consisting of H,
C1-C10 alkyl, C3-C10 cycloalkyl, C6-C14
aryl, C3-C13 heteroaryl, up to perhalosubstituted C1-C10 alkyl, up to perhalosubstituted C3-C10 cycloalkyl, and up
to per-halosubstituted, C6-C14 aryl or C3C13 heteroaryl,
Ra is C1-C10 alkyl, C3-C10 cycloalkyl, up to
per-halosubstituted C1-C10 alkyl and up to
per-halosubstituted C3-C10 cycloalkyl; and
Rb is hydrogen or halogen,
Rc is hydrogen, halogen, C1-C10 alkyl, up
to per-halosubstituted C1-C10 alkyl or
combines with R1 and the ring carbon
atoms to which R1 and Rc are bound to
form a 5- or 6- membered cycloalkyl, aryl
or hetaryl ring with 0-2 members selected
from O, N and S;
subject to the proviso that where A is
B is not
wherein n=2-4,
for the manufacture of a medicament for
the treatment of cancerous cell growth
mediated by raf kinase.
1927
Claimed as novel are compounds of the
formula
July 24, 2007– ‫ט' באב התשס"ז‬
wherein R2 is selected from the group
consisting of H, -C(O)R4, -CO2R4, C(O)NR3R3', C1-C10 alkyl, C3-C10
cycloalkyl, substituted C1-C10 alkyl,
substituted C3-C10 cycloalkyl, where if R2
is a substituted group, it is substituted by
one or more substituents independently
selected from the group consisting of –CN,
-CO2R4, -C(O)NR3R3', -NO2, -OR4, -SR4,
and halogen up to per-halosubstitution,
wherein R3 and R3' are independently
selected from the group consisting of H,
C1-C10 alkyl, C3-C10 cycloalkyl, up to perhalosubstituted C1-C10 alkyl, and up to perhalosubstituted C3-C10 cycloalkyl, and
wherein R4 and R4' are independently
selected from the group consisting of H,
C1-C10 alkyl, C3-C10 cycloalkyl, up to perhalosubstituted C1-C10 alkyl, and up to perhalosubstituted C3-C10 cycloalkyl, wherein
R1 is selected from the group consisting of
C3-C6 alkyl, C3-C6 cycloalkyl, up to perhalosubstituted C3-C6 alkyl and up to perhalosubstituted C3-C6 cycloalkyl,
B is phenyl, pyridinyl, indolinyl,
isoquinolinyl, quinolinyl, or naphthyl;
substituted by C6-C14 aryl, C3-C13
heteroaryl, or –Y-Ar, wherein the cyclic
structures of B are optionally substituted
by halogen, up to per halo, and optionally
substituted by X1n and wherein n=0-2;
each X1 is independently selected from the
group of –CN, -CO2R5, -C(O)R5, C(O)NR5R5', -OR5, -NO2, -NR5R5', C1-C10
alkyl, C2-10-alkenyl, C1-C10-alkoxy, C3-C10
cycloalkyl, -SR5, -NR5C(O)OR5',
NR5C(O)R5', substituted C1-C10 alkyl,
substituted C2-10 alkenyl, substituted C1-
July 24, 2007– ‫ט' באב התשס"ז‬
C10-alkoxy, substituted C3-C10 cycloalkyl,
wherein if X1 is a substituted group, it is
substituted by one or more substituents
independently selected from the group
consisting of –CN, -CO2R5, -C(O)R5, C(O)NR5R5', -OR5, -SR5, -NR5R5', NO2, NR5C(O)R5', -NR5C(O)OR5' and halogen
up to per-halosubstitution;
wherein R5 and R5' are independently
selected from H, C1-C10 alkyl, C2-10alkenyl, C3-C10 cycloalkyl, C6-C14 aryl, C3C13 heteroaryl, C7-C24 alkaryl, C4-C23
alkheteroaryl, up to per-halosubstituted C1C10 alkyl; up to per-halosubstituted C2-10alkenyl, and up to per-halosubstituted C3C10 cycloalkyl, wherein Y is –O-, -S-, N(R5)-, -(CH2)-m, -C(O)-, -CH(OH)-, (CH2)mO-, -NR5C(O)NR5R5'-, -NR5C(O)-,
-C(O)NR5-, -(CH2)mS-, (CH2)mN(R5)-, O(CH2)m-, -CHXa, -CXa2-, -S-(CH2)m- and
–N(R5)(CH2)m-, m=1-3, and Xa is halogen;
and
Ar is a 5-10 member aromatic structure
containing 0-4 members of the group
consisting of nitrogen, oxygen and sulfur
which is optionally substituted by halogen
up to per-halo and optionally substituted
by Znl, wherein nl is 0 to 3 and each Z is
independently selected from the group
consisting of –CN, -CO2R5, =O, C(O)NR5R5', -C(O)R5, -NO2, -OR5, -SR5, NR5R5', -NR5C(O)OR5', NR5C(O)R5', SO2R5, -SO2R5 R5' C1-C10 alkyl, C1-C10
alkoxy, C3-C10 cycloalkyl, substituted C1C10 alkyl, and substituted C3-C10
cycloalkyl, wherein if Z is a substituted
group, it is substituted by one or more
substituents independently selected from
1928
the group consisting of –CN, -CO2R5, C(O)NR5R5', =O, -OR5, -SR5, -NO2, NR5R5', -NR5C(O)R5', -NR5C(O)OR5', C1-
wherein R1 is selected from the group
consisting of C3-C10 alkyl, C3-C10
cycloalkyl, up to per-halosubstituted C3C10 alkyl and up to per-halosubstituted C3C10 cycloalkyl,
B is phenyl, pyridinyl, indolinyl,
isoquinolinyl, quinolinyl or naphthyl
which is substituted by phenyl, pyridinyl
or Y-Ar, wherein the cyclic structures of B
are optionally substituted by halogen, up to
per-halosubstitution, and optionally
substituted by X1n wherein n=0-2;
each X1 is independently selected from the
group consisting of –CN, -CO2R5, C(O)R5, -C(O)NR5R5', -OR5, -NO2, NR5R5', C1-C10 alkyl, C2-10-alkenyl, C1-10alkoxy, C3-C10 cycloalkyl, and C6-C14 aryl,
-SR5, -NR5C(O)OR5', -C3-C10 heteroaryl,
substituted C1-C10 alkyl, substituted C2-10alkenyl, substituted C1-10-alkoxy,
substituted C3-C10 cycloalkyl, substituted
C6-C14 aryl, substituted C3-C13 heteroaryl,
and independently selected from the group
consisting of –CN, -CO2R5, -C(O)R5, C(O)NR5R5', -OR5, -SR5, -NR5R5', NO2, NR5C(O)R5', -NR5C(O)OR5', NR5C(O)OR5' and halogen up to perhalosubstitution; wherein R5 and R5' are
independently selected from H, C1-C10
alkyl, C2-10-alkenyl, C3-C10 cycloalkyl, C6C4 aryl, C3-C13 heteroaryl, C7-C24 alkaryl,
1929
C10 alkyl, C1-C10 alkoxyl, and C3-C10
cycloalkyl;
or of the formula
C4-C23 alkheteroaryl, up to perhalosubstituted C1-C10 cycloalkyl wherein
Y is –O-, -S-, -N(R5)-, -(CH2)-m, -C(O)-, CH(OH)-, (CH2)mO-, -NR5C(O)OR5', NR5C(O)-, -C(O)NR5-, -(CH2)mS-, (CH2)mN(R5)-, -O(CH2)m-, -CHXa, -CXa2-,
-S-(CH2)m- and –N(R5)(CH2)m-, m = 1-3,
and Xa is halogen; and
Ar is a 5-10 member aromatic structure
containing 0-4 members of the group
consisting of nitrogen, oxygen and sulfur
which is unsubstituted or substituted by
halogen up to per-halo and optionally
substituted by Zn1, wherein n1 is 0 to 3 and
each Z is independently selected from the
group consisting of CN, -CO2R5, -C(O)R5,
=O, -C(O)NR5R5', -C(O)R5, -NO2, -OR5, SR5, -NR5R5', -NR5C(O)OR5', NR5C(O)R5', -SO2R5, -SO2R5R5', C1-C10
alkyl, C1-C10 alkoxy, C3-C10 cycloalkyl,
substituted C1-C10 alkyl, and substituted
C3-C10 cycloalkyl, wherein if Z is a
substituted group, it is substituted by one
or more substituents independently
selected from the group consisting of CN,
-CO2R5, -C(O)R5, =O, -OR5, -SR5, -NO2, NR5R5', -NR5C(O)R5', -NR5C(O)OR5', C1C10 alkyl, C1-C10 alkoxy, and C3-C10
cycloalkyl, subject to the proviso that
where R1 is t-butyl,
B is not
July 24, 2007– ‫ט' באב התשס"ז‬
wherein R6 is –NHC(O)-O-t-butyl, -O-npentyl, -O-n-butyl, -O-propyl-, C(O)NH-
(CH3)2, -OCH2CH(CH3)2, or
or of the formula
wherein R1 is selected from the group
consisting of C3-C10 alkyl, C3-C10
cycloalkyl, up to per-halosubstituted C3C10 alkyl and up to per-halosubstituted C3C10 cycloalkyl,
Rb is hydrogen or halogen and B is phenyl,
pyridinyl, indolinyl, isoquinolinyl,
quinolinyl, or naphthyl substituted by
phenyl, pyridinyl or –Y-Ar,
wherein the cyclic structures of B are
optionally substituted by halogen, up to per
halo, and optionally substituted by X1n
and wherein n=0-2; each X1 is
independently selected from the group
consisting of CN, -OR5, -NR5R5', C1-C10
alkyl;
-CO2R5, -C(O)NR5R5', -C(O)R5, -NO2, SR5, -NR5C(O)OR5', -NR5C(O)R5', C3-C10
cycloalkyl, substituted C1-C10 alkyl,
substituted C2-C10-alkenyl, substituted C1C10-alkoxy, and substituted C3-C10
cycloalkyl, wherein if X1 is a substituted
group, it is substituted by one or more
substituents independently selected from
the group consisting of –CN, -CO2R5, C(O)R5, -C(O)NR5R5', -OR5, -NR5R5', NO2, -NR5C(O)R5', -NR5C(O)OR5' and
halogen up to per-halo substitution;
July 24, 2007– ‫ט' באב התשס"ז‬
wherein R5 and R5' are independently
selected from H, C1-C10 alkyl, C2-10alkenyl, C3-C10 cycloalkyl, up to perhalosubstituted C1-C10 alkyl, up to perhalosubstituted C2-10-alkenyl, and up to
per-halosubstituted C3-C10 cycloalkyl,
wherein Y is –O-, -S-, -N(R5)-, -(CH2)m-, C(O)-, -CH(OH)-, -(CH2)mO-, -CHXa, CXa2-, -S-(CH2)m- and –N(R5)(CH2)m-, m
= 1-3, and Xa is halogen; and
Ar is a 5-10 member aromatic structure
containing 0-4 members of the group
consisting of nitrogen, oxygen and sulfur
which is unsubstituted or substituted by
halogen up to per-halosubstitution and
optionally substituted by Zn1, wherein n1 is
0 to 3 and each Z is independently selected
from the group consiting of –CN, -CO2R5,
-C(O)R5, =O, -C(O)NR5R5', -C(O)-, NR5, NO2, -OR5, -SR5, -NR5R5', -NR5C(O)OR5',
-NR5C(O)R5', -SO2R5, -SO2R5R5', C1-C10
alkyl, C1-C10 alkoxy, C3-C10 cycloalkyl,
substituted C1-C10 alkyl, and substituted
C3-C10 cycloalkyl, wherein if Z is a
substituted group, it is substituted by the
one or more substituents independently
selected from the group consisting of –CN,
-CO2R5, -C(O)NR5R5', =O, -OR5, -SR5, -
1930
NO2, -NR5R5', -NR5C(O)R5',
NR5C(O)OR5', C1-C10 alkyl, C1-C10
alkoxyl, and C3-C10 cycloalkyl, subject to
the proviso that where R1 is t-butyl and Rb
is H, B is not of the formula
or a compound of the formula
wherein Ra is C1-C10 alkyl, C3-C10
cycloalkyl, up to per-halosubstituted, C1C10 alkyl and up to per-halosubstituted C3C10 cycloalkyl;
and B is phenyl, pyridinyl, indolinyl,
isoquinolinyl, quinolinyl, or naphthyl;
substituted by phenyl, pyridinyl or –Y-Ar;
wherein the cyclic structures of B are
optionally substituted by halogen, up to per
halo, and optionally substituted by X1n
wherein n=0-2,
each X1 is independently selected from the
group consisting of –CN, -NO2, -OR5 and
C1-C10 alkyl, -SR5, -CO2R5, -C(O)R5, C(O)NR5R5', -NR5C(O)OR5', -NR5C(O)R5',
-C3-C10 cycloalkyl,
substituted C1-C10 alkyl, substituted C2C10-alkenyl, substituted C1-C10-alkoxy, and
substituted C3-C10 cycloalkyl, wherein if
X1 is a substituted group, it is substituted
by one or more substituents independently
selected from the group consisting of –CN,
-CO2R5, -C(O)R5, -C(O)NR5R5', -OR5 –
SR5, -NR5R5', -NO2, NR5C(O)R5', NR5C(O)OR5' and halogen up to perhalosubstitution;
wherein R5 and R5' are independently
selected from H, C1-C10 alkyl, -C2-C10alkenyl, C3-C10 cycloalkyl, up to perhalosubstituted C1-C10 alkyl, up to per-
1931
halosubstituted C2-C10-alkenyl, and up to
per-halosubstituted C3-C10 cycloalkyl
wherein Y is –O-, -S-, -N(R5)-, -(CH2)m-, C(O)-, -CH(OH)-, -(CH2)mO-, NR5C(O)NR5R5'-, -NR5C(O)-, -C(O)NR5-,
-(CH2)mS-, -(CH2)mN(R5)-, -O(CH2)m-, CHXa, -CXa2-, -S-(CH2)m- and
N(R5)(CH2)m-, m=1-3, and Xa is halogen;
and Ar is a 5-10 aromatic structure
containing 0-4 members of the group
consisting of nitrogen, oxygen and sulfur
which is unsubstituted or substituted by
halogen up to per-halo and optionally
substituted by Zn1, wherein n1 is 0 to 3 and
each Z is independently selected from the
group consisting of –CN, -CO2R5, C(O)R5, =O, -C(O)NR5R5', -C(O)R5, -NO2,
-OR5, -SR5, -NR5R5', -NR5C(O)OR5', NR5C(O)R5', -SO2R5, -SO2R5R5', C1-C10
alkyl, C1-C10 alkoxy, C3-C10 cycloalkyl,
substituted C1-C10 alkyl, substituted C3-C10
cycloalkyl, wherein if Z is a substituted
group, it is substituted by one or more
substituents independently selected from
the group consisting of –CN, -CO2R5, C(O)NR5R5', =O, -OR5, -SR5, -SR5, -NO2, NR5R5', -NR5C(O)R5' and –NR5C(O)OR5',
C1-C10 alkyl, C1-C10 alkoxyl, and C3-C10
cycloalkyl;
or of the formula
July 24, 2007– ‫ט' באב התשס"ז‬
R1 is selected from the group consisting of
halogen, C3-C10 alkyl, C3-13-heteroaryl, C614 aryl, C7-24-alkaryl, C3-C10 cycloalkyl, up
to per-halosubstituted C1-C10 alkyl, up to
per-halosubstituted C3-C10 cycloalkyl, up
to per-halosubstituted C1-13-heteroaryl, up
to per-halosubstituted C6-14-aryl, and up to
per-halosubstituted C7-24-alkaryl;
B is phenyl, pyridinyl, indolinyl,
isoquinolinyl, quinolinyl, or naphthyl
substituted by phenyl, pyridinyl or –Y-Ar,
wherein the cyclic structures of B are
optionally substituted by halogen, up to per
halo, and optionally substituted by X1n,
wherein n = 0-2 each X1 is independently
selected from the group consisting of –CN,
-OR5, -NR5R5', C1-C10 alkyl; -CO2R5, C(O)NR5R5', -C(O)R5, =O, -NO2, -SR5, NR5C(O)OR5', -NR5C(O)R5', C3-C10
cycloalkyl, substituted C2-10-alkenyl,
substituted C1-10-alkoxy, substituted C3-C10
cycloalkyl, wherein if X1 is a substituted
group, it is substituted by one or more
substituents independently selected from
the group consisting of –CN, -CO2R5, C(O)R5, -C(O)NR5R5', -OR5, -NR5R5', NO2, -NR5C(O)R5', -NR5C(O)OR5' and
halogen up to per-halo substitution;
wherein R5 and R5' are independently
selected from H, C1-C10 alkyl, C2-10alkenyl, C3-C10 cycloalkyl, up to per-
July 24, 2007– ‫ט' באב התשס"ז‬
halosubstituted C1-C10 alkyl, up to perhalosubstituted C2-10-alkenyl, and up to
per-halosubstituted C3-C10 cycloalkyl,
wherein Y is –O-, -S-, -N(R5)-, -(CH2)m-, C(O)-, -CH(OH)-, -(CH2)mO-, NR5C(O)NR5R5'-, -NR5C(O)-, -C(O)NR5-,
-(CH2)mS-, -(CH2)mN(R5)-, -O(CH2)m-, CHXa, -CXa2-, -S-(CH2)m- and –
N(R5)(CH2)m-, m=1-3, and Xa is halogen;
and Ar is a 5-10 member aromatic
structure containing 0-4 members of the
group consisting of nitrogen, oxygen and
sulfur which is unsubstituted or substituted
by halogen up to per-halosubstitution and
optionally substituted by Zn1, wherein n1 is
0 to 3 and each Z is independently selected
from the group consisting of –CN, -CO2R5,
=O, -C(O)R5, -C(O)NR5R5', -C(O)-, NR5, NO2, -OR5, -SR5, -NR5R5', -NR5C(O)OR5',
-NR5C(O)R5', -SO2R5, -SO2R5R5', C1-C10
alkyl, C1-C10 alkoxy, C3-C10 cycloalkyl,
substituted C1-C10 alkyl, substituted C3-C10
cycloalkyl, wherein if Z is a substituted
group, it is substituted by the one or more
substituents independently selected from
the group consisting of –CN, -CO2R5, C(O)NR5R5', =O, -OR5, -SR5, -NO2, NR5R5', -NR5C(O)R5', -NR5C(O)OR5', C1C10 alkyl, C1-C10 alkoxyl and C3-C10
cycloalkyl;
or of the formula
1932
wherein R1 is selected from the group
consisting of C3-C10 alkyl, C3-C10
cycloalkyl, up to per-halosubstituted C3C10 alkyl and up to per-halosubstituted C3C0 cycloalkyl, Rb is hydrogen or halogen,
and
wherein B is phenyl, pyridinyl, indolinyl,
isoquinolinyl, quinolinyl, or naphthyl
substituted by phenyl, pyridinyl or –Y-Ar,
wherein the cyclic structures of B are
optionally substituted by halogen, up to per
halo, and optionally substituted by X1n,
n=0-3 and each X1 is independently
selected from the group consisting of –CN,
-CO2R5, -C(O)NR5R5', -C(O)R5, -NO2, OR5, -SR5, -NR5R5' –NR5C(O)OR5', NR5C(O)R5', C1-C10 alkyl, C2-C10-alkenyl,
substituted C1-C10-alkoxy, and substituted
C3-C10 cycloalkyl,
wherein if X1 is a substituted group, it is
substituted by one or more substituents
independently selected from the group
consisting of –CN, -CO2R5, -C(O)R5, C(O)NR5R5', -OR5, -SR5, -NR5R5', -NO2, NR5C(O)R5', -NR5C(O)OR5' and halogen
up to per-halosubstitution;
wherein R5 and R5' are independently
selected from H, C1-C10 alkyl, C2-10alkenyl, C3-C10 cycloalkyl, up to perhalosubstituted C1-C10 alkyl, up to per-
halosubstituted C2-10-alkenyl, and up to
per-halosubstituted C3-C10 cycloalkyl,
wherein Y is –O-, -S-, -N(R5)-, -(CH2)m-, C(O)-, -CH(OH)-, -(CH2)mO-, NR5C(O)NR5R5'-, NR5C(O)-, -C(O)NR5-, (CH2)mS-, -(CH2)mN(R5)-, -O(CH2)m-, CHXa, -CXa2-, -S-(CH2)m- and –
N(R5)(CH2)m-,
m = 1-3 and Xa is halogen; and
Ar is a 5-10 member aromatic structure
containing 0-4 members of the group
consisting of nitrogen, oxygen and sulfur
which is unsubstituted or substituted by
halogen up to per-halo and optionally
substituted by Zn1, wherein n1 is 0 to 3 and
each Z is independently selected from the
group consisting of –CN, -CO2R5, C(O)R5, =O, -C(O)NR5R5', -C(O)R5, -NO2,
-OR5, -SR5, -NR5R5', -NR5C(O)OR5', NR5C(O)R5', -SO2R5, -SO2 R5R5', C1-C10
alkyl, C3-C10 cycloalkyl, substituted C1-C10
alkyl, substituted C3-C10 cycloalkyl,
wherein if Z is a substituted group, it is
substituted by one or more substituents
independently selected from the group
consisting of –CN, -CO2R5, -C(O)NR5R5',
=O, -OR5, -SR5, -NO2, -NR5R5', NR5C(O)R5', -NR5C(O)OR5', C1-C10 alkyl,
C1-C10 alkoxyl, and C3-C10 cycloalkyl.
__________
]11[]21[
1933
136855
July 24, 2007– ‫ט' באב התשס"ז‬
IFNAR2/IFN ‫קומפלקס‬
]54[
IFNAR2/IFN COMPLEX
]22[
]31[
]51[
18.12.1998
60/068295
]32[ 19.12.1997
]33[ US
Int. Cl.8 A61K 038/19, 038/21, C07K 014/555, 014/715, 019/00, C12N 015/12,
015/62
APPLIED RESEARCH SYSTEMS
ARS HOLDING N.V.,
NETHERLANDS ANTILLES
WO/1999/032141
INTERPHARM LABORATORIES
,‫אינטרפארם מעבדות בע"מ‬
LTD.,
,‫ פארק לתעשיות עתירות ידע‬,‫קרית ויצמן‬
KIRYAT WEIZMANN
‫ציונה‬-‫נס‬
NES ZIONA 76110
]71[
]87[
]74[
[57] A complex comprising a Type I
interferon (IFN) and a subunit of the
human interferon α/β receptor (INFAR)
which is capable of binding to the Type I
IFN of the complex, wherein said Type I
IFN is:
(a) a native Type I IFN;
(b) a fragment of (a) which has Type I IFN
biological activity;
(c) a variant of (a) or (b) which has at least
70% sequence identity with (a) or (b) and
which has Type I IFN biological activity;
(d) a variant of (a) or (b) which is encoded
by a DNA sequence which hybridizes to
the complement of the native DNA
sequence encoding (a) or (b) under
moderately stringent conditions and which
has Type-I IFN biological activity; or
(e) a salt or functional derivative of (a),
(b), (c) or (d) which has Type I IFN
.
biological activity; and wherein said
IFNAR is:
(f) a native human IFNAR polypeptide
chain;
(g) a fragment of (f) which has IFNAR
biological activity;
(h) a variant of (f) or (g) which has at least
70% sequence identity with (f) or (g) and
which has IFNAR biological activity;
(i) a variant of (f) or (g) which is encoded
by a DNA sequence which hybridizes to
the complement of the native DNA
sequence encoding (f) or (g) under
moderately stringent conditions and which
has IFNAR biological activity; or
(j) a salt or functional derivative of (f), (g),
(h), or (i) which has IFNAR biological
activity.
__________
]11[]21[
July 24, 2007– ‫ט' באב התשס"ז‬
137403
1934
– ‫ ) – ציס‬R4,S1( ‫תכשירי רוקחות המכילים‬
– )‫ – (ציקלופרופילאמינו‬6 – ‫ – אמינו‬2[– 4
1 – ‫ – ציקלופנטן‬2 – ]‫ – איל‬9 – ‫ – פורין‬H9
‫– מתאנול‬
]54[
PHARMACEUTICAL
COMPOSITIONS COMPRISING
(1S,4R) – CIS – 4 – [2 – AMINO – 6 –
(CYCLOPROPYLAMINO) – 9H –
PURIN – 9 – YL] – 2 –
CYCLOPENTENE – 1 –
METHANOL
]22[
]31[
]51[
]71[
04.02.1999
9802472.2
]32[ 06.02.1998
]33[ GB
Int. Cl.8 A61K 031/52, A61P 031/18, C07D 473/16, C12P 017/18
GLAXO GROUP LIMITED, UNITED
KINGDOM
WO/1999/039691
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
[57] A pharmaceutical composition
comprising (1S, 4R)-cis-4-[2-amino-6cyclopropylamino)-9H-purin-9-yl)-2cyclopentene-1-methanol, or a
pharmaceutically acceptable derivative
thereof, a metal chelator, and at least one
sweetening agent selected from the group
consisting of sorbitol, saccharin,
acesulfame, fructose, sucralose, and
aspartame, at a pH range of 2.0 to 4.5.
__________
]11[]21[
]54[
ERYTHROPOIETIN LIPOSOMAL
DISPERSION
]22[
]31[
]51[
]71[
12.02.1999
98103111.5
]32[ 23.02.1998
Int. Cl.8 A61K 009/00, 009/127, 038/18
CILAG GMBH INTERNATIONAL,
SWITZERLAND
WO/1999/042085
DR. SHLOMO COHEN & CO.,
124 IBN GABIROL ST.,
P.O.B. 11490,
TEL AVIV 62038
]87[
]74[
137808
‫פיזור של אריתרופויאטין כלפוזומים‬
]33[
EP
,'‫ד"ר שלמה כהן ושות‬
‫ תל אביב‬,11490 .‫ד‬.‫ ת‬, 124 ‫אבן גבירול‬
[57] A liposome-based parenteral
composition comprising:
(a) an effective amount of an active
ingredient comprising erythropoietin or its
pharmaceutically acceptable derivatives
1935
July 24, 2007– ‫ט' באב התשס"ז‬
having the biological properties of causing
bone marrow cells to increase production
of reticulocytes and red blood cells;
(b) a lipidic phase comprising:
(i) lecithin or hydrogenated lecithin;
(ii) a charged electropositive or
electronegative lipid compound and
(iii) cholesterol or a derivative thereof
selected from cholesterol esters,
polyethylene glycol derivatives of
cholesterol (PEG-cholesterols), and
organic acid derivatives of cholesterols;
and
(c) a phosphate buffer.
__________
]11[]21[
138453
‫תכשירים והרכבים של פפטידים והשימוש‬
‫בהם‬
]54[
PEPTIDE COMPOSITIONS AND
FORMULATIONS AND USE OF
SAME
]22[
]31[
]51[
]71[
12.03.1999
09/039308
]32[ 13.03.1998
]33[ US
Int. Cl.8 A61K 038/00, 038/06, 038/07, 038/17, C07K 014/435
CONNECTIVE TISSUE
IMAGINEERING LLC, U.S.A.
LAWRENCE B SANDBERG, PHILIP
J ROOS, THOMAS F MITTS
WO/1999/045941
EDWARD LANGER,
,‫אדוארד לנגר‬
44-46 MONTEFIORE STREET
‫ תל אביב‬,44-46‫מונטיפיורי‬
TEL AVIV 65201
]72[
]87[
]74[
[57] A composition useful in treating
mammalian tissue, said composition being
comprised of a peptide selected from the
group consisting of SEQ ID NO:17
(Valine-Valine-Proline-Glutamine), SEQ
ID NO:18 (Valine-Alanine-Alanine-
Arginine-Proline-Glycine), SEQ ID NO:19
(Leucine-Glycine-Alanine-GlycineGlycine-Alanine-Glycine), and SEQ ID
NO: 23 (Valine-Glycine-ValineHydroxyproline-Glycine).
__________
]11[]21[
July 24, 2007– ‫ט' באב התשס"ז‬
138831
1936
‫מערכת מידע מופעלת ע"י מבט‬
]54[
GAZE-ACTUATED
INFORMATION SYSTEM
]22[
]51[
]71[
03.10.2000
Int. Cl.8 G01C 021/00
RAFAEL-ARMAMENT
DEVELOPMENT AUTHORITY
LTD.
DR. MARK FRIEDMAN LTD.,
MOSHE AVIV TOWER, 54TH
FLOOR
7 JABOTINSKY STREET
52520
RAMAT GAN
]74[
[57] A method for providing a pilot with
information associated with at least one
region of a field of view visible to the pilot
from within a cockpit without requiring a
visual display, the method comprising the
steps of:
(i) determining an eye gaze direction
relative to a given frame of reference for at
least one eye of the pilot by:
(a) employing a helmet-mounted system to
derive direction information related to a
relative eye gaze direction for at least one
eye of the pilot relative to a helmet worn
by the pilot,
(b) deriving position information related to
a position of said helmet within a cockpit,
and
,‫רפא"ל רשות לפיתוח אמצעי לחימה בע"מ‬
‫חיפה‬
,‫ד"ר מרק פרידמן בע"מ‬
,77 ‫ ז'בוטינסקי‬54 ‫ קומה‬,‫מגדל משה אביב‬
‫ גן‬-‫רמת‬
(c) processing said direction information
and said position information to derive
said eye gaze direction relative to a frame
of reference associated with said cockpit;
(ii) determining a reference direction
relative to said given frame of reference;
(iii) comparing said eye gaze direction
with said reference direction; and
(iv) if said eye gaze direction and said
reference direction are equal to within a
given degree of accuracy, generating audio
output audible to the pilot and indicative of
information associated with said reference
direction.
__________
]11[]21[
1937
138856
July 24, 2007– ‫ט' באב התשס"ז‬
‫אקטינסידינים סמי–סינטטיים ותכשירי‬
‫רוקחות המכילים אותם‬
]54[
SEMI-SYNTHETIC
ECTEINASCIDINS AND
PHARMACEUTICAL
COMPOSITIONS CONTAINING
THEM
]22[
]31[
]51[
]71[
05.04.1999
60/080802
]32[ 06.04.1998
]33[ US
Int. Cl.8 A61K 031/4995, 035/00, A61P 035/00, C07D 515/00
THE BOARD OF TRUSTEES OF THE
UNIVERSITY OF ILLINOIS, U.S.A.
WO/1999/051238
EITAN, PEARL, LATZER AND
,‫ לצר וכהן צדק‬,‫ פרל‬,‫איתן‬
COHEN ZEDEK,
‫ הרצליה‬,12688 .‫ד‬.‫ ת‬, 7 ‫רחוב שנקר‬
P.O.B. 12688,
HERZLIYA 46733
]87[
]74[
[57] The compound Et 757, of the formula
__________
]11[]21[
July 24, 2007– ‫ט' באב התשס"ז‬
138911
1938
‫תוצר ביניים גיפפטיד בהכנת חומרים‬
‫הגורמים להפרשה מוגברת של הורמון‬
‫הגדילה‬
]54[
DIPEPTIDE INTERMEDIATE
COMPOUND IN THE SYNTHESIS
OF GROWTH-HORMONE
SECRETAGOGUES
]22[
]31[
]51[
]62[
]71[
]87[
]74[
04.12.1996
60/009469
]32[ 28.12.1995
]33[ US
Int. Cl.8 A61K 038/05, A61P 005/06, 019/10, C07D 417/04, C07K 005/02, 005/06
DIVISION FROM 124449
PFIZER INC., U.S.A.
WO/1997/024369
LUZZATTO & LUZZATTO,
,‫לוצאטו את לוצאטו‬
INDUSTRIAL PARK, OMER,
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
P.O.B. 5352,
BEER-SHEVA 84152
[57] Compounds of the formula
the racemic-diastereomeric mixtures and
optical isomers of said compounds,
wherein Z200 is T-BOC, CBZ, CF3C(O)-,
FMOC, TROC, trityl, or tosyl;
e is 0 or 1;
n and w are each independently 0, 1 or 2,
provided that w and n cannot both be 0 at
the same time;
Y is oxygen or sulfur;
R1 is hydrogen, -CN, (CH2)qN(X6)C(O)X6, (CH2)qN(X6)C(O)(CH2)t-A1,
-(CH2)qN(X6)SO2-(CH2)t-A1, (CH2)qN(X6)SO2X6, (CH2)qN(X6)C(O)N(X6)(CH2)t-A1,
-(CH2)qN(X6)C(O)N(X6)(X6), (CH2)qC(O)N(X6)(X6), (CH2)qC(O)N(X6)(CH2)t-A1;
-(CH2)qC(O)OX6, -(CH2)qC(O)O(CH2)tA1, -(CH2)qOX6, -(CH2)qOC(O)X6,
-(CH2)qOC(O)(CH2)t-A1, (CH2)qOC(O)N(X6)(CH2)t-A1, -
1939
(CH2)qOC(O)N(X6)(X6),
-(CH2)qC(O)X6, -(CH2)qC(O)(CH2)t-A1, (CH2)qN(X6)C(O)OX6,
-(CH2)qN(X6)SO2N(X6)(X6), (CH2)qS(O)mX6, -(CH2)qS(O)m(CH2)t-A1;
-(C1-C10) alkyl, -(CH2)t-A1, -(CH2)q-(C3C7) cycloalkyl, -(CH2)q-Y1-(C1-C6) alkyl,
-(CH2)q-Y1-(CH2)t-A1 or -(CH2)q-Y1(CH2)t-(C3-C7) cycloalkyl;
where the alkyl and cycloalkyl groups in
the definition of R1 are optionally
substituted with (C1-C4) alkyl, hydroxyl,
(C1-C4) alkyl, hydroxyl, carboxyl, CONH2, -S(O)m(C1-C6) alkyl, -CO2(C1-C4)
alkyl ester, 1H-tetrazol-5-yl or 1, 2 or 3
fluoro;
Y1 is O, S(O)m, -C(O)NR6-, -CH=CH-, C=C-, -N(X6)C(O)-, -C(O)NX6-,
-C(O)O-, -OC(O)N(X6)- or –OC(O)-;
q is 0, 1, 2, 3 or 4;
t is 0, 1, 2 or 3;
July 24, 2007– ‫ט' באב התשס"ז‬
said (CH2)q group and (CH2)t group may
each be optionally substituted with
hydroxyl, (C1-C4) alkoxy, carboxyl, CONH2, -S(O)m(C1-C6) alkyl, -CO2(C1-C4)
alkyl, 1H-tetrazol-5-yl, 1 to 3 fluoro or 1
or 2 (C1-C4) alkyl;
R2 is hydrogen (C1-C8) alkyl, -(C0-C3)
alkyl-(C3-C8) cycloalkyl, -(C1-C4) alkyl-A1
or A1;
where the alkyl groups and the cycloalkyl
groups in the definition of R2 are
optionally substituted with hydroxyl, C(O)OX6. –C(O)N(X6)(X6), -N(X6)(X6),
-S(O)m(C1-C6) alkyl, -C(O)A1, -C(O)(X6),
CF3, CN or 1, 2 or 3 halogen;
R3 is A1, (C1-C10) alkyl, (C1-C6) alkyl-A1, (C1-C6) alkyl-(C3-C7) cycloalkyl;
-(C1-C5) alkyl-X1-(C1-C5) alkyl-(C3-C7)
cycloalkyl;
where the alkyl groups in the definition of
R3 are optionally substituted with
S(O)m(C1-C6) alkyl, -C(O)OX3, 1, 2, 3, 4
or 5 halogens, or 1, 2, or 3 OX3;
X1 is S(O)m –N(X2)C(O)-, -C(O)N(X2)-, OC(O)-, -C(O)O-, -CX2=CX2-; N(X2)C(O)O-, =OC(O)N(X2)- or –C=C-;
R4 is hydrogen, (C1-C6) alkyl or (C3-C7)
cycloalkyl, or R4 is taken together with R3
and the carbon atom to which they are
attached and form (C5-C7) cycloalkyl, (C5C7) cycloalkenyl, a partially saturated or
fully saturated 4- to 8-membered ring
having 1 to 4 heteroatoms independently
selected from the group consisting of
oxygen, sulfur and nitrogen, or is a
bicyclic ring system consisting of a
partially saturated or fully saturated 5- or
6-membered ring, fused to a partially
saturated, fully unsaturated or fully
saturated 5- or 6-membered ring,
optionally having 1 to 4 heteroatoms
independently selected from the group
consisting of nitrogen, sulfur and oxygen;
X4 is hydrogen or (C1-C6) alkyl or X4 is
taken together with R4 and the nitrogen
atom to which X4 is attached and the
carbon atom to which R4 is attached and
form a five to seven membered ring; R6 is
a bond or is
where a and b are independently 0, 1, 2 or
3;
X5 and X5a are each independently selected
from the group consisting of hydrogen,
trifluoromethyl, A1 and optionally
substituted (C1-C6) alkyl; the optionally
substituted (C1-C6) alkyl in the definition
X5 and X5a is optionally substituted with a
substituent selected from the group
consisting of A1, -OX2, -S(O)m(C1-C6)
alkyl, -C(O)OX2, (C3-C7) cycloalkyl, N(X2)(X2) and –C(O)N(X2)(X2);
or the carbon bearing X5 and X5a forms an
alkylene bridge with the nitrogen atom
bearing Z200 and R8 where the alkylene
bridge contains 1 to 5 carbon atoms
provided that X5 or X5a but not both may
be on the carbon atom and Z200 or R8 but
not both may be on the nitrogen atom;
or X5 is taken together with X5a and the
carbon atom to which they are attached
and form a partially saturated or fully
saturated 3- to 7-membered ring, or a
partially saturated or fully saturated 4- to
8-membered ring having 1 to 4
heteroatoms independently selected from
the group consisting of oxygen, sulfur and
nitrogen;
or X5 is taken together with X5a and the
carbon atom to which they are attached
and form a bicyclic ring system consisting
of a partially saturated or fully saturated 5or 8-membered ring, optionally having 1 or
2 heteroatoms independently
July 24, 2007– ‫ט' באב התשס"ז‬
1940
selected from the group consisting of
nitrogen, sulfur and oxygen, fused to a
partially saturated, fully saturated or fully
unsaturated 5- or 6-membered ring,
optionally having 1 to 4 heteroatoms
independently selected from the group
consisting of nitrogen, sulfur and oxygen;
Z1 is bond, O or N-X2, provided that when
a and b are both 0 then Z1 is not N-X2 or
O-;
R8 is hydrogen or optionally substituted
(C1-C6) alkyl;
where the optionally substituted (C1-C6)
alkyl in the definition of R8 is optionally
independently substituted with A1, C(O)O-(C1-C6) alkyl, -S(O)m(C1-C6) alkyl,
1 to 5 halogens, 1 to 3 hydroxy, 1 to 3 –OC(O) (C1-C10) alkyl or 1 to 3 (C1-C6)
alkoxy;
A1 for each occurrence is independently
(C5-C7) cycloalkenyl, phenyl or a partially
saturated, fully saturated or fully
unsaturated 4- to 8-membered ring
optionally having 1 to 4 heteroatoms
independently selected from the group
consisting of oxygen, sulfur and nitrogen,
or a bicylic ring system consisting of a
partially saturated, fully unsaturated or
fully saturated 5- or 6-membered ring,
optionally having 1 to 4 heteroatoms
independently selected from the group
consisting of nitrogen, sulfur and oxygen,
fused to a partially saturated, fully
saturated or fully unsaturated 5- or 6membered ring, optionally having 1 to 4
heteroatoms independently selected from
the group consisting of nitrogen, sulfur and
oxygen;
A1 for each occurrence is independently
optionally substituted, in one or optionally
both rings if A1 is a bicyclic ring system,
with up to three substituents, each
substituent independently selected from
the group consisting of F, Cl, Br, I, OCF3,
OCF2H, CF3, CH3, OCH3, -OX6, C(O)N(X6)(X6), -C(O)OX6, oxo, (C1-C6)
alkyl, nitro, cyano, benzyl, -S(O)m(C1-C6)
alkyl, 1H-tetrazol-5-yl, phenyl, phenoxy,
1941
phenylalkyloxy, halophenyl,
methylenedioxy, -N(X6)(X6), -N(X6)(X6), N(X6)C(O)(X6), -SO2N(X6)(X6), N(X6)SO2X6, -CONX11X12, -SO2NX11X12,
-NX6SO2X12, -NX6CONX11X12, NX6SO2NX11X12, -NX6C(O)X12,
imidazolyl, thiazolyl and tetrazolyl,
provided that if A1 is optionally substituted
with methylenedioxy then it can only be
substituted with one methylenedioxy;
where X11 is hydrogen or optionally
substituted (C1-C6) alkyl; the optionally
substituted (C1-C6) alkyl defined for X11 is
optionally independently substituted with
phenyl, phenoxy, (C1-C6) alkoxycarbonyl,
-S(O)m(C1-C6) alkyl, 1 to 5 halogens, 1 to
3 hydroxy, 1 to 3 (C1-C10) alkanoyloxy or
1 to 3 (C1-C6) alkoxy;
X12 is hydrogen, (C1-C6) alkyl, phenyl,
thiazolyl, imidazolyl, furyl or thienyl,
provided that when X12 is not hydrogen,
X12 is optionally substituted with one to
three substituents independently selected
from the group consisting of Cl, F, CH3
OCH3, OFC3 and CF3;
or X11 and X12 are taken together to form –
(CH2)r-L1-(CH2)r;
L1 is C(X2)(X2), O, S(O)m or N(X2);
R for each occurrence is independently 1,
2 or 3;
X2 for each occurrence is independently
hydrogen, optionally substituted (C1-C6)
alkyl, or optionally substituted (C3-C7)
cycloalkyl, where the optionally
substituted (C1-C6) alkyl and optionally
substituted (C3-C7) cycloalkyl in the
definition of X2 are optionally
independently substituted with –S(O)m(C1C6) alkyl, -C(O)OX3, 1 to 5 halogens or 1
to 3 –OX3;
X3 for each occurrence is independently
hydrogen or (C1-C6) alkyl;
X6 for each occurrence is independently
hydrogen, optionally substituted (C1-C6)
alkyl, (C2-C6) halogenated alkyl,
optionally substituted (C3-C7) cycloalkyl,
(C3-C7)-halogenated cycloalkyl, where
optionally substituted (C1-C6) alkyl and
July 24, 2007– ‫ט' באב התשס"ז‬
optionally substituted (C3-C7) cycloalkyl in
the definition of X6 is optionally
independently substituted with hydroxyl,
(C1-C4) alkoxy, carboxyl, CONH2, S(O)m(C1-C6) alkyl, -CO2(C1-C4) alkyl,
1H-tetrazol-5-yl or 1 or 2 (C1-C4) alkyl; or
when there are two X6 groups on one atom
and both X6 are (C1-C6) alkyl, the two (C1C6) alkyl groups may be optionally joined
and, together with the atom to which the
two X6 groups are attached, form a 4- to 9membered ring optionally having oxygen,
sulfur or NX7;
X7 is hydrogen or (C1-C6) alkyl optionally
substituted by hydroxyl; and
m for each occurrence is independently 0,
1 or 2;
with the proviso that:
X6 and X12 cannot be hydrogen when it is
attached to C(O) or SO2 in the form
C(O)X6, C(O)X12, SO2X12; and
when R is a bond then L is N(X2) and each
r in the definition –(CH2)r-L-(CH2)r- is 2 or
3.
__________
]11[]21[
]54[
PREPARATIONS FOR THE
APPLICATION OF ANTI
INFLAMMATORY, ESPECIALLY
ANTISEPTIC AGENTS AND/OR
AGENTS PROMOTING THE
HEALING OF WOUNDS, TO THE
UPPER RESPIRATORY TRACT
AND/OR THE EAR
]22[
]31[
]51[
]71[
27.05.1999
60/086895
]32[ 27.05.1998
Int. Cl.8 A61K 045/00
EURO – CELTIQUE S.A.,
LUXEMBOURG
WO/1999/060998
DR. YITZHAK HESS & PARTNERS,
279 HAYARKON ST.,
P.O.B. 6451,
TEL AVIV 61063
]87[
]74[
[57] The use of povidone iodine combined
with a liposome preparation, in the
manufacture of a pharmaceutical
preparation for the prevention or the
treatment of infections, the treatment of
139230
,‫תכשירים עבור היישום של אנטי– זיהומים‬
‫במיוחד גורמים מחטאים ו\או גורמים‬
‫המסייעים לריפוי של פצעים לשטח‬
‫הנשימתי העליון ו\או האוזן‬
]33[
US
,‫ד"ר יצחק הס ושותפיו‬
‫ תל אביב‬,6451 .‫ד‬.‫ ת‬, 279 ‫רחוב הירקון‬
wounds and/or for functional tissue
remodeling and repair, in the ciliary
epithelial tissue of the upper respiratory
tract and the ear.
_________
]11[]21[
July 24, 2007– ‫ט' באב התשס"ז‬
139360
1942
‫כימרות נגיפיות המורכבות מיחידות‬
HIV–1–‫ ו‬CAEV–‫גנטיוות מ‬
]54[
VIRAL CHIMERAS COMPRISED
OF CAEV AND HIV-1 GENETIC
ELEMENTS
]22[
]31[
30.04.1999
60/083652
]32[ 30.04.1998
]33[ US
09/302171
29.04.1999
US
Int. Cl.8 A61K 039/21, A61P 031/18, 037/04, C07K 014/005, 014/15, C12N 007/01,
015/62, 015/867
UNIVERSITY OF SOUTHERN
CALIFORNIA, U.S.A.
WO/1999/056774
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
]51[
]71[
]87[
]74[
[57] A polynucleotide comprising a
chimeric retroviral genome (CHIV),
wherein the chimeric retroviral genome
comprises expression control segments
that direct its expression in a mammalian
host cell, and wherein the retroviral
particle produced by expressing the
retroviral genome in a host cell generates
an immune response against HIV-1 but is
not pathogenic to a primate, characterized
in that the chimeric retroviral genome
consists of a caprine arthirits encephalitis
virus (CAEV) viral genome, wherein the
HIV-1 envelope gene has been substituted
for the CAEV envelope gene.
_________
]11[]21[
139612
‫תרכובות מ–מורקסלה קטרהליס‬
]54[
COMPOUNDS FROM
MORAXELLA CATARRHALIS
]22[
]31[
]51[
]71[
07.05.1999
9810285.8
]32[ 13.05.1998
]33[ GB
Int. Cl.8 A61K 039/02, 039/395, C07K 014/195, 016/12, C12N 015/31
SMITHKLINE BEECHAM
BIOLOGICALS S.A., BELGIUM
WO/1999/058684
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
[57] An isolated polypeptide useful in a
vaccine against Moraxella catarrhalis
infection comprising an amino acid
sequence which has at least 85% identity
1943
July 24, 2007– ‫ט' באב התשס"ז‬
to the amino acid sequence selected from
the group consisting of: SEQ ID NO:4 and
SEQ ID NO:6 over the entire length of
SEQ ID NO:4 or SEQ ID NO:6
respectively.
_________
]11[]21[
]54[
CONTINUOUS POLYAMIDATION
PROCESS
]22[
]31[
]51[
]71[
]87[
]74[
26.05.1999
60/087316
]32[ 29.05.1998
Int. Cl.8 C08G 069/28
SOLUTIA INC., U.S.A.
WO/1999/061511
EITAN, MEHULAL, PAPPO,
KUGLER,
11 HAMENOFIM ST.
HERZLIYA 46120
[57] A process for producing a polyamide
from dicarboxylic acid monomer and
diamine monomer, comprising: mixing
molten dicarboxylic acid monomer and
molten diamine monomer in equimolar
amounts, thereby producing a molten
reaction mixture; flowing the reaction
mixture through at least one unvented
reaction vessel, the residence time of the
reaction mixture in the at least one
139816
‫תהליך פוליאמידציה מתמשך‬
]33[
US
,‫ קוגלר‬,‫ פאפו‬,‫ מהולל‬,‫איתן‬
‫ הרצליה‬,11‫המנופים‬
unvented reaction vessel being between
0.01 minutes and 30 minutes, thereby
forming a first product stream that
comprises polyamide and water of
polymerization; and flowing the first
product stream through at lest one vented
vessel, whereby water of polymerization is
removed, thereby forming a second
product stream that comprises polyamide.
________
]11[]21[
July 24, 2007– ‫ט' באב התשס"ז‬
139995
1944
]54[
SYSTEM AND METHOD FOR
SPHERICAL STEREOSCOPIC
PHOTOGRAPHING
]22[
]51[
]71[
]74[
29.11.2000
Int. Cl.8 G03B 035/00
RVC LLC, U.S.A.
NAOMI ASSIA & CO. LAW
OFFICES,
32 HABARZEL ST.
RAMAT HACHAYAL
TEL AVIV 69710
‫מערכת ושיטה לצילום סטריאוסקופי ספירי‬
,‫נעמי אסיא ושות' משרד עורכי דין‬
‫אביב‬-‫ תל‬,‫ רמת החייל‬32 ‫רח' הברזל‬
[57] A photographing system for
capturing a full stereoscopic spherical
image, or a continuous part thereof, said
system comprising a three dimensional
array of cameras (5, 5', 5''), positioned at
an equal distance from a common center
and pointing out from said common centre,
such that the lenses of all said cameras are
lying on a spherical surface, wherein the
collective field of view (11, 12, 13)
captured by all said lenses covers the
whole visual environment surrounding said
photographing system, or a continuous part
thereof, and wherein any point in said
collective field of view is captured by at
least two of said lenses.
_________
]11[]21[
1945
140141
July 24, 2007– ‫ט' באב התשס"ז‬
‫העברת קידוד בתקשורת נתונים‬
]54[
TRANSCODING IN DATA
COMMUNICATIONS
]22[
]31[
]51[
07.12.2000
99811158.7
]32[ 14.12.1999
]33[ EP
Int. Cl.8 G06F 017/00, G06Q 002/000000 H03M 007/00, 007/14, H04L 009/00,
009/32, H04N 007/26
IBM CORPORATION, U.S.A.
SANFORD T.COLB & CO.,
,'‫ קולב ושות‬.‫סנפורד ט‬
P.O.B. 2273,
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
REHOVOT
]71[
]74[
[57] A method of transcoding a data
message, comprising a plurality of data
fields and an authentication code, to
produce a transcoded message for
transmission to a destination device, the
data message being received from a source
device wherein said data fields have been
coded in accordance with a first coding
system, whereby respective data field
codes are generated for said data fields and
a message code is derived from said data
field codes, and wherein said message
code has been coded in accordance with a
second coding system to generate said
authentication code, the method
comprising; determining for each data field
of the received data message whether to
maintain, modify or omit that field; for a
July 24, 2007– ‫ט' באב התשס"ז‬
field to be maintained, maintaining that
field in said transcoded message; for a
field to be omitted, coding the field in
accordance with said first coding system to
generate an omitted field code dependent
upon the data field code for that field, and
replacing that field by said omitted field
code in the transcoded message; for a field
to be modified, coding that field in
accordance with said first coding system to
generate modified field code dependent
upon the data field code for that field, and
replacing that field by a modified field,
comprising modified data and said
modified field code, in the transcoded
message; and including said authentication
code in the transcoded message.
1946
‫_________‬
‫ט' באב התשס"ז –‪July 24, 2007‬‬
‫‪1947‬‬
]11[]21[
]54[
PROCESSES TO GENERATE
SUSPENSIONS OF WATERINSOLUBLE BIOLOGICALLY
ACTIVE COMPOUNDS
CONTAINING PARTICLES OF
SIZES OF UP TO TWO MICRONS
]22[
]31[
]51[
]71[
]72[
18.06.1999
60/089852
]32[ 19.06.1998
Int. Cl.8 A61K 009/00, 009/16, 009/51
RTP PHARMA INC., U.S.A.
GARY W. PACE, G. MICHAEL
VACHON, K. AWADHESH MISHRA,
INGE B. HENRIKSEN, VAL
KRUKONIS, ANTHONY GODINAS
WO/1999/065469
JEREMY M. BEN-DAVID & CO.
LTD.,
HAR HOTZVIM HI-TECH PARK,
P.O.B. 45087,
JERUSALEM 91450
]87[
]74[
[57] A process for preparing a suspension
of particles of a water-insoluble or
substantially water-insoluble biologically
active compound of up to 2000 nm in size
comprising the steps of:
(a) dissolving a water-insoluble or
substantially water-insoluble biologically
active compound and a first surface
modifier in a liquefied compressed gas
140276
‫תהליכים להכנת תרחיפים של תרכובות‬
‫שאינן נמסות במים בעלות פעילות‬
‫ביולוגית המכילים חלקיקים בגודל עד שני‬
‫מיקרונים‬
]33[
US
,‫דוד ושות' בע"מ‬-‫ בן‬.‫ירמיהו מ‬
,45087 .‫ד‬.‫ ת‬, ‫ הר חוצבים‬,‫רחוב המרפא‬
‫ירושלים‬
solvent therefor and forming a solution;
and
(b) expanding the compressed fluid
solution prepared in step (a) into water or
an aqueous solution or dispersion
comprising a second surface modifier and
optional further water-soluble agents
thereby producing a suspension of
microparticles, wherein the first and
second surface modifiers are different.
__________
July 24, 2007– ‫ט' באב התשס"ז‬
1948
]11[]21[
]54[
TRAY OF A THERMOPLASTIC
MATERIAL FOR THE
PACKAGING OF FOODSTUFFS
WHICH TEND TO RELEASE BAD
SMELLING VOLATILE
SUBSTANCES
]22[
]31[
]51[
]71[
]72[
02.01.2001
00830018.8
]32[ 18.01.2000
Int. Cl.8 B65D 081/26
SIRAP-GEMA S.P.A., ITALY
PIERGIOVANNI LUCIANO,
FEDERICO LANZANI, RENATO
MAURI, MATTEO BRAZZOLI,
PATRIZIA FAVA
DR. MARK FRIEDMAN LTD.,
MOSHE AVIV TOWER, 54TH FLOOR
7 JABOTINSKY STREET
52520
RAMAT GAN
]74[
[57] A tray for packaging food products
which may release smelly volatile
substances, produced from a sheet of
substantially open-cell expanded
140677
‫מגש מחומר טרמופלסטי לאריזת דברי מזון‬
‫הנוטים לשחרר חומרים המדיפים ריח רע‬
]33[
EP
,‫ד"ר מרק פרידמן בע"מ‬
,77 ‫ ז'בוטינסקי‬54 ‫ קומה‬,‫מגדל משה אביב‬
‫ גן‬-‫רמת‬
thermoplastic material characterized in that
said sheet contains a finely divided solid
material provided with adsorbing
properties towards said substances.
____________
]11[]21[
]54[
ACID-TRIGGERED RELEASE
MICROCAPSULES
]22[
]31[
]51[
]71[
28.07.1999
126333
]32[ 30.07.1998
Int. Cl.8 A01N 025/00, B01J 013/00
SYNGENTA LIMITED, UNITED
KINGDOM
WO/2000/005952
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
1949
141066
‫מיקרוקפסולות המשחררות את חומר‬
‫הפעיל בנוכחות חומצה‬
]33[
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
July 24, 2007– ‫ט' באב התשס"ז‬
[57] A microcapsule formed of a polyurea
shell wall and an encapsulated ingredient
or ingredients enclosed within the shell
wall, the wall comprising at least one
oligomeric acetal moiety.
_________
]11[]21[
]54[
BENZAZOLES: BENZOXAZOLE,
BENZTHIAZOLE AND
BENZIMIDAZOLE DERIVATIVES
]22[
]31[
]51[
]71[
21.07.1999
9816654.9
]32[ 30.07.1998
Int. Cl.8 A01N 043/78, C07D 417/00
SYNGENTA LIMITED, UNITED
KINGDOM
WO/2000/006566
S. HOROWITZ & CO.,
ZION HOUSE,
41-45 ROTHSCHILD BLVD.,
TEL AVIV 65784
]87[
]74[
141109
‫ בנזיתיאזול‬,‫ נגזרות בנזוקסאזול‬:‫בנזאזולים‬
‫ובנזימידאזול‬
]33[
GB
,'‫ הורוביץ ושות‬.‫ש‬
‫ תל‬,41-45 ‫ שדרות רוטשילד‬,‫בית ציון‬
‫אביב‬
[57] A compound of the formula
wherein X is O or S; n is 0 or 1; Y is O, S
or NR7; R1 is hydrogen, halogen, C1-6
alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6
haloalkoxy, C1-6 alkylthio, C1-6
haloalkylthio, C3-6 cycloalkyl, C1-6alkoxy
(C1-6) alkyl or SF5; R2 is hydrogen,
halogen, C1-6 alkyl, C1-6 alkoxy, C1-6
haloalkoxy, C1-6 alkylthio, C1-6
haloalkylthio, C1-6 alkylsulfinyl, C1-6
haloalkylsulfinyl, C1-6 alkylsulfonyl, C1-6
haloalkylsulfonyl, C1-6 haloalkyl, cyano,
nitro, CHO, CH=NOR5, C1-6 alkylcarbonyl,
C1-6 alkoxycarbonyl or SF5; or together R1
and R2 form a five or six membered
saturated or unsaturated carbocyclic ring,
July 24, 2007– ‫ט' באב התשס"ז‬
optionally substituted by one or two C1-6
alkyl groups; R3 is hydrogen, C1-6 alkyl,
CH2 (C1-4 haloalkyl), C1-6 cyanoalkyl, C3-6
alkenyl, C3-6 alkynyl, C1-6 alkoxy (C1-6)
alkyl, C1-6 alkylthio (C1-6) alkyl, C1-6
alkoxy (C1-6) alkyl, C1-6 alkylcarbonyl, C1-6
alkoxycarbonyl, formyl, C1-6 alkylcarbonyl
(C1-6) alkyl, C1-6 alkoxycarbonyl (C1-6)
alkyl, C1-6 alkylaminocarbonyl, di(C1-6)
alkylaminocarbonyl, optionally substituted
phenoxycarbonyl, optionally substituted
phenyl (C1-4) alkyl or S(O)qR6; R4 is
hydrogen, halogen, cyano, C1-8 alkyl, C1-6
haloalkyl, C1-6 cyanoalkyl, C2-6 alkenyl, C26 alkynyl, C3-7 cycloalkyl, C3-7
1950
halocycloalkyl, C3-7 cyanocycloalkyl, C1-3
alkyl (C3-7) cycloalkyl, C1-3 alkyl (C3-7)
halocycloalkyl, C3-6 cycloalkyl (C1-6) alkyl,
C5-6 cycloalkenyl, C5-6 cycloalkenyl (C1-6)
alkyl, C2-6 haloalkenyl, C1-6 cyanoalkenyl,
C1-6 alkoxy (C1-6) alkyl, formyl, C1-6
carboxyalkyl, C1-6 alkylcarbonyl, (C1-6)
alkyl, C1-6 alkoxycarbonyl (C1-6) alkyl, C1-6
alkylthio (C1-6) alkyl, C1-6 alkylsulfinyl
(C1-6) alkyl, C1-6 alkylsulfonyl (C1-6) alkyl,
aminocarbonyl (C1-6) alkyl, C1-6
alkylaminocarbonyl (C1-6) alkyl, di (C1-6)
alkylaminocarbonyl (C1-6) alkyl, C1-6
alkoxycarbonyl, di(C1-6)
alkylaminocarbonyl, optionally substituted
phenyl, optionally substituted phenyl (C1-4)
alkyl, optionally substituted phenyl (C2-4)
alkenyl, optionally substituted heteroaryl,
optionally substituted heteroaryl (C1-4)
alkyl, optionally substituted heterocyclyl,
optionally substituted heterocyclyl (C1-4)
alkyl, a group OR8, a group SH, a group
S(O)pR9, a group NR10R11 or a group
C(R12)=NOR13; R5 is hydrogen, C1-6 alkyl,
optionally substituted phenyl or optionally
substituted phenyl (C1-4) alkyl; R6 is C1-6
alkyl, C1-6 haloalkyl or optionally
substituted phenyl; R7 is hydrogen, cyano,
C1-8 alkyl, C1-6 haloalkyl, C1-6 cyanoalkyl,
C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl,
C2-6 haloalkenyl, C3-6 cycloalkyl (C1-6)
alkyl, C1-6 alkoxy (C1-6) alkyl, C1-6
alkoxycarbonyl, C1-6 alkylcarbonyl, C1-6
alkylaminocarbonyl, di(C1-6)
alkylaminocarbonyl, optionally substituted
phenyl or optionally substituted heteroaryl;
R8 is hydrogen, C1-6 alkyl, C1-6 haloalkyl,
C3-6 alkenyl, C1-4 cyanoalkyl, C1-6
alkoxycarbonyl (C1-6) alkyl, optionally
substituted phenyl, optionally substituted
phenyl (C1-4) alkyl, optionally substituted
heteroaryl, N=C(CH3)2; R9 is C1-6 alkyl,
C1-6 haloalkyl, C3-6 alkenyl, cyano, C1-4
cyanoalkyl, C1-6 alkoxycarbonyl (C1-6)
alkyl, optionally substituted phenyl,
optionally substituted phenyl (C1-4) alkyl
or optionally substituted heteroaryl; R10
and R11 are, independently, hydrogen, C1-8
alkyl, C3-7 cycloalkyl, C3-6 alkenyl, C3-6
alkynyl, C2-6 haloalkyl, C1-6 alkoxy (C1-6)
alkyl, C1-6 alkoxycarbonyl, optionally
substituted phenoxycarbonyl, formyl, C1-6
alkylcarbonyl, C1-6 alkylSO2, optionally
substituted phenylSO2 or optionally
substituted phenyl (C1-4) alkyl; R12 is C1-3
alkyl; R13 is C1-6 alkyl, optionally
substituted phenyl (C1-2) alkyl; and p and q
are, independently 0, 1 or 2.
________
]11[]21[
]54[
PURINE ACYCLIC NUCLEOSIDE
DERIVATIVES AND THEIR
PREPARATION
]22[
]31[
]51[
]71[
]87[
]74[
05.08.1999
09/130214
]32[ 06.08.1998
Int. Cl.8 C07D 473/18, C12P 017/18
MEDIVIR AB, SWEDEN
WO/2000/008025
LUZZATTO & LUZZATTO,
INDUSTRIAL PARK, OMER,
P.O.B. 5352,
BEER-SHEVA 84152
1951
141161
‫תולדות של פיורין נוקלאוסיד אציקלי‬
‫והכנתן‬
]33[
US
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
July 24, 2007– ‫ט' באב התשס"ז‬
[57] A compound of the formula
wherein R6 and R7 are lower alkyl or
benzyl or R6 and R7 taken together are
-CH2CH2-, -CH2CH2CH2- or
-CH2CH2CH2CH2-, R8 is C1-C21 saturated
or monounsaturated, optionally substituted
alkyl, R25 is hydrogen or –C(O)NR27R28
wherein R27 and R28 are independently
selected from lower alkyl, phenyl and
benzyl or R27 and R28, taken together with
the nitrogen to which they are attached,
form a pyrrolidinyl group or a piperidinyl
group and R26 is lower alkyl, phenyl or
benzyl, wherein the term "lower alkyl"
stands for straight or branched chain alkyl
radicals containing from 1 to 7 carbon
atoms. They are intermediates for antiviral
compounds.
_________
]11[]21[
141370
,‫חומצות גרעין המבקרות את הביטוי של‬
‫ בעגבניות ושימוש בהן‬B ‫ומקודדת לגן‬
‫לשינוי ביוסינטיזה של קרטנואידים‬
]54[
POLYNUCLEOTIDES
CONTROLLING THE
EXPRESSION OF AND CODING
FOR GENE B IN TOMATO AND
USE OF SAME FOR ALTERING
CAROTENOID BIOSYNTHESIS
]22[
]31[
]51[
12.08.1999
09/134607
]32[ 14.08.1998
]33[ US
Int. Cl.8 A01K 067/00, C07K 014/415, C12N 009/12, 015/29, 015/52, 015/55,
015/70, 015/82
YISSUM RESEARCH
‫יישום חברה לפיתוח המחקר של‬
DEVELOPMENT COMPANY OF
‫ ירושלים‬,‫האוניברסיטה העברית בירושלים‬
THE HEBREW UNIVERSITY OF
JERUSALEM
WO/2000/008920
G.E. EHRLICH (1995) LTD.,
,‫) בע"מ‬1995( ‫ארליך‬.‫אי‬.‫ג'י‬
AYALON TOWER, 15TH FLOOR,
,11 ‫רחוב מנחם בגין‬, 15 ‫ קומה‬,‫מגדל אילון‬
11 MENACHEM BEGIN STREET,
‫רמת גן‬
52521 RAMAT GAN
]71[
]87[
]74[
[57] An isolated polynucleotide encoding
a polypeptide having an amino acid
sequence at least 95% similar to SEQ ID
July 24, 2007– ‫ט' באב התשס"ז‬
NO:17, SEQ ID NO:18 or SEQ ID NO:19,
wherein said polypeptide has a major
lycopene cyclase activity, said major
1952
lcopene cyclase activity comprising
production of at least a few percent βcarotene when said polynucleotide is
introduced into lycopene-accumulating E.
coli cells.
________
]11[]21[
141562
‫תכשירים עם חלקיקים לנתינה דרך‬
‫הריאות ותהליכים להכנתם‬
]54[
PARTICULATE COMPOSITIONS
FOR PULMONARY DELIVERY
AND METHODS FOR THE
PREPARATION THEREOF
]22[
]31[
]51[
]71[
]87[
]74[
13.09.1999
60/100163
]32[ 14.09.1998
]33[ US
Int. Cl.8 A61K 009/00, 009/72, 047/36, 047/38
NEKTAR THERAPEUTICS, U.S.A.
WO/2000/015262
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.,
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
[57] Particles for delivery of an active
agent to the alveoli of a human patient,
said particles comprising the active agent
and at least about 40% by weight of a
hygroscopic growth inhibitor selected from
the group consisting of β-cyclodextrin,
hydroxypropyl-β-cyclodextrin,
sulfobutylether β-cyclodextrin,
hydroxyethylstarch, dextranomer, and
maltodextrins, wherein the hygroscopic
growth inhibitor is incorporated within the
particles, and wherein the particles exhibit
a drop in emitted dose under simulated
lung conditions of not more than about
25%.
_________
1953
July 24, 2007– ‫ט' באב התשס"ז‬
]11[]21[
141990
‫תאים המציגים אנטיגנים עם בטוי ציטוקין‬
‫המוגבר באופן גנטי‬
]54[
ANTIGEN-PRESENTING CELLS
WITH GENETICALLY
ENHANCED CYTOKINE
EXPRESSION
]22[
]31[
]51[
14.09.1999
60/100468
]32[ 15.09.1998
]33[ US
Int. Cl.8 A61K 038/20, 048/00, C07K 014/54, C12N 005/08, 015/24, 015/86, G01N
033/574
UNIVERSITY OF PITTSBURGH OF
THE COMMONWEALTH SYSTEM
OF HIGHER EDUCATION, U.S.A.
WO/2000/015264
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.,
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
]71[
]87[
]74[
[57] Use of an effective amount of
genetically modified dendritic cells which
have not been pre-loaded with tumor
associated antigen, for the manufacture of
an injectable medicament for treating an
individual having a tumor wherein said
dendritic cells have been genetically
modified to enhance expression of IL-12
by transduction with a vector encoding IL12, and whereby the injection of said
dendritic cells results in the treatment of
said tumor.
__________
July 24, 2007– ‫ט' באב התשס"ז‬
1954
]11[]21[
142172
‫תכשיר תרופתי לטיפול ברסטנוזיס‬
]54[
PHARMACEUTICAL
COMPOSITION FOR THE
TREATMENT OF RESTENOSIS
]22[
]31[
]51[
14.07.1999
125336
]32[ 14.07.1998
]33[ IL
Int. Cl.8 A61K 009/127, 031/66, 031/663, A61P 009/00, 009/14, C07F 009/38,
009/58
YISSUM RESEARCH
‫יישום חברה לפיתוח המחקר של‬
DEVELOPMENT COMPANY OF
‫ ירושלים‬,‫האוניברסיטה העברית בירושלים‬
THE HEBREW UNIVERSITY OF
,‫הדסית שרותי מחקר רפואי ופתוח בע"מ‬
JERUSALEM
‫ירושלים‬
HADASIT MEDICAL RESEARCH
SERVICES AND DEVELOPMENT
LTD.
WO/2000/003677
EITAN, PEARL, LATZER AND
,‫ לצר וכהן צדק‬,‫ פרל‬,‫איתן‬
COHEN ZEDEK,
‫ הרצליה‬,12688 .‫ד‬.‫ ת‬, 7 ‫רחוב שנקר‬
P.O.B. 12688,
HERZLIYA 46733
]71[
]87[
]74[
[57] Use of an active ingredient being
particulate bisphosphonate (BP), or a
particulate complex or salt of BP, or
particulate polymer of BP, being in a
micronized particulate form having a
diameter within the range of 0.01-10 μm,
for the preparation of a pharmaceutical
composition for the prevention or
treatment of vascular restenosis.
A pharmaceutical composition wherein
said BP has the formula
R1 is H, OH or halogen group; and
R2 is halogen; linear or branched C1-C10
alkyl or C2-C10 alkenyl optionally
substituted by heteroaryl or heterocyclyl
C1-C10 alkylamino or C3-C8 cycloalkyl-
amino where the amino may be a primary,
secondary or tertiary; -NHY where Y is
hydrogen, C3-C8 cycloalkyl, aryl or
heteroaryl; or –SZ where Z is
chlorosubstituted phenyl or pyridinyl.
__________
1955
July 24, 2007– ‫ט' באב התשס"ז‬
]11[]21[
]54[
METHOD AND APPARATUS FOR
COVERING A STENT
]22[
]31[
]51[
]71[
]74[
21.03.2001
09/532653
]32[ 22.03.2000
Int. Cl.8 A61F 002/06, A61M 029/00
MEDINOL LTD.
EITAN, MEHULAL, PAPPO,
KUGLER,
11 HAMENOFIM ST.
HERZLIYA 46120
[57] A covered stent comprising: an
expandable stent with a longitudinal axis,
the stent being expandable from a first
diameter to a second diameter; a covering
affixed to the stent, the cover being formed
of linear fibers of pericardium, wherein in
142176
‫התקן ושיטה לכיסוי מרחיב\תומך כלי דם‬
]33[
US
‫אביב‬-‫ תל‬,‫מדינול בע"מ‬
,‫ קוגלר‬,‫ פאפו‬,‫ מהולל‬,‫איתן‬
‫ הרצליה‬,11‫המנופים‬
the first diameter, the pericardium fibers
form a first angle with respect to the
longitudinal axis of the stent, and in the
second diameter, the pericardium fibers
form a second angle with respect to the
longitudinal axis of the stent.
__________
]11[]21[
]54[
DEVICE FOR THE DELIVERY OF
AN AEROSOLIZED ACTIVE
AGENT
]22[
]31[
]51[
]71[
]87[
]74[
07.10.1999
60/103702
]32[ 09.10.1998
Int. Cl.8 A61M 015/00
NEKTAR THERAPEUTICS, U.S.A.
WO/2000/021594
WOLFF, BREGMAN AND GOLLER,
19B KEREN HAYESOD ST.,
P.O.B. 1352,
JERUSALEM 91013
[57] A device for controlling the delivery
of an aerosolized active agent to the lungs
of a human patient, said device comprising
a flow resistance modulator adapted to
change the flow resistance during delivery
over one inhalation of an aerosolized
142215
‫התקן לנתינת חומר פעיל כתרסיס‬
]33[
US
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
active agent to the lungs of a human
patient from a first flow resistance during
an initial time period to a second flow
resistance following the initial time period
wherein the second flow resistance is less
than the first flow resistance.
__________
July 24, 2007– ‫ט' באב התשס"ז‬
1956
]11[]21[
142391
‫תולדות של איזוסורביד מונוניטראט‬
‫והשימוש בהן כאמצעים מרחיבי כלי דם‬
‫בעלי סבילות משופרת‬
]54[
DERIVATIVES OF ISOSORBID
MONONITRATE AND THEIR
UTILIZATION AS VASODILATOR
AGENTS WITH REDUCED
TOLERANCE
]22[
]31[
]51[
]71[
]87[
]74[
04.10.1999
P9802076
]32[ 07.10.1998
]33[ ES
Int. Cl.8 A61K 031/34, A61P 009/00, C07D 493/04
LACER, S.A., SPAIN
WO/2000/020420
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
[57] A derivative of isosorbide
mononitrate, or a pharmaceutically
acceptable salt thereof, of the formula
wherein one of A and B represents –ONO2
and the other represents
wherein:
either (i) Z is a sulphur atom and R is an
optionally substituted C1-C4 alkyl group,
1957
an optionally substituted aryl group or an
optionally substituted aralkyl group;
or (ii) Z is an oxygen atom and R is the
group
July 24, 2007– ‫ט' באב התשס"ז‬
wherein R1 is hydrogen or an optionally
substituted C1-C4 alkyl group, an
optionally substituted aryl group or an
optionally substituted aralkyl group.
___________
]11[]21[
]54[
USE OF VALSARTAN OR A
PHARMACEUTICALLY
ACCEPTABLE SALT THEREOF
FOR PRODUCING A
PHARMACEUTICAL
PREPARATION FOR THE
TREATMENT OF INVASIVE
LUNG AND INVASIVE BREAST
CANCER
]22[
]31[
22.12.1999
98811257.9
]32[ 23.12.1998
98811258.7
23.12.1998
Int. Cl.8 A61K 031/41
NOVARTIS AG, SWITZERLAND
WO/2000/038676
LUZZATTO & LUZZATTO,
INDUSTRIAL PARK, OMER,
P.O.B. 5352,
BEER-SHEVA 84152
]51[
]71[
]87[
]74[
[57] Use of valsartan or a
pharmaceutically acceptable salt thereof
for producing a pharmaceutical preparation
The applications for division
from this application have
not yet been published
143233
‫שימוש בוולסרטן או במלח רוקחי מקובל‬
‫שלו להכנת תכשיר רפואי לטיפול בסרטן‬
‫ריאות ובסרטן שד פולשיים‬
]33[
EP
EP
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
for the treatment of invasive lung and
invasive breast cancer.
,179017,179016,179015
‫בקשות חלוקה מבקשה זו‬
.‫שטרם פורסמו‬
____________
July 24, 2007– ‫ט' באב התשס"ז‬
1958
]11[]21[
143830
‫ – בנזיסוקסאזולילפנטיל‬2 ‫תולדות‬
a2 ‫ – בנזואילפנטילפירידואינדול‬2 –‫ו‬
‫– אדרנוספטור אנטגוניסטים‬
‫ הכנתן ותכשירי‬,‫ואנלוגים שלהן‬
‫רוקחות המכילים אותן‬
]54[
A2- ADRENOCEPTOR ANTAGONIST 2 BENZISOXAZOLYLPENTYL AND 2 BENZOYLPENTYLPYRIDOINDOLE
DERIVATIVES AND ANALOGS
THEREOF, THEIR PREPARATION AND
PHARMACEUTICAL COMPOSITIONS
CONTAINING THEM
]22[
]31[
]51[
14.12.1999
98204358.0
]32[
21.12.1998
]33[ EP
Int. Cl.8 A61K 031/395, A61P 003/10, 015/00, 025/00, C07D 471/04, 491/048,
495/04
JANSSEN PHARMACEUTICA N.V.,
BELGIUM
WO/2000/037466
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
‫אביב‬
TEL AVIV 61040
]71[
]87[
]74[
[57] A compound of the formula
a N-oxide form, a pharmaceutically
acceptable addition salt or a
stereochemically isomeric form thereof,
wherein:
Alk is 1,5-pentanediyl;
n is 1 or 2;
p is 1 and q is 2; or
p is 2 and q is 1;
X is –O-, -S-, or NH;
each R1 is independently hydrogen,
halogen, C1-6 alkyl, nitro, hydroxyl or C1-4
alkyloxy;
D is a radical of the formula
wherein m is 1 or 2;
each R3 independently is hydrogen, C1-4
alkyl, C1-4 alkyloxy or halo.
_________
1959
July 24, 2007– ‫ט' באב התשס"ז‬
]11[]21[
144040
‫תת מערכת לאספקת אנרגיה חשמלית‬
‫ליחידת קצה המחוברת בכבלי תקשורת‬
]54[
POWER SUPPLY SUBSYSTEM
FOR POWERING A NODE OVER
COMMUNICATION CABLING
]22[
]31[
19.12.1999
60/115628
]32[ 12.01.1999
]33[ US
09/293343
16.04.1999
US
09/365584
02.08.1999
US
Int. Cl.8 G06F 001/26, H02G 003/00, H04L 012/10, 012/44, 029/06, 029/08, H04Q
007/00
POWERDSINE LTD.
‫ הוד השרון‬,‫פאורדסיין בע"מ‬
WO/2000/041496
SIMON KAHN C/O POWERDSINE
,)‫סיימון קאהן (פאורדסיין בע"מ‬
LTD.,
‫השרון‬-‫ הוד‬,7220 .‫ד‬.‫ ת‬, 1‫רח' הנגר‬
1 HANAGAR ST.
P.O.BOX 7220
HOD HASHARON 45421
]51[
]71[
]87[
]74[
[57] A power supply subsystem for
providing electrical power to at least node
over communication cabling, the power
supply subsystem comprising: a
management and control unit; a power
supply interface for distributing power into
the communication cabling substantially
without interfering with data
communication; and current limiting
circuitry controlling current of said power
distributed into said communication
cabling via said power supply interface;
wherein said current limiting circuitry is
July 24, 2007– ‫ט' באב התשס"ז‬
operative to provide a first current limit
level which is never exceeded, and a
second current limit level which is not
exceeded for more than a predetermined
period of time, and wherein said
management and control unit is operative
to interrogate the at least one node to
which it is intended to transmit power over
the communication cabling in order to
determine whether the node's
characteristics allow it to receive power
over the communication cabling.
1960
The applications for division
from this application have
not yet been published
,157292
‫בקשות חלוקה מבקשה זו‬
.‫שטרם פורסמו‬
__________
]11[]21[
144055
5 – )‫ – (היטרוציקלילסולפונאמידו‬4
)‫ – מתוקסיפנוקס‬2( –6 –‫– מתוקסי‬
‫ –פניל – פירידלפרימידנים‬2 –
]54[
4 - (HETEROCYCLYLSULFONAMIDO)- 5
- METHOXY - 6 - (2 METHOXYPHENOXY ) - 2 - PHENYLPYRIDYLPYRIMIDINES
]22[
]31[
]51[
]71[
10.01.2000
99100784.0
]32[
18.01.1999
]33[ EP
Int. Cl.8 A61K 031/505, A61P 043/00, C07D 401/12, 403/12, 413/12, 417/12
F. HOFFMANN-LA ROCHE AG,
SWITZERLAND
WO/2000/042035
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
‫תל אביב‬
TEL AVIV 61040
]87[
]74[
[57] A compound of the formula
1961
July 24, 2007– ‫ט' באב התשס"ז‬
wherein R1 is pyridyl, pyridyl substituted
with halogen, lower alkyl, hydroxy-lower
alkyl or lower alkenyl, pyrrolyl, pyrrolyl
substituted with halogen, lower alkyl,
hydroxy-lower alkyl or lower alkenyl,
imidazolyl, imidazolyl substituted with
halogen, lower alkyl, hydroxy-lower alkyl
or lower alkenyl, thiazolyl, thiazolyl
substituted with halogen, lower alkyl,
hydroxy-lower alkyl or lower alkenyl,
thiazolinyl, thiazolinyl substituted with
halogen, lower alkyl, hydroxy-lower alkyl
or lower alkenyl, oxazolyl, or oxazolyl
substituted with halogen, lower alkyl,
hydroxy-lower alkyl or lower alkenyl;
R2 is (i) R21, (ii) –Y-R22, (iii) heterocyclyl
selected from the group consisting of
pyrimidinyl, imidazolyl, oxadizolyl,
oxazolyl and thiazolyl, or (iv) heterocyclyl
selected from the group consisting of
pyrimidinyl, imidazolyl, oxadiazolyl,
oxazolyl and thiazolyl, which is mono-,
di- or tri-substituted, independently, with
hydroxy, lower alkenyl, amino, lower
alkanoylamino, lower
alkoxycarbonylamino, lower alkyl or
hydroxyl-lower alkyl;
R21 is cyano, hydroxy-lower alkyl,
carboxy, -C(O)NRaRb, -(CH2)1-4NHRc, (CH2)1-4 NHC(O)NH(CH2)0-3CH3,
amidino, hydroxyamidino, lower
alkoxycarbonyl or hydroxy-lower
alkoxycarbonyl;
R22 is hydrogen, lower alkanoyl, carboxylower alkyl, lower alkoxycarbonyl, lower
alkoxycarbonyl-lower alkyl, carbamoyllower alkyl, di-lower alkylcarbamoyllower alkyl, allyl, lower alkyl or hydroxylower alkyl;
Ra is hydrogen, lower alkyl, or lower alkyl
substituted with hydroxy or lower alkoxy;
Rb is hydrogen or lower alkyl;
Rc is hydrogen, acetyl or lower
alkylsulfonyl;
X is –CH- or –N; and
Y is –O-, -NH-;
or a pharmaceutically acceptable salt or
ester thereof.
__________
July 24, 2007– ‫ט' באב התשס"ז‬
1962
]11[]21[
]54[
MEDICAL SYSTEM
CALIBRATION WITH STATIC
METAL COMPENSATION
]22[
]31[
]51[
]71[
]74[
11.07.2001
09/621322
]32[ 20.07.2000
Int. Cl.8 A61B 005/00, 005/06
BIOSENSE, INC., U.S.A.
DR. SHLOMO COHEN & CO.,
124 IBN GABIROL ST.,
P.O.B. 11490,
TEL AVIV 62038
[57] A method for calibrating a medical
system capable of generating a magnetic
field for tracking a position of a medical
device, the method comprising the steps
of:
(a) defining a mapping volume within the
generated magnetic field;
(b) placing a metallic object within the
mapping volume;
(c) aligning a sensor at a first point within
the mapping volume and measuring the
magnetic field at the first point the sensor
to establish a first coordinate position (Xi,
Yi, Zi));
(d) moving the sensor to a next point (Xi +
dx, Yi + dy, Zi + dz) along one coordinate
axis by an added distance component (dx,
dy, dz) and measuring the magnetic field at
the next point to establish a next
coordinate position;
(e) interpolating the magnetic field at an
intermediate point between the first
144271
‫כיול של מערכת רפואית באמצעות פיצוי‬
‫סטטי מתכתי‬
]33[
US
,'‫ד"ר שלמה כהן ושות‬
‫ תל אביב‬,11490 .‫ד‬.‫ ת‬, 124 ‫אבן גבירול‬
position and the next coordinate position to
establish an interpolated intermediate
coordinate position;
(f) determining the position difference
between the interpolated intermediate
coordinate position and an actual
intermediate coordinate position;
(g) comparing the position difference to an
error limit;
(h) setting (Xi, Yi, Zi) of the next point as
(Xi=Xi+dx, Yi=Yi+dy, Zi=Zi+dz) if the
position difference is within the error limit
and repeating steps (d)-(g) along another
coordinate axis; and
(i) setting the added distance component
(dx, dy, dz) by decreasing the value of the
added distance component if the position
difference is not within the error limit and
repeating steps (d)-(g) along the same
coordinate axis.
_________
1963
July 24, 2007– ‫ט' באב התשס"ז‬
]11[]21[
]54[
METHOD OF ENHANCING
NEEDLELESS TRANSDERMAL
POWDERED DRUG DELIVERY
]22[
]31[
21.01.2000
60/116907
]32[ 22.01.1999
09/235944
22.01.1999
Int. Cl.8 A61M 005/30
POWDERJECT RESEARCH
LIMITED, UNITED KINGDOM
WO/2000/043058
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060, TEL AVIV 61040
]51[
]71[
]87[
]74[
[57] Use of a therapeutic agent in the
manufacture of a medicament for
administering the therapeutic agent to a
predetermined area of skin or mucosa of a
vertebrate subject by a method comprising:
(a) accelerating particles into, across or
both into and across the area of skin or
mucosa, and
144380
‫שיטה להגברת שיחרור תת–עורי של‬
‫ ללא מחט‬,‫תרופה בצורת אבקה‬
]33[
US
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
(b) topically positioning a first transdermal
drug delivery device or a first occlusive
dressing over the area of skin or mucosa,
wherein the particles or the first
transdermal drug delivery device or the
first occlusive dressing, or a combination
thereof, comprise the therapeutic agent.
__________
]11[]21[
144757
‫צורה גבישית של אפלרנון‬
]54[
EPLERENONE CRYSTALLINE
FORM
]22[
]31[
04.12.2000
60/169639
]32[ 08.12.1999
]33[ US
60/169556
08.12.1999
US
60/169683
08.12.1999
US
60/169807
08.12.1999
US
60/169707
08.12.1999
US
60/169608
08.12.1999
US
Int. Cl.8 A61K 031/58, A61P 009/00, 013/06, C07J 071/00
PHARMACIA CORPORATION,
U.S.A.
WO/2001/041535
LUZZATTO & LUZZATTO,
,‫לוצאטו את לוצאטו‬
INDUSTRIAL PARK, OMER,
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
P.O.B. 5352,
BEER-SHEVA 84152
]51[
]71[
]87[
]74[
July 24, 2007– ‫ט' באב התשס"ז‬
1964
[57] A pharmaceutical composition in an
oral dosage form comprising from about
0.5 mg to about 500 mg eplerenone, and at
least one pharmaceutically acceptable
excipient, wherein:
(a) the eplerenone present in the
composition has a phase purity of from
about 90% to about 100% Form L
crystalline eplerenone, and
(b) the Form L crystalline eplerenone is
characterized by an X-ray powder
diffraction pattern at a wavelength of
1.54056Å comprising one or more peaks
that are selected from the group consisting
of 8.0±0.2 degrees 2θ, 12.4±0.2 degrees
2θ, 12.8±0.2 degrees 2θ, and 13.3±0.2
degrees 2θ.
____________
]11[]21[
144761
‫צורת מצב מוצק של סלקוקסיב בעל יכולת‬
‫חיים מוגברת‬
]54[
SOLID-STATE FORM OF
CELECOXIB HAVING
ENHANCED BIOAVAILABILITY
]22[
]31[
06.12.2000
60/169856
]32[ 08.12.1999
]33[ US
09/730663
06.12.2000
US
Int. Cl.8 A61K 009/14, 031/42, C07D 261/00, 261/08
PHARMACIA CORPORATION,
U.S.A.
WO/2001/042221
LUZZATTO & LUZZATTO,
,‫לוצאטו את לוצאטו‬
INDUSTRIAL PARK, OMER,
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
P.O.B. 5352,
BEER-SHEVA 84152
]51[
]71[
]87[
]74[
[57] Amorphous celecoxib, wherein said
amorphous celecoxib exhibits a glass
transition measurable by differential
scanning calorimetry.
___________
1965
July 24, 2007– ‫ט' באב התשס"ז‬
]11[]21[
]54[
SYSTEM AND METHOD FOR
PROCESSING FINANCIAL
TRANSACTIONS
]22[
]31[
]51[
]71[
]87[
]74[
18.02.2000
60/120760
]32[ 19.02.1999
Int. Cl.8 G06Q 002/000000 003/00000
MOBIL OIL CORPORATION, U.S.A.
WO/2000/049551
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
[57] A method for processing transactions
comprising the steps of: transmitting a
signal to one of a plurality of point-of-sale
devices, said signal comprising customer
identification data; transmitting an
authorization request from one of said
plurality of point-of-sale devices to a
transaction processing system, said
authorization request comprising a
merchant identifier, transaction data, and
144846
‫מערכת ושיטה לניהול העברות פיננסיות‬
]33[
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
said customer identification data;
determining, from said customer
identification data, a payment processor
that corresponds to said merchant
identifier; transmitting said authorization
request to said payment processor; and
transmitting to one of said plurality of
point-of-sale devices, said payment
processor's response to said authorization
request.
__________
July 24, 2007– ‫ט' באב התשס"ז‬
1966
]11[]21[
144910
‫תרכובות ציקליות ותכשירי רוקחות‬
‫המכילים אותן‬
]54[
CYCLIC COMPOUNDS AND
PHARMACEUTICAL
COMPOSITIONS CONTAINING
THE SAME
]22[
]31[
]51[
12.04.2000
60/129510
]32[ 15.04.1999
]33[ US
Int. Cl.8 A61K 031/426, A61P 011/06, C07C 237/40, C07D 213/81, 231/38, 233/90,
239/42, 263/48, 277/00, 277/56, 409/12, 417/12
BRISTOL-MYERS SQUIBB
COMPANY, U.S.A.
WO/2000/062778
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.,
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
]71[
]87[
]74[
[57] A compound or a salt thereof of the
formula
as described in the specification.
____________
1967
July 24, 2007– ‫ט' באב התשס"ז‬
]11[]21[
145052
‫פרו–תרופות המכילות זרחן‬
]54[
PHOSPHORUS-CONTAINING
PRODRUGS
]22[
]31[
03.03.2000
60/123013
]32[ 05.03.1999
]33[ US
60/153127
08.09.1999
US
Int. Cl.8 A61K 031/66, A61P 003/10, 009/00, 031/12, 033/00, 035/00, C07F 009/00,
009/02, 009/6584
METABASIS THERAPEUTICS, INC.,
U.S.A.
WO/2000/052015
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
]51[
]71[
]87[
]74[
[57] A compound of the formula
wherein: V, W, and W' are independently
selected from the group consisting of –H,
alkyl, aralkyl, alicyclic, aryl, substituted
aryl, heteroaryl, substituted heteroaryl, 1alkenyl, and 1-alkynyl; or together V and
Z are connected via an additional 3-5
atoms to form a cyclic group containing 57 ring atoms, optionally 1 heteroatom,
substituted with hydroxy, acyloxy,
alkoxycarbonyloxy, or aryloxycarbonyloxy
attached to a carbon atom that is three
atoms from both Y groups attached to the
phosphorus; or together V and Z are
connected via an additional 3-5 atoms to
form a cyclic group, optionally containing
1 heteroatom, said cyclic group is fused to
an aryl group at the beta and gamma
position to the Y adjacent to V; together V
July 24, 2007– ‫ט' באב התשס"ז‬
and W are connected via an additional 3
carbon atoms to form an optionally
substituted cyclic group containing 6
carbon atoms and substituted with one
substituent selected from the group
consisting of hydroxy, acyloxy,
alkoxycarbonyloxy, alkylthiocarbonyloxy,
and aryloxycarbonyloxy, attached to one
of said additional carbon atoms that is
three atoms from a Y attached to the
phosphorus; together Z and W are
connected via an additional 3-5 atoms to
form a cyclic group, optionally containing
one heteroatom, and V must be aryl,
substituted aryl, heteroaryl, or substituted
heteroaryl; together W and W' are
connected via an additional 2-5 atoms to
form a cyclic group, optionally containing
1968
0-2 heteroatoms, and V must be aryl,
substituted aryl, heteroaryl, or substituted
heteroaryl;
Z is selected from the group consisting of
–CHR2OH, -CHR2OC(O)R3, CHR2OC(S)R3, -CHR2OC(S)OR3, CHR2OC(O)SR3, -CHR2OCO2R3, -OR2, SR2, -CHR2N3, -CH2aryl, -CH(aryl)OH, CH(CH=CR22)OH, -CH(C≡CR2)OH, -R2, NR22, -OCOR3, -OCO2R3, -SCOR3, SCO2R2, -NHCOR2, -NHCO2R3, CH2NHaryl, -(CH2)p-OR12, and –(CH2)pSR12;
p is an integer 2 or 3;
with the provisos that:
(a) V, Z, W, W' are not all –H;
(b) when Z is –R2, then at least one of V,
W, and W' is not –H, alkyl, aralkyl, or
alicyclic;
R2 is selected from the group consisting of
R3 and –H;
R3 is selected from the group consisting of
alkyl, aryl, alicyclic, and aralkyl;
R6 is selected from the group consisting of
–H, and lower alkyl, acyloxycarbonyl,
alkoxycarbonyloxy alkyl and lower acyl;
R12 is selected from the group cosnsiting of
–H, and lower acyl;
each Y is independently selected from the
group consisting of –O-, -NR6- with the
proviso that at least one Y is –NR6-;
M is selected from the group that when
attached to PO2-3, P2O3-6, P3O94- or
P(O)(NHR6)O- is a biologically active
agent but is not an FBPase inhibitor, and is
attached to the phosphorus in formula I via
a carbon, oxygen, sulfur or nitrogen atom;
with the proviso that:
(1) M is not –NH(lower alkyl), -N(lower
alkyl)2, -NH(lower alkylhalide), -N(lower
alkylhalide)2, or –N(lower alkyl) (lower
alkylhalide); and
(2) R6 is not lower alkylhalide; and
pharmaceutically acceptable prodrugs and
salts thereof.
_________
]11[]21[
]54[
METHOD FOR THE
IDENTIFICATION, ISOLATION,
OR SEPARATION OF IDENTICAL
NUCLEIC ACID FRAGMENTS
FROM A MIXTURE OF AT LEAST
TWO NUCLEIC ACID
POPULATIONS
]22[
]31[
]51[
]71[
]87[
]74[
09.03.2000
19911130.8
]32[ 12.03.1999
Int. Cl.8 C12Q 001/68
INTEGRAGEN, S.A.S., FRANCE
WO/2000/053802
LUZZATTO & LUZZATTO,
INDUSTRIAL PARK, OMER,
P.O.B. 5352,
BEER-SHEVA 84152
1969
145141
‫ של קטעי‬,‫ או הפרדה‬,‫ בידוד‬,‫שיטה לזיהוי‬
‫חומצות גרעין זהות מתוך תערובת של‬
‫לפחות שתי אוכלוסיות של חומצות גרעין‬
]33[
DE
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
July 24, 2007– ‫ט' באב התשס"ז‬
[57] A method for the identification (or
isolation or separation) of identical nucleic
acid fragments from a mixture of at least
two nucleic acid populations, comprising:
(a) separate digestion of the nucleic acids
of said at least two populations with at
least one restriction enzyme;
(b) ligation of an adaptor sequence to the
restriction fragments;
(c) amplification of the adaptor-ligated
restriction fragments generated in (a) and
.
(b) using differently labeled adaptorspecific primers;
(d) hybridization of the amplification
products from the different nucleic acid
populations with each other;
(e) elimination of homohybrids based on
labeling of primers;
and (f) identification (or isolation or
separation) of the identical, fully matched,
heterohybrid fragments
__________
]11[]21[
145299
‫גליצרופוספאטים ציקליים ואנלוגיים‬
‫שלהם‬
]54[
CYLIC GLYCEROPHOSPHATES
AND ANALOGS THEREOF
]22[
]31[
]51[
]71[
24.03.2000
129179
]32[ 25.03.1999
]33[ IL
Int. Cl.8 A61K 031/66, A61P 005/00, 035/00, 035/02, C07F 009/00, 009/02
YEDA RESEARCH AND
‫ רחובות‬,‫ידע חברה למחקר ופיתוח בע"מ‬
DEVELOPMENT CO. LTD.
WO/2000/057864
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
[57] A pharmaceutical composition
comprising a pharmaceutically acceptable
July 24, 2007– ‫ט' באב התשס"ז‬
carrier and, as an active ingredient, a
compound of the formula
1970
wherein Y is –(CH2)m-, -CH(OH)- or –
C(=O)-, and m is 1-3;
X is H, alkyl, -CH2OH-, CH2Oacyl or –
CH2acyl; and
R is H, a cation, alkyl or optionally
substituted aryl; provided that: said
compound is not one of: phenyl 1,3-cyclic
propanediol phosphate; cyclic
dihydroxyacetone phosphate; 1,3-cyclic
propanediol phosphate; 1,3-cyclic
glycerophosphate.
__________
]11[]21[
145357
‫ תכשירי‬,‫ תהליך להכנתם‬,‫מעכבי אמיד‬
‫רוקחות המכילים אותם והשימוש בהם‬
‫לייצור תרופות לטיפול במחלות המתווכות‬
‫על ידי ציטוקין‬
]54[
AMIDE INHIBITORS, PROCESS
FOR THEIR PREPARATION,
PHARMACEUTICAL
COMPOSITIONS CONTAINING
THEM AND THEIR USE IN THE
MANUFACTURE OF
MEDICAMENTS FOR THE
TREATMENT OF CYTOKINE
MEDIATED DISEASES
]22[
]31[
13.03.2000
9906279.6
]32[ 17.03.1999
]33[ GB
9926667.8
11.11.1999
GB
Int. Cl.8 A61K 031/505, A61P 043/00, C07D 239/88, 401/12, 403/12, 405/12, 409/12
ASTRAZENECA AB, SWEDEN
WO/2000/055153
S. HOROWITZ & CO.,
,'‫ הורוביץ ושות‬.‫ש‬
ZION HOUSE,
‫ תל‬,41-45 ‫ שדרות רוטשילד‬,‫בית ציון‬
41-45 ROTHSCHILD BLVD.,
‫אביב‬
TEL AVIV 65784
]51[
]71[
]87[
]74[
[57] An amide derivative of the formula
wherein X is –NHCO- or –CONH;
m is 0, 1, 2 or 3;
R1 is hydroxy, halogeno, trifluoromethyl,
cyano, mercapto, nitro, amino, carboxy,
carbamoyl, formyl, (1-6C) alkyl, (2-6C)
alkenyl, (2-6C) alkynyl, (1-6C) alkoxy, (16C) alkylthio, (1-6C) alkylsuphinyl, (1-6C)
alkylsulfphonyl, (1-6C) alkylamino, di-[(1-
1971
6C) alkyl] amino, (1-6C) alkoxycarbonyl,
N-(1-6C) alkylcarbamoyl, N,N-di[(16C)alkyl] carbamoyl, (2-6C) alkanoyl, (26C) alkanoyloxy, (1-6C) alkanoylamino,
N-(1-6C) alkyl-(1-6C) alkanoylamino, N(1-6C) alkylsulphamoyl, N,N-di[(16C)alkyl) sulphamoyl, (1-6C)
alkanesulphonylamino, N-(1-6C)alkyl-(1-
July 24, 2007– ‫ט' באב התשס"ז‬
6C) alkanesulphonylamino, halogeno-(16C) alkyl, hydroxyl-(1-6C) alkyl, (1-6C)
alkoxy-(1-6C) alkyl, cyano-(1-6C) alkyl,
amino-(1-6C) alkyl, (1-6C) alkylamino-(16C) alkyl, di[[(1-6C) alkyl] amino-(1-6C)
alkyl, carboxy-(1-6C) alkyl, (1-6C)
alkoxycarbonyl-(1-6C) alkyl, carbamoyl(1-6C) alkyl, N-(1-6C) alkylcarbamoyl-(16C) alkyl, N,N-di[(1-6C) alkyl]
carbamoyl-(1-6C) alkyl, halogeno-(2-6C)
alkoxy, hydroxy-(2-6C) alkoxy, (1-6C)
alkoxy-(2-6C) alkoxy, cyano-(1-6C)
alkoxy, carboxy-(1-6C) alkoxy, (1-6C)
alkoxycarbonyl-(1-6C) alkoxy, carbamoyl(1-6C) alkoxy, N-(1-6C) alkylcarbamoyl(1-6C) alkoxy, N,N-di-[(1-6C) alkyl]
carbamoyl-(1-6C) alkoxy, amino-(2-6C)
alkoxy, (1-6C) alkylamino-(2-6C) alkoxy,
di-[(1-6C) alkyl] amino-(2-6C) alkoxy,
halogeno-(2-6C) alkylamino, hydroxy-(26C) alkylamino, (1-6C) alkoxy-(2-6C)
alkylamino, cyano-(1-6C) alkylamino,
carboxy-(1-6C) alkylamino, (1-6C)
alkoxycarbonyl-(1-6C) alkylamino,
carbamoyl-(1-6C) alkylamino, N-(1-6C)
alkylcarbamoyl-(1-6C) alkylamino, N,Ndi-[(1-6C) alkyl] carbamoyl-(1-6C)
alkylamino, amino-(2-6C) alkylamino, (16C) alkylamino-(2-6C) alkylamino, di-[(16C) alkyl] amino-(2-6C) alkylamino, N-(16C) alkyl-halogeno-(1-6C) alkylamino, N(1-6C) alkyl-hydroxy-(2-6C) alkylamino,
N-(1-6C) alkyl-(1-6C) alkoxy-(2-6)
alkylamino, N-(1-6C) alkyl-cyano-(1-6C)
alkylamino, N-(1-6C)alkyl-carboxy-(1-6C)
alkylamino, N-(1-6C) alkyl-(1-6C)
alkoxycarbonyl-(1-6C) alkylamino, N-(16C) alkyl-carbamoyl-(1-6C) alkylamino,
N-(1-6C) alkyl-N-(1-6C) alkylcarbamoyl(1-6C) alkylamino-N-(1-6C) alkyl-N,Ndi[(1-6C) alkyl] carbamoyl-(1-6C)
alkylamino, N-(1-6C) alkylamino-(2-6C)
alkylamino, N-(1-6C) alkyl-(1-6C)
alkylamino-(2-6C) alkylamino, N-(1-6C)
alkyl-di-[(1-6C) alkyl] amino-(2-6C)
alkylamino, halogeno-(2-6C)
alkanoylamino, hydroxyl-(2-6C)
alkanoylamino, (1-6C) alkoxy-(2-6C)
July 24, 2007– ‫ט' באב התשס"ז‬
alkanoylamino, cyano-(2-6C)
alkyanoylamino, carboxy-(2-6C)
alkanoylamino, (1-6C) alkoxycarbonyl-(26C) alkanoylamino, carbamoyl-(2-6C)
alkanoylamino, N-(1-6C) alkylcarbamoyl(2-6C) alkanoylamino, N,N-di[(1-6C)
alkyl] carbamoyl-(2-6C) alkanoylamino,
amino-(2-6C) alkanoylamino, (1-6C)
alkylamino-(2-6C) alkanoylamino or di[(1-6C) alkyl] amino-(2-6C)
alkanoylamino,
or R1 is aryl, aryl-(1-6C) alkyl, aryl-(16C) alkoxy, aryloxy, arylamino, N-(1-6C)
alkyl-arylamino, aryl-(1-6C) alkylamino,
N-(1-6C) alkyl-aryl-(1-6C) alkylamino,
aroylamino, arylsulphonylamino, Narylsulphamoyl, aryl-(2-6C)
alkanoylamino, heteroaryl, heteroaryl-(16C) alkyl, heteroaryloxy, heteroaryl-(16C) alkoxy, heteroarylamino, N-(1-6C)
alkyl-heteroarylamino, heteroaryl-(1-6C)
alkylamino, N-(1-6C) alkyl-heteroaryl-(16C) alkylamino, heteroarylcarbonylamino,
heteroarylsulphonylamino, Nheteroarylsulphamoyl, heteroaryl-(2-6C)
alkanoylamino, heteroaryl-(1-6C) alkoxy(1-6C) alkyl, heteroaryl-(1-6C)
alkylamino-(1-6C) alkyl, N-(1-6C) alkylheteroaryl-(1-6C) alkylamino-(1-6C) alkyl,
heterocyclyl, heterocyclyl-(1-6C) alkyl,
heterocyclyloxy, heterocyclyl-(1-6C)
alkoxy, heterocyclamino, N-(1-6C) alkylheterocyclylamino, heterocyclyl-(1-6C)
alkylamino, N-(1-6C) alkyl-heterocyclyl(1-6C) alkylamino,
heterocyclylcarbonylamino,
heterocyclcylsulphonylamino, Nheterocyclcylsulphamoyl, heterocyclyl-(26C) alkanoylamino, heterocyclyl-(1-6C)
alkoxy-(1-6C) alkyl, heterocyclyl-(1-6C)
alkylamino-(1-6C) alkyl or N-(1-6C)
alkyl-heterocyclyl-(1-6C) alkylamino-(16C) alkyl, or (R1)m is a (1-3C)
alkylenedioxy group,
and wherein any of the R1 substituents
defined hereinbefore which comprises a
CH2 group which is attached to 2 carbon
atoms or a CH3 group which is attached to
1972
a carbon atom may optionally bear on each
said CH2 or CH3 group a substituent
selected from hydroxy, amino, (1-6C)
alkoxy, (1-6C) alkylkamino, di-[(1-6C)
alkyl] amino and heterocyclyl,
and wherein any aryl, heteroaryl or
heterocyclyl group in a R1 substituent may
optionally bear 1 or 2 substituents selected
from hydroxy, halogeno, (1-6C) alkyl, (16C) alkoxy, carboxy, (1-6C)
alkoxycarbonyl, N-(1-6C) alkylcarbamoyl,
N,N-di-[(1-6C) alkyl] carbamoyl, (2-6C)
alkanoyl, amino, (1-6C) alkylamino, di[(1-6C) alkyl] amino, halogeno-(1-6C)
alkyl, hydroxy-(1-6C) alkyl, (1-6C)
alkoxy-(1-6C) alkyl, cyano-(1-6C) alkyl,
amino-(1-6C) alkyl, (1-6C) alkylamino-(16C) alkyl, di-[(1-6C) alkyl, di-[(1-6C)
alkyl] amino-(1-6C) alkyl, aryl and aryl(1-6C) alkyl, and wherein any heterocyclyl
group in a R1 substituent may optionally
bear 1 or 2 oxo or thioxo substituents;
n is 0, 1 or 2;
R2 is hydroxy, halogeno, trifluoromethyl,
cyano, mercapto, nitro, amino, carboxy,
(1-6C) alkoxycarbonyl, (1-6C) alkyl, (26C) alkenyl, (2-6C) alkynyl, (1-6C)
alkoxy, (1-6C) alkylamino or di-[(1-6C)
alkyl] amino;
R3 is hydrogen, halogeno, (1-6C) alkyl or
(1-6C) alkoxy;
q is 0, 1, 2 3 or 4; and
Q is aryl, aryloxy, aryl-(1-6C) alkoxy,
arylamino, N-(1-6C) alkyl-arylamino, aryl(1-6C) alkylamino, N-(1-6C) alkyl-aryl-(16C) alkylamino, aroylamino,
arylsulphonylamino, N-arylcarbamoyl, Narylsulphamoyl, aryl-(2-6C)
alkanoylamino, (3-7C) cycloalkyl,
heteroaryl, heteroaryloxy, heteroaryl-(16C) alkoxy, heteroarylamino, N-(1-6C)
alkyl-heteroarylamino, heteroaryl-(1-6C)
alkylamino, N-(1-6C) alkyl-heteroaryl-(16C) alkylamino, heteroarylcarbonylamino,
heteroarylsulphonylamino, Nheteroarylcarbamoyl, Nheteroarylsulphamoyl, heteroaryl-(2-6C)
alkanoylamino, heterocyclyl,
1973
heterocyclcyloxy, heterocyclyl-(1-6C)
alkoxy, heterocyclylamino, N-(1-6C)
alkyl-heterocyclylamino, heterocyclyl-(16C) alkylamino, N-(1-6C) alkylheterocyclyl-(1-6C) alkylamino,
heterocyclcarbonylamino,
heterocyclylsulphonylamino, Nheterocyclcarbamoyl, Nheterocyclylsulphamoyl or heterocyclyl(2-6C) alkanoylamino, and Q is optionally
substituted with 1, 2 or 3 substituents
selected from hydroxy, halogeno,
trifluoromethyl, cyano, mercapto, nitro,
amino, carboxy, carbamoyl, formyl, (1-6C)
alkyl, (2-6C) alkenyl, (2-6C) alkynyl, (16C) alkoxy, (1-6C) alkylthio, (1-6C)
alkylsulphinyl, (1-6C) alkylsulphonyl, (16C) alkylamino, di-[(1-6C) alkyl] amino,
(1-6C) alkoxycarbonyl, N-(1-6C)
alkylcarbamoyl, N,N-di[(1-6C) alkyl]
carbamoyl, (2-6C) alkanoyl, (2-6C)
alkanoyloxy, (1-6C) alkanoylamino, N-(16C) alkyl-(1-6C) alkanoylamino, N-(1-6C)
alkylsulphamoyl, N,N-di-[(1-6C)
sulphamoyl, (1-6C)
alkanesulphonylamino, N-(1-6C) alkyl-(16C) alkanesulphonylamino, halogeno-(16C) alkyl, hydroxy-(1-6C) alkyl, (1-6C)
alkoxy-(1-6C) alkyl, cyano-(1-6C) alkyl,
amino-(1-6C) alkyl, (1-6C) alkylamino(1-6C) alkyl, di-[(1-6C) alkyl] amino-(16C) alkyl, carboxy-(1-6C) alkyl, (1-6C)
alkoxycarbonyl-(1-6C) alkyl, carbamoyl(1-6C) alkyl, N-(1-6C) alkylcarbamoyl-(16C) alkyl, N-N-di-[(1-6C) alkyl]
carbamoyl-(1-6C) alkyl, halogeno-(2-6C)
alkoxy, hydroxy-(2-6C) alkoxy (1-6C)
alkoxy-(2-6C) alkoxy, cyano-(1-6C)
alkoxy, carboxy-(1-6C) alkoxy, (1-6C)
alkoxycarbonyl-(1-6C) alkoxy, carbamoyl(1-6C) alkoxy, N-(1-6C) alkylcarbamoyl(1-6C) alkoxy, N,N-di-[(1-6C) alkyl]
carbamoyl-(1-6C) alkoxy, amino-(2-6C)
alkoxy, halogeno-(2-6C) alkylamino,
hydroxy-(2-6C) alkylamino, (1-6C)
alkoxy-(2-6C) alkylamino, cyano-(1-6C)
alkylamino, carboxy-(1-6C) alkylamino,
(1-6C) alkoxycarbonyl-(1-6C) alkylamino,
July 24, 2007– ‫ט' באב התשס"ז‬
carbamoyl-(1-6C) alkylamino, N-(1-6C)
alkylcarbamoyl-(1-6C) alkylamino, N,Ndi-[(1-6C) alkyl] carbamoyl-(1-6C)
alkylamino, amino-(2-6C) alkylamino, (16C) alkylamino-(2-6C) alkylamino, di-[(16C) alkyl] amino-(2-6C) alkylamino, N-(16C) alkyl-halogeno-(1-6C) alkylamino, N(1-6C) alkyl-hydroxy-(2-6C) alkylamino,
N-(1-6C) alkyl-(1-6C) alkoxy-(2-6C)
alkylamino, N-(1-6C) alkyl-cyano-(1-6C)
alkylamino, N-(1-6C) alkyl-carboxy-(16C)-alkylamino, N-(1-6C) alkyl-(1-6C)
alkoxycarbonyl-(1-6C) alkyamino, N-(16C) alkyl-carbamoyl-(1-6C) alkylamino,
N-(1-6C) alkyl-N-(1-6C) alkylcarbamoyl(1-6C) alkylamino, N-(1-6C) alkyl-N,N-di[(1-6C) alkyl] carbamoyl-(1-6C)
alkylamino, N-(1-6C) alkylamino-(2-6C)
alkylamino, N-(1-6C) alkyl-(1-6C)
alkylamino-(2-6C) alkylamino, N-(1-6C)
alkyl-di-[(1-6C) alkyl] amino-(2-6C)
alkylamino, halogeno-(2-6C)
alkanoylamino, hydroxy-(2-6C)
alkanoylamino, (1-6C) alkoxy-(2-6C)
alkanoylamino, cyano-(2-6C)
alkanoylamino, carboxy-(2-6C)
alkanoylamino, (1-6C) alkoxycarbonyl-(26C) alkanoylamino, carboxy-(2-6C)
alkanoylamino, (1-6C) alkoxycarbonyl-(26C) alkanoylamino, carboxy-(2-6C)
alkanoylamino, (1-6C) alkoxycarbonyl-(26C) alkanoylamino, carbamoyl-(2-6C)
alkanoylamino, N-(1-6C) alkylcarbamoyl(2-6C) alkanoylamino, N,N-di-[(1-6C)
alkyl] carbamoyl-(2-6C) alkanoylamino,
amino-(2-6C) alkanoylamino, (1-6C)
alkylamino-(2-6C) alkanoylamino, di-[(16C) alkyl] amino-(2-6C) alkanoylamino,
aryl, aryl-(1-6C) alkyl, aryl-(1-6C) alkoxy,
aryloxy, arylamino, N-(1-6C) alkylarylamino, aryl-(1-6C) alkylamino, N-(16C) alkyl-aryl-(1-6C) alkylamino,
aroylamino, arylsulphonylamino, Narylsulphamoyl, aryl-(2-6C)
alkanoylamino, heteroaryl, heteroaryl-(16C) alkyl, heteroaryloxy, heteroaryl-(1-6C)
alkoxy, heteroarylamino, N-(1-6C) alkylheteroarylamino, heteroaryl-(1-6C)
July 24, 2007– ‫ט' באב התשס"ז‬
alkylamino, N-(1-6C) alkyl-heteroaryl-(16C) alkylamino, heteroarylcarbonylamino,
heteroarylsulphonylamino, Nheteroarylsulphamoyl, heteroaryl-(2-6C)
alkanoylamino, heteroaryl-(1-6C) alkoxy(1-6C) alkyl, heteroaryl-(1-6C)
alkylamino-(1-6C) alkyl, N-(1-6C) alkylheteroaryl-(1-6C) alkylamino-(1-6C) alkyl,
heterocyclyl, heterocyclyl-(1-6C) alkyl,
heterocyclyloxy, heterocyclyl-(1-6C)
alkoxy, heterocyclylamino, N-(1-6C)
alkyl-heterocyclylamino, heterocyclyl-(16C) alkylamino, N-(1-6C) alkylheterocyclyl-(1-6C) alkylamino,
heterocyclylcarbonylamino,
heterocyclylsulphonylamino, Nheterocyclylsulphamoyl, heterocyclyl-(26C) alkanoylamino, heterocyclyl-((1-6C)
alkoxy-(1-6C) alkyl, heterocyclyl-(1-6C)
alkylamino-(1-6C) alkyl and N-(1-6C)
alkyl-heterocyclyl-(1-6C) alkylamino-(16C) alkyl,
or Q is substituted with a (1-3C)
alkylenedioxy group, and wherein any of
the substituents on Q defined hereinbefore
which comprises a CH2 group which is
attached to 2 carbon atoms or a CH3 group
which is attached to a carbon atom may
optionally bear on each said CH2 or CH3
group a substituent selected from hydroxy,
amino, (1-6C) alkoxy, (1-6C) alkylamino,
di-[(1-6C) alkyl] amino and heterocyclyl,
and wherein any aryl, heteroaryl or
heterocyclyl group in a substituent on Q
may optionally bear 1 or 2 substituents
selected from hydroxy, halogeno, (1-6C)
alkyl, (1-6C) alkoxy, carboxy (1-6C)
alkoxycarbonyl, N-(1-6C) alkylcarbamoyl,
N,N-di-[(1-6C) alkyl] carbamoyl, (2-6C)
alkanoyl, amino, (1-6C) alkylamino, di[(1-6C) alkyl] amino, halogeno-(1-6C)
alkyl, hydroxy(1-6C) alkyl, (1-6C) alkoxy(1-6C) alkyl, cyano-(1-6C) alkyl, amino(1-6C) alkyl, (1-6C) alkylamino-(1-6C)
alkyl, di-[(1-6C) alkyl] amino-(1-6C)
alkyl, aryl and aryl-(1-6C) alkyl, and
wherein Q when it is a heterocyclyl group
or it contains a heterocyclyl group or any
1974
heterocyclyl group in a substituent on Q
may optionally bear 1 or 2 oxo or thioxo
substituents; or a pharmaceuticallyacceptable salt or in-vivo-cleavable ester
thereof; wherein an in-vivo-cleavable ester
of a compound of the formula Ia is a
pharmaceutically-acceptable ester of a
compound of the formula Ia containing a
carboxy group selected from a (1-6C)
alkanoyloxymethyl ester, a (3-8C)
cycloalkoxycarbonyloxy (1-6C) alkyl
ester, a 1,3-dioxolan-2-ylmethyl ester and
a (1-6C) alkoxycarbonyloxyethyl ester;
and wherein R1 or Q when it is aryl, a
substituent on Q when it is aryl or the aryl
group within a R1 substituent or a Q group
or within a substituent on Q is phenyl,
indenyl, indanyl, naphthyl,
tetrahydronaphthyl or fluorenyl; and
wherein R1 or Q when it is heteroaryl, the
heteroaryl group within a R1 substituent or
a Q group, a substituent on Q when it is
heteroaryl or the heteroaryl group within a
substituent on Q is an aromatic 5- or 6membered monocyclic ring, a 9- or 10membered bicyclic ring or a 13- or 14membered tricyclic ring each with up to
five ring heteroatoms selected from
oxygen, nitrogen and sulphur; and wherein
R1 or Q when it is heterocyclyl, a
substituent on Q when it is heterocyclyl or
the heterocyclyl group within a R1
substituent or a Q group or within a
substituent on Q is a non-aromatic
saturated or partially saturated 3- to 10membered monocyclic or bicyclic ring
with up to five heteroatoms selected from
oxygen, nitrogen and sulphur; except that
3-(5-benzamido-2-methylphenyl)-2methyl-3,4-dihydroquinazolin-4-one, 3-[5(4-methylbenzamido)-2-methylphenyl]-2methyl-3,4-dihydroquinazolin-4-one and
3-[5-(4-methoxybenzamido)-2methylphenyl]-2-methyl-3,4dihydroquinazolin-4-one are excluded.
__________
]11[]21[
145401
‫תכשריי רוקחות‬,‫תרכובות הטרוציקליות‬
‫המכילים אותן והשימוש בהן בטיפול באי‬
‫סדרים הקשורים בקולטן הכמוקין‬
]54[
HETEROCYCLIC COMPOUNDS,
PHARMACEUTICAL
COMPOSITIONS COMPRISING
THEM AND THEIR USE FOR
TREATING DISORDERS
INVOLVING A CHEMOKINE
RECEPTOR
]22[
]31[
]51[
24.03.2000
60/125823
]32[ 24.03.1999
]33[ US
Int. Cl.8 A61K 031/395, A61P 043/00, C07D 213/00, 213/36, 215/16, 401/12,
405/12, 409/12, 413/12, 417/12
ANORMED, INC., CANADA
WO/2000/056729
REINHOLD COHN AND
,‫ריינהולד כהן ושותפיו‬
PARTNERS,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]71[
]87[
]74[
1975
July 24, 2007– ‫ט' באב התשס"ז‬
[57] A compound of the formula
and the salts thereof,
wherein, W is a nitrogen atom and Y is
void or, W is a carbon atom and Y=H;
R1 to R7 may be the same or different and
are independently hydrogen or an
unsubstituted straight, branched or cyclic
C1-6 alkyl, or R1 and R2 together represent
=O
R8 is an unsubstituted heterocyclic group
or an aromatic group;
Ar is an aromatic or heteroaromatic ring;
n and n' are independently, 0-2;
X is a group of the formula
wherein, Ring A is a saturated or
unsaturated 5 or 6-memberd ring, and P is
C, N, S or O, optionally substituted with
halogen, lower alkyl or alkoxy, or
hydroxy; wherein Ring B is a 5 to 7membered ring;
wherein Ring A or Ring B is bound to
group W from any position through group
V;
wherein V is a chemical bond or V is a
(CH2)n'- group (where n''=0-2), or V is a
C=O group, and
wherein Z is hydrogen; a C0-6 alkyl group
substituted with a fused or unfused
aromatic or heterocyclic group; a C2-6 alkyl
group; a C0-6 alkylamino or C3-7
cycloalkylamino group wherein one or
more carbons in said C0-6 alkyl, C2-6 alkyl,
or C0-6 alkylamino are optionally replaced
with one or more heteroatoms, are
substituted with =O, or both; or Z is a
carbonyl or a sulfonyl, each optionally
substituted with a C1-7 alkyl, amino, aryl,
C1-6 alkaryl or a heterocyclic ring; each Z
is optionally substituted with one or more
halogen; nitro, cyano, carbonyl, carboxyl,
alkyl, alkenyl, cycloalkyl, hydroxyl, thiol,
amino, acyl, carboxylate, sulfonate,
carboxamide, sulfonamide, C1-4 alkoxy
optionally substituted with halogen, C2-4
alkanoyl, C1-4 alkylsulfonyl, aryl, aryloxy
or heterocyclyl; and the pharmaceutically
acceptable acid addition salts thereof; and
any stereoisonteric forms and mixtures of
stereoisomeric forms thereof.
__________
July 24, 2007– ‫ט' באב התשס"ז‬
1976
]11[]21[
]54[
FORWARD LINK POWER
CONTROL OF MULTIPLE DATA
STREAMS TRANSMITTED TO A
MOBILE STATION USING A
COMMON POWER CONTROL
CHANNEL
145652
‫בקרת כוח בקישור קידמי של אפיקי מידע‬
‫מרובים המשודרים לתחנה ניידת בשימוש‬
‫בערוץ בקרת כוח משותף‬
]22[
]31[
]51[
]71[
06.04.2000
09/288262
]32[ 08.04.1999
]33[ US
Int. Cl.8 H04B 007/005, 007/26, H04J 013/00
QUALCOMM INCORPORATED,
U.S.A.
]87[ WO/2000/062443
]74[ SANFORD T.COLB & CO.,
,'‫ קולב ושות‬.‫סנפורד ט‬
P.O.B. 2273,
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
REHOVOT
[57] In a mobile radio telephone
(e) transmitting the power control signal
communication system, a method for
from the mobile station to the at least one
controlling transmit power levels of a
base station;
plurality of different data streams
(f) receiving the power control signal at the
transmitted from at least one base station
at least one base station;
to a mobile station, comprising the steps
(g) forming a first received stream of
of:
power control commands from the
(a) transmitting a first data stream from the
received power control signal at the at least
at least one base station to the mobile
one base station; and
station, and transmitting a second data
(h) controlling a transmit power level of
stream from the at least one base station to
the first data stream from the at least base
the mobile station;
station in accordance with the first
(b) receiving the first and second data
received stream of power control
streams at the mobile station;
commands, and controlling a transmit
(c) forming a first stream of power control
power level of the second data stream from
commands at the mobile station in
the at least one base station in accordance
accordance with either the first or second
with the first received stream of power
received data stream;
control commands.
(d) forming a power control signal at the
mobile station from the first stream of
power control commands;
1977
July 24, 2007– ‫ט' באב התשס"ז‬
,178966
The applications for division
from this application have
not yet been published
‫בקשות חלוקה מבקשה זו‬
.‫שטרם פורסמו‬
_________
]11[]21[
]54[
ANTAGONIST OF THE INTEGRIN
ALPHA-4 SUBUNIT FOR THE
TREATMENT OF FIBROSIS
]22[
]31[
21.04.2000
60/130847
]32[ 22.04.1999
60/137214
01.06.1999
Int. Cl.8 A61K 039/395
BIOGEN IDEC MA INC., U.S.A.
WO/2000/064474
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]51[
]71[
]87[
]74[
[57] Use of a composition comprising an
antibody homolog which is an antagonist
of an interaction between an alpha4
subunit-bearing integrin and a ligand for
The applications for division
from this application have
not yet been published
145898
‫ – של‬4 ‫אנטגוניסט של תת–יחידת אלפא‬
‫אינטגרין לטיפול בלייפת‬
]33[
US
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
an alpha4 subunit-bearing integrin for the
preparation of a pharmaceutical
composition for the treatment of fibrosis in
a subject.
,182908
‫בקשות חלוקה מבקשה זו‬
.‫שטרם פורסמו‬
_____________
July 24, 2007– ‫ט' באב התשס"ז‬
1978
]11[]21[
]54[
METHOD FOR THE
PREPARATION OF
CITALOPRAM
]22[
]31[
]51[
]71[
]87[
]74[
22.11.1999
PA199900920 ]32[ 25.06.1999
Int. Cl.8 C07D 307/00, 307/87
H. LUNDBECK A/S, DENMARK
WO/2000/013648
DR. SHLOMO COHEN & CO.,
124 IBN GABIROL ST.,
P.O.B. 11490,
TEL AVIV 62038
145959
‫שיטה להכנה של ציטאלופרם‬
]33[
DK
,'‫ד"ר שלמה כהן ושות‬
‫ תל אביב‬,11490 .‫ד‬.‫ ת‬, 124 ‫אבן גבירול‬
[57] A method for the preparation of
citalopram comprising reaction of a
compound of the formula
where R is halogen, or CF3-(CF2)n-SO2-Owherein n is an integer in the range 0-8,
incl., with a cyanide source in a
stoichiometric amount or in excess in the
presence of a palladium catalyst and a
catalytic amount of Cu+ or Zn2+, or with
Zn(CN)2 in the presence a palladium
catalyst, and isolation of the corresponding
5-cyano compound, i.e. citalopram
as the base or a pharmaceutically
acceptabls salt thereof.
The compound of the formula
1979
July 24, 2007– ‫ט' באב התשס"ז‬
wherein R is CF3-(CF2)n-SO2-O- wherein n
is an integer in the range 0-8 or R is iodo is
claimed as novel.
.
___________
]11[]21[
145962
‫נגזרות אינדאזול או בנזוטריאזול להדברת‬
‫ תכשריים‬,‫ תהליך להכנתן‬,‫מזיקים‬
‫המכילים נגזרות כאלה ושיטות לשימוש‬
‫בהן‬
]54[
PESTICIDAL INDAZOLE OR
BENZOTRIAZOLE DERIVATIVES,
A PROCESS FOR THEIR
PREPARATION, COMPOSITIONS
CONTAINING SUCH
DERIVATIVES AND METHODS
FOR THE USE THEREOF
]22[
]31[
04.04.2000
9909062.3
]32[ 20.04.1999
]33[ GB
0002039.6
28.01.2000
GB
Int. Cl.8 A01N 043/64, 043/72, C07D 401/12, 413/12, 417/12
SYNGENTA LIMITED, UNITED
KINGDOM
WO/2000/063207
S. HOROWITZ & CO.,
,'‫ הורוביץ ושות‬.‫ש‬
ZION HOUSE,
‫ תל‬,41-45 ‫ שדרות רוטשילד‬,‫בית ציון‬
41-45 ROTHSCHILD BLVD.,
‫אביב‬
TEL AVIV 65784
]51[
]71[
]87[
]74[
[57] A compound of the formula
wherein G is either
July 24, 2007– ‫ט' באב התשס"ז‬
1980
wherein A, R1, R3, R4, R5, R6, J, E, D, M1,
M2 are as defined in the specification.
___________
]11[]21[
]54[
ANTI-CD20 ANTIBODY FOR USE
IN TREATMENT OF
RHEUMATOID ARTHRITIS
]22[
]31[
04.05.2000
60/133018
]32[ 07.05.1999
60/139621
17.06.1999
Int. Cl.8 A61K 039/395, A61P 037/00
GENENTECH, INC., U.S.A.
BIOGEN IDEC INC., U.S.A.
]51[
]71[
]87[
]74[
WO/2000/067796
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
146005
‫ לטיפול בדלקת מפרקים‬CD20 ‫נוגדן כנגד‬
‫ראומטואידית‬
]33[
US
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
[57] Use of an anti-CD20 antibody in the
manufacture of a medicament for treatment
of rheumatoid arthiritis in a mammal.
___________
1981
July 24, 2007– ‫ט' באב התשס"ז‬
]11[]21[
]54[
PROCESS FOR PREPARING
IMIDACHLOPRID
]22[
]31[
]51[
]71[
18.10.2001
09/752416
]32[ 29.12.2000
Int. Cl.8 C07D 401/06
SINON CORPORATION, TAIWAN
R.O.C.
G.E. EHRLICH (1995) LTD.,
AYALON TOWER, 15TH FLOOR,
11 MENACHEM BEGIN STREET,
52521 RAMAT GAN
]74[
[57] A process for preparing
imidachloprid, comprising: reacting 2nitroiminoimidazolidine with 2-chloro-5chloromethyl pyridine in the presence of
an alkali carbonate in an organic solvent,
wherein a stoichiometric amount of the 2-
146027
‫תהליך להכנת אימידאכלופריד‬
]33[
US
,‫) בע"מ‬1995( ‫ארליך‬.‫אי‬.‫ג'י‬
,11 ‫רחוב מנחם בגין‬, 15 ‫ קומה‬,‫מגדל אילון‬
‫רמת גן‬
chloro-5-chloromethyl pyridine is
gradually added into mixture of a
corresponding stoichiometric amount of
the 2-nitroiminoimidazolidine and the
organic solvent under reflux condition.
__________
]11[]21[
]54[
EL TYPE PULVERIZERS
]22[
]31[
]51[
]71[
25.10.2001
09/698558
]32[ 27.10.2000
Int. Cl.8 B02C 015/12
THE BABCOCK & WILCOX
COMPANY, U.S.A.
WOLFF, BREGMAN AND GOLLER,
19B KEREN HAYESOD ST.,
P.O.B. 1352,
JERUSALEM 91013
]74[
[57] An EL type pulveriser (10),
comprising: a housing (12), a top grinding
ring (18) having a continuous arcuate
grinding track formed on a bottom surface
of the top grinding ring and adapted to
receive a plurality of pulveriser balls (14)
each having an OD and circumference, and
at least one integral snubber casted as part
July 24, 2007– ‫ט' באב התשס"ז‬
146157
EL ‫כותשים מסוג‬
]33[
US
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
of the parent material of the top grinding
ring and formed on an outer edge of the
top grinding ring, snubber attachment
means attached to the housing for securing
the integral snubber to the housing, and a
plurality of equally spaced apart flutes (26)
extending downwardly from the outer
edge of the top grinding ring.
1982
____________
]11[]21[
146228
‫שיטה מחוץ לגוף לסינון תרכובות‬
]54[
IN-VITRO METHOD OF
SCREENING COMPOUNDS
]22[
]31[
]51[
]71[
]87[
]74[
27.06.2000
60/141563
]32[ 29.06.1999
]33[ US
Int. Cl.8 C12N 009/02, C12Q 001/26, G01N 033/50, 033/68
NEW YORK UNIVERSITY, U.S.A.
WO/2001/001131
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.,
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
[57] An in-vitro method of screening for
compounds that inhibit melanogenesis, the
method comprising: treating cells
expressing a tyrosinase-encoding gene
with a test compound, and determining the
cellular localization of tyrosinase in the
presence of the test compound; wherein a
change in the cellular localization of
tyrosinase in the presence of the test
compound as compared to in the absence
of the test compound indicates that the test
compound is a candidate for a compound
that inhibits melanogenesis.
___________
1983
July 24, 2007– ‫ט' באב התשס"ז‬
]11[]21[
]54[
EXTRUDED AERATED
COMPOSITIONS AND PROCESS
AND APPARATUS FOR
PREPARING SUCH
COMPOSITIONS
]22[
]31[
]51[
]71[
06.11.2001
00310835.4
]32[ 06.12.2000
Int. Cl.8 A23G 000/93200
UNILEVER PLC, UNITED
KINGDOM
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]74[
[57] A cold extruded composition
comprising a fat phase and having an
overrun of at least 90%, characterized in
146357
‫הרכבים אווריריים ותהליך והתקן לייצורם‬
]33[
EP
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
that at least 45% w/w of the fat phase is
liquid at -5˚C.
_____________
]11[]21[
146731
VIIa ‫מעכבי פקטור‬
]54[
FACTOR VIIA INHIBITORS
]22[
]31[
]51[
]71[
27.05.2000
99111109.7
]32[ 08.06.1999
]33[ EP
Int. Cl.8 A61K 038/05, A61P 007/02, C07K 005/068
SANOFI-AVENTIS DEUTSCHLAND
GMBH, GERMANY
WO/2000/075172
EITAN, PEARL, LATZER AND
,‫ לצר וכהן צדק‬,‫ פרל‬,‫איתן‬
COHEN ZEDEK,
‫ הרצליה‬,12688 .‫ד‬.‫ ת‬, 7 ‫רחוב שנקר‬
P.O.B. 12688,
HERZLIYA 46733
]87[
]74[
[57] A compound of the formula
July 24, 2007– ‫ט' באב התשס"ז‬
1984
wherein
r is 0, 1, 2 or 3;
s is 0, 1, 2, 3 or 4;
t is 0, 1 or 2;
R1 is selected from the series consisting of
hydrogen, R11-CO- and R12-SO2-;
R11 is selected from the series consisting of
hydrogen, (C1-C8)-alkyl, (C6-C14)-aryl,
(C6-C14)-aryl-(C1-C4)-alkyl-, Het-, Het(C1-C4)-alkyl-,(C1-C8)-alkyloxy-(C6-C14)aryloxy-, (C6-C14)-aryl-(C1-C4)-alkyloxyamino, (C1-C8)-alkylamino-, (C6-C14)arylamino- and (C8-C14)-aryl-(C1-C4)alkylamino-, where all these groups are
unsubstituted or substituted by one or more
identical or different substituents R40;
R12 is selected from the series consisting of
(C1-C8)-alkyl, (C6-C14)-aryl, (C6-C14)-aryl(C1-C4)-alkyl-, Het-, Het-(C1-C4)-alkyl-,
di((C1-C8(-alkyl)amino- and di((C6-C14)aryl-(C1-C4)-alkyl) amino-, where all these
groups are unsubstituted or substituted by
one or more identical or different
substituents R40;
R2 is hydrogen, R21(R22)CH-, R23-Het(CH2)k-, R23(R24)N-(CH2)m-D-(CH2)n- or
R25(R26)N-CO-(CH2)p-D-(CH2)q-, where D
is a divalent residue –C(R31)(R32)-, a
divalent (C6-C14)-arylene residue or a
divalent residue derived from an aromatic
group Het containing 5 to 10 ring atoms of
which 1, 2, 3 or 4 are identical or different
ring heteroatoms selected from the series
consisting of nitrogen, oxygen and sulfur,
and the numbers k, m, n, p and q which are
independent of each other and can be
1985
identical or different are 0, 1, 2, 3, 4 or 5,
with the proviso that in case D is –
C(R31)(R32)- the sum m+n cannot be 0 and
the sum p+q cannot be 0;
R21 and R22 which are independent of each
other and can be identical or different are
selected from the series consisting of
hydrogen, (C1-C12)-alkyl, (C6-C14)-aryl,
(C6-C14)-aryl-(C1-C4)-alkyl-, Het- and Het(C1-C4)-alkyl-, where all these groups are
unsubstituted or substituted by one or more
identical or different substituents from the
series consisting of R40, (C1-C8)alkylamino-, di-((C1-C8)-alkyl)-amino-,
(C6-C14)-aryl-(C1-C4)-alkylamino, (C6C14)-arylamino-, aminocarbonyl- and
aminocarbonyl-(C1-C8)-alkyl-,
or R21 and R22 together with the carbon
atom to which they are bonded form a
saturated or unsaturated 3-membered to 8membered carbocyclic ring which can be
condensed to one or two ring systems
which are heteroaromatic rings containing
5 to 10 ring atoms of which 1, 2 or 3 are
identical or different heteroatoms selected
from the series consisting of nitrogen,
oxygen and sulfur, and/or (C6-C10)
carbocyclic aromatic rings, where the
resulting group R21(R22)CH- is
unsubstituted or substituted by one or more
identical or different substituents from the
series consisting of R40, ((C1-C8)alkylamino-, di-((C1-C8)-alkyl)-amino-,
(C6-C14)-aryl-(C1-C4)-alkylamino-, (C6C14)-arylamino-, aminocarbonyl- and
aminocarbonyl-(C1-C8)-alkyl-;
July 24, 2007– ‫ט' באב התשס"ז‬
R23 is hydrogen, R27-SO2- or R28-CO-;
R24 is selected from the series consisting of
hydrogen, (C1-C8)-alkyl, (C6-C14)-aryl and
(C6-C14)-aryl-(C1-C4)-alkyl;
R25 and R26 which are independent of each
other and can be identical or different are
selected from the series consisting of
hydrogen, (C1-C8)-alkyl, (C6-C14)-aryl,
(C6-C14)-aryl-(C1-C4)-alkyl-, Het- and Het(C1-C4)-alkyl-, where all these groups are
unsubstituted or substituted by one or more
identical or different substituents R40;
R27 is selected from the series consisting of
(C1-C8)-alkyl, (C6-C14)-aryl, (C6-C14)-aryl(C1-C4)-alkyl-, Het-, Het-(C1-C4)-alkyl-,
amino, (C1-C8)-alkylamino-, di-((C1-C8)alkyl)amino-, (C6-C14)-arylamino- and (C6C14)-aryl-(C1-C4)-alkylamino-, where all
these groups are unsubstituted or
substituted by one or more identical or
different substituents R40;
R24 is selected from the series consisting of
R27, (C1-C8)-alkyloxy- (C6-C14)-aryloxyand (C6-C14)-aryl-(C1-C4)-alkyloxy-, where
all these groups are unsubstituted or
substituted by one or more identical or
different substituents R40;
R31 and R32 which are independent of each
other and can be identical or different are
selected from the series consisting of
hydrogen, (C1-C12)-alkyl, (C6-C14)-aryl,
(C6-C14)-aryl-(C1-C4)-alkyl-, Het- and Het(C1-C4)-alkyl- where all these groups are
unsubstituted or substituted by one or more
identical or different substituents R40;
R40 is selected from the series consisting of
halogen, hydroxy, (C1-C8)-alkyloxy-, (C6C14)-aryl-(C1-C8)-alkyloxy-, (C6-C14)aryloxy-, (C1-C8)-alkyl, (C6-C14)-aryl, (C6C14)-aryl-(C1-C8)-alkyl-, (C1-C8)-
alkylsulfonyl, trifluoromethyl,
acetylamino-, amino, amidino, guanidine,
oxo, nitro and cyano, where the groups R40
are independent of each other and can be
identical or different;
R91, R92 and R93 which are independent of
each other and can be identical or different
are selected from the series consisting of
hydrogen, (C1-C8)-alkyl, (C6-C14)-aryl,
(C6-C14)-aryl-(C1-C4)-alkyl-, Het- and Het(C1-C4)-alkyl-;
R94 is selected from the series consisting of
(C1-C4)-alkyl, (C6-C14)-aryl, amino, nitro,
halogen, trifluoromethyl, hydroxy, (C1C4)-alkyloxy-, where the groups
R94 are independent of each other and can
be identical or different;
R95 is selected from the series consisting of
amidino, guanidine, ((C1-C4)-alkyl)
oxycarbonylamidino-, ((C1-C4)-alkyl)
oxycarbonylguanidino- and
hydroxyamidino-;
R96 is hydrogen;
R97 is R99 –(C1-C8)-alkyl-;
R99 is selected from the series consisting of
hydroxycarbonyl-, (C1-C8)alkoxycarbonyl, -(C6-C14)-aryl-(C1-C4)alkyloxycarbonyl-, aminocarbonyl- and
(C1-C8)-alkylaminocarbonyl-;
Het is a saturated, partially unsaturated or
aromatic monocyclic or bicyclic
heterocyclic ring system containing 3 to 10
ring atoms of which 1, 2, 3 or 4 are
identical or different heteroatoms selected
from the series consisting of nitrogen,
oxygen and sulfur;
in all its stereoisomeric forms and mixtures
thereof in any ratio, and its physiologically
tolerable salts.
___________
July 24, 2007– ‫ט' באב התשס"ז‬
1986
]11[]21[
]54[
METHOD AND INSTALLATION
FOR TAPPING FRESH WATER
AND DETECTING FRESH WATER
SOURCE AT SEA
]22[
]31[
]51[
]71[
]87[
]74[
15.05.2000
99/07991
]32[ 18.06.1999
Int. Cl.8 G01V 009/02
NYMPHEA WATER, FRANCE
WO/2000/079309
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
[57] A method of collecting fresh water
that is resurgent at sea, the method being
characterized in that: an installation is used
which comprises an immersed reservoir,
with its open concave side facing
downwards and suitable for trapping fresh
water, the circumference of the bottom end
of said reservoir surrounding said fresh
water resurgence, and fitting closely to the
outline of the relief of the bottom of the
sea so as to provide leakproofing between
said circumference and the bottom of the
146846
‫שיטה והתקן לאגירת מיים מתוקים ולגילוי‬
‫מקור מים מתוקים במי ים‬
]33[
FR
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
sea, said reservoir being constituted by a
double-walled envelope into which there is
injected a slurry of concrete of specific
gravity close to 1, so as to enable the
double-walled envelope to retain a shape
of spherical cap after it has been filled with
concrete; and fresh water is collected by
means of a pipe with its first end opening
out inside the reservoir, preferably into the
top portion thereof and its second end
opening out into a zone on land situated
below sea level.
__________
1987
July 24, 2007– ‫ט' באב התשס"ז‬
]11[]21[
146979
‫מיכל‬
]54[
CONTAINER
]22[
]31[
]51[
]71[
07.06.2000
336144
]32[ 08.06.1999
]33[ NZ
Int. Cl.8 B65D 081/18, 088/74, F25D 017/04
QPOD SYSTEMS LIMITED, NEW
ZEALAND
WO/2000/075041
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.,
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
]87[
]74[
[57] A container comprising a base (4),
four side walls (5) and a top (14), the side
walls having ducts therein through which
gas can flow, wherein the gas moves up an
adjacent pair of said side walls and down
an opposing adjacent pair of side walls to
form a pair of pathways, the pair of
pathways crossing each other at the top
without intersection of the pathways.
___________
July 24, 2007– ‫ט' באב התשס"ז‬
1988
]11[]21[
]54[
APPARATUS AND METHOD FOR
MEASURING INCLINATION
]22[
]31[
]51[
]71[
06.12.2001
140206
]32[ 10.12.2000
Int. Cl.8 G01C 009/12
YUVAL SINGER
FEDERICO SINGER, U.S.A.
]74[
YUVAL SINGER,
86 HATISHBI ST,
HAIFA 34522
[57] Inclination measurement apparatus
for mounting on a surface for measuring its
inclination with respect to a desired
measurement axis, the apparatus
comprising:
(a) a reference clinometer for issuing
inclination measurement Vref responsive
to the inclination of the surface with
respect to the desired measurement axis;
(b) an indexable turntable bearing a
clinometer and rotatable between a pair of
precisely reproducible diametrically
opposite orientations with respect to the
1989
146981
‫התקן ושיטה למדידת שיפוע‬
]33[
IL
‫ חיפה‬,‫יובל זינגר‬
,‫יובל זינגר‬
‫ חיפה‬,86‫התישבי‬
desired measurement axis for respectively
issuing inclination measurements V0 and
V180 responsive to the inclination of the
surface with respect to the desired
measurement axis; and
(c) a controller for calculating a bias
corrected inclination measurement Vreal
of the inclination of the surface with
respect to the desired measurement axis
from an inclination measurement Vref at
least during a periodic bias correction
procedure for updating at least one of said
clinometers' transient bias values.
July 24, 2007– ‫ט' באב התשס"ז‬
____________
]11[]21[
]54[
METHOD FOR DATA CARE IN A
NETWORK OF PARTIALLY
REPLICATED DATABASE
SYSTEMS
]22[
]31[
13.05.2000
19928035.5
]32[ 18.06.1999
99120009.8
14.10.1999
Int. Cl.8 G06F 017/00
SAP AG, GERMANY
WO/2000/079408
LUZZATTO & LUZZATTO,
INDUSTRIAL PARK, OMER,
P.O.B. 5352,
BEER-SHEVA 84152
]51[
]71[
]87[
]74[
[57] Method for data maintenance in an
offline-distributed database network
system (DBNS) which comprises a central
system (CS) having a central database
(CD), and a number of node systems (NS)
having local databases (LD), wherein the
local databases (LD) at least in some cases
contain different subsets of the data from
July 24, 2007– ‫ט' באב התשס"ז‬
147105
‫שיטה לטיפול בנתונים ברשת של מערכות‬
‫בסיס נתונים משוכפלות חלקית‬
]33[
DE
EP
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
the central database (CD), change
information relating to the data stored in
the database (CD, LD) in the database
network system (DBNS) is recorded in a
plurality of node systems (NS), the change
information is transmitted, when an online
connection exists, as replication objects
which are structured in a plurality of
1990
different types and contain an
identification key, from the node systems
to the central system or from the central
system to the node systems, if there is no
online connection, the replication objects
are queued, in an outbound queue, for
subsequent transmission, characterized in
that the replication objects are, in a
replication algorithm in the central system
(CS), allocated by means of at least one
lookup table (LUT) together with the
change information to the node systems
(NS) as responsibles to which they are
intended to be transmitted, and the at least
one lookup table is updated, in a
realignment algorithm, taking account of
the change information.
___________
]11[]21[
]54[
SYSTEM AND METHOD FOR
MIGRATION OF SUBSCRIBER
DATA
]22[
]31[
]51[
]71[
]74[
17.12.2001
09/739745
]32[ 20.12.2000
Int. Cl.8 G06F 017/30, H04Q 007/38
COMVERSE, INC., U.S.A.
G.E. EHRLICH (1995) LTD.,
AYALON TOWER, 15TH FLOOR,
11 MENACHEM BEGIN STREET,
52521 RAMAT GAN
[57] A method of relocating data in a
communication system having at least one
central management server and
information servers geographically
distributed to provide access to
subscribers, said method comprising:
1991
147137
‫מערכת ושיטה לשינוע נתוני מנוי‬
]33[
US
,‫) בע"מ‬1995( ‫ארליך‬.‫אי‬.‫ג'י‬
,11 ‫רחוב מנחם בגין‬, 15 ‫ קומה‬,‫מגדל אילון‬
‫רמת גן‬
generating at the information servers an
activity log file including location data and
identifiers, the location data indicating
which of the information servers provided
access by the subscribers to information
locally accessible by the information
July 24, 2007– ‫ט' באב התשס"ז‬
servers and each identifier being associated
with one of a communication device and a
person using the communication system;
initially storing the activity log file at the
information servers; transferring log data
derived from the activity log file from each
of the information servers to the central
management server; automatically
performing pattern analysis at the central
management server based on the location
data and the identifiers; and relocating
private data, associated with one of the
identifiers, from a first location to a second
location within the communication system
when the pattern analysis indicates that
service can be provided more efficiently
from the second location.
___________
]11[]21[
‫פורמולציות של הורמון הגדילה‬
]54[
GROWTH HORMONE
FORMULATIONS
]22[
]31[
11.07.2000
9916252.1
]32[ 12.07.1999
9918902.9
12.08.1999
Int. Cl.8 A61K 038/27, 047/26
SANDOZ AG, SWITZERLAND
WO/2001/003741
LUZZATTO & LUZZATTO,
INDUSTRIAL PARK, OMER,
P.O.B. 5352,
BEER-SHEVA 84152
]51[
]71[
]87[
]74[
147253
[57] A multi-dosage, storage stable liquid
human growth hormone formulation
consisting essentially of growth hormone
in isotonic phosphate buffered solution, a
preservative and a non-ionic surfactant,
]33[
GB
GB
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
wherein isotonicity of the phosphate
buffered solution is provided by a neutral
salt, a monosaccharide, a disaccharide or a
sugar alcohol, the formulation having a pH
in the range of 6.15 to 6.5.
____________
July 24, 2007– ‫ט' באב התשס"ז‬
1992
]11[]21[
]54[
TELEPHONE NETWORK-BASED
METHOD AND SYSTEM FOR
AUTOMATIC INSERTION OF
ENHANCED PERSONAL
ADDRESS BOOK CONTACT
DATA
]22[
]31[
]51[
]71[
]74[
24.12.2001
09/774088
]32[ 31.01.2001
Int. Cl.8 G10L 015/00, H04M 003/42
COMVERSE LTD.
G.E. EHRLICH (1995) LTD.,
AYALON TOWER, 15TH FLOOR,
11 MENACHEM BEGIN STREET,
52521 RAMAT GAN
[57] A telephone network-based system
for automatic insertion of web-enhanced
contact data into a personal address book
associated with a user that has access to an
electronic communications network, said
system comprising: a first application unit
operable to host the telephone networkbased system; a second application unit
programmed to present the user with
contact data obtained via the electronic
communications network and assist the
user in selecting at least a portion of the
contact data for entry into the personal
address book, said second application unit
comprising: a voice response unit operable
to route a user-initiated call into the
system, to said second application unit; a
recognition server comprising an
automatic speech recognizer operable to
convert a verbalized form of a new contact
1993
147276
‫שיטה ומערכת מבוססות רשת טלפון‬
‫להחדרה אוטומטית של מידע משופר של‬
‫תוכן ספר כתובות‬
]33[
US
‫ רמת החייל‬,‫קומברס בע"מ‬
,‫) בע"מ‬1995( ‫ארליך‬.‫אי‬.‫ג'י‬
,11 ‫רחוב מנחם בגין‬, 15 ‫ קומה‬,‫מגדל אילון‬
‫רמת גן‬
name to a text form, wherein the text form
of the new contact name forms part of the
user-initiated call; a storage unit operable
to store at least one textual directory for
loading into said recognition server; a
comparison unit operable to compare the
converted text form of the new contact
name with a plurality of text entries in the
at least one stored textual directory; and a
textual directory unit for searching the
electronic communications network to
locate and select the contact data based on
a telephone number corresponding to the
new contact name, wherein the selected
contact data is inserted into the personal
address book associated with the user and
wherein further, the selected contact data is
data other than the new contact name and
the telephone number corresponding to the
new contact name.
July 24, 2007– ‫ט' באב התשס"ז‬
__________
]11[]21[
147370
‫שיטה ומערכת להכוונת רכב מרוחק‬
‫באמצעות ערוץ תקשורת מפגר‬
]54[
METHOD AND SYSTEM FOR
GUIDING A REMOTE VEHICLE
VIA LAGGED
COMMUNICATION CHANNEL
]22[
]51[
]71[
27.12.2001
Int. Cl.8 F41G 003/00, 007/00, G01S 005/00, 013/00, G05D 001/00, H04N 007/26
RAFAEL ARMAMENT
,‫רפא"ל רשות לפיתוח אמצעי לחימה בע"מ‬
DEVELOPMENT AUTHORITY
‫חיפה‬
LTD.
ITZAK FLORENTIN, LIAT
‫ אמיר קליסמן‬,‫ ליאת ברגר‬,‫יצחק פלורנטין‬
BERGER, AMIR KALISMAN
LUZZATTO & LUZZATTO,
,‫לוצאטו את לוצאטו‬
INDUSTRIAL PARK, OMER,
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
P.O.B. 5352,
BEER-SHEVA 84152
]72[
]74[
[57] A method for guiding from a remote
control center a vehicle towards a target
object, said remote control center
communicating with the vehicle by means
of a lagged communication channel,
comprising: at the vehicle:
July 24, 2007– ‫ט' באב התשס"ז‬
(i) periodically capturing frame images by
a camera, assigning to each of said
captured frames an associated unique time
stamp, and saving within a storage at the
vehicle full frame data or partial frame
data of captured frames and their
associated time stamps;
1994
(ii) for a plurality of saved frames, sending
to the control center via the lagged
communication channel full frame data,
partial frame data or a combination thereof
with the corresponding associated time
stamp for each sent frame so that
approximate or exact version of the sent
frames can be reconstructed and displayed
at the control center;
at the control center:
(iii) receiving said frame data and
associated time stamps, sequentially
reconstructing frame images from each
said sent full and/or partial frame data, and
displaying the reconstructed images on a
display;
(iv) upon marking by an operator at the
control center a point on a specific
displayed frame, sending coordinates
indication relating to said marked point as
appearing on said specific frame or on a
reference frame available at the control
center, and the time stamp associated with
said specific or reference frame, as is the
case, to the vehicle;
at the vehicle:
(v) receiving said coordinates indication as
marked and the sent frame time stamp;
(vi) given the coordinates indication and
frame time stamp as received, fast forward
tracing said point or object coordinates
from the said frame towards the most
recently available captured frame, thereby
finding the coordinates of the same point
or object as appearing in the most recently
available captured frame; and
(vii) providing the coordinates of the target
point or object within the most recently
available captured frame, as found, to an
inner guidance sub-system of the vehicle,
for enabling it to track said object.
_____________
1995
July 24, 2007– ‫ט' באב התשס"ז‬
]11[]21[
147495
‫ – און מותמרות‬2 – ‫תרכובות פיפראזין‬
]54[
SUBSTITUTED PIPERAZINE - 2 ONE COMPOUNDS
]22[
]31[
]51[
]71[
26.07.2000
09/363196
]32[ 28.07.1999
]33[ US
Int. Cl.8 A61K 031/395, A61P 007/00, C07D 403/14, 409/14, 471/02, 495/02
AVENTIS PHARMACEUTICALS
INC., U.S.A.
WO/2001/007436
EITAN, PEARL, LATZER AND
,‫ לצר וכהן צדק‬,‫ פרל‬,‫איתן‬
COHEN ZEDEK,
‫ הרצליה‬,12688 .‫ד‬.‫ ת‬, 7 ‫רחוב שנקר‬
P.O.B. 12688,
HERZLIYA 46733
]87[
]74[
[57] A compound of the formula
or a pharmaceutically acceptable salt
thereof, an N-oxide thereof, a hydrate
thereof or a solvate thereof, wherein
L1 and L2 are independently methylene or
ethylene;
Cy1 is thiophen-isoxazol, thiophenoxadiazol, thiophen-thiadiazol, thiophentriazol, thiophen-pyridin or phenyl-triazol;
wherein Cy2 is unsubstituted or substituted
with one or more groups selected from
amino, halo, which is selected from the
group consisting of fluoro, chloro, bromo
or iodo, hydroxyl, aryl, which is selected
from the group consisting of phenyl or
naphthyl,
amidino, which is a group of formula
alkyl, which is selected from the group
consisting of methyl, ethyl or propyl,
acylamino, which is selected from the
group consisting of formylamino,
acetylamino, propanoylamino, 2-
July 24, 2007– ‫ט' באב התשס"ז‬
methylpropanoylamino, butanoylamino or
palmitoylamino, carbamoyl, which is
selected from the group consisting of
carbamoyl or dimethylaminocarbamoyl,
cyano, alkoxy, which is selected from the
1996
group consisting of methoxy, ethoxy, npropoxy, i-propoxy, n-butoxy or heptoxy,
nitro, carbamate, which is selected from
the group consisting of methylcarbamate,
ethylcarbamate, t-butylcarbamate,
benzylcarbamate or phenylcarbamate, or
sulfamoyl;
Cy2 is amino-quinazolin or pyrrolopyridin; wherein Cy2 is unsubstituted or
substituted with one or more groups
selected from amino, carbamoyl, which is
as defined above, acylamino, which is as
defined above, alkyl, which is as defined
above, amidino, which is as defined above,
alkyloxycarbonyl, which is selected from
the group consisting of methoxycarbonyl,
ethoxycarbonyl, or t-butyloxycarbonyl,
hydroxyl, alkoxy, which is as defined
above, aryl, which is selected from the
group consisting of phenyl or naphthyl,
isourea, which is a group of the formula
guanidino, which is a group of the formula
acylhydrazino, which is a group of the
formula H2N-NHC(O)-, acyl, which is
selected from the group consisting of
formyl, acetyl, propanoyl, 2methylpropanoyl, butanoyl and palmitoyl,
cyano, carboxyl, sulfamoyl, or halo, which
is as defined above; and
R1, R1a, R2, R2a, R4 and R4a are
independently selected from hydrogen or
alkyl, which is selected from the group
consisting of methyl, ethyl or propyl.
.
___________
1997
July 24, 2007– ‫ט' באב התשס"ז‬
]11[]21[
]54[
EXPANDING PARALLEL JAW
DEVICE FOR USE WITH AN
ELECTROMECHANICAL DRIVER
DEVICE
]22[
]31[
]51[
]71[
11.07.2000
351534
]32[ 12.07.1999
Int. Cl.8 A61B 017/04
POWER MEDICAL
INTERVENTIONS, INC., U.S.A.
WO/2001/003587
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
[57] A fastening and cutting device for
cutting and fastening a section of tissue,
comprising: a first jaw (80); a second jaw
(50) disposed in parallel and opposed
correspondence with the first jaw; a
vertical driver means coupled to said first
jaw, which driver means causes the first
jaw to linearly travel along an axis
perpendicular to the axis of parallel
correspondence of the first and second
jaws, such that the first jaw separates from
the second jaw when the driver means is
biased for opening of the jaws and closes
towards the second jaw when the driver
means is biased for closing of the jaws;
147511
‫שימוש בהתקן בעל זרועות מקבילים יחד‬
‫עם רכיב אלקטרומכני דוחף‬
]33[
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
and a cutting and stapling means (230,
232) disposed within the second jaw and
coupled with a horizontal driver means for
cutting and stapling a section of tissue
disposed between the first and second jaws
once the first jaw has been closed onto the
second jaw; wherein the vertical driver
means further includes a pair of threaded
turning shafts and a horizontal threaded
gearing shaft (130) disposed in turning and
gearing relationship with said pair of
threaded turning shafts, the rotation of the
horizontal gearing shaft thereby causing
the first jaw to translate.
____________
July 24, 2007– ‫ט' באב התשס"ז‬
1998
]11[]21[
147630
‫מערכת עורך המביטה פנימה ושיטה‬
‫לתרגום תוכנה‬
]54[
INTROSPECTIVE EDITOR
SYSTEM, PROGRAM AND
METHOD FOR SOFTWARE
TRANSLATION
]22[
]31[
]51[
]71[
13.07.2000
09/362615
]32[ 28.07.1999
]33[ US
Int. Cl.8 G06F 003/00, 009/44, 009/45, 009/46, 017/20
INTERNATIONAL BUSINESS
MACHINES CORPORATION, U.S.A.
WO/2001/008006
SANFORD T.COLB & CO.,
,'‫ קולב ושות‬.‫סנפורד ט‬
P.O.B. 2273,
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
REHOVOT
]87[
]74[
[57] A method for editing textual data for
a software program, comprising:
displaying a user interface containing a
first textual data within a non-data, user
interaction portion of the user interface;
responsive to selection of the first textual
data within the displayed user interface by
a user for editing, introspecting source
code for generating the user interface to
identify a software object that includes the
first textual data; receiving a second
textual data which the user desires to
replace the first textual data from a user
input while the user interface is being
displayed; storing the second textual data
in a machine-readable form within the
software object in place of the first textual
data; and during execution of the source
code for generating the user interface
display after storing the second textual
string within the software object,
displaying the second textual data in place
of the first textual data within the user
interface.
____________
1999
July 24, 2007– ‫ט' באב התשס"ז‬
]11[]21[
147719
‫שיטה והתקן לעיבוד בו זמני של מספר‬
‫שיחות במערכת תקשורות פורשת טווח‬
‫תדר‬
]54[
METHOD AND APPARATUS FOR
CONCURRENTLY PROCESSING
MULTIPLE CALLS IN A SPREAD
SPECTRUM
COMMUNICATIONS SYSTEM
]22[
]31[
11.08.2000
60/148790
]32[ 13.08.1999
]33[ US
09/519003
03.03.2000
US
Int. Cl.8 H04J 013/02, 013/04, H04Q 007/22, 007/32, 007/38
QUALCOMM INCORPORATED,
U.S.A.
WO/2001/013669
SANFORD T.COLB & CO.,
,'‫ קולב ושות‬.‫סנפורד ט‬
P.O.B. 2273,
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
REHOVOT
]51[
]71[
]87[
]74[
[57] A method for processing one or more
calls concurrently in a spread spectrum
communications system, the method
comprising: receiving an indication of a
particular call to be processed;
instantiating a type of a call control state
machine in accordance with the type of the
particular call, wherein the instantiated call
control state machine is identified with and
used to control processing of the particular
call; and exchanging one or more data
transmissions related to the particular call.
__________
July 24, 2007– ‫ט' באב התשס"ז‬
2000
]11[]21[
147799
‫שיטה להחלפת מידע בין טלפונים ניידים‬
]54[
METHOD OF EXCHANGING
DATA BETWEEN MOBILE
PHONES
]22[
]31[
]51[
]71[
23.01.2002
2001-5795
]32[ 07.02.2001
]33[ KR
Int. Cl.8 H04B 001/38, H04M 001/274, 001/725, H04Q 007/20
SK TELETECH CO., LTD.,
REPUBLIC OF KOREA
REINHOLD COHN AND
,‫ריינהולד כהן ושותפיו‬
PARTNERS,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]74[
[57] A method of exchanging data
between mobile phones through an interworking function in an IS-95A/B network,
comprising: a first step in which a
receiving mobile phone enters data
reception mode as a receiving user selects
data call receiving mode; a second step in
which a transmitting mobile phone initiates
a data call to the receiving mobile phone; a
third step in which as the receiving mobile
phone answers the call, data exchange
between the mobile phones proceeds; and
a fourth step in which data transmission
from the transmitting mobile phone to the
receiving mobile phone is completed.
___________
]11[]21[
2001
147954
July 24, 2007– ‫ט' באב התשס"ז‬
]54[
METHOD AND APPARATUS FOR
MODELING OF THE INTRA-AND
EXTRAVASCULAR
OPERATIONS ON THE
DIFFERENT SECTIONS OF THE
CIRCULATION SYSTEM AND
FOR TESTING OF THE
INTRAVASCULAR DEVICES
THEREFOR
]22[
]51[
]71[
]72[
03.02.2002
Int. Cl.8 A61B 005/021, G09B 023/28
EDWARD G.SHIFRIN
EDWARD G. SHIFRIN, GENNADY
S. NICKELSHPUR, ARKADY S.
NICKELSHPUR, NACHMAN
KUDLIK, WESLY S. MOORE,
PETER RF BELL
WOLFF, BREGMAN AND GOLLER,
19B KEREN HAYESOD ST.,
P.O.B. 1352,
JERUSALEM 91013
]74[
[57] A stand (1) for modeling
intravascular and extravascular operation
on circulation system sections and for
testing intravascular devices for these
operations, including a supporting
structure, peristaltic pump (12) with a
working head, reservoir (16) with fluid
imitating blood, models (18, 20) of internal
organs or some circulation system section,
as well as tubing (22) to connect the
peristaltic pump with the reservoir and
with models of internal organs or of
circulation system sections, wherein the
improvement comprises:
(a) a supporting structure with a bearing
surface, and at least one peristaltic pump
serving for providing circulation of liquid
imitating blood and it is provided with a
system for adjusting fluid circulation rate
and direction of circulation;
(b) a tubing passing through the working
head of at least one peristaltic pump and
including at least one closed tube (26)
made substantially of transparent material,
and at least a part of the closed tube
July 24, 2007– ‫ט' באב התשס"ז‬
‫שיטה והתקן להדגמה של ניתונים תוך כלי‬
‫הדם ומחוץ לכלי הדם בחלקים שונים של‬
‫מערכת מחזור הדם לבדיקת התקנים‬
‫לשימוש תוך כלי הדם‬
‫שיפרין‬.‫אדוארד ג‬
,‫ ניקלשפור‬.‫ גנאדי ס‬,‫ שיפרין‬.‫אדוארד ג‬
.‫ וסלי ס‬,‫ נחמן קודלין‬,‫ ניקלשפור‬.‫ארכדי ס‬
‫ פיטר רפ בל‬,‫מור‬
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
disposed in the area of the working head of
peristaltic pump is made of flexible
material;
(c) a hermetically sealed chamber (30) of
transparent material mounted on the
bearing surface of supporting structure, at
least a part of said closed tube being
disposed within said hermetically sealed
chamber and detachable;
(d) at least one model (32, 34) of a
circulation system section mounted within
the hermetically sealed chamber, between
detachable ends of said closed tube, in
such a way that said model forms, together
with the closed tube, a single unit for
circulation system imitation, the model
being provided with an axial passage for
introducing medical instrument therein,
and said axial passage has an input port,
disposed outside the hermetically sealed
chamber and provided with a back valve;
(e) means for filling the unit for circulation
system imitation with a fluid imitating
blood and taken from said reservoir;
(f) means for filling the hermetically
2002
sealed chamber with transparent fluid
under pressure to imitate the density of
tissues surrounding outside the circulation
system section;
(g) means (50) for detecting leakages of
fluid imitating blood from the circulation
system section in modeling a surgical
operation within said section;
(h) means for removing air from the fluid
circulating over the unit for imitation of
blood circulation system, whereby there
are modeled intravascular and
extravascular surgical operations
performed by minimally invasive surgery
techniques inside circulation system
sections, such as operation for placing
within the aorta with an aneurysm a stentgraft and fixating it from inside to the aorta
walls by means of special staplers, as well
there are tested the performance and
efficacy of new intravascular instruments
developed for application in minimally
invasive surgery techniques.
__________
]11[]21[
148002
‫ על ידי הטבעת‬,‫שיטה להגנה מהעתקה‬
‫סימני–מים בוידאו‬
]54[
SCALING INDEPENDENT COPY
PROTECTION TECHNIQUE FOR
WATERMARKING IMAGES
]22[
]31[
]51[
]71[
01.08.2000
09/369642
]32[ 06.08.1999
]33[ US
Int. Cl.8 G06T 001/00, G11B 020/10, H04N 005/91, 005/92, 007/26
MACROVISION CORPORATION,
U.S.A.
WO/2001/011890
EITAN, PEARL, LATZER AND
,‫ לצר וכהן צדק‬,‫ פרל‬,‫איתן‬
COHEN ZEDEK,
‫ הרצליה‬,12688 .‫ד‬.‫ ת‬, 7 ‫רחוב שנקר‬
P.O.B. 12688,
HERZLIYA 46733
]87[
]74[
[57] A method to prevent illicit copying of
video information comprising:
2003
(a) embedding a watermark having a first
scale selected from the range of scales in
July 24, 2007– ‫ט' באב התשס"ז‬
the video information for a first time
period;
(b) during or at the end of the first
predetermined period, embedding a
watermark having another scale selected
from the range of scales in the content of
the video information for a second time
period; and
(c) repeating step (b) using a different
scale until a N number of scales is reached.
____________
]11[]21[
]54[
TOOLHOLDER ASSEMBLY
]22[
]31[
]51[
]71[
]87[
]74[
23.08.2000
09/388258
]32[ 01.09.1999
Int. Cl.8 B23B 029/04
KENNAMETAL INC., U.S.A.
WO/2001/015841
WOLFF, BREGMAN AND GOLLER,
19B KEREN HAYESOD ST.,
P.O.B. 1352,
JERUSALEM 91013
[57] An apparatus for releasably holding a
toolholder (25) with a shank (30) having
lockable surfaces (90, 95) and a releasable
surface (185), the apparatus comprising:
(a) a tool support member (15) having a
forwardly facing surface (35) and a bore
(40) along a longitudinal axis (L), wherein
the bore intersects the forwardly facing
surface and extends rearwardly therefrom
for receiving the shank of the toolholder;
(b) a rotatable actuating bolt (20)
positioned within the tool support member
along a radial axis (R1) relative to the
longitudinal axis and having a first end
with a bolt locking segment having a bolt
locking surface, wherein the actuating bolt
further includes a releasing segment
July 24, 2007– ‫ט' באב התשס"ז‬
148284
‫מכלל מחזיק כלים‬
]33[
US
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
having a releasing surface for abutting and
urging forwardly the releasable surface of
the shank to eject the toolholder shank
from the tool support member;
(c) an actuating nut (75) rotatably fixed
within the tool support member, threadably
secured to a second end of the actuating
bolt and having a nut locking segment
having a nut locking surface, and
(d) wherein rotation of the actuating bolt in
a locking direction causes the actuating nut
to be drawn to the bolt first end thereby
drawing together the nut locking surface
and the bolt locking surface such that they
engage the toolholder lockable surfaces
and lock the toolholder within the tool
support member.
2004
__________
]11[]21[
148775
‫מערכת ושיטה לבדיקת הרשאה עבור‬
‫העברת תוכן מוגן‬
]54[
SYSTEM AND METHOD OF
VERIFYING AUTHORIZATION
FOR COMMUNICATING
PROTECTED CONTENT
]22[
]31[
]51[
]71[
19.10.2000
60/160355
]32[ 19.10.1999
]33[ US
Int. Cl.8 H04L 009/32, H04N 005/00, 007/16
THOMSON LICENSING S.A.,
FRANCE
WO/2001/030083
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
[57] A method for authenticating at least
one security key and at least one identifier
used to access protected content, said
method comprising:
receiving at a first device a plurality of
security keys with said content; receiving
said identifier at said first device to be
2005
used to provide said content to a second
device, said identifier being associated
with said second device; selecting one of
said plurality of security keys using said
first device; and, providing said content to
said second device using said first device
and selected security key.
July 24, 2007– ‫ט' באב התשס"ז‬
___________
]11[]21[
148926
‫מערכת ושיטה למתן שירותים סלולרים‬
‫ברשתות שונות‬
]54[
SYSTEM AND METHOD FOR
SHARING CELLULAR
COMMUNICATION SERVICES
AMONG MOBILE STATIONS OF
DIFFERENT NETWORKS
]22[
]51[
]71[
]74[
27.03.2002
Int. Cl.8 H04L 029/06, H04Q 003/00, 007/20, 007/24, 007/38
CELLCOM ISRAEL LIMITED
‫ נתניה‬,‫סלקום ישראל בע"מ‬
REINHOLD COHN AND
,‫ריינהולד כהן ושותפיו‬
PARTNERS,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
[57] A wireless multi-protocol
communications system for use by a
subscriber, the system comprising:
(a) a plurality of incompatible wireless
single-protocol networks;
(b) a plurality of single-protocol mobile
stations, such that for each of said wireless
single-protocol networks there is at least
one of said single-protocol mobile stations
operative to communicating thereover; and
(c) a common telephone number which is
shared among at least two of said mobile
stations which are operative to
communicating over incompatible wireless
July 24, 2007– ‫ט' באב התשס"ז‬
single-protocol networks; wherein at least
a first of said at least two mobile stations is
operative over a first network having a
Home Location Register (HLR)
accommodating a configuration that
includes a Calling Line Identity (CLI)
associated with the first mobile station;
said HLR is configured to comprise a new
CLI, said CLI is associated with said
common telephone number, thereby
allowing the subscriber to utilize any of
said at least two mobile stations to conduct
communications according to said
common telephone number.
2006
,182840
The applications for
division from this
application have not yet
been published
‫בקשות חלוקה מבקשה זו‬
.‫שטרם פורסמו‬
___________
]11[]21[
]54[
CUTTING TISSUE WITH
ELECTROSURGICALLY
DEPLOYED ELECTRODES
]22[
]31[
]51[
]71[
10.10.2000
09/418923
]32[ 15.10.1999
Int. Cl.8 A61B 018/18
NEOTHERMIA CORPORATION,
U.S.A.
WO/2001/028445
G.E. EHRLICH (1995) LTD.,
AYALON TOWER, 15TH FLOOR,
11 MENACHEM BEGIN STREET,
52521 RAMAT GAN
]87[
]74[
[57] Apparatus for electrosurgically
cutting a targeted region of tissue, utilizing
the output, including a return, of an
electrosurgical generator, comprising: a
support member extending between a tip
and a base region, having a forward end
region extending along a longitudinal axis
from said tip and positionable in an
insertion mode into adjacency with said
2007
148989
–‫חיתוך רקמה עם אלקטרודות חשמל‬
‫ניתוחיות נפרשות‬
]33[
US
,‫) בע"מ‬1995( ‫ארליך‬.‫אי‬.‫ג'י‬
,11 ‫רחוב מנחם בגין‬, 15 ‫ קומה‬,‫מגדל אילון‬
‫רמת גן‬
targeted region of tissue, and having a
deployment portion at said forward end
region adjacent said tip; said support
member forward end region being
substantially cylindrical and said
deployment portion including an
outwardly open slot extending along said
longitudinal axis from a securement region
adjacent said tip to a forward location,
July 24, 2007– ‫ט' באב התשס"ז‬
thence along a deployment slot region to a
rearward location, having a slot width
defined between oppositely disposed slot
sides extending a slot depth to a slot
bottom, including an electrically insulative
surface located at said slot sides and
bottom, said support member forward end
region slot depth exhibiting a first
dimensional extent from said securement
region to an output location, and exhibiting
a second dimensional extent greater than
said first dimensional extent therefrom
rearwardly toward said base region, said
support member including a barrier fluid
delivery channel having a fluid input in the
vicinity of said base region and extending
within said slot beneath said electrode to
said output location, a thin, resilient
electrode extending within said
deployment portion during said insertion
mode and deployable to move outwardly
from two spaced apart support locations to
define an electrode cutting portion and
retractable to move toward said
deployment portion; said electrode having
a distal end positioned within said slot
securement region and extending an arch
defining distance beyond said rearward
location; an actuator and electrical circuit
assembly extending along said support
member from said base region,
mechanically connected with said
electrode for effecting said deployment
and retraction thereof, and having a
terminal assembly electrically connectable
with said generator for coupling a first said
applied output to said electrode providing,
in operative association with said return,
electrosurgical cutting of said tissue by
said electrode along said cutting portion
when deployed; including a forward
retainer component positioned over said
electrode within said slot securement
region and retaining it within said slot, and
a rearward retainer component positioned
within said slot over said electrode, said
electrode being slidably mounted therebeneath; and said actuator assembly being
configured to deploy said electrode by
urging it fowardly in compression to effect
outward movement thereof generally
transversely to said longitudinal axis to an
extent curving it into an outwardly
depending arch formation, and effecting
retraction of said electrode by urging it
rearwardly to effect inward movement
thereof toward said slot.
___________
]11[]21[
July 24, 2007– ‫ט' באב התשס"ז‬
149049
2008
N – [R1)) – 2 – ] – ‫ – אמינו‬2
– N', N', N( – 3 – ‫() – בנזיל‬3R
)‫טרימתילהידראזינוקרבוניל‬
– H1( – 1 – ]‫ – איל‬1 – ‫פיפרידין‬
– 2 – )‫ – אילמתיל‬3 – ‫אינדול‬
‫ תכשירי‬,‫מתילפרופיאונאמיד‬
‫רוקחות המכילים אותו והשימוש‬
‫בו להכנת תרופות לשחרור‬
‫הורמון גדילה‬
]54[
2 – AMINO – N – [(1R) – 2 – [(3R) – 3
BENZYL – 3 – (BENZYL – 3 – (N', N', N –
TRIMETHYLHYDRAZINOCARBONYL)
PIPERIDIN – 1 – YL] – 1 – (1H – INDOL – 3 –
YLMETHYL) – 2 OXOETHYL] – 2 –
METHYLPROPIONAMIDE,
PHARMACEUTICAL COMPOSITION
COMPRISING IT AND ITS USE FOR THE
MANUFACTURING OF MEDICAMENTS
FOR RELEASING GROWTH HORMONE
]22[
]31[
]51[
]71[
]87[
]74[
10.11.2000
PA199901618
]32[
10.11.1999
]33[ DK
Int. Cl.8 A61K 031/395, A61P 005/00, C07D 401/06
NOVO NORDISK A/S, DENMARK
WO/2001/034593
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
‫תל אביב‬
TEL AVIV 61040
[57] 2-Amino-N[(1R)-2-[(3R)-3-benzyl-3(N, N', N'-trimethylhydrazinocarbonyl)
piperidin-1-yl)-1- (1 H-indol-3-ylmethyl)2-oxoethyl]-2-methylpropionamide
or a pharmaceutically acceptable salt thereof.
____________
]11[]21[
2009
149177
July 24, 2007– ‫ט' באב התשס"ז‬
‫תרכובות הטרוציקליות ושימוש בהן‬
‫כתרופות‬
]54[
HETEROCYCLIC COMPOUNDS
AND THEIR USE AS MEDICINES
]22[
]31[
03.11.2000
99/13858
]32[ 05.11.1999
]33[ FR
00/06535
23.05.2000
FR
Int. Cl.8 A61K 031/34, 031/35, 031/40, A61P 039/06, C07D 207/00, 263/02, 263/24,
307/00, 307/24, 317/00, 405/12, 407/12, 413/12, 521/00
SOCIETE DE CONSEILS DE
RECHERCHES ET
D'APPLICATIONS SCIENTIFIQUES
(S.C.R.A.S.), FRANCE
WO/2001/032654
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
]51[
]71[
]87[
]74[
[57] Compounds of the formula
in racemic, enantiomeric,
diastereoisomeric form or all combinations
of these forms, in which
R1 represents a hydrogen atom, an –OR3, SR3, oxo or cyclic acetal radical, in which
R3 represents a hydrogen atom, an alkyl,
arylalkyl, heterocycloalkycarbonyl,
alkylcarbonyl, arylcarbonyl or
aralkylcarbonyl radical, in which the alkyl,
aryl or heterocycloalkyl radicals are
optionally substituted by one or more
identical or different substituents chosen
from: alkyl, OH, alkoxy, nitro, cyano,
halogen, or –NR4R5;
R4 and R5 represent, independently, a
hydrogen atom or an alkyl radical, or R4
July 24, 2007– ‫ט' באב התשס"ז‬
and R5 together with the nitrogen atom to
which they are attached form an optionally
substituted heterocycle,
R2 represents a hydrogen atom, an alkyl,
aryl, or aralkyl radical, the aryl group
being optionally substituted by one or
more identical or different radicals chosen
from: -OR6,-NR7R8, halogen, cyano, nitro
or alkyl,
in which R6, R7 and R8 represent,
independently, a hydrogen atom, an alkyl,
aryl, aralkyl, alkylcarbonyl, arylcarbonyl
or aralkylcarbonyl radical;
A represents a radical
2010
in which R9, R10, R11, R12, R13 represent,
independently, a hydrogen atom, a
halogen, the OH group, an alkyl, alkoxy,
cyano, nitro or –NR15R16 radical,
R15 and R16 represent, independently, a
hydrogen atom, an alkyl radial or a –
COR17 group, or R15 and R16 together with
the nitrogen atom to which they are
attached form an optionally substituted
heterocycle,
R17 represents a hydrogen atom, an alkyl,
alkoxy or –NR18R19 radical,
R18 and R19 represent, independently, a
hydrogen atom or an alkyl radical, or R18
and R19 together with the nitrogen atom to
which they are attached form an optionally
substituted heteroycle,
R14 represents a hydrogen atom, an alkyl
radical or a –COR20 group,
R20 represents a hydrogen atom, an alkyl,
alkoxy, aryl, aralkyl, hetrocycloalkyl or –
NR21R22 radical,
in which the alkyl, aryl or heterocycloalkyl
radicals are optionally substituted by one
or more identical or different substituents
chosen from: alkyl, OH, alkoxy, nitro,
cyano, halogen or –NR4R5;
R21 and R22 represent, independently, a
hydrogen atom or an alkyl radical, or R21
and R22 together with the nitrogen atom to
which they are attached form an optionally
substituted heterocycle,
W represents S;
X represents –(CH2)n-, -(CH2)n-CO-, N(R45)-CO-(CH2)n-CO-, -N(R45)-CO-DCO-,
-CO-N(R45)-D-CO-, -CO-D-CO-, CH=CH-(CH2)n-CO-, -N(R45)-(CH2)n-CO-,
2011
-N(R45)-CO-C(R46R47)-CO-, -O-(CH2)nCO-, -N(R45)-CO-NH-C(R46R47)-CO-,
-CO-N(R45)-C(R46R47)-CO-, -S(CH2)n-COor –Z-CO-;
D represents a phenylene radical optionally
substituted by one or more identical or
different radicals chosen from alkyl,
alkoxy, OH, nitro, halogen, cyano, or
carboxyl optionally esterified by an alkyl
radical;
Z represents a heterocycle,
R45 represents a hydrogen atom or an alkyl
radical,
R46 and R47 represent, independently, a
hydrogen atom, an alkyl, aryl or aralkyl
radical, the alkyl and aryl groups of which
are optionally substituted by one or more
identical or different substituents chosen
from: the OH, -SH, halogen, nitro, alkyl,
alkoxy, alkylthio, aralkoxy, aryl-alkylthio,
-NR48R49 and carboxyl group optionally
esterified by an alkyl radical;
R48 and R49 represent, independently, a
hydrogen atom, an alkyl radical or a –
COR50 group, or R48 and R49 together with
the nitrogen atom to which they are
attached form an optionally substituted
heterocycle,
R50 represents a hydrogen atom, an alkyl,
alkoxy or –NR51R52 radical,
R51 and R52 represent, independently, a
hydrogen atom or an alkyl radical, or R51
and R52 together with the nitrogen atom to
which they are attached, form an
optionally substituted heterocycle;
n being an integer comprised between 0
and 6;
Y represents –(CH2)p-, -C(R53R54)-(CH2)p-,
July 24, 2007– ‫ט' באב התשס"ז‬
p being an integer comprised between 0
and 6;
Het represents a heterocycle,
as well as the addition salts with mineral
and organic acids or with mineral and
organic bases of said compound of formula
(I),
with the exception of the compounds of
formula (I) in which when Het represents
tetrahydrofuran or tetrahydropyran, R1
represents the OR3 radical with R3
representing a hydrogen atom, an alkyl,
arylalkyl, heterocycloalkylcarbonyl radical
the heterocycloalkyl radical of which is
connected by a carbon atom,
alkylcarbonyl, aralcarbonyl or
aralkylcarbonyl radical, R2 represents a
hydrogen and Y represents the –(CH2)pradical with p=0, then X represents –CON(R45)-C(R46R47)-CO- with R45 = R46 = H.
-C(R53R54)-CO-;
R53 and R54 represent, independently, a
hydrogen atom, an alkyl radical, an aralkyl
radical the aryl group of which is
optionally substituted by one or more
identical or different substituents chosen
from: the OH, halogen, nitro, alkyl,
alkoxy, -NR55R56 group, R55 and R56
represent, independently, a hydrogen atom,
an alkyl radical or a –COR57 group, or R55
and R56 together with the nitrogen atom to
which they are attached, form an
optionally substituted heterocycle,
R57 represents a hydrogen atom, an alkyl,
alkoxy or –NR58R59 radical,
R58 and R59 represent, independently, a
hydrogen atom or an alkyl radical, or R58
and R59 together with the nitrogen atom to
which they are attached form an optionally
substituted heterocycle;
,173429
The applications for division
from this application have
not yet been published
‫בקשות חלוקה מבקשה זו‬
.‫שטרם פורסמו‬
___________
]11[]21[
149180
‫מערכת תקשורת אישית מיידית‬
]54[
PERSONAL INSTANT
COMMUNICATION SYSTEM
]22[
]31[
20.10.2000
60/161135
]32[ 22.10.1999
]33[ US
09/472999
28.12.1999
US
Int. Cl.8 H04M 003/00, 003/42, 003/487, 003/493, 003/56
COMVERSE LTD.
‫קומברס בע"מ‬
WO/2001/030057
G.E. EHRLICH (1995) LTD.,
,‫) בע"מ‬1995( ‫ארליך‬.‫אי‬.‫ג'י‬
AYALON TOWER, 15TH FLOOR,
,11 ‫רחוב מנחם בגין‬, 15 ‫ קומה‬,‫מגדל אילון‬
11 MENACHEM BEGIN STREET,
‫רמת גן‬
52521 RAMAT GAN
]51[
]71[
]87[
]74[
[57] Method for carrying out telephone
conversations between two or more users
(110), characterized by the following
steps:
July 24, 2007– ‫ט' באב התשס"ז‬
(a) each user registers and communicates
his personal profile and preferences to a
system (100) and assigns a weight to each
2012
preference according to its importance;
(b) said system receives from the users
said profiles and said weighted preferences
and stores them;
(c) said system matches between said users
according to their profiles and weighted
preferences;
(d) said system presents to users a list of
candidates for conversations according to
the results of said match;
(e) users select one or more said candidates
from said results; and
(f) said system creates a telephone
connection between users and selected
candidates.
____________
]11[]21[
]54[
ZWITTERIONIC SILOXANE
POLYMERS AND IONICALLY
CROSS-LINKED POLYMERS
FORMED THEREFROM
]22[
]31[
]51[
]71[
]87[
]74[
26.10.2000
09/427216
]32[ 26.10.1999
Int. Cl.8 C08G 077/38
MONA INDUSTRIES, INC., U.S.A.
WO/2001/030886
S. HOROWITZ & CO.,
ZION HOUSE,
41-45 ROTHSCHILD BLVD.,
TEL AVIV 65784
2013
149196
‫פולימרים סילוקסן זוויטריוניים ופולימרים‬
‫מחוברי יינון בהצלבה הנוצרים מהם‬
]33[
US
,'‫ הורוביץ ושות‬.‫ש‬
‫ תל‬,41-45 ‫ שדרות רוטשילד‬,‫בית ציון‬
‫אביב‬
July 24, 2007– ‫ט' באב התשס"ז‬
[57] A method of preparing an ionically
cross-linked composition of a thickened
gel-like consistency comprising reacting
(A) a diamino containing polysiloxane of
the formula:
wherein:
R, which can be the same or different, is
selected from substituted or unsubstituted
alkyl or –OR9, wherein R9 is hydrogen or
alkyl;
R1 can be the same or different and is
selected from R, R2 and a diamino
containing radical of the formula –F1-NR5F—NH2; with the proviso that at least one
R1 group is a diamino containing radical
wherein: F1 is linear or branched alkylene
of 1-12 carbon atoms; F is linear or
branched alkylene of 1-10 carbon atoms;
and R5 is hydrogen or lower alkyl;
R2 can be the same or different and is
selected from substituted or unsubstituted
alkyl or –OR9, wherein R9 is hydrogen or
alkyl, aryl and olefinic (vinyl);
R3 and R4, which can be the same or
different, are selected from substituted or
unsubstituted alkyl, aryl, capped or
uncapped polyoxyalkylene, alkarylene,
aralkylene or alkenyl;
a is an integer from 0 to 10,000; and
b is an integer from 10 to 1000; with the
proviso that when a pendant R1 group is a
diamino containing radical a can be 0 or a
and b are present in the ratio of a:b of least
1:1 to about 200:1;
with (B), an acid containing reactant
selected from itaconic acid and/or the
trialkylsilyl ester derivatives thereof;
substituted or unsubstituted cyclic acid
anhydride; substituted or unsubstituted
conjugated olefinic acid and mixtures of
the same at an elevated temperature in the
presence of (C) a low molecular weight
silicone oil or other solvent for a time
sufficient to form ionically cross-linked
zwitterionic siloxane polymer of a gel-like
consistency containing both carboxylic
acid and secondary and/or tertiary amino
radicals.
__________
July 24, 2007– ‫ט' באב התשס"ז‬
2014
]11[]21[
149205
‫או סימנים ושירות‬/‫שיטה לייצור תווים ו‬
‫מידע מתקשורת הקשורים בכך‬
]54[
METHOD FOR GENERATING
CHARACTERS AND/OR
SYMBOLS AND THE
INFORMATION AND
COMMUNICATION SERVICE
METHOD USING THEM
]22[
]31[
]51[
]71[
21.10.2000
1999/45925
]32[ 21.10.1999
]33[ KR
Int. Cl.8 G06F 003/00, 003/023, G09G 005/00, 005/22
HEE-SUNG CHUNG, REPUBLIC OF
KOREA
WO/2001/029976
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060, TEL AVIV 61040
]87[
]74[
[57] A method for generating characters
or symbols, comprising the steps
of:defining
and 'O' as basic strokes; compounding at
least one basic stoke in sequence to define
a composition rule for generating each
language character or symbol;
processing basic stroke input from keys to
which the basic strokes are assigned,
according to the composition rule to
generate the corresponding character or
symbol.
2015
July 24, 2007– ‫ט' באב התשס"ז‬
__________
]11[]21[
149206
VIH ‫שיטה והתקן להבטל‬
]54[
METHOD AND DEVICE FOR
INACTIVATION OF HIV
]22[
]51[
]71[
18.04.2002
Int. Cl.8 A01N 059/20, B01J 020/02, C12N 007/00
THE CUPRON CORPORATION,
U.S.A.
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.,
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352, JERUSALEM 91013
]74[
[57] A device for inactivation of airborne
epidemial viruses said device being
provided with a virus-inactivating fibrous
material, said material having incorporated
therein copper oxide molecules which
release ions of copper selected from the
The applications for
division from this
application have not yet
been published
group consisting of Cu+ and Cu++ ions
and combinations thereof from the copper
oxide molecules which are bound to the
fibers in said material, wherein said device
is a face mask.
,174247
‫בקשות חלוקה מבקשה זו‬
.‫שטרם פורסמו‬
___________
July 24, 2007– ‫ט' באב התשס"ז‬
2016
]11[]21[
149308
‫ –אמינואינדן לצורך‬1 ‫שימוש בנגזרות של‬
–‫יצור תרופה לטיפול בהפרעה במניה‬
‫ביפולרת‬
]54[
USE OF 1-AMINOINDAN
DERIVATIVES FOR THE
MANUFACTURE OF A
MEDICAMENT FOR THE
TREATMENT OF MANIA IN
BIPOLAR DISORDER
]22[
]31[
]51[
]71[
27.10.2000
60/161817
]32[ 27.10.1999
]33[ US
Int. Cl.8 A61K 031/135, A61P 025/00, C07C 211/00, 211/42
TEVA PHARMACEUTICAL
‫ פתח‬,‫טבע תעשיות פרמצבטיות בע"מ‬
INDUSTRIES LTD.
‫תקווה‬
WO/2001/030339
TEVA PHARMACEUTICAL
,‫טבע תעשיות פרמצבטיות בע"מ‬
INDUSTRIES LTD.,
‫ פתח תקוה‬,3190 .‫ד‬.‫ ת‬, 5‫בזל‬
5 BASEL ST., P.O.BOX 3190,
PETAH TIQVA 49131
]87[
]74[
[57] Use of a therapeutically effective
amount of a compound of the formula
wherein n is 0 or 1;
each of R1 and R2 are hydrogen, C1-C4
alkyl, or halogen;
R3 is hydrogen, C1-C4 alkyl, hydroxy, or
C1-C4 alkoxy;
R4 is hydrogen, or C1-C4 alkyl;
R6 is hydrogen, substituted or
unsubstituted C1-C12 alkyl, C6-C12 aryl, C7C12 aralkyl or A-N- R9R10, provided that
R6 is not methyl when R1, R2, R3 and R4
are hydrogen atoms,
wherein A is substituted or unsubstituted
C1-C12 alkyl, substituted or unsubstituted
C6-C12 aryl, or substituted or unsubstituted
C7-C12 aralkyl, and each of R9 and R10 are
independently hydrogen, C1-C12 alkyl, C6C12 aryl, C7-C12 aralkyl, COOtBu, or
indanyl; or a racemic mixture, enantiomer,
or salt thereof for the manufacture of a
medicament for the treatment of mania in
bipolar disorder in a subject.
____________
2017
July 24, 2007– ‫ט' באב התשס"ז‬
]11[]21[
149412
‫– מתילן סטרואיד‬3 ‫נגזרות של‬
]54[
3-METHYLENE STEROID
DERIVATIVES
]22[
]31[
]51[
]71[
23.11.2000
99204000.6
]32[ 29.11.1999
]33[ EP
Int. Cl.8 A61K 031/56, A61P 019/02, 037/00, C07J 001/00, 071/00
N.V. ORGANON, THE
NETHERLANDS
WO/2001/040253
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
[57] A 3-methylene steroid derivative of
the formula
wherein
R1 is H or together with R3 forms a βepoxide or R1 is absent if there is a 5-10 or
4-5 double bond;
R2 is (C1-C5) alkyl or CF3;
R3 is βH, βCH3 or together with R1 forms
a β-epoxide or R3 is absent if there is a 510 double bond;
R4 is H, (C1-C6) alkyl;
Y is [H, H] [OH, H], =O, (C1-C6) alkyl],
[OH, (C2-C5) alkenyl],
[OH, (C2-C5) alkynyl] or (C1-C6)
alkylidene, whereby said alkyl, alkenyl,
alkynyl and alkylidene is optionally
halogenated; or =NOR5, whereby
R5 is H, (C1-C6) alkyl;
dotted lines represent an optional double
bond;
or esters or ethers at 17-OH thereof,
with the proviso that the 3-methylene
steroid derivative is not any one from the
list (7α, 17β)-7α-methyl-3-methylene-4estren-17-ol, (7α, 17α)-7-methyl-3methylene-19-norpregn-4-ene-17-ol, (7α,
17α)-7-methyl-3-methylene-19, 21dinorpregn-4-ene-17-ol, (7α)-17-keto-7methyl-3-methylene-4-estrene, (7α, 17α)7-methyl-3-methylene-19-norpregn-4-en20-yn-17-ol, 17β-hydroxy-7α-methyl-3methylene-17α-(2-propenyl)-4-estrene, and
17β-hydroxy-7α-(2-methyl-2-propenyl)-4estrene.
_________
July 24, 2007– ‫ט' באב התשס"ז‬
2018
]11[]21[
]54[
PHARMACEUTICAL
COMPOSITIONS CONTAINING
FED MODE INDUCING AGENTS
]22[
]31[
]51[
]71[
]87[
]74[
30.10.2000
09/432881
]32[ 02.11.1999
Int. Cl.8 A61K 047/00
DEPOMED, INC., U.S.A.
WO/2001/032217
WOLFF, BREGMAN AND GOLLER,
19B KEREN HAYESOD ST.,
P.O.B. 1352,
JERUSALEM 91013
149421
‫תכשירי רוקחות המכילים גורמים‬
‫המעוררים את דרכי ההזנה‬
]33[
US
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
[57] A pharmaceutical composition
comprising:
a drug retained in a solid matrix in a
manner causing release of said drug from
said solid matrix when said solid matrix is
in the stomach, said solid matrix when in
the stomach being of a size large enough to
promote retention of said solid matrix in
the stomach during the fed mode, and a fed
mode inducing agent selected from the
group consisting of:
(a) glycylglycine and salts thereof,
(b) alkali and alkaline earth metal
docusates,
(c) β-casomorphins,
(d) dithioorganic acids of the formula
in which n is 3 to 13,
(e) arginine and arginine salts,
(f) 3, 4-dihydro-1,2,3,-oxathiazin-4-ones of
the formula
2019
July 24, 2007– ‫ט' באב התשס"ז‬
in which R1 and R2 are independently
selected from the group consisting of H
and C1-C10 alkyl, and salts thereof;
in an amount that causes onset of the fed
mode.
__________
]11[]21[
149433
SMS-‫מענה וטיפול אטומטיים ל‬
]54[
SMS AUTOMATIC REPLY AND
AUTOMATIC HANDLING
]22[
]31[
]51[
]71[
]72[
01.05.2002
09/848339
]32[ 04.05.2001
]33[ US
Int. Cl.8 H04M 003/50, 003/53, 003/533, H04Q 007/22
COMVERSE LTD.
‫ רמת החייל‬,‫קומברס בע"מ‬
GIDEON FOSTICK, YUVAL
‫ יובל שמואלביץ‬,‫גדעון פוסטיק‬
SHMUELEVITZ
G.E. EHRLICH (1995) LTD.,
,‫) בע"מ‬1995( ‫ארליך‬.‫אי‬.‫ג'י‬
AYALON TOWER, 15TH FLOOR,
,11 ‫רחוב מנחם בגין‬, 15 ‫ קומה‬,‫מגדל אילון‬
11 MENACHEM BEGIN STREET,
‫רמת גן‬
52521 RAMAT GAN
]74[
[57] A method of managing Short
Message Service (SMS) messages
including the steps of identifying an SMS
message for a Message Recipient (MR)
(12), determining whether the MR has set
up at least one alternative handling
instruction for SMS messages; and if it is
determined that the MR has set up an
alternative handling instruction for SMS
messages, then executing the alternative
handling instruction, the method
characterized in that the at least one
alternative handling instruction includes a
saving instruction for saving SMS
messages in a personalized folder for the
MR.
__________
July 24, 2007– ‫ט' באב התשס"ז‬
2020
]11[]21[
]54[
BI-CORTICAL DENTAL
IMPLANT
]22[
]31[
]51[
]71[
09.08.2001
138457
]32[ 13.09.2000
Int. Cl.8 A61C 008/00
ADVANCED DENTAL
ENGINEERING LTD.
ZVI LASTER, SIMON GIRSHOVICH,
DANIEL BARUC
WO/2002/022037
JEREMY M. BEN-DAVID & CO.
LTD.,
HAR HOTZVIM HI-TECH PARK,
P.O.B. 45087,
JERUSALEM 91450
]72[
]87[
]74[
[57] A complementary system, which
includes:
an implant member (16), having:
a portion which protrudes from the
jawbone, when said implant member is
installed in the jawbone; and a through
conduit (46) at a far portion with respect to
an operator, invisible to the operator, when
said implant member is installed in the
jawbone; and a template (60), having: a
distal vertical section, running generally
along a distal cortical plate of the jawbone,
2021
149563
‫שתל דנטלי דו–קורטיקלי‬
]33[
IL
‫הנדסה דנטלית מתקדמת בע''מ‬
‫ דניאל ברוך‬,‫ שמעון גרשוביץ‬,‫צבי לסטר‬
,‫דוד ושות' בע"מ‬-‫ בן‬.‫ירמיהו מ‬
,45087 .‫ד‬.‫ ת‬, ‫ הר חוצבים‬,‫רחוב המרפא‬
‫ירושלים‬
operative to press against the distal cortical
plate; a proximal vertical section, running
generally along a proximal cortical plate of
the jawbone, which includes: a drill-bitchannel housing; and a drill-bit guide
channel, located within said drill-bitchannel housing; and a lateral section (66),
arranged to mesh with said portion of said
implant member which protrudes from the
jawbone, thus aligning said drill-bit guide
channel with said through conduit of said
implant member.
July 24, 2007– ‫ט' באב התשס"ז‬
‫ לתקנות‬35 ‫פירוט זה נבחן בהתאם לתקנה‬
1968 – ‫ תשכ"ח‬,‫הפטנטים‬
This specification was examined in
accordance with regulation 35 of the Patent
Regulations, 5728 - 1968
__________
]11[]21[
]54[
IMAGE SEARCHING DEFECT
DETECTOR
]22[
]31[
]51[
]71[
]74[
10.05.2002
60/290010
]32[ 11.05.2001
Int. Cl.8 G01B 009/08, G06F 019/00
ORBOTECH LTD.
ORBOTECH LTD.,
P.O.B. 215 ,
YAVNE 81102
[57] A method for detecting defects in
electrical circuits, comprising: generating
an acquired image corresponding to a part
of an electrical circuit to be inspected;
making a comparison of said acquired
image with least two reference images, at
least one of said reference images
149588
‫מערכת לגילוי תקלות באמצעות חיפוש‬
‫בתמונות‬
]33[
US
‫ יבנה‬,‫אורבוטק בע"מ‬
,‫אורבוטק בע"מ‬
‫ יבנה‬,215 .‫ד‬.‫ ת‬,
representing a defect and at least one of
said reference images representing an
absence of a defect; and based on said
comparison, providing an indication of a
correspondence of said acquired image to a
defect or to an absence of a defect.
__________
July 24, 2007– ‫ט' באב התשס"ז‬
2022
]11[]21[
149594
‫שיטה לאיתור ולהסרה אוטומטית של‬
‫חדירה לרשת‬
]54[
METHOD FOR AUTOMATIC
INTRUSION DETECTION AND
DEFLECTION IN A
NETWORK
]22[
]31[
]51[
]71[
29.11.2000
09/449531
]32[ 29.11.1999
]33[ US
Int. Cl.8 G06F 002/120000 013/00, H04L 012/24
FORESCOUT TECHNOLOGIES INC.,
U.S.A.
ODED COMAY, DORON
SHIKMONI, YEHEZKEL
YESHURUN, ODED AMIR
WO/2001/039379
DR. MARK FRIEDMAN LTD.,
,‫ד"ר מרק פרידמן בע"מ‬
MOSHE AVIV TOWER, 54TH
,77 ‫ ז'בוטינסקי‬54 ‫ קומה‬,‫מגדל משה אביב‬
FLOOR
‫ גן‬-‫רמת‬
7 JABOTINSKY STREET
52520
RAMAT GAN
]72[
]87[
]74[
[57] A method for detecting and handling
a communication from an unauthorized
source on a network, the method
comprising the steps of:
(a) receiving the communication from the
unauthorized source;
(b) analyzing the communication for
detecting an information gathering
procedure;
(c) if said information-gathering procedure
is detected, indicating a source address of
the communication as an intruder source
address;
2023
(d) returning an earmark to the
unauthorized source of the
communications;
(e) analyzing each subsequent
communication for a presence of said
earmark;
(f) if said earmark is present, indicating
said source address of the communication
as said intruder source address; and
(g) if said source address is said intruder
source address, handling the
communication from said intruder source
address.
July 24, 2007– ‫ט' באב התשס"ז‬
____________
]11[]21[
]54[
INHALER
]22[
]31[
]51[
]71[
01.12.2000
9928265.9
]32[ 01.12.1999
Int. Cl.8 A61M 015/00
INNOVATA BIOMED LIMITED,
UNITED KINGDOM
WO/2001/039823
LUZZATTO & LUZZATTO,
INDUSTRIAL PARK, OMER,
P.O.B. 5352,
BEER-SHEVA 84152
]87[
]74[
[57] A delivery device which comprises a
reservoir (14, 15), a delivery passage for
the delivery of material and a frusto
conical metering member (18)
characterised in that the delivery device
(13) is provided with a plurality of
July 24, 2007– ‫ט' באב התשס"ז‬
149623
‫משאף‬
]33[
GB
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
reservoirs and that the metering member is
provided with a plurality of measuring
cups (22) adapted to transfer a plurality of
measured doses of material from a
plurality of the reservoirs to the delivery
passage.
2024
__________
]11[]21[
149656
‫התקן ושיטה להקצאה ערוץ פקט משותף‬
CDMA ‫במערכת תקשורת‬
]54[
APPARATUS AND METHOD FOR
ASSIGNING A COMMON PACKET
CHANNEL IN A CDMA
COMMUNICATION NETWORK
]22[
]31[
29.11.2000
1999/53630
]32[ 29.11.1999
]33[ KR
2000/8316
21.02.2000
KR
2000/10823
29.02.2000
KR
2000/11184
02.03.2000
KR
2000/17743
04.04.2000
KR
Int. Cl.8 H04B 001/707, 007/216, 007/26, H04J 011/00, H04L 012/56, H04Q 007/36,
007/38
SAMSUNG ELECTRONICS CO.,
LTD., REPUBLIC OF KOREA
WO/2001/039386
SANFORD T.COLB & CO.,
,'‫ קולב ושות‬.‫סנפורד ט‬
P.O.B. 2273,
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
REHOVOT
]51[
]71[
]87[
]74[
[57] A method of base station operation
in a CDMA (Code Division Multiple
access) communication system,
comprising the steps of: transmitting use
state formation of each physical packet
channel and maximum available data rate
information of the physical packet channel
on a channel state indication channel;
receiving, in the base station, information
indicating that a mobile station has data to
transmit and selecting an unused physical
packet channel, using an access preamble;
and transmitting an acquisition indicator
signal for indicating an allowance of usage
of the selected physical packet channel to
the mobile station when the base station
allows usage of the currently unused
selected physical packet channel.
___________
2025
July 24, 2007– ‫ט' באב התשס"ז‬
]11[]21[
]54[
SYSTEM AND METHOD
PROTECTING THE IDENTITY OF
TARGET TELEPHONE NUMBERS
FROM UNAUTHORIZED ACCESS
]22[
]31[
]51[
]71[
]74[
16.05.2002
09/903859
]32[ 13.07.2001
Int. Cl.8 H04M 001/667, 003/22
COMVERSE, INC., U.S.A.
G.E. EHRLICH (1995) LTD.,
AYALON TOWER, 15TH FLOOR,
11 MENACHEM BEGIN STREET,
52521 RAMAT GAN
[57] A system to protect a target telephone
number from unauthorized access,
comprising: a first one-way encoding unit
encoding a target telephone number using
non-reversible encoding; a storage unit
storing the encoded target telephone
number; a second one-way encoding unit
encoding a calling telephone number and a
receiving telephone number using the nonreversible encoding; a monitoring unit; and
a comparing unit determining whether the
149697
‫מערכת ושיטה להגנה על הזהות של‬
‫מספרי טלפון מטרה מגישה לא מאושרת‬
]33[
US
,‫) בע"מ‬1995( ‫ארליך‬.‫אי‬.‫ג'י‬
,11 ‫רחוב מנחם בגין‬, 15 ‫ קומה‬,‫מגדל אילון‬
‫רמת גן‬
stored encoded target telephone number
matches the encoded calling telephone
number and/or the receiving telephone
number and routing a call between the
calling telephone number and the receiving
telephone number matching the target
telephone number to the monitoring unit,
wherein the monitoring unit monitors
and/or records the call and connects the
calling telephone number to the receiving
telephone number.
__________
]11[]21[
July 24, 2007– ‫ט' באב התשס"ז‬
149981
2026
]54[
CONNECTING ASSEMBLY FOR
SPINAL OSTEOSYNTHESIS
]22[
]31[
]51[
]71[
]87[
]74[
01.12.2000
99/15295
]32[ 03.12.1999
Int. Cl.8 A61B 017/70
SPINEVISION S.A., FRANCE
WO/2001/039677
SANFORD T.COLB & CO.,
P.O.B. 2273,
REHOVOT
[57] Connection assembly for spinal
osteosynthesis comprising an osseous
means including a connection area
designed to cooperate with a connection
means, characterised in that the bottom
part of the connection means comprises a
spherical shape (20) so that a connection
means can be freely positioned in a
‫הרכבה מחברת עבור אוסטיוסינטיזה‬
‫שדרתית‬
]33[
FR
,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
connector (8) or in a connection element
said spherical shape forming a longitudinal
positioning stop with the connector or with
the connection element, characterised in
that the said connector or connection
element has a complementary shaped
cavity.
___________
]11[]21[
2027
149994
July 24, 2007– ‫ט' באב התשס"ז‬
]54[
USE OF A COMBINATION OF A
COMPOUND
WHICH IS A SEROTONIN
REUPTAKE
INHIBITOR, AND
DERAMCICLANE,
FOR THE PREPARATION OF A
PHARMACEUTICAL
COMPOSITION
USEFUL FOR THE TREATMENT
OF
DEPRESSION, ANXIETY
DISORDERS
AND OTHER AFFECTIVE
DISORDERS
]22[
]31[
]51[
]71[
]87[
]74[
06.12.2000
60/169245
]32[ 06.12.1999
Int. Cl.8 A61K 045/00
H. LUNDBECK A/S, DENMARK
WO/2001/041701
DR. YITZHAK HESS & PARTNERS,
279 HAYARKON ST.,
P.O.B. 6451,
TEL AVIV 61063
[57] The use of a combination of a
compound , which is a serotonin reuptake
inhibitor, and deramciclane, for the
preparation of a pharmaceutical
composition useful for the treatment of
depression, anxiety disorders and other
affective disorders, such as generalized
anxiety disorder, panic anxiety, obsessive
compulsive disorder, acute stress disorder,
‫השימוש של שילוב של תרכובת של מעכב‬
‫סירוטונין‬
‫ ודראמאסיסלין עבור ההכנה של‬,‫רפיוטייק‬
‫תרכובת‬
,‫רוקחות המועילה עבור טיפול בדיכאון‬
‫הפרעות‬
‫חרדה והפרעות רגש אחרות‬
]33[
US
,‫ד"ר יצחק הס ושותפיו‬
‫ תל אביב‬,6451 .‫ד‬.‫ ת‬, 279 ‫רחוב הירקון‬
post traumatic stress disorder and social
anxiety disorder, eating disorders such as
bulimia, anorexia and obesity, phobias,
dysthymia, premenstrual syndrome,
cognitive disorders, impulse control
disorders, attention deficit hyperactivity
disorder, drug abuse or any other disorder
responsive to serotonin reuptake inhibitors.
__________
]11[]21[
July 24, 2007– ‫ט' באב התשס"ז‬
150390
2028
‫תכשירי רוקחות המכילים דיאסארין‬
‫לטיפול בספחת‬
]54[
PHARMACEUTICAL
COMPOSITIONS CONTAINING
DIACEREIN FOR TREATING
PSORIASIS
]22[
]31[
]51[
]71[
08.01.2001
0053/00
]32[ 12.01.2000
]33[ CH
Int. Cl.8 A61K 031/192, 031/222, A61P 017/06, C07C 069/00, 069/157
LABORATOIRE MEDIDOM S.A.,
SWITZERLAND
WO/2001/051044
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.,
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
]87[
]74[
[57] Use of diacerein or a
pharmaceutically acceptable derivative
thereof for the manufacture of a
pharmaceutical composition for the
treatment of psoriasis and diseases
associated therewith.
__________
]11[]21[
150474
‫שיטה ומערכת לאספקת רשימת מדיה‬
‫המתואמת למשתמש‬
]54[
METHOD AND SYSTEM FOR
PROVIDING A CUSTOMIZED
MEDIA LIST
]22[
]31[
]51[
]71[
11.01.2001
09/487120
]32[ 19.01.2000
]33[ US
Int. Cl.8 G06Q 003/000000 H04N 005/445, 007/16, 007/173
INDIVIDUAL NETWORK, LLC,
U.S.A.
WO/2001/054403
SANFORD T.COLB & CO.,
,'‫ קולב ושות‬.‫סנפורד ט‬
P.O.B. 2273,
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
REHOVOT
]87[
]74[
[57] A method for providing customized
video media to a user over an electronic
network comprising:
receiving data from a user, directly or
through an intermediary, which data
identifies the user; generating a customized
media list by a computer system, based on
a personal preference of the user, wherein
said list comprises a program or
advertisement including at least one
entertainment or information program or
2029
advertisement, or any combination of such
programs or advertisements, which
program or advertisement is selected from
media options available independent of a
broadcast schedule; sending said
customized media list, directly or through
an intermediary to said user of an
electronic network; and transmitting
customized video media from said
customized media list, wherein said
customized video media is transmitted
July 24, 2007– ‫ט' באב התשס"ז‬
independent of a broadcast schedule;
wherein the user is able to watch the
customized video media at the user's
The applications for division
from this application have
not yet been published
leisure rather than according to said
broadcast schedule.
,182204
‫בקשות חלוקה מבקשה זו‬
.‫שטרם פורסמו‬
__________
]11[]21[
July 24, 2007– ‫ט' באב התשס"ז‬
150617
2030
]54[
SOLID OXIDE FUEL CELL AND A
PROCESS FOR PRODUCING
ENERGY UTILIZING THE SAME
]22[
]31[
09.11.2001
60/247444
]32[ 09.11.2000
60/269525
19.02.2001
60/289462
08.05.2001
60/308313
27.07.2001
Int. Cl.8 H01M 004/86, 008/04, 008/12
TRUSTEES OF THE UNIVERSITY
OF PENNSYLVANIA, U.S.A.
WO/2002/058169
WOLFF, BREGMAN AND GOLLER,
19B KEREN HAYESOD ST.,
P.O.B. 1352,
JERUSALEM 91013
]51[
]71[
]87[
]74[
[57] A process of producing electrical
energy, comprising:
(a) providing a solid oxide fuel cell
comprising a solid oxide electrolyte that is
an electronic insulator which allows
transfer of anions, a ceramic metal
composite anode containing at least ceria
and/or copper, and a cathode, at least the
solid electrolyte and anode being prepared
by forming at least two layers to form a
‫תא סוללה עם תחמוצת מוצקה ושיטה‬
‫להפקת אנרגיה המשתמשת בו‬
]33[
US
US
US
US
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
porous anode layer and a dense solid
electrolyte layer, and then impregnating
the porous anode layer with at least ceria
and/or copper;
(b) contacting said cathode with an oxygen
source; and
(c) contacting said anode with a fuel
comprising a sulfur-containing
hydrocarbon having a sulfur content of
from about 1 ppm to about 5000 ppm.
__________
]11[]21[
2031
150728
July 24, 2007– ‫ט' באב התשס"ז‬
,‫ איחסון‬,‫שיטה ומערכת לרישום מאובטח‬
‫ניהול וקישור של מידע אישי אמין מאומת‬
‫במערכת תקשורת נתונים‬
]54[
METHOD AND SYSTEM FOR
SECURE REGISTRATION,
STORAGE, MANAGEMENT AND
LINKAGE OF PERSONAL
AUTHENTICATION
CREDENTIALS DATA OVER A
NETWORK
]22[
]31[
]51[
]71[
]87[
]74[
16.01.2001
60/176020
]32[ 14.01.2000
]33[ US
Int. Cl.8 G06F 002/120000 G06Q 003/000000 H04L 009/32
CATAVAULT, U.S.A.
WO/2001/052023
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
[57] A method of managing and linking a
user's personal authentication credentials
over a network, comprising the steps of:
registering the user with a secure network
based system; inputting the user's user
profile; creating a personal homepage and
personal database for the user that resides
on the system; inputting the user's
authentication credentials for a plurality of
third parties into the personal database;
July 24, 2007– ‫ט' באב התשס"ז‬
linking to one of the plurality of third
parties by the user via the personal
homepage and/or personal database;
retrieving and securely transmitting
appropriate authentication credentials from
the personal database on the system for the
one of the plurality of third parties; and
logging the user onto the one of the
plurality of third party sites.
2032
__________
]11[]21[
]54[
ACOUSTIC METHOD FOR
DISCRIMINATING BETWEEN
PAPER AND PLASTIC
ENVELOPES
]22[
]31[
]51[
]71[
]87[
]74[
02.04.2001
00/04443
]32[ 07.04.2000
Int. Cl.8 B07C 005/00, 005/34
SOLYSTIC, FRANCE
WO/2001/076775
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
[57] In a machine for processing mail
articles, a method of distinguishing
between mail articles (P1, P2, P3)
contained in envelopes made out of paper
and mail articles contained in envelopes
made out of plastics material, the method
2033
150792
‫שיטה אקוסטית להפרדת מעטפות נייר‬
‫ופלסטיק‬
]33[
FR
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
being characterized in that it consists in
displacing each mail article in front of a
pressure member (5) so as to produce an
acoustic signal that results from a suction
effect of the pressure member on one face
of said article while it moves in front of
July 24, 2007– ‫ט' באב התשס"ז‬
said pressure member, and in comparing
said acoustic signal with a reference signal
in order to detect whether the envelope of
said article is made out of paper or out of
plastics material.
____________
]11[]21[
]54[
METAL MATERIAL WITH
MODIFIED SURFACE,
PREPARATION METHOD AND
USE OF SAME
]22[
]31[
]51[
]71[
09.02.2001
00/01716
]32[ 11.02.2000
Int. Cl.8 C23C 022/02, C25D 011/00
UNIVERSITE PARIS 7-DENIS
DIDEROT, FRANCE
WO/2001/059178
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
[57] A metallic material, the surface of
which is modified by bonding aromatic
groups to the said surface, optionally
substituted by functional groups, the nature
of the bond between the surface and the
150839
,‫חומר מתכתי בעל פני שטח שעברו שינוי‬
‫שיטת הכנה והשימוש בו‬
]33[
FR
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
aromatic groups that modify it being a
carbon-metal bond of covalent type, and in
particular being such that it withstands
ultrasonic cleaning.
__________
July 24, 2007– ‫ט' באב התשס"ז‬
2034
]11[]21[
]54[
METHOD OF LINKING STEEL
TUBES TO ALUMINUM RIBS
]22[
]31[
18.01.2001
10003874.3
]32[ 28.01.2000
10057180.8
17.11.2000
Int. Cl.8 B23K 031/02
GEA ENERGIETECHNIK GMBH,
GERMANY
BENEDICT KORISCHEM, HORIA
DINULESCU, RAIMUND WITTE,
ECKARD VOLKMER
WO/2001/054840
EDWARD LANGER,
44-46 MONTEFIORE STREET
TEL AVIV 65201
]51[
]71[
]72[
]87[
]74[
[57] A method of connecting aluminum
rib strips folded so as to be corrugated, to
the flat sides of flat steel tubes,
characterized in that a layer of soldering
agent consisting of a zinc-aluminum alloy
with an aluminum content of 0.5% to 20%
is applied to the flat sides to the flat tubes
and a fluxing agent in the form of cesiumaluminum tetrafluoride is applied to the
150875
‫תהליך לחיבור צינורות פלדה לחוליות‬
‫אלומיניום‬
]33[
DE
DE
,‫אדוארד לנגר‬
‫ תל אביב‬,44-46‫מונטיפיורי‬
contact zones of the rib strips with the flat
sides, the application being carried out at
room temperature, whereupon the rib strips
are brought into mechanical contact with
the flat sides and then, in that
configuration, are heated in a furnace to a
soldering temperature between 370oC and
470oC, and are finally exposed to room
temperature for cooling.
____________
]11[]21[
]54[
AUTO-TORQUE, TAMPERPROOF SCREWS
]22[
]51[
]71[
]74[
04.08.2002
Int. Cl.8 F16B 023/00
MEIR AVGANIM
DANIEL FREIMANN & CO.,
5 DROYANOV ST. ,10TH FLOOR ,
TEL AVIV 63143
[57] A screw (10) having a screwthreaded shank (14) and a circular head
(12), the head being provided with at least
one radially extending screwdriver tip
receiving portion defined between a first
2035
151060
‫ברגים חסיני חבלה ומותאמי פיתול מעצמם‬
‫ נחל שורק‬.‫נ‬.‫ ד‬,‫מאיר אבגנים‬
,'‫דניאל פריימן ושות‬
‫ תל אביב‬,10 ‫ בית כלל קומה‬5‫דרויאנוב‬
integrally formed projection (16a) of a
generally right-angled triangle crosssection seen in a plane parallel to the axis
of the screw head wherein the hypotenuse
(16b) of the right angled triangle slopes
July 24, 2007– ‫ט' באב התשס"ז‬
from the bottom of the first projections to
the top thereof such that it is designed to
become shaved-off the screw head by a
pre-set shear force applied during
tightening of the screw, and a second
integrally formed projection designed to
withstand a shear force greater than the
said said pre-set force applied during
slackening of the screw.
___________
]11[]21[
]54[
SYSTEM AND METHOD FOR ONLINE MONITORING AND
BILLING OF POWER
CONSUMPTION
]22[
]31[
]51[
]71[
28.02.2001
60/185832
]32[ 29.02.2000
Int. Cl.8 G01D 004/00, G01R 022/00
QUADLOGIC CONTROLS
CORPORATION, U.S.A.
WO/2001/065823
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
[57] A system for monitoring energy
usage on a power line, comprising:
(a) an electronic microprocessor-controlled
digital electricity metering device coupled
to a power line and including a non-
July 24, 2007– ‫ט' באב התשס"ז‬
151406
‫מערכת ושיטה לניטור וחיוב צריכת‬
‫אנרגיה‬
]33[
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
volatile, non-battery-powered data-storage
device, wherein said metering device is
operable to perform interval metering,
store data acquired by said interval
metering in said data-storage device,
2036
receive a data request, and transmit data in
response to said request over said power
line; and
(b) a data collector coupled to said
metering device via said power line, said
data collector operable to:
(i) receive data from and transmit data to
said metering device over said power line,
(ii) store data received from said metering
device over said power line, and
(iii) receive data from and transmit data to
a remotely located computer.
,180435
The applications for division
from this application have
not yet been published
‫בקשות חלוקה מבקשה זו‬
.‫שטרם פורסמו‬
____________
]11[]21[
]54[
TELEMATICS METHOD FOR
HELICOPTERS
]22[
]31[
]51[
]71[
28.02.2001
10010134.8
]32[ 03.03.2000
Int. Cl.8 G01S 005/00, 005/14, 007/00
EADS DEUTSCHLAND GMBH,
GERMANY
WO/2001/065273
DR. YITZHAK HESS & PARTNERS,
279 HAYARKON ST.,
P.O.B. 6451,
TEL AVIV 61063
]87[
]74[
2037
151466
‫שיטה טלמטית עבור מסוקים‬
]33[
DE
,‫ד"ר יצחק הס ושותפיו‬
‫ תל אביב‬,6451 .‫ד‬.‫ ת‬, 279 ‫רחוב הירקון‬
July 24, 2007– ‫ט' באב התשס"ז‬
[57] Telematics method for helicopters
with an all-weather flight command and
hazard warning system, which uses
ground-based or satellite-supported mobile
radio networks for mobile communication,
characterized in that the system is
connected with a satellite-supported and/or
ground-based positioning system,
whereby:
(a) a completely or partially computerized
transmission of positioning and
deployment information takes place
between the helicopters and a center, based
on the connection of a positioning system
with mobile voice and/or data
transmission, to build up a formation and
fleet management;
(b) automatic, semi-automatic or manually
controlled communication with databases
takes place, in order, on one hand, to
retrieve relevant data for the purposes of
missions and/or flight safety, and, on the
other hand, to transfer accurate data
concerning the environment of the
helicopter – such as weather, hazard
settings, images, – to databases;
(c) a direct or indirect mobile radio
connection to existing ground-based
systems for emergency and breakdown
assistance, traffic and control systems of
all kinds, is established and maintained;
(d) transmission of patient diagnosis data
takes place, for the purpose of determining
the most appropriate hospital, which thus
prepares for the primary treatment as well
as to make available specialists for the
emergency doctors aboard the helicopter;
and
(e) data on the status of the helicopter
and/or crew are transmitted for the purpose
of effective deployment planning,
maintenance and spare parts supply.
___________
]11[]21[
151611
‫משק יעודי מודולי לטלפונים סלולריים‬
]54[
MODULE SPECIFIC INTERFACE
FOR CELLULAR PHONES
]22[
]31[
]51[
]71[
]87[
]74[
04.02.2002
09/775500
]32[ 05.02.2001
]33[ US
Int. Cl.8 H04M 001/06, 001/21, 001/725
MOSHE SHEALTIEL
‫משה שאלתיאל‬
WO/2002/063902
DR. MARK FRIEDMAN LTD.,
,‫ד"ר מרק פרידמן בע"מ‬
MOSHE AVIV TOWER, 54TH
,77 ‫ ז'בוטינסקי‬54 ‫ קומה‬,‫מגדל משה אביב‬
FLOOR
‫ גן‬-‫רמת‬
7 JABOTINSKY STREET
52520
RAMAT GAN
[57] A system for routing a call between
at least one radio communication
transceiver and at least one of a plurality of
conventional telephones, the system
comprising:
(a) at least one detachable adaptor, each
said adaptor operative for connecting to
July 24, 2007– ‫ט' באב התשס"ז‬
the at least one radio communication
transceiver, each said adaptor having:
(i) a transceiver docking connector, said
connector operative for connecting to the
radio communication transceiver, and
(ii) an interface module operatively
connected to said docking connector, said
2038
module designed and configured for
enabling information transfer between the
at least one of a plurality of conventional
telephones and the at least one transceiver;
(b) a transceiver docking station for the at
least one transceiver;
(c) a system controller unit, operatively
connected to said plurality of conventional
telephones, for controlling operation of the
system so as to route the call between the
at least one radio communication
transceiver and at least one of said
plurality of conventional telephones, via
said adaptor and said docking station.
___________
]11[]21[
]54[
SECURITY BAR TRANSFER
MECHANISM ASSEMBLY
]22[
]31[
]51[
]71[
13.03.2001
524089
]32[ 13.03.2000
Int. Cl.8 E04F 010/08
RAVCO INNOVATIONS INC.,
CANADA
WO/2001/069029
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
151668
‫מכלול למנגנון של מחיצת בטחון הניתנת‬
‫להעברה‬
]33[
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
[57] A security bar assembly for an
opening comprising: a plurality of security
bars driven by a bar drive chain and a
2039
July 24, 2007– ‫ט' באב התשס"ז‬
storage drive chain; and a transfer
mechanism comprising a transfer arm for
moving bars between the bar drive chain
and the storage drive chain.
____________
]11[]21[
]54[
SCANNING NEAR-FIELD
OPTICAL MICROSCOPE
]22[
]31[
06.02.2002
0102953.7
]32[ 06.02.2001
0124948.1
17.10.2001
Int. Cl.8 G02B 021/00
THE UNIVERSITY OF BRISTOL,
UNITED KINGDOM
WO/2002/063368
WOLFF, BREGMAN AND GOLLER,
19B KEREN HAYESOD ST.,
P.O.B. 1352,
JERUSALEM 91013
]51[
]71[
]87[
]74[
[57] A scanning near-field optical
microscope comprising:
a probe (20) which is moveable into a
near-field region (22) surrounding a
surface of an illuminated sample (14);
driving means arranged to provide relative
motion between the probe and the sample
July 24, 2007– ‫ט' באב התשס"ז‬
151949
‫מיקרוסקופ אופטי לתירת שדה ליד גוף‬
‫קורן‬
]33[
GB
GB
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
surface; means for oscillating the probe
across the surface, and a detector (24)
arranged to detect electromagnetic
radiation affected by an interaction
between probe, field and sample in the
near-field region; characterised in that, the
microscope is arranged, in operation, to
2040
carry out a scan of the sample surface
wherein scan area is covered by an
arrangement of scan lines, each scan line
being collected by oscillating the probe at
or near its resonant frequency such that
oscillation amplitude determines scan line
length and their arrangement is provided
by operation of the driving means.
__________
]11[]21[
]54[
MILK SAMPLING APPARATUS
AND METHOD
]22[
]31[
]51[
]71[
]87[
]74[
28.03.2001
0001196-5
]32[ 03.04.2000
Int. Cl.8 A01J 005/04
DELAVAL HOLDING AB, SWEDEN
WO/2001/074149
EITAN, PEARL, LATZER AND
COHEN ZEDEK,
P.O.B. 12688,
HERZLIYA 46733
[57] A milk sampling apparatus for use
with an automated milking system, said
apparatus comprising a cassette (7)
wherein milk sample collecting elements
(9) are placed, and at least one filling
member (27) capable of being placed
above a selected one of said milk sample
collecting elements by means of a
positioning system, and capable of
bringing a milk sample. representatively
2041
151990
‫מכשיר ושיטה לדגימת חלב‬
]33[
SE
,‫ לצר וכהן צדק‬,‫ פרל‬,‫איתן‬
‫ הרצליה‬,12688 .‫ד‬.‫ ת‬, 7 ‫רחוב שנקר‬
taken from milk yielded during a milking
of an animal by means of said automated
milking system, into said selected one of
said milk sample collecting elements,
wherein said positioning system comprises
an arm (34) extending in a first direction
(Y) in a plane (XY) above said milk
sample collecting elements (9) and being
movable in a second direction (X) in said
plane, said first and second directions
July 24, 2007– ‫ט' באב התשס"ז‬
being orthogonal; a first runner (32)
holding said filling member and being
movable along said arm; and characterized
in that first (29) and second (31) drive
means, wherein said first drive means is
effective to move said arm in said second
direction (X) in response to a first provided
signal value or a first provided number of
pulses and said second drive means is
effective to move said first runner along
said arm (Y direction) in response to a
second provided signal value or a second
provided number of pulses to position said
filling member above said selected one of
said milk sample collecting elements.
__________
]11[]21[
]54[
HAND TOOL FOR INSERTING A
VARIETY OF CONNECTORS
INTO NARROW PLASTIC
IRRIGATION PIPING
]22[
]51[
]71[
]74[
02.10.2002
Int. Cl.8 B25B 021/00, 023/14
MORDECHAI ELDAR
MORDECHAI ELDAR,
ODEM 12 NEVE SAVYON OR
YEHUDA
[57] A hand tool for inserting a selected
connector into plastic piping, said tool
comprising: a body (1) onto which a
handle (2) is connected, said handle is
capable of pivoting between an upward
position and a downward position with
respect to the body in response to pressure
exerted on the handle, an axle mounted
within the body with possibility for
reciprocate movement in response to the
July 24, 2007– ‫ט' באב התשס"ז‬
152089
‫מכשיר ידני לנעיצת מגוון מחברים לצינוריות‬
‫השקייה פלסטיות‬
‫ אור יהודה‬,‫מרדכי אלדר‬
,‫מרדכי אלדר‬
‫ אור יהודה‬,‫ נוה סביון‬12 ‫אודם‬
pivoting of the handle, said reciprocate
movement is respectively associated with
fixation of the piping vis-à-vis the selected
connector (22), bringing the piping (14) in
proximity to the selected connector,
inserting the selected connector into the
piping and releasing the piping thereafter,
grips (3), capable to be activated when said
axle reciprocates to ensure fixation of the
piping, bringing it towards the selected
2042
connector, inserting the selected connector
and releasing the piping after the insertion
is commenced, a spring means (6), cooperating with said handle and with said
grips, said spring means is capable of
resisting the pressure exerted on the
handle and to return the handle into its
upward position when the pressure is
released,
a drum (4), which is rotatably mounted on
the axle, the one side of said drum is
provided with at least two holes suitable
for deployment therein of connectors
having different size and shape, the
opposite side of the drum is provided with
a means for securing the drum in a position
in which the selected connector is vis-à-vis
the piping.
__________
]11[]21[
152092
‫מערכת ושיטה לשידור מאובטח של‬
‫נתונים‬
]54[
SECURE DATA TRANSMISSION
SYSTEM AND METHOD
]22[
]31[
11.04.2001
00810331.9
]32[ 17.04.2000
]33[ EP
1179/00
15.06.2000
CH
Int. Cl.8 H04L 009/00, 009/32, H04N 007/16
NAGRAVISION S.A.,
SWITZERLAND
WO/2001/080563
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.,
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
]51[
]71[
]87[
]74[
[57] A management system of the rights
of an audio/video data content encrypted
2043
by at least one control word accompanied
by an encrypted file containing the control
July 24, 2007– ‫ט' באב התשס"ז‬
word(s) and first conditions of using of the
encrypted content defined by the provider
of the content, characterised in that this
system comprises means for decrypting the
file, means for verifying if the first
conditions are completed and if so, for reencrypting this file by associating to it
second conditions of using defined by the
distributor.
____________
]11[]21[
]54[
HAEMOSTATICALLY ACTIVE
PREPARATION CONTAINING
VWF AND METHOD FOR THE
PRODUCTION THEREOF
]22[
]31[
]51[
]71[
]87[
]74[
04.04.2001
00108430.0
]32[ 18.04.2001
Int. Cl.8 C07K 001/16, 014/745
OCTAPHARMA AG, SWITZERLAND
WO/2001/079260
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
[57] A process for preparing a
hemostatically active preparation
containing von Willebrand factor (vWF)
from a fraction of human plasma by
(I) chromatographic purification of a vWFcontaining plasma fraction on an anionexchange material which has the anionexchanging groups on grafted polymeric
structures (tentacle materials), collecting a
152173
VWF ‫תכשיר המוסטטי פעיל המכיל‬
‫ושיטה להכנתו‬
]33[
EP
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
vWF-containing fraction, characterized in
that
(II) a purification of said fraction by sizeexclusion chromatography to prepare a
purified thermally stable vWF-containing
preparation follows; and
(III) the preparation in a lyophilized state
is heated to a temperature of more than
80oC for inactivating viruses.
____________
]11[]21[
July 24, 2007– ‫ט' באב התשס"ז‬
152320
2044
]54[
STORAGE CONTAINER FOR AT
LEAST ONE HYPODERMIC
NEEDLE
]22[
]31[
]51[
]71[
14.05.2001
00810415.0
]32[ 15.05.2000
Int. Cl.8 A61M 005/32
ARES TRADING S.A.,
SWITZERLAND
WO/2001/087388
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
[57] A storage container (1) for a
hypodermic needle (2), the hypodermic
needle having a connecting end which has
connectors that are complementary with
connectors on the tip of an injection
instrument, one of the connectors having
radial elasticity and devices for converting
an axial force exerted between the needle
and the injection instrument into at least
one radial component capable of
deforming the elastic connectors, the
container having a housing designed for
holding the needle entirely therein and in a
determined position, and an opening
giving access to the housing;
wherein an exterior wall (1e) bounding the
housing has a cylindrical guiding surface
coaxial with a longitudinal axis of the
housing and designed to engage with a
2045
‫מיכל אחסון עבור לפחות מחט תת–עורית‬
‫אחת‬
]33[
EP
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
complementary guiding surface of the
instrument so that the engagement of these
guiding surfaces with each other allows the
complementary connectors to be put in the
assembling position, following the exertion
on the devices for converting an axial force
into least one radial component of a
pressure coaxial with the longitudinal axis
of the housing, wherein the housing
holding the hypodermic needle in a
determined position has two coaxial
openings at a distance from each other, the
first of these openings having a fixed
diameter approximately equal to the
diameter of the connecting end, while the
second opening is delimited by elastically
radial devices so as to allow its diameter to
vary between a minimum diameter and
maximum diameter.
July 24, 2007– ‫ט' באב התשס"ז‬
__________
]11[]21[
]54[
APPARATUS FOR NONPENETRATING FILTRATION
SURGERY
]22[
]51[
]71[
]87[
]74[
08.05.2000
Int. Cl.8 A61B 018/20
I OPTIMA LTD
WO/2001/085044
FENSTER & COMPANY,
INTELLECTUAL PROPERTY LTD,
12 BASEL STREET
ENTRANCE 1
P.O.BOX 10256
PETACH TIKVA
[57] Apparatus for ophthalmic surgery
comprising:
a laser source (52) that generates a laser
beam (54); a scanner (56) comprising an
input for said laser beam and an output of a
spatially scanned laser beam; and
controlling circuitry configured to drive
said laser beam over an eye (40) in order to
July 24, 2007– ‫ט' באב התשס"ז‬
152343
‫התקן לניתוח סינון לא חודר‬
‫ ר"ג‬,‫איי אופטימה בע"מ‬
,‫קניין רוחני בע"מ‬,'‫פנסטר ושות‬
,10256 .‫ד‬.‫ ת‬, ‫ קרית אריה‬,1 ‫ כניסה‬12 ‫בזל‬
‫פתח תקוה‬
remove tissue, in a pattern suitable for
achieving percolation for non-penetrating
filtration of the eye, in which sufficient
tissue is removed to allow percolation of
fluid out of the eye and provide a reduction
in an elevated intra-ocular pressure,
without penetrating into the eye.
2046
_________
]11[]21[
]54[
MOTION-TRACKING
]22[
]31[
]51[
]71[
]87[
]74[
20.04.2001
556135
]32[ 21.04.2000
Int. Cl.8 A61B 005/103
INTERSENSE, INC., U.S.A.
WO/2001/080736
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
[57] A system for tracking the motion of
an object relative to a moving reference
frame, comprising: a first in inertial sensor
mounted on the tracked object; a second
inertial sensor mounted on the moving
reference frame; and an element coupled to
said first and second inertial sensors;
characterized in that said element is
2047
152359
‫מעקב אחר תנועה‬
]33[
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
configured to determine an orientation of
the object relative to the moving reference
frame based on the signals from the first
and second inertial sensors by integrating a
relative angular rate signal determined
from angular rate signals measured by the
first and second inertial sensors.
July 24, 2007– ‫ט' באב התשס"ז‬
___________
]11[]21[
]54[
SECURING SHELL ASSEMBLIES
TO PIPELINES
]22[
]31[
]51[
]71[
24.04.2001
0010329.1
]32[ 28.04.2000
Int. Cl.8 F16L 041/06, 055/16, 055/175
LATTICE INTELLECTUAL
PROPERTY LIMITED, UNITED
KINGDOM
WO/2001/084038
EITAN, PEARL, LATZER AND
COHEN ZEDEK,
P.O.B. 12688,
HERZLIYA 46733
]87[
]74[
[57] A method for securing a shell
assembly (1) to a pipeline (6), wherein the
shell assembly includes a first part (2) for
locating on a first side of the pipeline
removed from a second side that is
damaged or from which a branch is to
extend, and a second part (3), optionally
incorporating a branch (13), for locating on
the second side that is damaged or from
which the branch is to extend, the method
comprising: positioning a containment ring
(16) on the pipeline at a required position
on the pipeline and surrounding the
damaged area or the area from which the
branch is to extend; positioning an annular
seal (17) on the pipeline so that the annular
July 24, 2007– ‫ט' באב התשס"ז‬
152499
‫חיבור אבזרי מעטפת לצינורות‬
]33[
GB
,‫ לצר וכהן צדק‬,‫ פרל‬,‫איתן‬
‫ הרצליה‬,12688 .‫ד‬.‫ ת‬, 7 ‫רחוב שנקר‬
seal is wholly radially within the
containment ring; positioning the second
part of the shell assembly onto the annular
seal; positioning the first part of the shell
assembly on the pipeline and securing the
first and second parts together to compress
the annular seal and leave an annular space
between the first and second parts and an
external surface of the pipeline; providing
a sealing device substantially preventing
fluid from escaping from the annular
space, wherein upper and lower sides of
the containment ring are provided with an
upper and lower groove, respectively, with
the upper and lower annular grooves being
2048
connected to each other by a plurality of
passages extending through the
containment ring between the upper and
lower grooves; and introducing sealant by
a hole in a wall of the shell assembly, into
the upper groove to fill the lower groove,
the plurality of passages and the upper
groove to provide sealing between the
containment ring and the pipeline, and
between the containment ring and the shell
assembly.
__________
]11[]21[
]54[
AXIAL EXTERNAL FIXATOR
]22[
]31[
]51[
]71[
]72[
01.03.2001
00830381.0
]32[ 26.05.2000
Int. Cl.8 A61B 017/64
ORTHOFIX S.R.L., ITALY
DANIELE VENTURINI, MICHELE
COATI, LUIGI ROSSI
WO/2001/091654
MILLER-SIERADZKI,
P.O.B. 6145,
HAIFA 31061
]87[
]74[
[57] An axial unilateral external fixator
for stabilizing bone fractures, comprising
an extendible rod-like middle body (2) and
oppositely located bone screw clamps (5,
6) which are articulated to respective ends
(3, 4) of the rod-like middle body by
2049
152563
‫מקבע חיצוני אקסיאלי‬
]33[
EP
,‫שרצקי‬-‫מילר‬
‫ חיפה‬,6145 .‫ד‬.‫ ת‬, 18‫מחניים‬
means of ball joints, characterized in that a
ball-and-socket joint (16) is mounted to
each clamp, within a main body (20) with
which a clamping arrangement (25, 26, 21,
22, 23) of said bone screws is associated or
co-operates.
July 24, 2007– ‫ט' באב התשס"ז‬
__________
]11[]21[
152648
‫שיטה לאספקת שירות קריאת קול‬
‫בחבילת נתונים ברשת תקשורת אלחוטית‬
‫ומבנה רשת עבורה‬
]54[
METHOD OF PROVIDING
PACKET VOICE CALL SERVICE
IN WIRELESS COMMUNICATION
NETWORK AND NETWORK
ARCHITECTURE THEREFOR
]22[
]31[
]51[
]71[
11.01.2002
12459/2001
]32[ 10.03.2001
]33[ KR
Int. Cl.8 H04L 012/56, 012/66, H04M 007/00
SAMSUNG ELECTRONICS CO.,
LTD., REPUBLIC OF KOREA
WO/2002/073896
SANFORD T.COLB & CO.,
,'‫ קולב ושות‬.‫סנפורד ט‬
P.O.B. 2273,
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
REHOVOT
]87[
]74[
[57] A network architecture for providing
a packet voice call over a packet-based
network to a circuit network terminal
supporting wireless communication over a
circuit-based network, comprising: a radio
access network (RAN) (210) for providing
a call service to the circuit network
terminal; a mediation gateway (230)
connected to the RAN via a predetermined
signaling interface of the circuit-based
network, for performing location
registration, authorization, and mobility
management to provide a packet voice call
service to the circuit network terminal and
July 24, 2007– ‫ט' באב התשס"ז‬
making the circuit network terminal
recognized as a packet network terminal in
the packet-based network by performing IP
registration for the circuit network
terminal; and an access gateway (250)
connected to the mediation gateway via a
predetermined signaling interface, for
providing predetermined traffic interfacing
upon request from the mediation gateway,
and connected to the RAN, for transmitting
voice traffic from the circuit network
terminal to a terminal of a called party via
the packet-based network.
2050
__________
]11[]21[
]54[
DYNAMICALLY CONTROLLING
VIDEO AND DATA
TRANSMISSIONS
]22[
]31[
]51[
]71[
]87[
]74[
10.04.2001
09/574877
]32[ 19.05.2000
Int. Cl.8 H04N 007/173
INTEL CORPORATION, U.S.A.
WO/2001/091474
WOLFF, BREGMAN AND GOLLER,
19B KEREN HAYESOD ST.,
P.O.B. 1352,
JERUSALEM 91013
[57] A method comprising: broadcasting
selected content, including broadcast
programming together with viewer
selectable ancillary data, to a plurality of
viewers; receiving real time feedback from
those viewers indicative of the
demographics of the audience for the
2051
152798
‫בקרה דינמית של שידורי וידאו ונתונים‬
]33[
US
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
selected broadcast programming and
ancillary data, and automatically and
automatically and selectively modifying
the content being broadcast based on the
dynamic broadcast demographics and the
broadcast programming selected together
with the ancillary data.
July 24, 2007– ‫ט' באב התשס"ז‬
__________
]11[]21[
153229
– 1 – ‫ – (אימידזול‬2 – ‫ הידרוקסי‬1 –‫שימוש ב‬
,‫ – חומצה דו–פוספונית‬1 ,1 – ‫ייל) אתאן‬
‫בהכנת תרופה לטיפול למצבים של עלייה‬
‫לא–נורמלית של שינוי עצם‬
]54[
USE OF 1 – HYDROXY – 2 –
(IMIDAZOL – 1 – YL) ETHANE – 1,
1 – DIPHOSPHONIC ACID IN THE
PREPARATION OF A
MEDICAMENT FOR THE
TREATMENT OF CONDITIONS
OF ABNORMALLY INCREASED
BONE TURNOVER
]22[
]31[
18.06.2001
09/597135
]32[ 20.06.2000
]33[ US
60/267689
09.02.2001
US
Int. Cl.8 A61K 031/663, A61P 019/08, 019/10, C07F 009/00, 009/6503
NOVARTIS AG, SWITZERLAND
WO/2001/097788
LUZZATTO & LUZZATTO,
,‫לוצאטו את לוצאטו‬
INDUSTRIAL PARK, OMER,
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
P.O.B. 5352,
BEER-SHEVA 84152
]51[
]71[
]87[
]74[
[57] Use of 1-hydroxy-2-(imidazol-l-yl)
ethane-1, 1-diphosphonic acid, or a
pharmaceutically acceptable salt thereof,
or any hydrate thereof in the preparation of
a medicament for the treatment of
conditions of abnormally increased bone
turnover in which the 1-hydroxy-2-
(imidazol-1-yl) ethane-1, 1-diphosphonic
acid, or a pharmaceutically acceptable salt
thereof, or any hydrate thereof is
administered intermittently and in which
the period between administrations is at
least about 6 months.
___________
July 24, 2007– ‫ט' באב התשס"ז‬
2052
]11[]21[
]54[
COMPOSITIONS AND METHODS
FOR COATING MEDICAL
DEVICES
]22[
]31[
]51[
]62[
]71[
11.06.1997
08/662341
]32[ 12.06.1996
Int. Cl.8 A61F 002/54, A61L 027/00
DIVISION FROM 127446
THE REGENTS OF THE
UNIVERSITY OF MICHIGAN, U.S.A.
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]74[
[57] An in vivo medical treatment device
coated with a polymeric matrix, said
polymeric matrix comprising at least one
153374
‫תכשירים ושיטות לציפוי התקנים רפואיים‬
]33[
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
biocompatible biodegradable polymer and
a pharmceutially effective amount of at
least one nucleic acid.
_________
]11[]21[
153439
–6,1–‫–אוקסאדיאזוליל‬3 ‫תרופות המכילות‬
– ‫נאפטירידין‬
‫)–אונים עבור המניעה וטיפול‬H1(2
‫בסכיזופרניות‬
]54[
MEDICINES COMPRISING 3OXADIAZOLYL-1,6
NAPHTHYRIDIN- ...P
2(1H)-ONES FOR THE
PREVENTION AND TREATMENT
OF
SCHIZOPHRENIAS
]22[
]31[
]51[
]71[
12.06.2001
2000-185814 ]32[ 21.06.2000
]33[ JP
Int. Cl.8 A61K 031/4375, A61P 025/18, C07D 471/04
DAINIPPON SUMITOMO PHARMA
CO., LTD., JAPAN
WO/2001/098300
DR. YITZHAK HESS & PARTNERS,
,‫ד"ר יצחק הס ושותפיו‬
279 HAYARKON ST.,
‫ תל אביב‬,6451 .‫ד‬.‫ ת‬, 279 ‫רחוב הירקון‬
P.O.B. 6451,
TEL AVIV 61063
]87[
]74[
[57] A medicine for prevention and
treatment of schizophrenias comprising a
5-substituted-3-oxadiazolyl-1, 6-
2053
naphthyridin-2(1H)-one derivative of the
formula
July 24, 2007– ‫ט' באב התשס"ז‬
wherein:
Het is an oxadiazolyl group;
R1 is a hydrogen atom, a lower alkyl
group, a cyclolower alkyl group, a
trifluoromethyl group, a lower alkenyl
group, a lower alkynyl group, a lower
alkoxy group, a lower alkoxy-lower alkyl
group, a hydroxy-lower alkyl group, a
substituted or unsubstituted aryl group, or
a substituted or unsubstituted heteroaryl
group; and R2 is a hydrogen atom, a lower
alkyl group, a cyclolower alkyl group, a
cyclo-lower alkylmethyl group, a lower
alkenyl group, a cyclo-lower alkenyl
group, a lower alkynyl group, a substituted
or unsubstituted aryl group, or a
substituted or unsubstituted heteroaryl
group, or a physiologically acceptable acid
addition salt thereof.
__________
]11[]21[
]54[
SYSTEM FOR MONITORING
HEALTH, WELLNESS AND
FITNESS
]22[
]31[
]51[
]71[
]87[
]74[
22.06.2001
602537
]32[ 23.06.2000
Int. Cl.8 A61B 005/00
BODYMEDIA, INC., U.S.A.
WO/2002/000111
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060, TEL AVIV 61040
[57] An apparatus for monitoring and
reporting human physiological
information, comprising a sensor device
housing (10) adapted to be placed in
proximity with an individual's body, a
processor supported by said sensor device
housing, said processor being in electrical
communication with at least two sensors
selected from the group consisting of
physiological sensors and contextual
sensors, at least one of said at least two
sensors being adapted to generate data
July 24, 2007– ‫ט' באב התשס"ז‬
153516
‫ שביעות רצון‬,‫מערכת לניטור בריאות‬
‫וכשירות‬
]33[
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
indicative of at least a first parameter of
said individual, said first parameter being
physiological, and a second parameter of
said individual, and means in electrical
communication with said processor for
providing information to said individual,
characterized in that said processor is
adapted to derive physiological state
information from at least a portion of said
data indicative of at least a first parameter
and at least a portion of said data
indicative of at least a second parameter.
2054
___________
]11[]21[
153538
‫שיטה והתקן לטיפול בניגרים‬
]54[
METHOD AND APPARATUS FOR
TREATING FLUIDS
]22[
]31[
]51[
]71[
05.07.2001
60/216444
]32[ 06.07.2000
]33[ US
Int. Cl.8 B01F 005/06, B02C 019/06, B05B 001/34
LANCER PARTNERSHIP, LTD.,
U.S.A.
WO/2002/004124
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.,
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
]87[
]74[
[57] A method of rotating a fluid,
comprising: inletting a fluid flow
tangential and normal to a tapered
passageway (31) of a vortex nozzle (29)
2055
via a plurality of ports (37, 38, 39) and
rotating the fluid flow in the tapered
passageway.
July 24, 2007– ‫ט' באב התשס"ז‬
The applications for division
from this application have
not yet been published
,175207,175206,175205,175204
‫בקשות חלוקה מבקשה זו‬
.‫שטרם פורסמו‬
__________
]11[]21[
]54[
METHOD AND ROTARY
MILKING PARLOR FOR
IDENTIFYING A MILKING STALL
AND AN ANIMAL, ESPECIALLY A
COW, IN A ROTARY MILKING
PARLOR
]22[
]31[
]51[
]71[
21.06.2001
10033706.6
]32[ 12.07.2000
Int. Cl.8 A01K 001/12
WESTFALIASURGE GMBH,
GERMANY
WO/2002/003783
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
[57] Method for the identification of a
milking stall (4) and of an animnal located
in the milking stall, in particular a cow, in
a rotary milking parlor with a plurality of
milking stalls, which are disposed on a
rotatable milking platform (3), as well with
July 24, 2007– ‫ט' באב התשס"ז‬
153580
‫שיטה ומתקן חליבה מעגלי לזיהוי בעל‬
‫חיים בתא חליבה במיוחד פרה ומתקן‬
‫חליבה מעגלי‬
]33[
DE
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
an entrance path (1) and an exit path (2),
characterized by guiding of an animal with
a recognition device into a milking stall,
identification of the animal and of the
milking stall, in which the animal is
located, wherein the milking platform with
2056
the animal is passed by a fixed unit (10)
for animal recognition, said fixed unit
being disposed downstream of the entrance
path, as observed in the direction of
rotation of the milking platform, and by
transmission and evaluation of the
recognition data for the animal and for the
milking stall in a data processing system.
_________
]11[]21[
153632
‫נגזרות של בנזופורן והמלחים שלהם‬
‫המתאימים לשימוש תרופתי‬
]54[
BENZOFURAN DERIVATIVES
AND THEIR
PHARMACEUTICALLY
ACCEPTABLE SALTS
]22[
]31[
]51[
21.08.2001
00/10834
]32[ 23.08.2000
]33[ FR
Int. Cl.8 A61K 031/357, 031/41, 031/4155, 031/4525, 031/496, A61P 009/06, 009/10,
009/12, C07D 307/00, 307/78, 307/84, 405/12, 405/14, 407/04, 409/12, 409/14
SANOFI AVENTIS, FRANCE
WO/2002/016339
SANFORD T.COLB & CO.,
,'‫ קולב ושות‬.‫סנפורד ט‬
P.O.B. 2273,
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
REHOVOT
]71[
]87[
]74[
[57] Benzofuran derivatives of the
formula:
and their pharmaceutically acceptable
salts, in which formula: A represents a
linear or branched C3-C5 alkylene group
2057
optionally subsituted by a hydroxyl group
or A represents a group of the formula:
July 24, 2007– ‫ט' באב התשס"ז‬
-R19-O-R20in which R19 and R20, which are identical
or different, each represent a linear or
branched C1-C4 alkylene group, R30 and
R31, taken together, represent a carbonyl
-O-R29-Oin which R29 represents a C1-C4 alkylene
group,
T represents hydrogen or a C1-C4 alkyl
radical,
group with the carbon to which they are
attached or represent a group of general
formula:
R represents:
the cyano, hydroxymethyl, formyl or
tetrazolyl group,
or an ester group of the formula:
in which R4 represents a linear or branched
C1-C6 alkyl group or a C3-C6 cycloalkyl
group,
R1 represents hydrogen, a linear or
branched C1-C6 alkyl group, a C3-C6
cycloalkyl group, a benzyl group or a
phenyl group optionally substituted by one
or more substituents selected from halogen
atoms, C1-C4 alkyl groups or C1-C4 alkoxy
groups or R1 represents a group of the
formula:
in which R21 represents a linear or
branched C1-C4 alkylene group and R22
represents a linear or branched C1-C4 alkyl
group, or R1 represents a group of the
formula:
-R23-OH
in which R23 represents a linear or
branched C1-C6 alkylene group,
R2 and R3, which are identical or different,
represent hydrogen, a linear or branched
C1-C6 alkyl group optionally substituted by
one or more halogen atoms or by a
pyrrolidinyl group, a C3-C6 cycloalkyl
group or a group of the formula:
-R24-O-R25
in which R24 represents a linear or
branched C1-C4 alkylene group and R25
represents a linear or branched C1-C4 alkyl
group,
or R2 and R3, when they are taken together,
represent a linear or branched C3-C10
July 24, 2007– ‫ט' באב התשס"ז‬
alkylene group, W, W'; and Z are such
that:
when W and W', which are identical,
represent CH, Z represents –O- or –S-,
when W represents CH and W' represents
C-R13, Z represents
2058
R13 and R14 being identical or different and
representing hydrogen, a halogen atom, a
C1-C4 alkyl radical or a C3-c4 alkoxy
radical,
X represents –O-,
these benzofuran derivatives being in the
form of individual isomers or of mixtures
of the latter.
____________
]11[]21[
]54[
FUNGICIDAL COMPOSITION
COMPRISING IN PARTICULAR
AN OIL OF VEGETABLE ORIGIN
WITH HIGH DRYING POWER
]22[
]31[
]51[
]71[
19.07.2001
00/09898
]32[ 28.07.2000
Int. Cl.8 A01N 025/24, 043/36, 043/76
BAYER CROPSCIENCE S.A.,
FRANCE
WO/2002/009517
LUZZATTO & LUZZATTO,
INDUSTRIAL PARK, OMER,
P.O.B. 5352,
BEER-SHEVA 84152
]87[
]74[
[57] Fungicidal composition comprising
iprodione and at least one oil chosen from
linseed, sunflower, soya bean, maize,
cottonseed, safflower and rapeseed oil, this
oil being of plant origin and possessing a
153786
‫תכשיר קוטל פטריות המכיל במיוחד שמן‬
‫ממקור צמחי בעל יכולת ייבוש גבוה‬
]33[
FR
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
high siccative power characterized by an
iodine value which is greater than 90, the
oil/iprodione weight ratio being between
0.15 and 1.6.
___________
2059
July 24, 2007– ‫ט' באב התשס"ז‬
]11[]21[
153934
‫ אלפא על‬16 ‫אסטרגונים מותמרים בעמדה‬
‫ידי מתיל או אתיל‬
]54[
16 ALPHA-METHYL OR ETHYL
SUBSTITUTED ESTROGENS
]22[
]31[
]51[
]71[
23.07.2001
00202697.9
]32[ 28.07.2000
]33[ EP
Int. Cl.8 A61K 031/565, A61P 005/30, C07J 001/00
N.V. ORGANON, THE
NETHERLANDS
WO/2002/010188
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
[57] A 16α-substituted steroidal
compound of the formula
wherein:
the dotted ring is a fully saturated, a fully
aromatic or saturated ring with a ∆5-10
double bond;
R1 is (C1-C3) alkyl or (C2-C3) alkenyl, and
each of these groups can be substituted
with one or more halogens;
R2 is (C1-C4) alkyl, (C2-C4) alkenyl or
methylene, and each of these groups can
be substituted with one or more halogens;
R3 is methyl or ethyl.
____________
July 24, 2007– ‫ט' באב התשס"ז‬
2060
]11[]21[
]54[
METHOD AND ARRANGEMENT
IN ASEPTIC PREPARATION
]22[
]31[
]51[
]71[
]87[
]74[
09.08.2001
0002868-8
]32[ 10.08.2000
Int. Cl.8 A61M 005/31
CARMEL PHARMA AB, SWEDEN
WO/2002/011794
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
[57] A method for antiseptic preparation
by means of an injection syringe, said
injection syringe comprising a container
for an injection agent and an immovable
connection nozzle attached to the
container, the method involving the
153998
‫שיטה והתקנים להכנה נקיה‬
]33[
SE
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
charging of the container with air,
characterized in that charging the container
with air causes air to pass through the
connection nozzle and an air filter
arranged on the connection nozzle.
_________
2061
July 24, 2007– ‫ט' באב התשס"ז‬
]11[]21[
154144
‫שימוש במנה רפואית יעילה של פלווונואיד‬
‫להכנת תרופה לטיפול בתסמינים של‬
‫ דלקת אלרגית באף ודלקות‬,‫ששפעת‬
‫הקשורות במערכת הנשימה‬
]54[
USE OF A THERAPEUTICALY
EFFECTIVE DOSAGE OF A
FLAVONOID FOR PREPARING
MEDICAMENT FOR TREATING
SYMPTOMS OF COMMON COLD,
ALLERGIC RHINITIS AND
INFECTIONS RELATING TO THE
RESPIRATORY TRACT
]22[
]31[
23.07.2001
PA200001152 ]32[ 28.07.2000
]33[ DK
PA200001316
04.09.2000
DK
PA200001935
23.12.2000
DK
PA200100007
03.01.2001
DK
PA200100827
22.05.2001
DK
Int. Cl.8 A61K 031/315, 031/7048, A61P 011/00, 027/14, C07D 311/00, C07F
003/06, 019/00, C07H 003/04
IMMUPHARM APS, DENMARK
WO/2002/009699
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
]51[
]71[
]87[
]74[
[57] Use of a therapeutically effective
dosage of a flavonoid selected from the
group consisting of hydroxyethylrutosides
and pharmaceutically acceptable salts
thereof together with a pharmaceutically
acceptable carrier for the preparation of a
medicament for ameliorating and/or
curative treatment of a condition selected
from the group consisting of common cold,
viral and/or bacterial infection of the upper
and/or lower respiratory tract and/or eyes,
rhinitis and hay fever.
____________
July 24, 2007– ‫ט' באב התשס"ז‬
2062
]11[]21[
]54[
COMPOSITION AND METHOD
FOR COATING FOODSTUFFS
]22[
]31[
]51[
]71[
17.02.2003
1016018
]32[ 25.08.2000
Int. Cl.8 A23L 001/0532
W. RUITENBERG CZN. N.V., THE
NETHERLANDS
WO/2002/015715
BLUM, GADOR & CO.,,
53 HASHALOM RD,
GIVATAYIM 53454
]87[
]74[
[57] Composition for coating foodstuffs
which comprises a first polysaccharide that
is negatively charged in the composition
and gels under the influence of cations, the
first polysaccharide comprising alginate,
and at least a second polysaccaharide,
154489
‫תכשיר ושיטה לציפוי מאכלים‬
]33[
NL
,'‫ גדור ושות‬,‫בלום‬
,‫ מגדל הורד‬23 ‫ קומה‬,53 ‫דרך השלום‬
‫גבעתיים‬
which is neutral in the composition, the
second polysaccharide comprising
galactomannans, the composition
comprising 2-7 w/w % alginate and having
a viscosity of 80-110 Pa.s at a temperature
of 20oC.
____________
]11[]21[
]54[
VACUUM TUBE HOUSING
COMPRISING A PLURALITY OF
INTERMEDIATE PLANAR
PLATES HAVING NONMONOTONICALLY APERTURE
ARRANGEMENT
]22[
]31[
]51[
]71[
]87[
]74[
15.08.2001
652516
]32[ 31.08.2000
Int. Cl.8 H01J 001/62
INTEVAC, INC., U.S.A.
WO/2002/019365
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
[57] A housing (10) for a vacuum
microelectronic imaging device, said
housing comprising:
(a) a laminated structure (32) comprising
2063
154517
‫שרוול לצינור ואקום המורכב ממספר‬
‫לוחות ביניים מישוריות בעלי סידור לא‬
‫מונוטוני‬
]33[
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
first and second planar end plates and a
plurality of intermediate planar plates
disposed therebetween,
July 24, 2007– ‫ט' באב התשס"ז‬
(b) at least three of said intermediate
plates each comprising an aperture of
respective area and said three plates
disposed serially in substantial alignment
of said apertures whereby a cavity is
formed in said laminated structure, said at
least three aperture areas varying nonmonotonically in said series, one of said
end plates comprising a transparent
electrically insulating wall positioned
The applications for division
from this application have
not yet been published
across said cavity, a photocathode (29) on
the surface of said transparent end plate
positioned facing said cavity, a seal (31)
bonding the surface of said transparent end
plate facing said cavity to the surface of
the adjacent intermediate plate, and a
vacuum pocket within said cavity and
between said photocathode surface and
said other end plate.
,174680
‫בקשות חלוקה מבקשה זו‬
.‫שטרם פורסמו‬
__________
]11[]21[
154828
‫ שיטה‬,‫–פלואורואלקיל סטרואידים‬α17
‫ליצורם ותכשירי רוקחות המכילים אותם‬
]54[
17 α FLUOROALKYL STEROIDS,
METHOD FOR PRODUCING THE
SAME AND PHARMACEUTICAL
COMPOSITIONS
CONTAINING SAID COMPOUNDS
]22[
]31[
]51[
28.09.2001
10049736.5
]32[ 29.09.2000
]33[ DE
Int. Cl.8 A61K 031/565, 035/00, A61P 005/24, C07J 001/00, 011/00, 053/00, 071/00,
073/00
SCHERING
AKTIENGESELLSCHAFT,
GERMANY
WO/2002/026759
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
]71[
]87[
]74[
July 24, 2007– ‫ט' באב התשס"ז‬
2064
[57] 17α-Fluoroalkyl steroids of the
formula
in which
R1 stands for a C1-4-alkyl group,
R2 stands for a hydroxy group, a group
OC(O)-R20 or OR21, whereby R20 and R21
mean a C1-12-alkyl group, a C3-8-cycloalkyl
group, an aryl group or an aryl -C1-4-alkyl
group,
R3 stands for a radical of formula CnF2n+1,
whereby n = 1, 2, 3, 4,. 5 or 6, R4 and R5 in
each case stand for a hydrogen atom,
together for a double bond or a methylene
bridge,
R5 and R6 each stand for a hydrogen atom,
together for a double bond or a methylene
bridge, STEROID stands for a steroidal
ABC-ring system of the partial formulas
C
whereby an additional double bond can be
found in A and C in 1, 2-position, and one
or two additional double bonds can be
found in B in 8, 9-position and 11, 12position,
R7 means a hydrogen atom, a halogen
atom, a hydroxyl group or a
trifluoromethyl group,
X means an oxygen atom or two hydrogen
atoms,
R8 means a hydrogen atom, a methyl or
ethyl group,
R9 means a hydrogen atom or a halogen
2065
atom or together with R10 stands for a
double bond,
R10 means a hydrogen atom, a hydroxyl
group, a methyl or ethyl group or together
with R9 stands for a double bond,
R11 means a hydrogen atom, a C1-4-alkyl,
group, a nitrile group, a hydroxymethylene group or a formyl group,
R12 means a hydrogen atom, a C1-4-alkyl
group or a nitrile group,
R11 and R12, in addition to the abovementioned meanings, together mean a
methylene bridge,
July 24, 2007– ‫ט' באב התשס"ז‬
R13 means a hydrogen atom or together
with R7 means a double bond,
R14 and R15 together stand for a double
bond, an oxirane ring., a thiirane ring, a
[2,3c] oxadiazole ring, a [3,2c] isoxazole
ring or a [3, 2c] pyrazole ring,
Y stands for an oxygen or nitrogen atom,
and the wavy lines at R7, R8, R11, R12, R13,
R14 and R15 mean that these substituents
can be in α-or β-position, and the
following compounds are excluded:
17β-Hydroxy-17α-trifluoromethyl-androst4-en-3-one,
17β-Hydroxy-17α-trifluoromethyl-estr-4en-one,
17β-Hydroxy-17α-trifluoromethyl-estra4,9-dien-3-one,
17β-Hydroxy-17α-trifluoromethyl-estra4,9,11-trien-3-one,
13-Ethyl-17β-hydroxy-17αtrifluoromethyl-gon-4-en-3-one,
13-Ethyl-17β-hydroxy-17αtrifluoromethyl-gona-4,9-dien-3-one and
13-Ethyl-17β-hydroxy-17α-trifluromethylgona-4,9,11-trien-3-one.
___________
]11[]21[
155179
‫פולימרים ספחי שטח פנים והשימוש בהם‬
‫לטיפול במשטחים‬
]54[
SURFACE ADSORBING
POLYMERS AND THEIR USE IN
TREATING SURFACES
]22[
]31[
10.10.2001
60/239316
]32[ 10.10.2000
]33[ US
60/326091
28.09.2001
US
Int. Cl.8 B01L 011/00, B05D 001/00, G01N 033/543
SERONO GENETICS INSTITUTE
S.A., FRANCE
JAN SUDOR
WO/2002/030571
BEN-AMI & ASSOCIATES,
P.O.BOX 94, REHOVOT 76100
]51[
]71[
]72[
]87[
]74[
[57] A method of decreasing adsorption
of an organic material to a surface,
comprising: (a) providing a fluid sample
comprising an organic material; (b) adding
an effective amount of a surface adsorbing
polymer to said fluid sample; (c)
contacting said fluid sample comprising
said organic material and said surface
adsorbing polymer to a surface; and (d)
performing a fluid operation; wherein: (1)
said surface adsorbing polymer binds noncovalently to said surface; (2) said surface
adsorbing polymer reduces the amount of
adsorption of said organic material to said
July 24, 2007– ‫ט' באב התשס"ז‬
,'‫עמי ושות‬-‫בן‬
‫ רחובות‬,94 .‫ד‬.‫ ת‬,
surface; (3) said surface adsorbing polymer
is not one of the reactants of said fluid
operation or is added in excess of the
amount normally added to said fluid
sample; (4) said surface adsorbing polymer
does not inhibit the fluid operation; (5)
said fluid operation is a chemical reaction,
a dilution, a titration, a detection, a mixing
and drug screening assay, or a biochemical
reaction; and (6) said surface is part of an
apparatus and said surface is selected from
the group consisting of ninety-six well
microtiter plates, three hundred eightyfour well microtiter plates, one thousand
2066
five hundred thirty-six well microtiter
plates, microtiter plates comprising more
than one thousand five hundred thirty-six
wells, microcentrifuge tubes, test tubes,
pipettes, pipette tips, and multi-well plates.
____________
]11[]21[
]54[
PROCESS AND APPARATUS FOR
TREATING WASTEWATER
]22[
]31[
04.10.2001
678229
]32[ 04.10.2000
678095
04.10.2000
Int. Cl.8 C02F 001/24, 001/44, 009/00
GREAT CIRCLE TECHNOLOGIES,
INC., U.S.A.
WO/2002/028786
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]51[
]71[
]87[
]74[
[57] A method for treating wastewater
containing settleable solids to form a
reusable liquid fraction, comprising:
flowing a wastewater stream into a first
containment zone to create forces
separating the wastewater stream into a
first component and a second component
in the first containment zone, the first
component including an amount of
settleable solids greater than an amount of
settleable solids in the second component,
2067
155248
‫תהליך ומתקן לטיפול במי שופכין‬
]33[
US
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
and either: passing the second component
into a second containment zone including a
gas flotation separation system to form a
froth fraction and a reusable liquid
fraction; or applying the second
component to a membrane permeable to
selected ingredients of the second
component and concentrating the second
component on a surface of the membrane
to form a solids concentrate and a reusable
solids fraction.
July 24, 2007– ‫ט' באב התשס"ז‬
The applications for division
from this application have
not yet been published
,182907
‫בקשות חלוקה מבקשה זו‬
.‫שטרם פורסמו‬
__________
]11[]21[
155263
‫תמיסות רוקחיות של תרכובות מודאפיניל‬
]54[
PHARMACEUTICAL SOLUTIONS
OF MODAFINIL COMPOUNDS
]22[
]31[
11.10.2001
60/239488
]32[ 11.10.2000
]33[ US
09/974473
10.10.2001
US
Int. Cl.8 A61K 009/08, 031/16, 047/10, C07C 317/44
CEPHALON, INC., U.S.A.
WO/2002/030413
SANFORD T.COLB & CO.,
,'‫ קולב ושות‬.‫סנפורד ט‬
P.O.B. 2273,
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
REHOVOT
]51[
]71[
]87[
]74[
[57] A pharmaceutical composition
comprising a modafinil compound in
solution.
____________
]11[]21[
July 24, 2007– ‫ט' באב התשס"ז‬
155409
2068
‫אלקטרוליט פולימרי מסוג ג'ל ושימושים‬
‫שלו‬
]54[
GEL-TYPE POLYMER
ELECTROLYTE AND USE
THEREOF
]22[
]31[
]51[
]71[
18.10.2001
2000-318169 ]32[ 18.10.2000
]33[ JP
Int. Cl.8 C08G 065/00, C08J 005/22, H01M 006/22, 010/40
E.I. DUPONT DE NEMOURS AND
COMPANY, U.S.A.
NOBORU OYAMA, JAPAN
WO/2002/033765
SANFORD T.COLB & CO.,
,'‫ קולב ושות‬.‫סנפורד ט‬
P.O.B. 2273,
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
REHOVOT
]87[
]74[
[57] A gel-type polymer electrolyte,
wherein sad polymer comprises (A) an
ethylene-unsaturated carboxylic acid
copolymer or a derivative thereof and (B) a
polyalkylene oxide having a hydroxyl
group at one terminal thereof or a
derivative thereof, which are bonded
together by an ester bond, wherein the
polyalkylene oxide having a hydroxyl
group at one terminal thereof or the
derivative thereof (B) has a number
average molecular weight of from 200 to
100,000 and contains the ethylene oxide in
an amount of from 30 to 100 mol% and
wherein said gel-type polymer is
impregnated with an electrolytic solution
comprising an electrolytic salt and a non-
aqueous electrolytic solution, and wherein
said ethylene-unsaturated carboxylic acid
copolymer or the derivative thereof (A) –
has a composition containing ethylene in
an amount of from 50 to 98% by weight,
an unsaturated carboxylic acid or an
anhydride thereof in an amount of from 2
to 50% by weight, and other monomers in
an amount of from 0 to 30% by weight,
and wherein said ester bond is formed by
the esterification of a carboxylic acid
group of the ethylene-unsaturated
carboxylic acid copolymer with the
polyalkylene oxide having a hydroxyl
group at one terminal thereof or with a
derivative thereof.
_____________
]11[]21[
2069
155480
July 24, 2007– ‫ט' באב התשס"ז‬
]54[
FLAT SOFFIT, DOUBLY
PRESTRESSED, COMPOSITE,
ROOF-CEILING CONSTRUCTION
FOR LARGE SPAN
INDUSTRIAL BUILDINGS
]22[
]31[
]51[
]71[
]87[
]74[
02.10.2001
P20000906A
]32[ 28.12.2000
Int. Cl.8 E04B 007/08, E04C 003/293
MARA-INSTITUT D.O.O., CROATIA
WO/2002/053852
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
[57] A double prestressed, composite,
roof-ceiling construction with flat-soffit
construction for constructing large-span
buildings, the prestressed, composite, roofceiling construction with flat-soffit
comprising a wide and thin, finished,
centrally prestressed concrete soffit plate
(1) and two-part upper steel beam (2), the
two-part upper steel beam being connected
,‫מבנה תקרה–הגג עם תחתית שטוחה‬
,‫בעל הרכב מרוכב כלחץ מראש פעמיים‬
‫עבור מבני תעשיה בעלי ממתח גדול‬
]33[
HR
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
to the concrete soffit-plate by vertical
elements (3), the concrete soffit plate being
prestressed centrally, the two-part upper
steel beam being prestressed by a wedge
(7) located in a central gap in the two-part
upper steel beam and the wedge separating
the two steel parts at centrally located ends
of the two steel parts.
__________
July 24, 2007– ‫ט' באב התשס"ז‬
2070
]11[]21[
]54[
PALLET CONTAINER
]22[
]31[
]51[
]71[
18.08.2001
20018362.1
]32[ 26.10.2000
Int. Cl.8 B65D 077/06
MAUSER-WERKE GMBH & CO. KG,
GERMANY
WO/2002/034642
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
[57] Pallet container (10) having a thinwalled inner container (12) made of
thermoplastic material for the storage and
transportation of liquid or free-flowing
contents, having a tubular frame which is
made of metal bars and tightly encloses the
inner container as a supporting casing (14),
and having a base pallet (16), on which the
inner container rests and to which the
supporting casing is fixed, characterized in
that, for the case where a container is
dropped, special measures in the form of a
bending location, with reduction in the
2071
155579
‫מיכל על משטח‬
]33[
DE
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
tube cross section at certain
predeterminable locations, are taken only
in the vertical tubular bars (20) of the
supporting casing, these allowing plastic
deformation of the supporting casing
without individual tubular bars rupturing
or breaking off, in which case, in order to
produce the bending locations in the
vertical tubular bars of the two longer side
walls, shaped recesses (22) are formed in a
direction running parallel to the longer side
walls
July 24, 2007– ‫ט' באב התשס"ז‬
__________
]11[]21[
]54[
TENNIS BALL COLLECTING
AND STORING CART
]22[
]51[
]71[
]74[
06.05.2003
Int. Cl.8 A63B 047/00
ILAN SHERR
DANIEL FREIMANN & CO.,
5 DROYANOV ST. ,10TH FLOOR ,
TEL AVIV 63143
[57] A tennis ball collecting and storage
device comprising:
a receptacle (12) supported on castors
(16a-16d) at an elevated level; a chute-like
member (20) vertically mounted to the
receptacle, having a bottom opening
slightly less than the diameter of a tennis
ball, and an open top; the chute being
vertically displaceable between a first
position wherein the opening is located
July 24, 2007– ‫ט' באב התשס"ז‬
155796
‫עגלה לאיסוף ולאחסון כדורי טניס‬
‫ ראשון לציון‬,‫אילן שר‬
,'‫דניאל פריימן ושות‬
‫ תל אביב‬,10 ‫ בית כלל קומה‬5‫דרויאנוב‬
above the ground by a distance slightly
greater that the diameter of the ball, and a
second position wherein the opening
reaches down to the ground level; means
for selectively operating the chute between
the first and the second positions; and
means for rollingly guiding the balls piledup in the chute from the open top into the
receptacle.
2072
‫__________‬
‫ט' באב התשס"ז –‪July 24, 2007‬‬
‫‪2073‬‬
]11[]21[
155995
4 – ‫תהליך להכנת תרכובות של דיאריל‬
‫– אמינו – פיפרידיניל‬
]54[
PROCESS FOR THE PREPARATION
OF DIARYL - 4 - AMINOPIPERIDINYL COMPOUNDS
]22[
]31[
13.12.2001
PCT/SE00/02560 ]32[ 15.12.2000
]33[ WO
0101764-9
18.05.2001
SE
Int. Cl.8 C07D 211/58, 401/06, 405/06, 409/06, 413/06, 417/06
ASTRAZENECA AB, SWEDEN
ANDREW GRIFFIN
WO/2002/048108
LUZZATTO & LUZZATTO,
,‫לוצאטו את לוצאטו‬
INDUSTRIAL PARK, OMER,
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
P.O.B. 5352,
BEER-SHEVA 84152
]51[
]71[
]72[
]87[
]74[
[57] A process for the preparation of 1subsituted diaryl-4-amino-piperidinyl
compounds of the formula
wherein
R1 and R2 are independently selected from
the group consisting of hydrogen, hydroxy,
halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6
acyl, C1-C6 acyloxy, cyano, amino, nitro,
C1-C6 acylamino, C1-C6 alkylamino, (C1-C6
alkyl)2 amino, C1-C6 alkylthio, C1-C6
alkylsulfonyl, halogenated C1-C6 alkyl,
halogenated C1-C6 alkoxy, CO—NR8R9
and C1-C6 alkoxycarbonyl;
R3, R4, R5 and R6 are independently
selected from hydrogen and C1-C6 alkyl;
R7 is selected from the group consisting of
imidazolyl, thienyl, furanyl, pyrrolyl,
July 24, 2007– ‫ט' באב התשס"ז‬
thiazolyl, oxazolyl, pyridinyl, pyrazinyl,
pyrimidinyl and phenyl, all optionally and
independently mono-, di-, or tri-substituted
with a R' group;
R8 and R9 are independently selected from
hydrogen, C1-C6 alkyl, halogenated C1-C6
alkyl, phenyl, benzyl, all optionally and
independently mono-, di-, or tri-substituted
with a R" group; Ar—is phenyl, 1naphthyl or 2-naphthyl, each optionally
substituted with 0 to 3 R2 groups;
R' is independently selected from the
group consisting of hydroxy, halogen, C1C6 alkyl, C1-C6 alkoxy, C1-C6 acyl, C1-C6
2074
acyloxy, cyano, amino, nitro, C1-C6
acylamino, (C1-C6 alkyl)2 amino, C1-C6
alkylthio C1-C6 alkylsulfonyl, halogenated
C1-C6 alkyl, halogenated C1-C6 alkoxy;
R" is independently selected from the
group consisting of hydroxy; halogen, C1C6 alkyl, C1-C6 alkoxy, cyano, amino,
nitro, C1-C6 alkylthio, halogenated C1-C6
alkyl, halogenated C1-C6 alkoxy; and n is
1, 2, 3, 4, 5, 5 or 6; comprising the steps
of;
(A) a one-pot double arylation by (a)
reacting 4-amino piperidine of the formula
wherein R3 to R7, n, and R' are as
described above, with a first bromo
compound of the the formula
wherein R1, R8, R9, and R" are as described
above, in the presence of a strong base, a
palladium catalyst and a phosphine ligand
and (b) thereafter reacting the product of
reaction step(a) with second bromo
compound of the formula
R0-32-Ar-Br
wherein R , R , R , R" and Ar are as
1-substituted diaryl-4-amino-piperidinyl
described above; and a strong base to give
compounds of formula I.
1
8
9
__________
2075
July 24, 2007– ‫ט' באב התשס"ז‬
]11[]21[
]54[
HYBRID POWER SYSTEM FOR
CONTINUOUS RELIABLE POWER
AT REMOTE LOCATIONS
]22[
]31[
]51[
]71[
21.05.2003
10/152356
]32[ 22.05.2002
Int. Cl.8 F01K 001/00, 023/10
ORMAT TECHNOLOGIES INC.,
U.S.A.
Y. BECK,
P.O.BOX 68 YAVNE, ISRAEL
]74[
[57] A hybrid ultra reliable power
generating system comprising:
(a) a primary power unit producing electric
power that is supplied to a load; and
(b) a secondary power unit in the form of a
closed cycle vapor turbine (CCVT) system
that is capable of producing 100% of the
electric power that is produced by the
primary power unit and which is heated in
156048
‫מערכת לאספקה קבועה ואמינה של כח‬
‫למקומות מרוחקים המבססת על שני‬
‫אמצעי המרת אנרגיה חלופיים‬
]33[
US
,‫יונה בק‬
‫ יבנה‬86 .‫ד‬.‫ ת‬,‫אורמת תעשיות בע"מ‬
hot standby by rejected heat of the primary
power unit, wherein the vaporizer of the
CCVT is maintained during hot standby at
a temperature above its nominal operating
temperature and the vapor turbine of the
CCVT is maintained at idle hot standby at
a rotating speed above its nominal rotating
speed.
___________
July 24, 2007– ‫ט' באב התשס"ז‬
2076
]11[]21[
]54[
INSULATED BEVERAGE OR
FOOD CONTAINER
]22[
]31[
07.06.2002
60/298386
]32[ 18.06.2001
923332
08.08.2001
Int. Cl.8 B32B 027/10, B65D 081/38
APPLETON PAPERS INC., U.S.A.
WO/2002/102682
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]51[
]71[
]87[
]74[
[57] An insulated beverage container
comprising:
a container wall (1) having an upper side
portion (7), a lower side portion (8), and a
bottom portion (9) engaging said lower
side portion to define a beverage
containing space (11) inside the container
wall (1);
wherein said container wall comprises: a
paper stock layer (2) arranged along an
exterior surface of said container wall; a
laminated or extruded foam layer (3)
arranged inside said paper stock layer; and
a thin polyethylene film layer (4) also
2077
156108
‫מיכל מקודד עבור מזון או משקה‬
]33[
US
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
arranged inside said paper stock layer, and
wherein either:
(A) the foam layer forms the innermost
layer of the container wall and the thin
polyethylene film layer is sandwiched
between the foam layer and the paper stock
layer; or
(B) the thin polyethylene film layer is
applied onto the surface of the foam layer
such that the layer is sandwiched between
the paper stock layer and the thin
polyethylene film layer whereby the thin
polyethylene film layer forms the
innermost layer of the container wall.
July 24, 2007– ‫ט' באב התשס"ז‬
___________
]11[]21[
]54[
TRIBOLOGICAL DEBRIS
ANALYSIS SYSTEM
]22[
]31[
]51[
]71[
27.05.2003
162380
]32[ 04.06.2002
Int. Cl.8 G01N 015/02
LOCKHEED MARTIN
CORPORATION, U.S.A.
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]74[
[57] A tribological debris analysis system
comprising:
a general purpose computer (16); and
a tribological sensor system for placing a
fluid in a field of view and generating data,
said sensor system comprising:
an optical flow cell (24); a fluid delivery
system (20, 22) for delivering said fluid to
said optical flow cell; a laser (26) for
illuminating the fluid flowing through said
optical flow cell; and an imaging device
(14) for collecting imagery information of
July 24, 2007– ‫ט' באב התשס"ז‬
156143
‫מערכת בדיקה לנוכחות חלקיקי מתכת‬
‫זעירים‬
]33[
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
debris in the fluid illuminated by said laser
and generating a digital video signal, said
imaging device having an internal field
programmable gate array for receiving said
video signal and for processing said
imagery information and generating object
segments comprising a contiguous group
of pixels in a row which are collectively
representative of the debris, said field
programmable gate array sending said
object segments to said general purpose
computer for analysis.
2078
____________
]11[]21[
]54[
LIQUID FUEL COMPOSITIONS
FOR ELECTROCHEMICAL FUEL
CELLS
]22[
]31[
]51[
]71[
]72[
03.01.2002
09/752551
]32[ 03.01.2001
Int. Cl.8 C10L 001/00, H01M 008/04
MORE ENERGY LTD.
GENNADI FINKELSHTAIN, YURI
KATSMAN, BORIS FILANOVSKY
]87[
]74[
WO/2002/054506
DR. MARK FRIEDMAN LTD.,
MOSHE AVIV TOWER, 54TH
FLOOR
7 JABOTINSKY STREET
52520
RAMAT GAN
[57] A fuel composition for use in an
electrochemical fuel cell, comprising:
(a) a primary fuel including at least one
surface-active compound;
(b) an auxiliary fuel including at least one
hydrogen-containing compound with a
reduction potential such that a
156624
‫הרכבי ד לק נוזלי עבור תאי‬
‫אלקטרוכימיים‬
]33[
US
‫ לוד‬,‫מור אנרגיה בע"מ‬
‫ בוריס‬,‫ יורי קצמן‬,‫גנדי פינקלשטיין‬
‫פילנובסקי‬
,‫ד"ר מרק פרידמן בע"מ‬
,77 ‫ ז'בוטינסקי‬54 ‫ קומה‬,‫מגדל משה אביב‬
‫ גן‬-‫רמת‬
thermodynamic reversible potential of an
electrochemical cell including said
compound at an anode and an oxygen
cathode is greater than or equal to 1.56 V;
(c) an electrolyte with a pH about 7; and
(d) at least one additional compound.
__________
2079
July 24, 2007– ‫ט' באב התשס"ז‬
]11[]21[
]54[
PENETRATION-RESISTANT
MATERIAL COMPRISING
FABRIC WITH HIGH LINEAR
DENSITY RATIO OF TWO SETS
OF THREADS
]22[
]31[
]51[
]71[
08.03.2002
01200979.1
]32[ 15.03.2001
Int. Cl.8 F41H 001/02
TEIJIN TWARON GMBH,
GERMANY
WO/2002/075238
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
[57] A penetration-resistant material
comprising at least a double layer of
woven fabric, wherein the double layer
comprises: a first layer of fabric composed
of: a first set of threads comprising 3.5 to
20 threads/cm, having a linear density of at
least 210 dtex, and at least 65% of the
fabric weight, and a second set of threads
comprising 0.5 to 16 threads/cm and
having a linear density of at least 50 dtex,
with the second set of threads being
transverse to the first set of threads, and
the ratio of the number of threads/cm of
the first set to that of the second set is
greater than 1:1; and a second layer of
fabric composed of: a first set of threads
156645
‫חומר עמיד לחדירה המכיל אריג בעל יחס‬
‫צפיפות לינארי של שתי מערכות של‬
‫חוטים‬
]33[
EP
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
comprising 0.5 to 16 threads/cm and
having a linear density of at least 50 dtex;
and a second set of threads comprising 3.5
to 20 threads/cm, having a linear density of
at least 210 dtex, and comprising at least
65% of the fabric weight, with the second
set of threads being transverse to the first
set of threads, and the ratio of the number
of threads/cm of the second set to that of
the first set is greater than 1:1, and wherein
the first and second sets of threads of the
first layer have a parallel orientation
towards the first and second sets,
respectively, of threads of the second
layer.
_____________
July 24, 2007– ‫ט' באב התשס"ז‬
2080
]11[]21[
]54[
PESTICIDAL AND
ANTIPARASITIC COMPOSITIONS
]22[
]31[
]51[
]71[
17.12.2001
20010004
]32[ 03.01.2001
Int. Cl.8 A01N 063/00
CENTRO DE INGENIERIA
GENETICA Y BIOTECNOLOGIA,
CUBA
WO/2002/052934
EITAN, PEARL, LATZER AND
COHEN ZEDEK,
P.O.B. 12688,
HERZLIYA 46733
]87[
]74[
[57] A composition for agricultural and
veterinary use that comprises at least one
chitinolytic agent or a chitinolytic activity-
156700
‫רכיבים להדברת מזיקים וטפילים‬
]33[
CU
,‫ לצר וכהן צדק‬,‫ פרל‬,‫איתן‬
‫ הרצליה‬,12688 .‫ד‬.‫ ת‬, 7 ‫רחוב שנקר‬
inducing agent, and sulfide or a sulfideproducing agent.
_____________
]11[]21[
]54[
PROCESS FOR PREPARING THE
L – TARTRATE SALT OF (3AR) –
2, 3A, 4, 5, 6, 7 – HEXAHYDRO – 2 –
METHYL – 3A (PHENYLMETHYL) – 3H –
PYRAZOLO [4,3-C] PYRIDIN – 3 –
ONE
]22[
]31[
]51[
]62[
]71[
]74[
17.02.2000
60/122745
]32[ 26.02.1999
Int. Cl.8 C07K 005/023
DIVISION FROM 134599
PFIZER PRODUCTS, INC., U.S.A.
LUZZATTO & LUZZATTO,
INDUSTRIAL PARK, OMER,
P.O.B. 5352,
BEER-SHEVA 84152
157103
aR) 3( ‫תהליך להכנת מלח הטרטראט של‬
‫ – מתיל‬2 – ‫ – – הקסאהידרו‬2, 3a, 4, 5, 6, 7
] c–3,4[ ‫ – פיראזולו‬H3 – )‫ (פנילמתיל‬a3 –
‫ – און‬3 – ‫פירידינ‬
]33[
US
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
[57] A process for preparing a L-tartrate
salt of formula XX,
2081
July 24, 2007– ‫ט' באב התשס"ז‬
comprising the following consecutive
steps:
(a) reacting 4-oxo-piperidine-3-carboxylic
acid methyl ester, hydrocholoride with d-tbutyl-dicarbonate and triethylamine in
isopropyl ether to form 4-oxo-1,3piperidinedicarboxylic acid 1-(1,1dimethylethyl) 3-methyl ester;
(b) reacting said 4-oxo-1,3piperidinedicarboxylic acid 1-(1,1dimethylethyl) 3-methyl ester with benzyl
bromide and potassium carbonate in
tetrahydrofuran to form 4-oxo-3(phenylmethyl)-1,3-piperidinedicarboxylic
acid 1-(1,1-dimethylethyl) 3-methyl ester;
(c) reacting said 4-oxo-3-(phenylmethyl)1,3-piperidinedicarboxylic acid 1-(1,1dimethylethyl) 3-methyl ester with
methylhydrazine in acetic acid and methylt-butyl ether to form 2,3a,4,5,6,7hexahydro-2-methyl-3-oxo-3a(phenylmethyl)-3H-pyrazolo[4,3c]pyridine-4-carboxylic acid 1,1dimethylethyl ester; and
(d) reacting said 2,3a, 4,5,6,7-hexahydro2-methyl-3-oxo-3a- (phenylmethyl)-3Hpyrazolo[4,3-c] pyridine-5-carboxylic acid
1,1-dimethylethyl ester with trifluoroacetic
acid to form (3aR)-2,3a, 4, 5, 6, 7hexahydro-2-methyl-3a-(phenylmethyl)3H-pyrazolo[4,3-c] pyridine-3-one;
(e) reacting said (3aR)-2,3a, 4, 5, 6, 7hexahydro-2-methyl-3a- (phenylmethyl)3H-pyrazolo[4,3-c] pyridine-3-one with Ltartaric acid in acetone and water to form
said L-tartrate salt of formula XX.
__________
July 24, 2007– ‫ט' באב התשס"ז‬
2082
]11[]21[
]54[
STABILIZED HYPOBROMOUS
ACID SOLUTIONS
]22[
]31[
01.03.2002
2001/1795
]32[ 02.03.2001
2001/6301
31.07.2001
Int. Cl.8 C01B 011/00
MILBRIDGE INVESTMENTS (PTY)
LTD., SOUTH AFRICA
JAN BASTIAAN CILLIERS,
MARTHA SOPHIA CILLIERS
WO/2002/070404
JEREMY M. BEN-DAVID & CO.
LTD.,
HAR HOTZVIM HI-TECH PARK,
P.O.B. 45087,
JERUSALEM 91450
]51[
]71[
]72[
]87[
]74[
[57] A method for preparing a stabilized
stock hypobromous acid solution including
the following step: preparing a
hypochlorous acid solution with a pH of
less than 7,5; preparing a bromide solution
with a pH of less than 7.0; mixing the
157717
‫תמיסות חומצת היפוברומית מיוצבות‬
]33[
ZA
ZA
,‫דוד ושות' בע"מ‬-‫ בן‬.‫ירמיהו מ‬
,45087 .‫ד‬.‫ ת‬, ‫ הר חוצבים‬,‫רחוב המרפא‬
‫ירושלים‬
hypochlorous acid solution with the
bromide solution to form a hypobromous
acid solution; and immediately adding
stabilizer to the solution to provide a
stabilized stock hypobromous acid solution
with a pH of from 8 to 9.
_____________
]11[]21[
]54[
RECHARGEABLE ZINC
ELECTRODE
]22[
]31[
]51[
]71[
15.03.2002
510554
]32[ 15.03.2001
Int. Cl.8 H01M 004/60
MASSEY UNIVERSITY, NEW
ZEALAND
WO/2002/075830
SANFORD T.COLB & CO.,
P.O.B. 2273,
REHOVOT
]87[
]74[
[57] A rechargeable zinc electrode
including an active composition
comprising at least:
(a) a source of zinc capable of being
repeatedly cycled between an oxidized and
2083
157862
‫אלקטרודת אבץ הניתנת לטעינה מחדש‬
]33[
NZ
,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
a reduced state; and
(b) at least one compound selected from
the group consisting of C6-C30 fatty acids,
salts, esters and other derivatives thereof,
July 24, 2007– ‫ט' באב התשס"ז‬
and C6-C30 alkyl sulfonic acids, salts,
esters and other derivatives thereof.
___________
]11[]21[
]54[
METHOD OF TREATING
ATMOSPHERIC POLLUTANTS
]22[
]31[
]51[
]71[
15.05.2002
0111801.7
]32[ 15.05.2001
Int. Cl.8 B01D 053/60, B01J 023/80
JOHNSON MATTHEY PUBLIC
LIMITED COMPANY, UNITED
KINGDOM
WO/2002/092197
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
[57] A method of treating atmospheric
pollutants, which method comprises
contacting a first reducing agent with the at
least one atmospheric oxidizing pollutant
and contacting the gas leaving the first
reducing agent with at least one second
reducing agent for reducing at least one
atmospheric oxidizing pollutant, wherein
the first reducing agent comprises a
precious metal-free trap material including
at least one trapped atmospheric reducing
158439
‫שיטה לטיפול במזהמים אטמוספריים‬
]33[
GB
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
pollutant coated on a heat exchanged
device and wherein the at least one second
reducing agent comprises a manganesebased reducing agent, one or more
precious metals, copper, zinc, iron or a
mixture of any two or more of copper, zinc
and iron, whereby as the at least one
atmospheric oxidizing pollutant is reduced
the at least one trapped atmospheric
reducing pollutant is oxidized.
__________
]11[]21[
July 24, 2007– ‫ט' באב התשס"ז‬
158490
2084
]54[
PROCESS FOR THE
STEREOSELECTIVE
PREPARATION OF
INSECTICIDE 6,7,8,9,10, 10 –
HEXAHALO – 1,5,5A,6,9,9A –
HEXAHYDRO – 6,9 – METHANO
– 2,4,3 – BENZODIOXATHIEPIN –
3 – OXIDE
]22[
]51[
]71[
24.04.2001
Int. Cl.8 C07D 327/00, 327/10
EXCEL INDUSTRIES LIMITED,
INDIA
ASHWIN CHAMPRAJ SHROFF,
ABHIJIT PREMVALLABH
PUROHIT, SANJAY DHIRAJLAL
VADORARIA
WO/2002/085884
JEREMY M. BEN-DAVID & CO.
LTD.,
HAR HOTZVIM HI-TECH PARK,
P.O.B. 45087,
JERUSALEM 91450
]72[
]87[
]74[
‫תהליך להכנה סטריוסלקטיבית של מדביר‬
– ‫ – הקסאהלו‬6,7,8,9,10,10 – ‫החרקים‬
‫ – מתנו‬6 ,9 – ‫ – הקסאהידרו‬A,6,9,9A1,5,5
‫ – תחמוצת‬3 – ‫ – בנזודיוקסאתיאפינ‬2,4,3 –
,‫דוד ושות' בע"מ‬-‫ בן‬.‫ירמיהו מ‬
,45087 .‫ד‬.‫ ת‬, ‫ הר חוצבים‬,‫רחוב המרפא‬
‫ירושלים‬
[57] A process for the stereoselective
preparation of insecticide 6,7,8,9,10,10hexahalo-1,5,5a, 6,9,9a-hexahydro-6,9-
methano-2,4,3-benzodioxathiepin-3-oxide
of the formula
wherein X is a halogen selected from
fluorine, chlorine or bromine, comprising
reacting 1, 4, 5, 6, 7, 7-hexahalo-5norbornene-2,3-dimethanol of the formula
2085
July 24, 2007– ‫ט' באב התשס"ז‬
wherein X is a halogen selected from
fluorine, chlorine or bromine, with a cyclic
sulfite ring forming reagent optionally in
an inert organic solvent at ambient to 139o
C, wherein the reaction is carried out in the
presence of a stereoisomer directing agent
comprising an isomer of the compound of
the formula I different from the desired
isomer, the molar ratio of the stereoisomer
directing agent to the dimethanol
compound of the formula IV at least 0.07.
__________
]11[]21[
]54[
BRAKE CONTROL SYSTEM
DEFINED BY FIELD
PROGRAMABLE GATE ARRAY
]22[
]31[
]51[
]71[
25.02.2003
60/359867
]32[ 25.02.2002
Int. Cl.8 B60T 008/88, 017/18
AIR-CRAFT BRAKING SYSTEMS
CORPORATION, U.S.A.
WO/2003/072408
DR. SHLOMO COHEN & CO.,
124 IBN GABIROL ST.,
P.O.B. 11490,
TEL AVIV 62038
]87[
]74[
[57] A brake control system (10) for a
wheeled vehicle, comprising: a field
programmable gate array (12) configured
to perform an algorithm of brake control
subsystems taken from the group
comprising anti-skid control, nosewheel
steering, brake temperature monitoring,
and built-in tests; a wheel speed interface
(14) interposed between wheel speed
transducers of said wheeled vehicle and
July 24, 2007– ‫ט' באב התשס"ז‬
158541
‫מערכת בקרת בלם המוגדרת באמצעות‬
‫מערך שערים שניתן לתכנות בשדה‬
]33[
US
,'‫ד"ר שלמה כהן ושות‬
‫ תל אביב‬,11490 .‫ד‬.‫ ת‬, 124 ‫אבן גבירול‬
said field programmable gate array for
presenting signals to said field
programmable array corresponding to
instantaneous wheel speed; and a brake
temperature interface (16) interposed
between brakes of said vehicle and said
field programmable gate array and
providing signals corresponding to brake
temperature.
2086
_____________
]11[]21[
159891
‫או‬/‫חומר המבוסס על סיבים אורגניים ו‬
‫אנאורגנים ועל כיטוזן לשימוש לקיבוע של‬
‫איונים מתכתיים‬
]54[
MATERIAL BASED ON ORGANIC
AND/OR INORGANIC FIBERS
AND CHITOSAN FOR USE IN
FIXING METAL IONS
]22[
]31[
]51[
]71[
15.07.2002
01/09949
]32[ 25.07.2001
]33[ FR
Int. Cl.8 B01D 015/00, B01J 045/00, C02F 001/28
AHLSTROM CORPORATION,
FINLAND
WO/2003/009939
SANFORD T.COLB & CO.,
,'‫ קולב ושות‬.‫סנפורד ט‬
P.O.B. 2273,
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
REHOVOT
]87[
]74[
[57] A material based on organic and/or
inorganic fibres and chitosan manufactured
by means of a paper-machine process, for
use in fixing metal ions contained in an
effluent, characterised in that the chitosan
represents between 0.01 and 20% by dry
weight of fibres and that its degree of
deacetylation is higher than 90%.
___________
]11[]21[
2087
159990
July 24, 2007– ‫ט' באב התשס"ז‬
]54[
DEVICE, METHOD AND SYSTEM
FOR THE APPLICATION OF
CONTENT ONTO THE SURFACE
OF A BEVERAGE
]22[
]51[
]71[
21.01.2004
Int. Cl.8 A23L 001/27, A47G 019/14
EYAL ELIAV
DANNY LAVIE
]74[
NAOMI ASSIA & CO. LAW
OFFICES,
32 HABARZEL ST.
RAMAT HACHAYAL
TEL AVIV 69710
[57] A content application system for
applying content onto the surface of a
beverage comprising:
(a) a computing device adapted to receive
a baring signal from a distributed data
network; and
‫ מכשיר ומערכת להטבעת תוכן על‬,‫שיטה‬
‫פני שטחו של משקה‬
‫ תל אביב‬,‫אייל אליאב‬
‫ רמת השרון‬,‫דני לביא‬
,‫נעמי אסיא ושות' משרד עורכי דין‬
‫אביב‬-‫ תל‬,‫ רמת החייל‬32 ‫רח' הברזל‬
(b) a contenting application head adapted
to apply the received content by agitating
the surface of the beverage in a pattern
correlated to the content.
__________
]11[]21[
July 24, 2007– ‫ט' באב התשס"ז‬
160153
2088
–‫שיטות להכנת חומצה כלורית וכלור‬
‫דיאוקסיד‬
]54[
METHODS FOR MAKING
CHLOROUS ACID AND
CHLORINE DIOXIDE
]22[
]31[
]51[
]71[
29.07.2002
09/919918
]32[ 02.08.2001
]33[
Int. Cl.8 B01J 039/04, C01B 011/02, 011/08
RICHARD SAMPSON, U.S.A.
ALLISON SAMPSON, U.S.A.
]87[
]74[
WO/2003/011750
DR. MARK FRIEDMAN LTD.,
MOSHE AVIV TOWER, 54TH
FLOOR
7 JABOTINSKY STREET
52520
RAMAT GAN
[57] A process for generating chlorous
acid which comprises contacting a chlorite
salt solution with a cation exchange
material in the hydrogen form in a moist
environment for a time sufficient to effect
US
,‫ד"ר מרק פרידמן בע"מ‬
,77 ‫ ז'בוטינסקי‬54 ‫ קומה‬,‫מגדל משה אביב‬
‫ גן‬-‫רמת‬
an essentially complete substitution of
cations in the chlorite salt with hydrogen
ions on the cation exchange material to
form chlorous acid.
___________
]11[]21[
]54[
PRINTING CARTRIDGE WITH
BARCODE IDENTIFICATION
]22[
]31[
]51[
]71[
09.07.2002
09/922158
]32[ 06.08.2001
Int. Cl.8 B41J 002/175
SILVERBROOK RESEARCH PTY.
LTD., AUSTRALIA
WO/2003/013866
LUZZATTO & LUZZATTO,
INDUSTRIAL PARK, OMER,
P.O.B. 5352,
BEER-SHEVA 84152
]87[
]74[
[57] A printing cartridge (1230) that is
releasably engageable with a printing
device having a linear reader (1236) for
reading a barcode and a central processor
capable of interpreting data carried on a
barcode, the printing cartridge comprising
a housing (1234); a media supply
2089
160172
‫מחסנית הדפסה עם זיהוי ברקוד‬
]33[
US
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
arrangement positioned within the housing
and containing a supply of media; a feed
mechanism positioned in the housing for
feeding the media to a printing
mechanism; and a barcode (1232) depicted
on the housing, the barcode being readable
July 24, 2007– ‫ט' באב התשס"ז‬
by the linear reader and defining a code
representing data relating to the media.
___________
]11[]21[
]54[
KEYBOARD
]22[
]31[
]51[
]71[
06.08.2002
09/966293
]32[ 28.09.2001
Int. Cl.7 B41J 003/44
SILVERBROOK RESEARCH PTY.
LTD., AUSTRALIA
WO/2003/029012
LUZZATTO & LUZZATTO,
INDUSTRIAL PARK, OMER,
P.O.B. 5352,
BEER-SHEVA 84152
]87[
]74[
[57] A keyboard (10) which includes a
housing (12); an alphanumeric keypad (14)
carried by the housing, the keypad
including key switches mounted on a
circuit board; a page width printer
arranged in the housing; and a feed
July 24, 2007– ‫ט' באב התשס"ז‬
161088
‫מקלדת‬
]33[
US
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
mechanism for feeding sheets (24) from an
input slot (22) to the printer, the feed
mechanism being positioned between the
circuit board and an underside of the
housing.
2090
____________
]11[]21[
]54[
DUPLEX STAINLESS STEEL
]22[
]31[
]51[
]71[
]87[
]74[
20.03.2002
981074
]32[ 16.10.2001
Int. Cl.8 C21D 009/00, C22C 038/44
ATI PROPERTIES, INC., U.S.A.
WO/2003/033755
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
[57] A duplex stainless steel comprising,
in weight percent: up to 0.06 percent
carbon; 15 up to 22.5 percent chromium;
greater than 3 up to less than 4 percent
nickel; up to 3.75 percent manganese; 0.14
up to 0.35 percent nitrogen; up to 2 percent
silicon; greater than 1.4 up to less than 2.5
161175
‫חלד דו שכבתית‬-‫פלדת אל‬
]33[
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
percent molybdenum; up to less than 0.5
percent copper; up to less than 0.2 percent
cobalt; up to 0.05 percent phosphorus; up
to 0.005 percent sulfur; 0.001 up to 0.0035
percent boron; iron and incidental
impurities.
__________
2091
July 24, 2007– ‫ט' באב התשס"ז‬
]11[]21[
]54[
DUPLEX STAINLESS STEELS
]22[
]31[
]51[
]71[
]87[
]74[
01.03.2002
012908
]32[ 30.10.2001
Int. Cl.8 C21D 009/00, C22C 038/40
ATI PROPERTIES, INC., U.S.A.
WO/2003/038136
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
[57] A duplex stainless steel comprising,
in weight percent: up to 0.06 percent
carbon; 15 to less than 19 percent
chromium; 1 to less than 2 percent nickel;
greater than 2 percent up to 3.75 percent
manganese; greater than 0.12 up to 0.35
161289
‫שכבתית‬-‫חלד דו‬-‫פלדת אל‬
]33[
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
percent nitrogen; up to 2 percent silicon;
up to 1.5 percent molybdenum; up to 0.5
percent copper; up to 0.2 percent cobalt;
up to 0.05 percent phosphorus; up to 0.005
percent sulfur; up to 0.03 percent boron;
iron and incidental impurities.
__________
]11[]21[
161841
‫–אמינו–תיאזולין והשימוש בהן‬2‫נגזרות‬
‫ סינטאז בר–השראה‬NO – ‫כמעכבות‬
]54[
2-AMINO-THIAZOLINE
DERIVATIVES AND THEIR USE
AS INHIBITORS OF INDUCIBLE
NO-SYNTHASE
]22[
]31[
07.11.2002
01/14510
]32[ 09.11.2001
]33[ FR
60/352797
30.01.2002
US
Int. Cl.8 A61K 031/4439, 031/497, 031/506, A61P 025/00, 025/16, C07D 265/00,
265/06, 417/06, 417/12, 417/14
AVENTIS PHARMA S.A., FRANCE
WO/2003/040115
EITAN, PEARL, LATZER AND
,‫ לצר וכהן צדק‬,‫ פרל‬,‫איתן‬
COHEN ZEDEK,
‫ הרצליה‬,12688 .‫ד‬.‫ ת‬, 7 ‫רחוב שנקר‬
P.O.B. 12688,
HERZLIYA 46733
]51[
]71[
]87[
]74[
[57] Compounds of the formula
July 24, 2007– ‫ט' באב התשס"ז‬
2092
in which
either Y is a methylene (CH2) and X is
selected from the following groups: O, H,
N-(C1-C4) alkyl, N-Bn, N-Ph, N-(2-Py), N(3-Py), N-(4-Py), N-2-pyrimidyl, N-5pyrimidiyl, S, SO, SO2, CH2 or CHPh;
or Y is a carbonyl (C=O) and X is selected
from the following groups: NH, N-Ph, N(2-Py), N-(3-Py), N-(4-Py), N-2pyrimidiyl or N-5-pyrimidiyl
with the proviso that the (C1-C4) alkyl
radicals contain 1 to 4 carbons in a straight
or branched chain wherein the
abbreviations Bn, Py and Ph signify
benzyl, pyridyl and phenyl respectively,
their racemic mixtures, enantiomers,
diastereoisomers and mixtures thereof,
their tautomers and their pharmaceutically
acceptable salts.
_____________
]11[]21[
162871
‫ מוצר‬,‫שיטה להכנת מוצר תחליף לבשר‬
‫תחליף לבשר אשר הוכן לפי השיטה ומוצר‬
‫תחליף לבשר מוכן לאכילה‬
]54[
METHOD FOR THE
PREPARATION OF A MEAT
SUBSTITUTE PRODUCT, MEAT
SUBSTITUTE PRODUCT
OBTAINED WITH THE METHOD
AND READY TO CONSUME
MEAT SUBSTITUTE PRODUCT
]22[
]31[
]51[
]71[
17.09.2002
1019816
]32[ 22.01.2002
]33[ NL
Int. Cl.8 A23J 003/08, 003/22, A23L 001/0532, 001/059
NUG NAHRUNG-UND
GENUSSMITTEL
VERTRIEBSGESELLSCHAFT MBH,
GERMANY
WO/2003/061400
DVORA GADOR,
‫ גדור‬,‫בלום‬
‫דבורה גדור עו"ד‬
DERECH HASHLOM 53,
,'‫ושות‬
GIVATAYIM 53454
‫ קומה‬,53 ‫ גדור ושות' דרך השלום‬,‫בלום‬
‫ גבעתיים‬,23
]87[
]74[
[57] Method for the preparation of a meat
substitute product which comprises
protein, wherein:
(1) a protein material, a hydrocolloid
which precipitates with metal cations and
water are added to one another,
(2) the composition from step (1) is formed
2093
into a homogeneous mixture,
(3) the mixture from (2) is mixed with a
solution of metal cation with a valency of
at least 2, in order to form a fibrous
product,
(4) the fibrous product is isolated,
characterized in that
July 24, 2007– ‫ט' באב התשס"ז‬
(5) the protein material comprises a milk
protein material, and
(6) the mixture of milk protein material,
hydrocolloid which precipitates with metal
cations and water is formed in the presence
of an amount of a calcium complexforming agent.
,182324
The applications for division
from this application have
not yet been published
‫בקשות חלוקה מבקשה זו‬
.‫שטרם פורסמו‬
__________
]11[]21[
163061
‫מערכת בריאות מקוונת ושיטה לניהולה‬
]54[
SYSTEM AND METHOD FOR
ADMINISTRATION OF ON-LINE
HEALTHCARE
]22[
]51[
]71[
]72[
]74[
15.07.2004
Int. Cl.8 A61B 001/00, 005/00, A61N 005/00
MED DYNAMICS LTD.
AVNER MAN, AVNER AMIR
DR. EYAL BRESSLER,
11 TOVAL ST.
RAMAT GAN 52522
[57] A healthcare administration system
useful for the management of anamnesis
and medical records, data analysis, guided
diagnosis, medical treatment, and clinical
investigation; said system comprising:
(a) a plurality of self-sufficient subsystems
(12, 13, 14, 15, 16) adated to record, store,
share, clinically investigate and analyze
information by means of a common
medical information protocol (CMIP) (17);
(b) at least one end-unit device (11)
adapted to diagnose and/or treat patients,
July 24, 2007– ‫ט' באב התשס"ז‬
‫ מגדל העמק‬,‫מדדינמיקס בע"מ‬
‫ אבנר עמיר‬,‫אבנר מן‬
,‫דר' אייל ברסלר עו"פ‬
‫ רמת – גן‬,11 ‫תובל‬
in communication with a subsystem for
controlling, monitoring and recording the
treatment process and its outcome by
means of a medical protocol;
(c) a least one module adapted for a CMIP;
wherein said end-unit device is guided by
said CMIP so that anamnesis, diagnosis
and targeted treatment is dictated,
provided, monitored, recorded and/or
clinically investigated.
2094
___________
]11[]21[
163486
‫התקן הניתן להפעלה בריבוי ברמות ביצוע‬
‫ושיטה למדידת שימושו‬
]54[
DEVICE OPERABLE AT A
PLURALITY OF PERFORMANCE
LEVELS AND A METHOD OF
METERING ITS USAGE
]22[
]31[
]51[
]71[
12.02.2003
PS0481
]32[ 13.02.2002
]33[ AU
Int. Cl.7 B41F 031/02, 033/02, B41J 029/38, B41L 039/02, G07C 003/00
SILVERBROOK RESEARCH PTY.
LTD., AUSTRALIA
WO/2003/068517
LUZZATTO & LUZZATTO,
,‫לוצאטו את לוצאטו‬
INDUSTRIAL PARK, OMER,
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
P.O.B. 5352,
BEER-SHEVA 84152
]87[
]74[
[57] A device (100) operable at a
plurality of different performance levels,
the device including a metering system
(118) configured to measure usage of the
device in units of use, configured such that
2095
the number of units metered for
performing a particular task of the device
is varied in reliance on a level of
performance of the device for that task.
July 24, 2007– ‫ט' באב התשס"ז‬
_________
]11[]21[
]54[
PHARMACEUTICAL
FORMULATION OF IRESSA
COMPRISING A WATERSOLUBLE CELLULOSE
DERIVATIVE
]22[
]31[
24.02.2003
0204392.5
]32[ 26.02.2002
0212462.6
30.05.2002
0213267.8
11.06.2002
Int. Cl.8 A61K 047/38
ASTRAZENECA AB, SWEDEN
PAUL RICHARD GELLERT,
MICHAEL DAVIS PARKER,
MARCEL DE MATAS
WO/2003/072139
S. HOROWITZ & CO.,
ZION HOUSE,
41-45 ROTHSCHILD BLVD.,
TEL AVIV 65784
]51[
]71[
]72[
]87[
]74[
[57] A pharmaceutical composition
comprising 4-(3'-chloro-4'-fluoroanilino)7-methoxy-6-(3-morpholinopropoxy)
quinazoline or a pharmaceuticallyacceptable salt thereof and a water-soluble
cellulose ether or an ester of a water-
163642
‫תכשיר רוקחות של אירסה המכיל נגזרת‬
‫תאית מסיסה במים‬
]33[
GB
GB
GB
,'‫ הורוביץ ושות‬.‫ש‬
‫ תל‬,41-45 ‫ שדרות רוטשילד‬,‫בית ציון‬
‫אביב‬
soluble cellulose ether. The water-soluble
cellulose ether is preferably selected from
hydroxyethylcellulose,
hydroxypropylcellulose, hydroxypropyl
methyl cellulose and a water-soluble salt
of carboxymethylcellulose.
___________
July 24, 2007– ‫ט' באב התשס"ז‬
2096
]11[]21[
]54[
METHOD FOR REDUCING
SULFUR CONTENT OF
CARBONACEOUS MATERIALS
]22[
]31[
]51[
]71[
05.03.2003
PS0911
]32[ 05.03.2002
Int. Cl.8 C01B 031/02, C10L 009/02
KARALEE RESEARCH PTY LTD.,
AUSTRALIA
WO/2003/074639
SANFORD T.COLB & CO.,
P.O.B. 2273,
REHOVOT
]87[
]74[
[57] A process for reducing the amount of
sulfur-containing impurities in
carbonanceous materials, comprising
(a) contacting said materials with an
aqueous solution of hydroflurosilicic acid
in the absence of hydrogen fluoride under
163835
‫שיטה להפחתת כמות גפרית בחומרים‬
‫פחמניים‬
]33[
AU
,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
conditions wherein at least some of said
sulfur-containing impurities react with said
hydrofluorosilicic acid to form reaction
products, and
(b) separating said reaction products from
said carbonanceous materials.
_____________
]11[]21[
]54[
MOTION TRANSMITTING
STRUCTURE FOR A NOZZLE
ARRANGEMENT OF A
PRINTHEAD
]22[
]31[
]51[
]71[
13.06.2002
10/120347
]32[ 12.04.2002
Int. Cl.8 B41J 002/14
SILVERBROOK RESEARCH
PTY.LTD., AUSTRALIA
WO/2003/086769
LUZZATTO & LUZZATTO,
INDUSTRIAL PARK, OMER,
P.O.B. 5352,
BEER-SHEVA 84152
]87[
]74[
[57] A printhead chip for an inkjet
printhead, the printhead chip comprising:
a substrate; and a plurality of nozzle
arrangements (100) positioned on the
2097
164503
‫מבנה שידור תנועה לסידור נחיר של שבב‬
‫ראש הדפסה למדפסת הזרקת דיו‬
]33[
US
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
substrate (32), each nozzle arrangement
comprising: a nozzle chamber structure
that defines a nozzle chamber (106) in
which ink is received; an ink-ejecting
July 24, 2007– ‫ט' באב התשס"ז‬
member (140) that is positioned in the
nozzle chamber and is displaceable in the
nozzle chamber to eject ink from the
nozzle chamber; at least one actuator (148)
that is positioned on the substrate, the, or
each, actuator having a working position
that is displaceable with respect to the
substrate when the actuator receives a
drive signal; a sealing structure (130) that
is positioned on the substrate and is
interposed between the, or each, actuator
and the ink-ejecting member to inhibit a
passage of ink between the ink-ejecting
member and actuator; and a motion
transmitting structure (122) that bridges
the sealing structure, the motion
transmitting structure comprising an effort
formation (124) that is connected to the
working portion (156) of the actuator, a
load formation that is connected to the inkejecting member and a lever arm formation
that interconnects the effort formation and
the load formation, the lever arm formation
being pivotal with respect to the nozzle
chamber structure so that reciprocal
movement of the working portion of the
actuator is accommodated by pivotal
movement of the lever arm formation with
the result that the ink-ejecting member is
reciprocally displaced towards and away
form an ink ejection port.
_____________
]11[]21[
]54[
INFLATABLE PLUSH TOY
]22[
]31[
]51[
]71[
]74[
02.11.2004
03380286.9
]32[ 10.12.2003
Int. Cl.8 A63H 003/06
VICTORY PRODUCTS, S.L., SPAIN
EITAN, PEARL, LATZER AND
COHEN ZEDEK,
P.O.B. 12688,
HERZLIYA 46733
[57] Inflatable plush toy, comprising an
exterior covering (1) having a central body
portion and appendages, and an interior
July 24, 2007– ‫ט' באב התשס"ז‬
164992
‫צעצוע מקטיפה שניתן לניפוח‬
]33[
EP
,‫ לצר וכהן צדק‬,‫ פרל‬,‫איתן‬
‫ הרצליה‬,12688 .‫ד‬.‫ ת‬, 7 ‫רחוב שנקר‬
bag (2) located in only said central body
portion and being made of an airtight,
flexible material, the configuration
2098
of the interior bag, in an expanded form, is
shaped close to a shape of the central body
portion in final form, said interior bag
including an air valve (3) extending
through the exterior covering and being
accessible from outside the exterior
covering and being located in a place that
is at least partially hidden by at least one of
the appendages, said air valve including a
closure cap (4) to facilitate filling of the
toy with air and expelling of the air from
the toy.
_____________
]11[]21[
2099
165464
July 24, 2007– ‫ט' באב התשס"ז‬
]54[
MAGNETICALLY ACTIVE
SHEET PRODUCT AND A
METHOD OF USING SUCH A
PRODUCT FOR STORING AND
READING DIGITAL DATA
]22[
]31[
]51[
]71[
19.05.2003
0212358.6
]32[ 29.05.2002
Int. Cl.8 B41M 005/30, G11B 005/70
ARJO WIGGINS LIMITED, UNITED
KINGDOM
DAVID JOHN TAYLOR, RICHARD
DAVID SAUNDERS, MICHAEL
ERIC HOBSON
WO/2003/102926
JEREMY M. BEN-DAVID & CO.
LTD.,
HAR HOTZVIM HI-TECH PARK,
P.O.B. 45087,
JERUSALEM 91450
]72[
]87[
]74[
[57] A magnetically-activatable sheet
product (1) comprising a pair of laminated
outer sheets (2) at least one of which is
provided with a pigment/binder primer
coat on its inward facing surface, between
‫מוצר פעיל– מגנטי מורכב מיריעות ושיטה‬
‫לשימוש במוצר כזה לאחסון וקריאה של‬
‫נתונים דיגיטאליים‬
]33[
GB
,‫דוד ושות' בע"מ‬-‫ בן‬.‫ירמיהו מ‬
,45087 .‫ד‬.‫ ת‬, ‫ הר חוצבים‬,‫רחוב המרפא‬
‫ירושלים‬
which is a magnetic layer (3) comprising
magnetically-activatable particles in a
binder matrix, the outer sheets having
sufficient opacity to mask the appearance
of the magnetic layer.
__________
]11[]21[
July 24, 2007– ‫ט' באב התשס"ז‬
165759
2100
]54[
SPLIT VANE FLOW BLOCKER
]22[
]31[
]51[
]71[
14.12.2004
10/737599
]32[ 16.12.2003
Int. Cl.8 F01D 017/00, F02C 001/00
UNITED TECHNOLOGIES
CORPORATION, U.S.A.
WOLFF, BREGMAN AND GOLLER,
19B KEREN HAYESOD ST.,
P.O.B. 1352,
JERUSALEM 91013
]74[
[57] A gas path flow blocker assembly
(10) for use in a gas turbine engine having
a gas flowpath between an outer duct and
an inner support structure comprising: a
plurality of vanes (21) located in said gas
flowpath beween said outer duct and said
inner support structure of said gas turbine
engine, each of said vanes having an airfoil
shape and comprising a forward portion
(25) and an aft portion (23) defining a
plurality of gas paths;
‫שבשבת חצויה חוסמת זרימה‬
]33[
US
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
said flowpath being a secondary flowpath;
a forward ring (15) comprising a central
axis about which is circumferentially
disposed said plurality of forward portions;
and an aft ring (17) disposed about said
central axis about which is
circumferentially disposed said plurality of
aft portions (23), wherein said forward ring
and said aft ring are moveable with respect
to each other to at least partially block the
flow of a gas through said gas paths.
___________
]11[]21[
2101
165917
July 24, 2007– ‫ט' באב התשס"ז‬
]54[
TRANSDERMAL DELIVERY
SYSTEM
]22[
]31[
]51[
]71[
28.07.2003
02016864.7
]32[ 30.07.2002
Int. Cl.8 A61K 009/00
SCHWARZ PHARMA AG,
GERMANY
WO/2004/012719
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
[57] A transdermal delivery system
(TDS) comprising a backing layer inert to
the components of the matrix, a selfadhesive matrix containing an aminefunctional drug and a protective foil or
sheet to be removed prior to use,
characterized in that
the self-adhesive matrix consists of a
solid or semi-solid semi-permeable
polymer
(1) wherein an amine functional drug in its
free base form has been incorporated,
‫מערכת למתן תרופות דרך העור‬
]33[
EP
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
(2) which is saturated with the amine
functional drug and contains said drug as a
multitude of microreservoirs within the
matrix,
(3) which is highly permeable for the free
base of the amine functional drug,
(4) which is impermeable for the
protonated form of the amine functional
drug,
(5) wherein the maximum diameter of the
microreservoirs is less than the thickness
of the matrix.
___________
]11[]21[
]54[
SEPARATING DEVICE FOR A
PRINT ENGINE
]22[
]51[
]62[
]71[
30.06.2000
Int. Cl.8 B41J 011/70
DIVISION FROM 153727
SILVERBROOK RESEARCH PTY.
LTD., AUSTRALIA
WO/2002/002344
LUZZATTO & LUZZATTO,
INDUSTRIAL PARK, OMER,
P.O.B. 5352,
BEER-SHEVA 84152
]87[
]74[
[57] A motor arrangement for a printer
having a printhead with a nozzle guard,
July 24, 2007– ‫ט' באב התשס"ז‬
166725
‫התקן מוטורי עבור מנוע הדפסה‬
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
print media cartridge (504) and an air
pump (522) for reducing build up on the
nozzle guard, the motor comprising first
2102
(532) and second (538) gear trains,
wherein the first gear train is configured
for driving the air pump and the second
gear train is configured for driving a roller
assembly of the print media cartridge, such
that the air pump is only operational during
printing on the print media.
_____________
]11[]21[
166726
‫שיטה לחלוקת דיו ואוויר בראש המדפסת‬
]54[
PAPER THICKNESS SENSOR IN
A PRINTER
]22[
]51[
]62[
]71[
24.05.2000
Int. Cl.8 B41J 002/01, 002/21, 011/04, 011/20
DIVISION FROM 153032
SILVERBROOK RESEARCH PTY.
LTD., AUSTRALIA
WO/2001/089837
LUZZATTO & LUZZATTO,
,‫לוצאטו את לוצאטו‬
INDUSTRIAL PARK, OMER,
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
P.O.B. 5352,
BEER-SHEVA 84152
]87[
]74[
[57] A method of distributing ink and air
to print chips (27) in a printhead assembly
(11) of a printer, the method utilizing a
laminated ink distributing structure formed
as a number of micro-molded layers
adhered to one another with each layer
including a plurality of ink holes formed
therethrough, at least some of the ink holes
in each layer communicating with a
channel formed in one side of the said
layer allowing passage of at least one of
2103
ink and air to a transversely located
position within the structure, which
transversely located position aligns with an
aperture formed through an adjacent layer
of the structure via which at least one of
ink and air pass to the print chips, the
method including selectively supplying
different inks to pre-determined ones of
the holes to thereby transfer the different
inks to the printhead chips as required and
selectively supplying air to predetermined
July 24, 2007– ‫ט' באב התשס"ז‬
ones of the holes to thereby transfer air to
the printhead chips as required.
____________
]11[]21[
]54[
PRINTHEAD ASSEMBLY WITH
CAPPING ARRANGEMENT
]22[
]51[
]62[
]71[
24.05.2000
Int. Cl.8 B41J 002/165, 002/21
DIVISION FROM 153034
SILVERBROOK RESEARCH PTY.
LTD., AUSTRALIA
WO/2001/089848
LUZZATTO & LUZZATTO,
INDUSTRIAL PARK, OMER,
P.O.B. 5352,
BEER-SHEVA 84152
]87[
]74[
[57] An inkjet printhead assembly
comprising:
July 24, 2007– ‫ט' באב התשס"ז‬
166874
‫מכלול ראש הדפסה עם הסדר כיסוי‬
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
a printhead having plurality of print
nozzles (30) for selectively ejecting drops
2104
of ink towards a print medium (31) passing
the nozzles; a plurality of apertures (44)
spaced from the nozzles in the direction of
the ink ejection, each aperture being
aligned with a corresponding nozzle so
that ink drops ejected from the nozzles
pass through the apertures; and means for
sealing the space between the nozzles and
the apertures when the printhead assembly
is in a non-printing mode so as to reduce
drying of the ink.
__________
]11[]21[
]54[
INK SUPPLY ASSEMBLY FOR A
PRINT ENGINE
]22[
]51[
]62[
]71[
30.06.2000
Int. Cl.8 B41J 002/175
DIVISION FROM 153664
SILVERBROOK RESEARCH PTY.
LTD., AUSTRALIA
WO/2002/002335
LUZZATTO & LUZZATTO,
INDUSTRIAL PARK, OMER,
P.O.B. 5352,
BEER-SHEVA 84152
]87[
]74[
[57] An ink supply arrangement for a
printhead (516) of a print engine, the
printhead comprising a nozzle guard (757)
adjacent to a first surface (730) of a wafer
(724), an array of microelectromechanical
system (MEMS) ink ejection devices
mounted on the first surface of the wafer
and a plurality of ink supply passages
(734) extending through the wafer from an
opposed surface of the wafer to respective
ink ejection devices, the ink ejection
devices being arranged in a plurality of
groups, the ink supply arrangement
comprising: a block (726) of material
2105
166875
‫התקן לאספקת דיו למנוע הדפסה‬
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
mountable on the opposed surface of the
wafer, the block having a number of
channels (728) defined therein, each
channel corresponding to one of the
groups, and opening out into a first surface
of the block in abutment with the opposed
surface of the wafer; and a plurality of ink
supply inlet openings into a second surface
(746) of the block, the opening being
configured such that each of the channels
is in communication with at least one
opening, wherein ink from each ink
ejection device is ejected through the
nozzle guard.
July 24, 2007– ‫ט' באב התשס"ז‬
____________
]11[]21[
]54[
INKJET PRINTER HAVING
COMPENSATION FOR
OVERLAPPING PRINTHEAD
ELEMENTS
]22[
]51[
]62[
]71[
24.05.2000
Int. Cl.8 B41J 002/145
DIVISION FROM 153025
SILVERBROOK RESEARCH PTY.
LTD., AUSTRALIA
WO/2001/089845
LUZZATTO & LUZZATTO,
INDUSTRIAL PARK, OMER,
P.O.B. 5352,
BEER-SHEVA 84152
]87[
]74[
[57] A printer comprising an inkjet
printhead comprising a plurality of spaced
apart spatially overlapping print head
segments (2, 3) the printer further
comprising at least one means for
measurement of the degree of overlap
between adjacent print head segments;
July 24, 2007– ‫ט' באב התשס"ז‬
166876
‫מדפסת דיו בעלת פיצוי לרכיבי ראש מדפסת‬
‫חופפים‬
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
means for providing a half toning of a
continuous tone image and means for
adjusting said half toning means in a
region (10, 11, 12, 13) of overlap between
adjacent print head segments to reduce
artifacts between said adjacent segments.
2106
__________
]11[]21[
173678
‫גישה מרוחקת למחשב‬
]54[
REMOTE COMPUTER ACCESS
]22[
]51[
]62[
]71[
]87[
]74[
27.07.1998
Int. Cl.8 G06F 019/00, H04L 012/00, H04N 007/10
DIVISION FROM 141104
MICROSOFT CORPORATION
WO/2000/007091
REINHOLD COHN AND
,‫ריינהולד כהן ושותפיו‬
PARTNERS,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
[57] A method of bandwidth allocation
for transmitting video on a cable network,
the method comprising: providing a
plurality of data sources; differentially
converting said data sources into
compressed video streams, responsive to
an instantaneous resource restriction; and
multiplexing said compressed video
streams on a single transmission line;
wherein differentially converting said data
sources comprises identifying compression
.
2107
parameters to be used to compress the data
that is received from the plurality of data
sources to a desired depth of compression,
the compression parameters being based
on a function of types of data to be
displayed and a function of client
capabilities, wherein the types of data are
determined from content of data received
from the respective plurality of data
sources
July 24, 2007– ‫ט' באב התשס"ז‬
_____________
]11[]21[
174850
‫תרכובות המשמשות בהכנת תולדות של‬
‫פיפרידין אנטיהיסטמיניות‬
]54[
COMPOUNDS USEFUL IN THE
PREPARATION OF
ANTIHISTAMINIC PIPERIDINE
DERIVATIVES
]22[
]31[
]51[
]62[
]71[
]74[
22.06.1994
08/082693
]32[ 25.06.1993
]33[ US
08/144084
27.10.1993
US
08/237466
11.05.1994
US
Int. Cl.8 C07C 049/82, 049/86, 069/76, 255/16, C07D 211/22
DIVISION FROM 143611
AVENTIS INC., U.S.A.
DR. SHLOMO COHEN & CO.,
,'‫ד"ר שלמה כהן ושות‬
124 IBN GABIROL ST.,
‫ תל אביב‬,11490 .‫ד‬.‫ ת‬, 124 ‫אבן גבירול‬
P.O.B. 11490,
TEL AVIV 62038
[57]
A compound of the formula
July 24, 2007– ‫ט' באב התשס"ז‬
2108
wherein
Hal is Cl, Br or I;
n is an integer of from 1 to 5;
A is hydrogen or hydroxy; and
R5 is CH2OD wherein D is hydrogen,
acetate or benzoate, CHO, Br, Cl, I or CN;
or a compound of the formula
wherein
n is an integer of from 1 to 5;
A is a hydrogen or hydroxy; and
R5 is Br, Cl or I;
or a compound of the formula
wherein
R5 is Br, Cl or I; or a compound of the
formula
and individual optical isomers thereof;
or a compound of the formula
2109
July 24, 2007– ‫ט' באב התשס"ז‬
wherein
W represents –C(==O)-or –CH(OH)-;
R1 represents hydrogen or hydroxy;
R2 represents hydrogen; or
R1 and R2 taken together form a second
bond between the carbon atoms bearing R1
and R2;
m is an integer 0 or 1;
R5 is H, Br, Cl, I or CN;
A is hydrogen or hydroxy; and
pharmaceutically acceptable salts and
individual optical isomers thereof, with the
proviso that where R1 and R2 are taken
together to form a second bond between
the carbon atoms bearing R1 and R2 or
where R1 represented hydroxy, m is an
integer 0.
__________
]11[]21[
179054
‫ יחידת לקוח ורשת תיקשורות‬,‫יחידת שרת‬
‫עבור יישומי מכפל–משתמשים‬
]54[
SERVER UNIT, CLIENT UNIT
AND COMMUNICATIONS
NETWORK FOR MULTI-USER
APPLICATIONS
]22[
]31[
10.05.2000
9901694-1
]32[ 10.05.1999
]33[ SE
09/307712
10.05.1999
US
Int. Cl.8 A63F 009/24, G06F 017/30, 019/00, 161/00
DIVISION FROM 146348
TERRAPLAY SYSTEMS AB,
SWEDEN
WO/2000/068864
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.,
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
]51[
]62[
]71[
]87[
]74[
[57] A server unit connectable to at least a
July 24, 2007– ‫ט' באב התשס"ז‬
2110
first and a second client unit and adapted
to enable communication between the first
and the second client unit through the
server unit for running a distributed
interactive application having a state that
can be simultaneously affected and
contributed to by both the first and the
second client unit, the server unit being
characterized in that it includes; first
receiving means for receiving application
state information about the state of the
application from at least the first client
unit;
state information storing means for storing
application state information; second
receiving means for receiving priority
information from at least the first client
unit about application state information to
be sent to the first client unit; priority
information storing means for storing the
received priority information; first
transmission means cooperating with the
state information storing means for
transmitting application state information
to the first client unit in the dependence of
the priority information; at least one
application router including the first and
second transmission means and the first
and second receiving means, an
application server including the
information storing means.
___________
2111
July 24, 2007– ‫ט' באב התשס"ז‬
‫פטנטים‬
‫‪PATENTS‬‬
‫פטנטים שניתנו‬
‫‪PATENTS GRANTED‬‬
‫‪125894‬‬
‫‪141922‬‬
‫‪142549‬‬
‫‪142813‬‬
‫‪143279‬‬
‫‪143816‬‬
‫‪144117‬‬
‫‪144379‬‬
‫‪144642‬‬
‫‪144911‬‬
‫‪145080‬‬
‫‪145320‬‬
‫‪145639‬‬
‫‪169779‬‬
‫‪129332‬‬
‫‪131436‬‬
‫‪132437‬‬
‫‪146102‬‬
‫‪146374‬‬
‫‪146685‬‬
‫‪146840‬‬
‫‪147211‬‬
‫‪147542‬‬
‫‪147840‬‬
‫‪148078‬‬
‫‪148377‬‬
‫‪148691‬‬
‫‪148964‬‬
‫‪149212‬‬
‫‪149649‬‬
‫‪150037‬‬
‫‪150982‬‬
‫‪117420‬‬
‫‪138113‬‬
‫‪138987‬‬
‫‪139780‬‬
‫‪140241‬‬
‫‪141505‬‬
‫‪157986‬‬
‫‪2112‬‬
‫‪125143‬‬
‫‪141912‬‬
‫‪142470‬‬
‫‪142799‬‬
‫‪143184‬‬
‫‪143809‬‬
‫‪144049‬‬
‫‪144377‬‬
‫‪144626‬‬
‫‪144884‬‬
‫‪145057‬‬
‫‪145286‬‬
‫‪145619‬‬
‫‪168036‬‬
‫‪129085‬‬
‫‪131396‬‬
‫‪132166‬‬
‫‪146068‬‬
‫‪146277‬‬
‫‪146669‬‬
‫‪146835‬‬
‫‪147210‬‬
‫‪147540‬‬
‫‪147807‬‬
‫‪148058‬‬
‫‪148366‬‬
‫‪148548‬‬
‫‪148955‬‬
‫‪149165‬‬
‫‪149643‬‬
‫‪149998‬‬
‫‪150969‬‬
‫‪116216‬‬
‫‪137768‬‬
‫‪138746‬‬
‫‪139775‬‬
‫‪140234‬‬
‫‪141503‬‬
‫‪157899‬‬
‫‪124941‬‬
‫‪141902‬‬
‫‪142439‬‬
‫‪142732‬‬
‫‪143115‬‬
‫‪143731‬‬
‫‪143937‬‬
‫‪144325‬‬
‫‪144602‬‬
‫‪144813‬‬
‫‪145050‬‬
‫‪145244‬‬
‫‪145590‬‬
‫‪145807‬‬
‫‪129035‬‬
‫‪130995‬‬
‫‪132095‬‬
‫‪146037‬‬
‫‪146262‬‬
‫‪146609‬‬
‫‪146833‬‬
‫‪147178‬‬
‫‪147395‬‬
‫‪147746‬‬
‫‪148049‬‬
‫‪148357‬‬
‫‪148520‬‬
‫‪148888‬‬
‫‪149150‬‬
‫‪149622‬‬
‫‪149975‬‬
‫‪150938‬‬
‫‪151298‬‬
‫‪137639‬‬
‫‪138737‬‬
‫‪139607‬‬
‫‪140206‬‬
‫‪141399‬‬
‫‪141705‬‬
‫‪124579‬‬
‫‪141822‬‬
‫‪142400‬‬
‫‪142728‬‬
‫‪143028‬‬
‫‪143697‬‬
‫‪143928‬‬
‫‪144246‬‬
‫‪144559‬‬
‫‪144809‬‬
‫‪145036‬‬
‫‪145240‬‬
‫‪145523‬‬
‫‪145777‬‬
‫‪128741‬‬
‫‪130967‬‬
‫‪132062‬‬
‫‪145957‬‬
‫‪146224‬‬
‫‪146549‬‬
‫‪146831‬‬
‫‪147116‬‬
‫‪147380‬‬
‫‪147694‬‬
‫‪148020‬‬
‫‪148330‬‬
‫‪148438‬‬
‫‪148804‬‬
‫‪149143‬‬
‫‪149503‬‬
‫‪149886‬‬
‫‪150654‬‬
‫‪151276‬‬
‫‪137571‬‬
‫‪138733‬‬
‫‪139368‬‬
‫‪140199‬‬
‫‪141294‬‬
‫‪141665‬‬
‫‪124473‬‬
‫‪141794‬‬
‫‪142130‬‬
‫‪142669‬‬
‫‪142996‬‬
‫‪143575‬‬
‫‪143923‬‬
‫‪144136‬‬
‫‪144549‬‬
‫‪144794‬‬
‫‪145018‬‬
‫‪145206‬‬
‫‪145516‬‬
‫‪145748‬‬
‫‪114775‬‬
‫‪130333‬‬
‫‪131794‬‬
‫‪145877‬‬
‫‪146216‬‬
‫‪146532‬‬
‫‪146804‬‬
‫‪147058‬‬
‫‪147346‬‬
‫‪147682‬‬
‫‪147974‬‬
‫‪148242‬‬
‫‪148435‬‬
‫‪148794‬‬
‫‪149104‬‬
‫‪149482‬‬
‫‪149852‬‬
‫‪150378‬‬
‫‪151237‬‬
‫‪137517‬‬
‫‪138705‬‬
‫‪139283‬‬
‫‪140151‬‬
‫‪141194‬‬
‫‪141661‬‬
‫‪124112‬‬
‫‪141742‬‬
‫‪142106‬‬
‫‪142605‬‬
‫‪142969‬‬
‫‪143502‬‬
‫‪143831‬‬
‫‪144127‬‬
‫‪144545‬‬
‫‪144785‬‬
‫‪145012‬‬
‫‪145155‬‬
‫‪145488‬‬
‫‪145699‬‬
‫‪101769‬‬
‫‪130129‬‬
‫‪131770‬‬
‫‪132676‬‬
‫‪146200‬‬
‫‪146519‬‬
‫‪146750‬‬
‫‪147014‬‬
‫‪147304‬‬
‫‪147625‬‬
‫‪147945‬‬
‫‪148241‬‬
‫‪148434‬‬
‫‪148765‬‬
‫‪149094‬‬
‫‪149310‬‬
‫‪149732‬‬
‫‪150355‬‬
‫‪151181‬‬
‫‪137490‬‬
‫‪138442‬‬
‫‪139255‬‬
‫‪140144‬‬
‫‪141124‬‬
‫‪141651‬‬
‫‪108788‬‬
‫‪127813‬‬
‫‪141926‬‬
‫‪142571‬‬
‫‪142854‬‬
‫‪143347‬‬
‫‪143829‬‬
‫‪144124‬‬
‫‪144539‬‬
‫‪144758‬‬
‫‪144977‬‬
‫‪145105‬‬
‫‪145475‬‬
‫‪145647‬‬
‫‪101288‬‬
‫‪129851‬‬
‫‪131767‬‬
‫‪132632‬‬
‫‪146167‬‬
‫‪146504‬‬
‫‪146746‬‬
‫‪146995‬‬
‫‪147263‬‬
‫‪147609‬‬
‫‪147903‬‬
‫‪148219‬‬
‫‪148428‬‬
‫‪148764‬‬
‫‪149023‬‬
‫‪149272‬‬
‫‪149693‬‬
‫‪150282‬‬
‫‪151069‬‬
‫‪137410‬‬
‫‪138224‬‬
‫‪139216‬‬
‫‪139917‬‬
‫‪140981‬‬
‫‪141592‬‬
‫‪108586‬‬
‫‪127365‬‬
‫‪141923‬‬
‫‪142567‬‬
‫‪142833‬‬
‫‪143303‬‬
‫‪143818‬‬
‫‪144123‬‬
‫‪144382‬‬
‫‪144718‬‬
‫‪144935‬‬
‫‪145104‬‬
‫‪145326‬‬
‫‪145640‬‬
‫‪170293‬‬
‫‪129527‬‬
‫‪131508‬‬
‫‪132557‬‬
‫‪146159‬‬
‫‪146394‬‬
‫‪146700‬‬
‫‪146985‬‬
‫‪147241‬‬
‫‪147607‬‬
‫‪147877‬‬
‫‪148082‬‬
‫‪148379‬‬
‫‪148705‬‬
‫‪149007‬‬
‫‪149239‬‬
‫‪149663‬‬
‫‪150183‬‬
‫‪151038‬‬
‫‪137347‬‬
‫‪138223‬‬
‫‪139186‬‬
‫‪139890‬‬
‫‪140260‬‬
‫‪141549‬‬
‫ט' באב התשס"ז –‪July 24, 2007‬‬
‫‪159359‬‬
‫‪160854‬‬
‫‪162998‬‬
‫‪164980‬‬
‫‪132886‬‬
‫‪133973‬‬
‫‪134880‬‬
‫‪136655‬‬
‫‪137146‬‬
‫‪151984‬‬
‫‪152677‬‬
‫‪153378‬‬
‫‪153843‬‬
‫‪154432‬‬
‫‪155021‬‬
‫‪155902‬‬
‫‪156706‬‬
‫‪159137‬‬
‫‪160566‬‬
‫‪162626‬‬
‫‪164957‬‬
‫‪122942‬‬
‫‪133678‬‬
‫‪134763‬‬
‫‪136483‬‬
‫‪137099‬‬
‫‪151929‬‬
‫‪152664‬‬
‫‪153302‬‬
‫‪153544‬‬
‫‪154300‬‬
‫‪155017‬‬
‫‪155630‬‬
‫‪156535‬‬
‫‪159121‬‬
‫‪159958‬‬
‫‪161567‬‬
‫‪164690‬‬
‫‪167541‬‬
‫‪133586‬‬
‫‪134656‬‬
‫‪136250‬‬
‫‪136888‬‬
‫‪151698‬‬
‫‪152526‬‬
‫‪153256‬‬
‫‪153515‬‬
‫‪154174‬‬
‫‪154951‬‬
‫‪155578‬‬
‫‪156503‬‬
‫‪157790‬‬
‫ט' באב התשס"ז –‪July 24, 2007‬‬
‫‪158994‬‬
‫‪159761‬‬
‫‪161556‬‬
‫‪164648‬‬
‫‪166283‬‬
‫‪133449‬‬
‫‪134599‬‬
‫‪136030‬‬
‫‪136886‬‬
‫‪151682‬‬
‫‪152513‬‬
‫‪153216‬‬
‫‪153502‬‬
‫‪154154‬‬
‫‪154766‬‬
‫‪155336‬‬
‫‪156456‬‬
‫‪157646‬‬
‫‪158649‬‬
‫‪159608‬‬
‫‪161321‬‬
‫‪164446‬‬
‫‪166281‬‬
‫‪133386‬‬
‫‪134430‬‬
‫‪135836‬‬
‫‪136839‬‬
‫‪151587‬‬
‫‪152425‬‬
‫‪153126‬‬
‫‪153467‬‬
‫‪154105‬‬
‫‪154763‬‬
‫‪155308‬‬
‫‪156318‬‬
‫‪157403‬‬
‫‪158578‬‬
‫‪159574‬‬
‫‪161221‬‬
‫‪164251‬‬
‫‪165698‬‬
‫‪133319‬‬
‫‪134188‬‬
‫‪135508‬‬
‫‪136831‬‬
‫‪151582‬‬
‫‪152365‬‬
‫‪152954‬‬
‫‪153466‬‬
‫‪154104‬‬
‫‪154749‬‬
‫‪155264‬‬
‫‪156170‬‬
‫‪157346‬‬
‫‪158375‬‬
‫‪159505‬‬
‫‪161087‬‬
‫‪163942‬‬
‫‪164982‬‬
‫‪133101‬‬
‫‪134073‬‬
‫‪135503‬‬
‫‪136782‬‬
‫‪151366‬‬
‫‪152311‬‬
‫‪152755‬‬
‫‪153381‬‬
‫‪154019‬‬
‫‪154706‬‬
‫‪155114‬‬
‫‪156141‬‬
‫‪157035‬‬
‫‪158077‬‬
‫‪159425‬‬
‫‪161011‬‬
‫‪163370‬‬
‫‪164981‬‬
‫‪133060‬‬
‫‪134042‬‬
‫‪135384‬‬
‫‪136737‬‬
‫‪137216‬‬
‫‪152010‬‬
‫‪152728‬‬
‫‪153379‬‬
‫‪153969‬‬
‫‪154597‬‬
‫‪155028‬‬
‫‪156102‬‬
‫‪157034‬‬
‫‪2113‬‬
‫פטנטים שחודשו‬
‫‪PATENTS RENEWED‬‬
‫‪89686‬‬
‫‪89779‬‬
‫‪89841‬‬
‫‪89931‬‬
‫‪90484‬‬
‫‪90542‬‬
‫‪90622‬‬
‫‪90795‬‬
‫‪103939‬‬
‫‪104954‬‬
‫‪105146‬‬
‫‪105207‬‬
‫‪105268‬‬
‫‪105337‬‬
‫‪105372‬‬
‫‪105413‬‬
‫‪105516‬‬
‫‪105818‬‬
‫‪105946‬‬
‫‪106013‬‬
‫‪106076‬‬
‫‪106218‬‬
‫‪114775‬‬
‫‪119874‬‬
‫‪120399‬‬
‫‪120483‬‬
‫‪120547‬‬
‫‪120654‬‬
‫‪120725‬‬
‫‪120910‬‬
‫‪120985‬‬
‫‪121044‬‬
‫‪121076‬‬
‫‪121115‬‬
‫‪121174‬‬
‫‪122117‬‬
‫‪122526‬‬
‫‪123441‬‬
‫‪123840‬‬
‫‪125849‬‬
‫‪126083‬‬
‫‪126190‬‬
‫‪2114‬‬
‫‪89670‬‬
‫‪89763‬‬
‫‪89831‬‬
‫‪89896‬‬
‫‪90462‬‬
‫‪90533‬‬
‫‪90599‬‬
‫‪90775‬‬
‫‪103813‬‬
‫‪104926‬‬
‫‪105141‬‬
‫‪105205‬‬
‫‪105264‬‬
‫‪105325‬‬
‫‪105371‬‬
‫‪105410‬‬
‫‪105513‬‬
‫‪105817‬‬
‫‪105945‬‬
‫‪105988‬‬
‫‪106074‬‬
‫‪106155‬‬
‫‪113988‬‬
‫‪119728‬‬
‫‪120388‬‬
‫‪120481‬‬
‫‪120542‬‬
‫‪120651‬‬
‫‪120722‬‬
‫‪120907‬‬
‫‪120976‬‬
‫‪121032‬‬
‫‪121075‬‬
‫‪121112‬‬
‫‪121173‬‬
‫‪122101‬‬
‫‪122525‬‬
‫‪123336‬‬
‫‪123835‬‬
‫‪125812‬‬
‫‪126075‬‬
‫‪126187‬‬
‫‪89669‬‬
‫‪89749‬‬
‫‪89807‬‬
‫‪89880‬‬
‫‪90453‬‬
‫‪90527‬‬
‫‪90594‬‬
‫‪90752‬‬
‫‪103152‬‬
‫‪104923‬‬
‫‪105135‬‬
‫‪105204‬‬
‫‪105252‬‬
‫‪105323‬‬
‫‪105369‬‬
‫‪105403‬‬
‫‪105468‬‬
‫‪105746‬‬
‫‪105944‬‬
‫‪105987‬‬
‫‪106071‬‬
‫‪106142‬‬
‫‪113232‬‬
‫‪119727‬‬
‫‪120365‬‬
‫‪120465‬‬
‫‪120522‬‬
‫‪120623‬‬
‫‪120701‬‬
‫‪120890‬‬
‫‪120959‬‬
‫‪121018‬‬
‫‪121068‬‬
‫‪121109‬‬
‫‪121161‬‬
‫‪121316‬‬
‫‪122521‬‬
‫‪123259‬‬
‫‪123676‬‬
‫‪125795‬‬
‫‪126073‬‬
‫‪126186‬‬
‫‪89593‬‬
‫‪89748‬‬
‫‪89794‬‬
‫‪89879‬‬
‫‪90062‬‬
‫‪90510‬‬
‫‪90592‬‬
‫‪90731‬‬
‫‪101520‬‬
‫‪104915‬‬
‫‪105119‬‬
‫‪105203‬‬
‫‪105251‬‬
‫‪105306‬‬
‫‪105366‬‬
‫‪105400‬‬
‫‪105464‬‬
‫‪105744‬‬
‫‪105941‬‬
‫‪105970‬‬
‫‪106040‬‬
‫‪106135‬‬
‫‪109049‬‬
‫‪118578‬‬
‫‪120358‬‬
‫‪120436‬‬
‫‪120517‬‬
‫‪120587‬‬
‫‪120700‬‬
‫‪120889‬‬
‫‪120953‬‬
‫‪121013‬‬
‫‪121060‬‬
‫‪121102‬‬
‫‪121158‬‬
‫‪121230‬‬
‫‪122520‬‬
‫‪123130‬‬
‫‪123656‬‬
‫‪125628‬‬
‫‪126044‬‬
‫‪126185‬‬
‫‪89557‬‬
‫‪89735‬‬
‫‪89791‬‬
‫‪89875‬‬
‫‪90059‬‬
‫‪90502‬‬
‫‪90583‬‬
‫‪90730‬‬
‫‪101288‬‬
‫‪104912‬‬
‫‪105077‬‬
‫‪105187‬‬
‫‪105246‬‬
‫‪105303‬‬
‫‪105345‬‬
‫‪105396‬‬
‫‪105457‬‬
‫‪105706‬‬
‫‪105933‬‬
‫‪105969‬‬
‫‪106036‬‬
‫‪106116‬‬
‫‪108316‬‬
‫‪118418‬‬
‫‪120328‬‬
‫‪120435‬‬
‫‪120512‬‬
‫‪120586‬‬
‫‪120696‬‬
‫‪120857‬‬
‫‪120951‬‬
‫‪121009‬‬
‫‪121057‬‬
‫‪121092‬‬
‫‪121151‬‬
‫‪121195‬‬
‫‪122447‬‬
‫‪123025‬‬
‫‪123655‬‬
‫‪125006‬‬
‫‪125987‬‬
‫‪126177‬‬
‫‪89470‬‬
‫‪89692‬‬
‫‪89790‬‬
‫‪89867‬‬
‫‪90019‬‬
‫‪90501‬‬
‫‪90551‬‬
‫‪90674‬‬
‫‪97688‬‬
‫‪104911‬‬
‫‪105051‬‬
‫‪105161‬‬
‫‪105244‬‬
‫‪105302‬‬
‫‪105344‬‬
‫‪105383‬‬
‫‪105449‬‬
‫‪105702‬‬
‫‪105905‬‬
‫‪105959‬‬
‫‪106033‬‬
‫‪106111‬‬
‫‪107868‬‬
‫‪118279‬‬
‫‪120187‬‬
‫‪120429‬‬
‫‪120498‬‬
‫‪120584‬‬
‫‪120695‬‬
‫‪120820‬‬
‫‪120946‬‬
‫‪121008‬‬
‫‪121053‬‬
‫‪121089‬‬
‫‪121139‬‬
‫‪121194‬‬
‫‪122438‬‬
‫‪122998‬‬
‫‪123629‬‬
‫‪124941‬‬
‫‪125895‬‬
‫‪126146‬‬
‫‪89460‬‬
‫‪89691‬‬
‫‪89789‬‬
‫‪89847‬‬
‫‪89982‬‬
‫‪90500‬‬
‫‪90550‬‬
‫‪90665‬‬
‫‪97687‬‬
‫‪104910‬‬
‫‪105027‬‬
‫‪105153‬‬
‫‪105243‬‬
‫‪105279‬‬
‫‪105340‬‬
‫‪105382‬‬
‫‪105432‬‬
‫‪105662‬‬
‫‪105895‬‬
‫‪105958‬‬
‫‪106027‬‬
‫‪106109‬‬
‫‪107709‬‬
‫‪116609‬‬
‫‪120076‬‬
‫‪120420‬‬
‫‪120492‬‬
‫‪120574‬‬
‫‪120670‬‬
‫‪120814‬‬
‫‪120943‬‬
‫‪121007‬‬
‫‪121046‬‬
‫‪121079‬‬
‫‪121138‬‬
‫‪121186‬‬
‫‪122423‬‬
‫‪122765‬‬
‫‪123531‬‬
‫‪124617‬‬
‫‪125894‬‬
‫‪126123‬‬
‫‪89403‬‬
‫‪89688‬‬
‫‪89781‬‬
‫‪89845‬‬
‫‪89963‬‬
‫‪90488‬‬
‫‪90545‬‬
‫‪90662‬‬
‫‪90802‬‬
‫‪104839‬‬
‫‪104957‬‬
‫‪105152‬‬
‫‪105221‬‬
‫‪105276‬‬
‫‪105338‬‬
‫‪105377‬‬
‫‪105430‬‬
‫‪105658‬‬
‫‪105876‬‬
‫‪105956‬‬
‫‪106020‬‬
‫‪106099‬‬
‫‪107563‬‬
‫‪116398‬‬
‫‪119928‬‬
‫‪120416‬‬
‫‪120490‬‬
‫‪120554‬‬
‫‪120669‬‬
‫‪120800‬‬
‫‪120930‬‬
‫‪121005‬‬
‫‪121045‬‬
‫‪121078‬‬
‫‪121128‬‬
‫‪121179‬‬
‫‪122318‬‬
‫‪122699‬‬
‫‪123514‬‬
‫‪124072‬‬
‫‪125850‬‬
‫‪126120‬‬
‫ט' באב התשס"ז –‪July 24, 2007‬‬
‫‪126251‬‬
‫‪126318‬‬
‫‪126367‬‬
‫‪126394‬‬
‫‪126484‬‬
‫‪126551‬‬
‫‪126612‬‬
‫‪126717‬‬
‫‪126901‬‬
‫‪127013‬‬
‫‪127126‬‬
‫‪127231‬‬
‫‪127325‬‬
‫‪127378‬‬
‫‪127476‬‬
‫‪127542‬‬
‫‪127715‬‬
‫‪127770‬‬
‫‪128632‬‬
‫‪131396‬‬
‫‪132095‬‬
‫‪133544‬‬
‫‪135406‬‬
‫‪136655‬‬
‫‪137579‬‬
‫‪138984‬‬
‫‪139775‬‬
‫‪139983‬‬
‫‪140661‬‬
‫‪141741‬‬
‫‪141836‬‬
‫‪142112‬‬
‫‪142227‬‬
‫‪142400‬‬
‫‪142553‬‬
‫‪142783‬‬
‫‪143190‬‬
‫‪143457‬‬
‫‪143649‬‬
‫‪143787‬‬
‫‪143928‬‬
‫‪144105‬‬
‫‪144358‬‬
‫‪144626‬‬
‫‪144907‬‬
‫‪145244‬‬
‫‪126248‬‬
‫‪126314‬‬
‫‪126363‬‬
‫‪126393‬‬
‫‪126479‬‬
‫‪126545‬‬
‫‪126596‬‬
‫‪126716‬‬
‫‪126842‬‬
‫‪126989‬‬
‫‪127113‬‬
‫‪127218‬‬
‫‪127312‬‬
‫‪127365‬‬
‫‪127475‬‬
‫‪127540‬‬
‫‪127657‬‬
‫‪127769‬‬
‫‪128163‬‬
‫‪130955‬‬
‫‪132071‬‬
‫‪133264‬‬
‫‪135295‬‬
‫‪136388‬‬
‫‪137493‬‬
‫‪138837‬‬
‫‪139704‬‬
‫‪139982‬‬
‫‪140636‬‬
‫‪141707‬‬
‫‪141790‬‬
‫‪142098‬‬
‫‪142226‬‬
‫‪142373‬‬
‫‪142524‬‬
‫‪142781‬‬
‫‪143112‬‬
‫‪143443‬‬
‫‪143631‬‬
‫‪143731‬‬
‫‪143915‬‬
‫‪144100‬‬
‫‪144352‬‬
‫‪144599‬‬
‫‪144905‬‬
‫‪145131‬‬
‫‪126245‬‬
‫‪126311‬‬
‫‪126354‬‬
‫‪126392‬‬
‫‪126470‬‬
‫‪126541‬‬
‫‪126594‬‬
‫‪126690‬‬
‫‪126831‬‬
‫‪126985‬‬
‫‪127111‬‬
‫‪127212‬‬
‫‪127296‬‬
‫‪127364‬‬
‫‪127473‬‬
‫‪127539‬‬
‫‪127651‬‬
‫‪127766‬‬
‫‪128108‬‬
‫‪130287‬‬
‫‪132062‬‬
‫‪133162‬‬
‫‪134980‬‬
‫‪136287‬‬
‫‪137490‬‬
‫‪138737‬‬
‫‪139283‬‬
‫‪139981‬‬
‫‪140495‬‬
‫‪141702‬‬
‫‪141780‬‬
‫‪142020‬‬
‫‪142208‬‬
‫‪142345‬‬
‫‪142484‬‬
‫‪142728‬‬
‫‪143111‬‬
‫‪143425‬‬
‫‪143606‬‬
‫‪143727‬‬
‫‪143913‬‬
‫‪144084‬‬
‫‪144260‬‬
‫‪144545‬‬
‫‪144867‬‬
‫‪145080‬‬
‫ט' באב התשס"ז –‪July 24, 2007‬‬
‫‪126237‬‬
‫‪126307‬‬
‫‪126351‬‬
‫‪126384‬‬
‫‪126459‬‬
‫‪126535‬‬
‫‪126591‬‬
‫‪126677‬‬
‫‪126823‬‬
‫‪126976‬‬
‫‪127062‬‬
‫‪127208‬‬
‫‪127295‬‬
‫‪127360‬‬
‫‪127468‬‬
‫‪127534‬‬
‫‪127629‬‬
‫‪127741‬‬
‫‪127861‬‬
‫‪130129‬‬
‫‪132000‬‬
‫‪133078‬‬
‫‪134699‬‬
‫‪136250‬‬
‫‪137475‬‬
‫‪138711‬‬
‫‪139255‬‬
‫‪139980‬‬
‫‪140491‬‬
‫‪141676‬‬
‫‪141777‬‬
‫‪142004‬‬
‫‪142177‬‬
‫‪142335‬‬
‫‪142470‬‬
‫‪142716‬‬
‫‪142966‬‬
‫‪143423‬‬
‫‪143576‬‬
‫‪143721‬‬
‫‪143836‬‬
‫‪144058‬‬
‫‪144227‬‬
‫‪144544‬‬
‫‪144771‬‬
‫‪145036‬‬
‫‪126231‬‬
‫‪126304‬‬
‫‪126343‬‬
‫‪126381‬‬
‫‪126458‬‬
‫‪126534‬‬
‫‪126590‬‬
‫‪126655‬‬
‫‪126793‬‬
‫‪126975‬‬
‫‪127049‬‬
‫‪127207‬‬
‫‪127279‬‬
‫‪127357‬‬
‫‪127446‬‬
‫‪127526‬‬
‫‪127619‬‬
‫‪127740‬‬
‫‪127860‬‬
‫‪129814‬‬
‫‪131841‬‬
‫‪132845‬‬
‫‪134126‬‬
‫‪135811‬‬
‫‪137410‬‬
‫‪138425‬‬
‫‪139252‬‬
‫‪139979‬‬
‫‪140434‬‬
‫‪141642‬‬
‫‪141771‬‬
‫‪141963‬‬
‫‪142156‬‬
‫‪142325‬‬
‫‪142457‬‬
‫‪142649‬‬
‫‪142958‬‬
‫‪143315‬‬
‫‪143575‬‬
‫‪143697‬‬
‫‪143818‬‬
‫‪144036‬‬
‫‪144198‬‬
‫‪144488‬‬
‫‪144770‬‬
‫‪145018‬‬
‫‪126207‬‬
‫‪126299‬‬
‫‪126338‬‬
‫‪126380‬‬
‫‪126449‬‬
‫‪126532‬‬
‫‪126584‬‬
‫‪126646‬‬
‫‪126779‬‬
‫‪126934‬‬
‫‪127033‬‬
‫‪127180‬‬
‫‪127250‬‬
‫‪127349‬‬
‫‪127415‬‬
‫‪127519‬‬
‫‪127604‬‬
‫‪127735‬‬
‫‪127859‬‬
‫‪129789‬‬
‫‪131794‬‬
‫‪132437‬‬
‫‪134087‬‬
‫‪135618‬‬
‫‪137347‬‬
‫‪138317‬‬
‫‪139244‬‬
‫‪139978‬‬
‫‪140260‬‬
‫‪141501‬‬
‫‪141766‬‬
‫‪141961‬‬
‫‪142140‬‬
‫‪142293‬‬
‫‪142455‬‬
‫‪142606‬‬
‫‪142954‬‬
‫‪143285‬‬
‫‪143572‬‬
‫‪143694‬‬
‫‪143790‬‬
‫‪144035‬‬
‫‪144160‬‬
‫‪144486‬‬
‫‪144762‬‬
‫‪145012‬‬
‫‪126204‬‬
‫‪126283‬‬
‫‪126337‬‬
‫‪126371‬‬
‫‪126431‬‬
‫‪126497‬‬
‫‪126583‬‬
‫‪126643‬‬
‫‪126770‬‬
‫‪126924‬‬
‫‪127016‬‬
‫‪127144‬‬
‫‪127249‬‬
‫‪127343‬‬
‫‪127409‬‬
‫‪127510‬‬
‫‪127603‬‬
‫‪127730‬‬
‫‪127783‬‬
‫‪129561‬‬
‫‪131770‬‬
‫‪132166‬‬
‫‪134073‬‬
‫‪135610‬‬
‫‪137277‬‬
‫‪138099‬‬
‫‪139199‬‬
‫‪139977‬‬
‫‪140199‬‬
‫‪140804‬‬
‫‪141765‬‬
‫‪141926‬‬
‫‪142125‬‬
‫‪142245‬‬
‫‪142416‬‬
‫‪142601‬‬
‫‪142832‬‬
‫‪143248‬‬
‫‪143503‬‬
‫‪143658‬‬
‫‪143789‬‬
‫‪144010‬‬
‫‪144119‬‬
‫‪144382‬‬
‫‪144699‬‬
‫‪144968‬‬
‫‪126199‬‬
‫‪126282‬‬
‫‪126324‬‬
‫‪126368‬‬
‫‪126403‬‬
‫‪126496‬‬
‫‪126556‬‬
‫‪126628‬‬
‫‪126727‬‬
‫‪126911‬‬
‫‪127015‬‬
‫‪127133‬‬
‫‪127235‬‬
‫‪127342‬‬
‫‪127385‬‬
‫‪127509‬‬
‫‪127595‬‬
‫‪127726‬‬
‫‪127782‬‬
‫‪129193‬‬
‫‪131436‬‬
‫‪132101‬‬
‫‪133976‬‬
‫‪135503‬‬
‫‪137096‬‬
‫‪137605‬‬
‫‪138987‬‬
‫‪139917‬‬
‫‪140179‬‬
‫‪140710‬‬
‫‪141742‬‬
‫‪141918‬‬
‫‪142124‬‬
‫‪142228‬‬
‫‪142413‬‬
‫‪142571‬‬
‫‪142804‬‬
‫‪143201‬‬
‫‪143487‬‬
‫‪143657‬‬
‫‪143788‬‬
‫‪143937‬‬
‫‪144106‬‬
‫‪144379‬‬
‫‪144698‬‬
‫‪144911‬‬
‫‪2115‬‬
‫‪145400‬‬
‫‪145774‬‬
‫‪146224‬‬
‫‪146602‬‬
‫‪146807‬‬
‫‪146965‬‬
‫‪147425‬‬
‫‪148082‬‬
‫‪148548‬‬
‫‪148794‬‬
‫‪149039‬‬
‫‪149503‬‬
‫‪149989‬‬
‫‪150433‬‬
‫‪151095‬‬
‫‪151404‬‬
‫‪151643‬‬
‫‪151792‬‬
‫‪151997‬‬
‫‪152267‬‬
‫‪152459‬‬
‫‪152914‬‬
‫‪153106‬‬
‫‪153338‬‬
‫‪154104‬‬
‫‪154662‬‬
‫‪154979‬‬
‫‪155264‬‬
‫‪156169‬‬
‫‪156918‬‬
‫‪158456‬‬
‫‪159798‬‬
‫‪161031‬‬
‫‪162418‬‬
‫‪164448‬‬
‫‪173676‬‬
‫‪2116‬‬
‫‪145365‬‬
‫‪145651‬‬
‫‪146205‬‬
‫‪146588‬‬
‫‪146804‬‬
‫‪146953‬‬
‫‪147369‬‬
‫‪148058‬‬
‫‪148520‬‬
‫‪148765‬‬
‫‪149005‬‬
‫‪149499‬‬
‫‪149920‬‬
‫‪150373‬‬
‫‪151072‬‬
‫‪151366‬‬
‫‪151587‬‬
‫‪151773‬‬
‫‪151984‬‬
‫‪152175‬‬
‫‪152400‬‬
‫‪152851‬‬
‫‪153057‬‬
‫‪153294‬‬
‫‪154066‬‬
‫‪154511‬‬
‫‪154924‬‬
‫‪155211‬‬
‫‪156141‬‬
‫‪156639‬‬
‫‪158406‬‬
‫‪159763‬‬
‫‪160854‬‬
‫‪161963‬‬
‫‪164445‬‬
‫‪170201‬‬
‫‪145363‬‬
‫‪145619‬‬
‫‪146103‬‬
‫‪146460‬‬
‫‪146759‬‬
‫‪146927‬‬
‫‪147247‬‬
‫‪147849‬‬
‫‪148470‬‬
‫‪148764‬‬
‫‪148998‬‬
‫‪149476‬‬
‫‪149853‬‬
‫‪150282‬‬
‫‪151038‬‬
‫‪151336‬‬
‫‪151582‬‬
‫‪151770‬‬
‫‪151983‬‬
‫‪152171‬‬
‫‪152392‬‬
‫‪152833‬‬
‫‪153047‬‬
‫‪153260‬‬
‫‪153448‬‬
‫‪154440‬‬
‫‪154766‬‬
‫‪155187‬‬
‫‪155902‬‬
‫‪156631‬‬
‫‪158177‬‬
‫‪159762‬‬
‫‪160735‬‬
‫‪161962‬‬
‫‪163942‬‬
‫‪165734‬‬
‫‪145336‬‬
‫‪145616‬‬
‫‪146068‬‬
‫‪146394‬‬
‫‪146746‬‬
‫‪146926‬‬
‫‪147178‬‬
‫‪147694‬‬
‫‪148391‬‬
‫‪148725‬‬
‫‪148955‬‬
‫‪149441‬‬
‫‪149852‬‬
‫‪150183‬‬
‫‪150887‬‬
‫‪151298‬‬
‫‪151565‬‬
‫‪151756‬‬
‫‪151975‬‬
‫‪152056‬‬
‫‪152376‬‬
‫‪152789‬‬
‫‪153007‬‬
‫‪153256‬‬
‫‪153416‬‬
‫‪154355‬‬
‫‪154765‬‬
‫‪155114‬‬
‫‪155722‬‬
‫‪156535‬‬
‫‪158052‬‬
‫‪159760‬‬
‫‪160258‬‬
‫‪161961‬‬
‫‪163503‬‬
‫‪165710‬‬
‫‪145327‬‬
‫‪145561‬‬
‫‪146014‬‬
‫‪146374‬‬
‫‪146721‬‬
‫‪146925‬‬
‫‪147119‬‬
‫‪147614‬‬
‫‪148379‬‬
‫‪148691‬‬
‫‪148932‬‬
‫‪149440‬‬
‫‪149819‬‬
‫‪150138‬‬
‫‪150654‬‬
‫‪151276‬‬
‫‪151560‬‬
‫‪151750‬‬
‫‪151966‬‬
‫‪152050‬‬
‫‪152308‬‬
‫‪152752‬‬
‫‪152992‬‬
‫‪153146‬‬
‫‪153380‬‬
‫‪154330‬‬
‫‪154749‬‬
‫‪155076‬‬
‫‪155624‬‬
‫‪156503‬‬
‫‪157833‬‬
‫‪159245‬‬
‫‪160234‬‬
‫‪161820‬‬
‫‪163292‬‬
‫‪164782‬‬
‫‪145318‬‬
‫‪145523‬‬
‫‪145986‬‬
‫‪146261‬‬
‫‪146702‬‬
‫‪146917‬‬
‫‪146995‬‬
‫‪147607‬‬
‫‪148302‬‬
‫‪148684‬‬
‫‪148910‬‬
‫‪149338‬‬
‫‪149731‬‬
‫‪150098‬‬
‫‪150616‬‬
‫‪151273‬‬
‫‪151536‬‬
‫‪151701‬‬
‫‪151963‬‬
‫‪152010‬‬
‫‪152286‬‬
‫‪152619‬‬
‫‪152977‬‬
‫‪153145‬‬
‫‪153379‬‬
‫‪154253‬‬
‫‪154746‬‬
‫‪155028‬‬
‫‪155541‬‬
‫‪156456‬‬
‫‪157790‬‬
‫‪159213‬‬
‫‪160186‬‬
‫‪161612‬‬
‫‪162974‬‬
‫‪164576‬‬
‫‪145316‬‬
‫‪145517‬‬
‫‪145807‬‬
‫‪146260‬‬
‫‪146669‬‬
‫‪146876‬‬
‫‪146992‬‬
‫‪147557‬‬
‫‪148291‬‬
‫‪148629‬‬
‫‪148897‬‬
‫‪149214‬‬
‫‪149675‬‬
‫‪150038‬‬
‫‪150532‬‬
‫‪151241‬‬
‫‪151516‬‬
‫‪151678‬‬
‫‪151850‬‬
‫‪152000‬‬
‫‪152282‬‬
‫‪152558‬‬
‫‪152974‬‬
‫‪153126‬‬
‫‪153378‬‬
‫‪154174‬‬
‫‪154714‬‬
‫‪155003‬‬
‫‪155358‬‬
‫‪156279‬‬
‫‪157524‬‬
‫‪159121‬‬
‫‪159958‬‬
‫‪161556‬‬
‫‪162626‬‬
‫‪164505‬‬
‫‪145286‬‬
‫‪145486‬‬
‫‪145777‬‬
‫‪146259‬‬
‫‪146609‬‬
‫‪146835‬‬
‫‪146985‬‬
‫‪147542‬‬
‫‪148242‬‬
‫‪148553‬‬
‫‪148840‬‬
‫‪149087‬‬
‫‪149589‬‬
‫‪150017‬‬
‫‪150469‬‬
‫‪151204‬‬
‫‪151449‬‬
‫‪151677‬‬
‫‪151813‬‬
‫‪151999‬‬
‫‪152281‬‬
‫‪152534‬‬
‫‪152915‬‬
‫‪153112‬‬
‫‪153344‬‬
‫‪154171‬‬
‫‪154681‬‬
‫‪154983‬‬
‫‪155308‬‬
‫‪156170‬‬
‫‪157194‬‬
‫‪158994‬‬
‫‪159799‬‬
‫‪161065‬‬
‫‪162575‬‬
‫‪164504‬‬
‫ט' באב התשס"ז –‪July 24, 2007‬‬
‫פטנטים שתוקפם פקעו בגלל אי תשלום אגרת חידוש‬
PATENTS NOT IN FORCE DUE TO NON-PAYMENT OF RENEWAL
FEES
87275
87369
87436
87564
87664
87740
87836
88348
88443
102686
102794
102873
102947
103060
103630
103732
103825
103897
110804
119009
119112
119190
119255
119313
119381
119491
119542
119615
119704
120968
122826
123155
123372
123455
123489
123605
123724
123901
123977
124040
124095
124198
2117
87292
87377
87448
87568
87676
87755
87868
88350
88453
102703
102797
102881
102951
103062
103642
103753
103827
103900
116942
119019
119121
119192
119256
119317
119392
119492
119550
119616
119705
121050
122865
123164
123375
123471
123539
123614
123745
123902
123987
124046
124096
124200
87303
87390
87458
87623
87686
87756
87882
88354
88493
102711
102809
102884
102985
103065
103644
103776
103832
103906
117592
119020
119132
119201
119257
119327
119403
119493
119552
119659
119709
121051
122987
123165
123424
123480
123560
123615
123771
123915
123991
124048
124107
124205
87312
87392
87468
87632
87694
87760
88289
88365
88498
102745
102816
102898
103010
103078
103665
103778
103847
103936
118674
119021
119144
119207
119259
119330
119424
119501
119571
119668
119740
121196
123042
123213
123427
123482
123581
123650
123797
123916
123999
124049
124121
124212
87323
87413
87487
87636
87697
87802
88330
88377
88531
102760
102821
102904
103018
103096
103694
103782
103879
103953
118984
119055
119149
119212
119264
119331
119433
119512
119586
119672
119746
121341
123056
123250
123430
123484
123589
123662
123808
123918
124003
124056
124136
124217
87329
87415
87513
87642
87704
87816
88345
88397
88544
102784
102854
102906
103054
103123
103703
103798
103884
103962
118992
119064
119174
119230
119274
119369
119434
119521
119587
119678
119970
121432
123080
123319
123434
123485
123597
123692
123816
123941
124021
124067
124156
124227
87332
87427
87542
87658
87713
87828
88346
88410
101332
102791
102856
102924
103055
103128
103713
103802
103887
103963
118997
119083
119182
119246
119285
119374
119466
119525
119602
119692
120742
121459
123136
123345
123438
123486
123599
123696
123851
123950
124022
124087
124158
124241
87341
87430
87554
87661
87731
87829
88347
88429
102681
102792
102858
102936
103056
103150
103729
103821
103895
104695
119000
119094
119188
119251
119311
119377
119482
119533
119609
119703
120780
121916
123147
123371
123443
123488
123603
123705
123885
123966
124037
124094
124185
124290
July 24, 2007– ‫ט' באב התשס"ז‬
‫‪124411‬‬
‫‪124662‬‬
‫‪124776‬‬
‫‪129813‬‬
‫‪137770‬‬
‫‪138919‬‬
‫‪139650‬‬
‫‪141259‬‬
‫‪145340‬‬
‫‪148608‬‬
‫‪152236‬‬
‫‪2118‬‬
‫‪124396‬‬
‫‪124658‬‬
‫‪124775‬‬
‫‪128643‬‬
‫‪137437‬‬
‫‪138537‬‬
‫‪139633‬‬
‫‪141228‬‬
‫‪144682‬‬
‫‪148197‬‬
‫‪151728‬‬
‫‪165945‬‬
‫‪124385‬‬
‫‪124649‬‬
‫‪124774‬‬
‫‪128627‬‬
‫‪135768‬‬
‫‪138364‬‬
‫‪139622‬‬
‫‪140162‬‬
‫‪143877‬‬
‫‪148009‬‬
‫‪150884‬‬
‫‪154667‬‬
‫‪124375‬‬
‫‪124611‬‬
‫‪124765‬‬
‫‪127347‬‬
‫‪135032‬‬
‫‪138282‬‬
‫‪139581‬‬
‫‪140123‬‬
‫‪143476‬‬
‫‪146736‬‬
‫‪150264‬‬
‫‪154664‬‬
‫‪124365‬‬
‫‪124499‬‬
‫‪124730‬‬
‫‪125460‬‬
‫‪134592‬‬
‫‪138023‬‬
‫‪139550‬‬
‫‪140007‬‬
‫‪143134‬‬
‫‪146592‬‬
‫‪149629‬‬
‫‪153108‬‬
‫‪124340‬‬
‫‪124464‬‬
‫‪124729‬‬
‫‪124884‬‬
‫‪130805‬‬
‫‪137909‬‬
‫‪139490‬‬
‫‪139892‬‬
‫‪142898‬‬
‫‪145817‬‬
‫‪149284‬‬
‫‪152579‬‬
‫‪124339‬‬
‫‪124420‬‬
‫‪124677‬‬
‫‪124833‬‬
‫‪130440‬‬
‫‪137864‬‬
‫‪139211‬‬
‫‪139712‬‬
‫‪142849‬‬
‫‪145809‬‬
‫‪149198‬‬
‫‪152374‬‬
‫‪124338‬‬
‫‪124415‬‬
‫‪124668‬‬
‫‪124792‬‬
‫‪129872‬‬
‫‪137861‬‬
‫‪139174‬‬
‫‪139657‬‬
‫‪142646‬‬
‫‪145341‬‬
‫‪148660‬‬
‫‪152255‬‬
‫ט' באב התשס"ז –‪July 24, 2007‬‬
‫פטנטים שחודשו לעשרים שנה‬
‫‪PATENTS RENEWED FOR 20 YEARS‬‬
‫‪163265‬‬
‫ט' באב התשס"ז –‪July 24, 2007‬‬
‫‪163074‬‬
‫‪146159‬‬
‫‪145350‬‬
‫‪138891‬‬
‫‪2119‬‬
‫פטנטים שפג תוקפם‬
‫‪PATENTS EXPIRED‬‬
‫‪81572‬‬
‫‪81649‬‬
‫‪81713‬‬
‫‪81775‬‬
‫‪81841‬‬
‫‪81920‬‬
‫‪81967‬‬
‫‪82032‬‬
‫‪82073‬‬
‫‪82120‬‬
‫‪82213‬‬
‫‪82250‬‬
‫‪82323‬‬
‫‪82397‬‬
‫‪82474‬‬
‫‪82512‬‬
‫‪82604‬‬
‫‪82709‬‬
‫‪101990‬‬
‫‪2120‬‬
‫‪81542‬‬
‫‪81639‬‬
‫‪81712‬‬
‫‪81769‬‬
‫‪81838‬‬
‫‪81919‬‬
‫‪81960‬‬
‫‪82017‬‬
‫‪82072‬‬
‫‪82118‬‬
‫‪82192‬‬
‫‪82245‬‬
‫‪82311‬‬
‫‪82395‬‬
‫‪82472‬‬
‫‪82511‬‬
‫‪82601‬‬
‫‪82700‬‬
‫‪99897‬‬
‫‪81520‬‬
‫‪81633‬‬
‫‪81709‬‬
‫‪81750‬‬
‫‪81835‬‬
‫‪81913‬‬
‫‪81959‬‬
‫‪82016‬‬
‫‪82061‬‬
‫‪82116‬‬
‫‪82176‬‬
‫‪82244‬‬
‫‪82298‬‬
‫‪82387‬‬
‫‪82464‬‬
‫‪82510‬‬
‫‪82592‬‬
‫‪82693‬‬
‫‪98886‬‬
‫‪81481‬‬
‫‪81618‬‬
‫‪81695‬‬
‫‪81749‬‬
‫‪81803‬‬
‫‪81892‬‬
‫‪81952‬‬
‫‪82005‬‬
‫‪82054‬‬
‫‪82113‬‬
‫‪82165‬‬
‫‪82242‬‬
‫‪82271‬‬
‫‪82377‬‬
‫‪82456‬‬
‫‪82508‬‬
‫‪82564‬‬
‫‪82692‬‬
‫‪91062‬‬
‫‪81456‬‬
‫‪81611‬‬
‫‪81686‬‬
‫‪81748‬‬
‫‪81802‬‬
‫‪81888‬‬
‫‪81948‬‬
‫‪81988‬‬
‫‪82053‬‬
‫‪82103‬‬
‫‪82152‬‬
‫‪82231‬‬
‫‪82266‬‬
‫‪82373‬‬
‫‪82454‬‬
‫‪82504‬‬
‫‪82550‬‬
‫‪82687‬‬
‫‪82758‬‬
‫‪81450‬‬
‫‪81607‬‬
‫‪81669‬‬
‫‪81744‬‬
‫‪81795‬‬
‫‪81886‬‬
‫‪81946‬‬
‫‪81984‬‬
‫‪82050‬‬
‫‪82101‬‬
‫‪82149‬‬
‫‪82230‬‬
‫‪82265‬‬
‫‪82353‬‬
‫‪82430‬‬
‫‪82491‬‬
‫‪82541‬‬
‫‪82641‬‬
‫‪82746‬‬
‫‪81448‬‬
‫‪81597‬‬
‫‪81663‬‬
‫‪81740‬‬
‫‪81791‬‬
‫‪81855‬‬
‫‪81937‬‬
‫‪81973‬‬
‫‪82045‬‬
‫‪82091‬‬
‫‪82148‬‬
‫‪82225‬‬
‫‪82260‬‬
‫‪82343‬‬
‫‪82411‬‬
‫‪82481‬‬
‫‪82535‬‬
‫‪82624‬‬
‫‪82743‬‬
‫‪119895‬‬
‫‪81438‬‬
‫‪81573‬‬
‫‪81652‬‬
‫‪81737‬‬
‫‪81788‬‬
‫‪81851‬‬
‫‪81927‬‬
‫‪81970‬‬
‫‪82044‬‬
‫‪82085‬‬
‫‪82127‬‬
‫‪82220‬‬
‫‪82251‬‬
‫‪82331‬‬
‫‪82398‬‬
‫‪82478‬‬
‫‪82513‬‬
‫‪82615‬‬
‫‪82719‬‬
‫‪119484‬‬
‫ט' באב התשס"ז –‪July 24, 2007‬‬
‫צווי הארכה שחודשו‬
EXTENSION ORDERS RENEWED
70311
2121
73534
77111
77243
84054
84601
July 24, 2007– ‫ט' באב התשס"ז‬
‫הודעה‬
NOTICE
‫ לחוק‬60 ‫לפי סעיף‬
1967-‫ תשכ"ז‬,‫הפטנטים‬
‫הוגשה בקשה להחזר‬
‫תוקפו של הפטנט המפורט‬
‫ שתוקפו פקע מחמת‬,‫מטה‬
‫אי תשלום אגרות החידוש‬
:‫הקבועות‬
Under section 60 of the
Patent Law, 5727-1967
Application has been filed
for the restoration of the
patent recorded below,
which has lapsed through
non-payment of the
prescribed renewal fees:
No. of Patent
Acceptance published in
journal no:
Proprietors:
114731
2/2005
‫מס' הפטנט‬
:'‫קיבול פורסם ביומן מס‬
:‫שם בעל הפטנט‬
‫מדינול בע"מ‬
MEDINOL LTD.
:‫שם האמצאה‬
Title of invention:
‫סטנט מפרקי‬
ARTICULATED STENT
Any person may oppose the
said application within three
months from the date of this
Patents Journal, as
prescribed by section 61 of
the law and by regulation 92
of the Patent Regulations,
5728-1968
July 24, 2007– ‫ט' באב התשס"ז‬
‫כל אדם רשאי להתנגד‬
‫לבקשה האמורה תוך‬
‫שלושה חודשים מתאריך‬
‫ כפי שנקבע‬,‫יומן פטנטים זה‬
92 ‫ לחוק ובתקנה‬61 ‫בסעיף‬
-‫ תשכ"ח‬,‫לתקנות הפטנטים‬
1968
2122
‫הודעה‬
NOTICE
‫ לחוק‬60 ‫לפי סעיף‬
1967-‫ תשכ"ז‬,‫הפטנטים‬
‫הוגשה בקשה להחזר‬
‫תוקפו של הפטנט המפורט‬
‫ שתוקפו פקע מחמת‬,‫מטה‬
‫אי תשלום אגרות החידוש‬
:‫הקבועות‬
Under section 60 of the
Patent Law, 5727-1967
Application has been filed
for the restoration of the
patent recorded below,
which has lapsed through
non-payment of the
prescribed renewal fees:
No. of Patent
Acceptance published in
journal no:
Proprietors:
116685
2/2000
‫מס' הפטנט‬
:'‫קיבול פורסם ביומן מס‬
:‫שם בעל הפטנט‬
‫וסקולאר טכנולגיות בע"מ‬
VASCULAR TECHNOLOGIES LIMITED
:‫שם האמצאה‬
‫ציין חדירה לכלי דם‬
BLOOD VESSEL ENTRY INDICATOR
Any person may oppose the
‫כל אדם רשאי להתנגד‬
said application within three
‫לבקשה האמורה תוך‬
months from the date of this
‫שלושה חודשים מתאריך‬
Patents Journal, as
‫ כפי שנקבע‬,‫יומן פטנטים זה‬
prescribed by section 61 of
92 ‫ לחוק ובתקנה‬61 ‫בסעיף‬
the law and by regulation 92
-‫ תשכ"ח‬,‫לתקנות הפטנטים‬
of the Patent Regulations,
5728-1968
1968
Title of invention:
2123
July 24, 2007– ‫ט' באב התשס"ז‬
‫הודעה‬
NOTICE
‫ לחוק‬60 ‫לפי סעיף‬
1967-‫ תשכ"ז‬,‫הפטנטים‬
‫הוגשה בקשה להחזר‬
‫תוקפו של הפטנט המפורט‬
‫ שתוקפו פקע מחמת‬,‫מטה‬
‫אי תשלום אגרות החידוש‬
:‫הקבועות‬
Under section 60 of the
Patent Law, 5727-1967
Application has been filed
for the restoration of the
patent recorded below,
which has lapsed through
non-payment of the
prescribed renewal fees:
No. of Patent
Acceptance published in
journal no:
Proprietors:
116722
9/2000
‫מס' הפטנט‬
:'‫קיבול פורסם ביומן מס‬
:‫שם בעל הפטנט‬
‫פסקל אביזרי קשירה בע"מ‬
PASKAL BINDING ACCESSORIES LTD.
:‫שם האמצאה‬
‫מתלה משחרר חוט סלילי להדליית ירקות‬
ROPE RELEASING HOOK WITH SPOOL FOR TRELLISING VEGETABLES
Any person may oppose the
‫כל אדם רשאי להתנגד‬
said application within three
‫לבקשה האמורה תוך‬
months from the date of this
‫שלושה חודשים מתאריך‬
Patents Journal, as
‫ כפי שנקבע‬,‫יומן פטנטים זה‬
prescribed by section 61 of
92 ‫ לחוק ובתקנה‬61 ‫בסעיף‬
the law and by regulation 92
-‫ תשכ"ח‬,‫לתקנות הפטנטים‬
of the Patent Regulations,
5728-1968
1968
Title of invention:
July 24, 2007– ‫ט' באב התשס"ז‬
2124
‫הודעה‬
NOTICE
‫ לחוק‬60 ‫לפי סעיף‬
1967-‫ תשכ"ז‬,‫הפטנטים‬
‫הוגשה בקשה להחזר‬
‫תוקפו של הפטנט המפורט‬
‫ שתוקפו פקע מחמת‬,‫מטה‬
‫אי תשלום אגרות החידוש‬
:‫הקבועות‬
Under section 60 of the
Patent Law, 5727-1967
Application has been filed
for the restoration of the
patent recorded below,
which has lapsed through
non-payment of the
prescribed renewal fees:
No. of Patent
Acceptance published in
journal no:
Proprietors:
123446
7/2000
‫מס' הפטנט‬
:'‫קיבול פורסם ביומן מס‬
:‫שם בעל הפטנט‬
T-SYSTEMS INTERNATIONAL, INC.
Title of invention:
:‫שם האמצאה‬
‫שיטה לחיבור טמפטות תוך שימוש באמצעיי פנימיים לטפטפות‬
METHOD FOR SPLICING DRIP IRRIGATION HOSES USING SPLICING MEANS
INTERNAL TO THE HOSES
Any person may oppose the
‫כל אדם רשאי להתנגד‬
said application within three
‫לבקשה האמורה תוך‬
months from the date of this
‫שלושה חודשים מתאריך‬
Patents Journal, as
‫ כפי שנקבע‬,‫יומן פטנטים זה‬
prescribed by section 61 of
92 ‫ לחוק ובתקנה‬61 ‫בסעיף‬
the law and by regulation 92
-‫ תשכ"ח‬,‫לתקנות הפטנטים‬
of the Patent Regulations,
5728-1968
1968
2125
July 24, 2007– ‫ט' באב התשס"ז‬
‫הודעה‬
NOTICE
‫ לחוק‬60 ‫לפי סעיף‬
1967-‫ תשכ"ז‬,‫הפטנטים‬
‫הוגשה בקשה להחזר‬
‫תוקפו של הפטנט המפורט‬
‫ שתוקפו פקע מחמת‬,‫מטה‬
‫אי תשלום אגרות החידוש‬
:‫הקבועות‬
Under section 60 of the
Patent Law, 5727-1967
Application has been filed
for the restoration of the
patent recorded below,
which has lapsed through
non-payment of the
prescribed renewal fees:
No. of Patent
Acceptance published in
journal no:
Proprietors:
126729
5/2001
‫מס' הפטנט‬
:'‫קיבול פורסם ביומן מס‬
:‫שם בעל הפטנט‬
CABOT CORPORATION
Title of invention:
:‫שם האמצאה‬
‫שיטה לייצור אבקת מתכת טנטל עם פיזור גודל מבוקר ומוצרים המיוצרים ממנה‬
METHOD OF MAKING TANTALUM METAL POWDER WITH CONTROLLED SIZE
DISTRIBUTION AND PRODUCTS MADE THEREFROM
Any person may oppose the
‫כל אדם רשאי להתנגד‬
said application within three
‫לבקשה האמורה תוך‬
months from the date of this
‫שלושה חודשים מתאריך‬
Patents Journal, as
‫ כפי שנקבע‬,‫יומן פטנטים זה‬
prescribed by section 61 of
92 ‫ לחוק ובתקנה‬61 ‫בסעיף‬
the law and by regulation 92
-‫ תשכ"ח‬,‫לתקנות הפטנטים‬
of the Patent Regulations,
5728-1968
1968
July 24, 2007– ‫ט' באב התשס"ז‬
2126
‫הודעה‬
NOTICE
‫ לחוק‬60 ‫לפי סעיף‬
1967-‫ תשכ"ז‬,‫הפטנטים‬
‫הוגשה בקשה להחזר‬
‫תוקפו של הפטנט המפורט‬
‫ שתוקפו פקע מחמת‬,‫מטה‬
‫אי תשלום אגרות החידוש‬
:‫הקבועות‬
Under section 60 of the
Patent Law, 5727-1967
Application has been filed
for the restoration of the
patent recorded below,
which has lapsed through
non-payment of the
prescribed renewal fees:
No. of Patent
Acceptance published in
journal no:
Proprietors:
‫מס' הפטנט‬
:'‫קיבול פורסם ביומן מס‬
137470
9/2004
:‫שם בעל הפטנט‬
‫) בע"מ‬1993( ‫טבעול‬
TIVALL (1993) LIMITED
:‫שם האמצאה‬
‫מוצר מזון תזונתי ותהליך להכנתו‬
NUTRITIONAL FOOD PRODUCT AND
PROCESS FOR ITS PREPARATION
Any person may oppose the
‫כל אדם רשאי להתנגד‬
said application within three
‫לבקשה האמורה תוך‬
months from the date of this
‫שלושה חודשים מתאריך‬
Patents Journal, as
‫ כפי שנקבע‬,‫יומן פטנטים זה‬
prescribed by section 61 of
92 ‫ לחוק ובתקנה‬61 ‫בסעיף‬
the law and by regulation 92
-‫ תשכ"ח‬,‫לתקנות הפטנטים‬
of the Patent Regulations,
5728-1968
1968
Title of invention:
2127
July 24, 2007– ‫ט' באב התשס"ז‬
‫הודעה‬
NOTICE
‫ לחוק‬60 ‫לפי סעיף‬
1967-‫ תשכ"ז‬,‫הפטנטים‬
‫הוגשה בקשה להחזר‬
‫תוקפו של הפטנט המפורט‬
‫ שתוקפו פקע מחמת‬,‫מטה‬
‫אי תשלום אגרות החידוש‬
:‫הקבועות‬
Under section 60 of the
Patent Law, 5727-1967
Application has been filed
for the restoration of the
patent recorded below,
which has lapsed through
non-payment of the
prescribed renewal fees:
No. of Patent
Acceptance published in
journal no:
Proprietors:
151651
6/2005
‫מס' הפטנט‬
:'‫קיבול פורסם ביומן מס‬
:‫שם בעל הפטנט‬
PLASTICOS MONDRAGON S.A.
Title of invention:
:‫שם האמצאה‬
‫שסטום הידרולי דיאפרגמתי לוויסות זרם נוזלים‬
HYDRAULIC DIAPHRAGM VALVE FOR FLUID FLOW REGULATION
Any person may oppose the
‫כל אדם רשאי להתנגד‬
said application within three
‫לבקשה האמורה תוך‬
months from the date of this
‫שלושה חודשים מתאריך‬
Patents Journal, as
‫ כפי שנקבע‬,‫יומן פטנטים זה‬
prescribed by section 61 of
92 ‫ לחוק ובתקנה‬61 ‫בסעיף‬
the law and by regulation 92
‫ תשכ"ח‬,‫לתקנות הפטנטים‬
of the Patent Regulations,
5728-1968
1968
July 24, 2007– ‫ט' באב התשס"ז‬
2128
‫הודעה‬
NOTICE
‫ לחוק‬60 ‫לפי סעיף‬
1967-‫ תשכ"ז‬,‫הפטנטים‬
‫הוגשה בקשה להחזר‬
‫תוקפו של הפטנט המפורט‬
‫ שתוקפו פקע מחמת‬,‫מטה‬
‫אי תשלום אגרות החידוש‬
:‫הקבועות‬
Under section 60 of the
Patent Law, 5727-1967
Application has been filed
for the restoration of the
patent recorded below,
which has lapsed through
non-payment of the
prescribed renewal fees:
No. of Patent
Acceptance published in
journal no:
Proprietors:
151728
10/2005
‫מס' הפטנט‬
:'‫קיבול פורסם ביומן מס‬
:‫שם בעל הפטנט‬
‫איתמר בורשטיין‬
ITAMAR BURSTEIN
:‫שם האמצאה‬
‫שיטה והתקן לשמירת פריטי לבוש יחדיו‬
METHOD AND DEVICE FOR SECURING APPAREL ARTICLES TOGETHER
Any person may oppose the
‫כל אדם רשאי להתנגד‬
said application within three
‫לבקשה האמורה תוך‬
months from the date of this
‫שלושה חודשים מתאריך‬
Patents Journal, as
‫ כפי שנקבע‬,‫יומן פטנטים זה‬
prescribed by section 61 of
92 ‫ לחוק ובתקנה‬61 ‫בסעיף‬
the law and by regulation 92
-‫ תשכ"ח‬,‫לתקנות הפטנטים‬
of the Patent Regulations,
5728-1968
1968
Title of invention:
2129
July 24, 2007– ‫ט' באב התשס"ז‬
NOTICE under section 64E of the
Patents Law, 5727-1967
‫ה לחוק‬64 ‫הודעה לפי סעיף‬
1967-‫הפטנטים התשכ"ז‬
‫בכוונת רשם הפטנטים ליתן צו‬
‫להארכת תקופת הגנה ע"פ פרק‬
,‫ לחוק הפטנטים‬1‫ סימן ב‬,'‫ד‬
‫ לגבי הפטנט‬1967-‫התשכ"ז‬
:‫המפורט מטה‬
It is the intention of the
Commissioner of Patents to grant an
order for the extension of the period
of protection of the following patent
in accordance with Chapter Four,
Article Two bis, of the Patents Law,
5727-1967
No. of basic patent:
84863
:‫מס' פטנט בסיסי‬
Title of invention:
:‫שם האמצאה‬
‫ תהליך להכנתם ותכשירים תרופתיים‬,3 ‫–אריאלאוקסי פרפאנאמינים מותמרים בעמדה‬3
‫המכילים אותם‬
-3ARYLOXY-3-SUBSTITUTED PROPANAMINES, PROCESS FOR THEIR
PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING
THEM
Proprietors:
:‫בעלי הפטנט‬
ELI LILLY AND COMPANY
Any person desiring to oppose the
‫כל המעוניין להתנגד למתן צו‬
said grant of an order may, within
‫הארכה רשאי תוך שלושה‬
three months from the date of this
‫ להגיש‬,‫חודשים מתאריך יומן זה‬
journal, serve to the Commissioner
‫התנגדות‬
‫לרשם הפטנטים הודעה‬
of Patents a notice of opposition
‫בדרך‬
,‫ו לחוק‬64 ‫לפי סעיף‬
under Section 64F of the Law, as
‫ לתקנות‬3 ‫הקבועה בתקנה‬
prescribed by Rule 3 of the Patent
Regulations (extension of period of
‫הפטנטים (הארכת תקופה הגנה‬
protection – procedure of
,‫– סדרי דין בבקשה לצו‬
application for order, opposition to
,)‫ ובבקשה לביטול‬,‫בהתנגדות לצו‬
order, application to annul) 57581998-‫התשנ"ח‬
1998.
July 24, 2007– ‫ט' באב התשס"ז‬
2130
‫שינויים בפרטים רשומים בפנקס‬
CHANGES IN PARTICULARS ENTERED IN REGISTER
‫שינוי שם הבעלים‬
CHANGE OF NAME OF PROPRIETORS
No. of Patent:
,160923 ,160922 ,156758 ,156148 ,128551 ,51634
163428 ,162232 ,162169 ,161564
:‫מס' פטנט‬
:‫השם הקודם‬
Previous name:
SYNTHES AG CHUR
:‫השם החדש‬
New name:
AO TECHNOLOGY AG
‫שינוי בעלות‬
CHANGES IN PROPRIETORSHIP
No. of Patent:
113024
Previous Proprietors:
RECORDATI S.A., CHEMICAL AND
PHARMACEUTICAL COMPANY
New Proprietors:
RECORDATI IRELAND LIMITED
:‫מס' פטנט‬
:‫הבעלים הקודמים‬
No. of Patent:
135814
Previous Proprietors:
KOSLOW TECHNOLOGIES
CORPORATION
New Proprietors:
KX INDUSTRIES, L.P.
:‫מס' פטנט‬
:‫הבעלים הקודמים‬
No. of Patent:
138057
Previous Proprietors:
RESPIRATORY SUPPORT PRODUCTS
INC.
New Proprietors:
SMITHS MEDICAL ASD
:‫מס' פטנט‬
:‫הבעלים הקודמים‬
2131
:‫הבעלים החדשים‬
:‫הבעלים החדשים‬
:‫הבעלים החדשים‬
July 24, 2007– ‫ט' באב התשס"ז‬
No. of Patent:
139313
Previous Proprietors:
HUBERT ERIC WALTER
New Proprietors:
MGS MODULAR GALLERY SYSTEMS
AG
:‫מס' פטנט‬
:‫הבעלים הקודמים‬
No. of Patent:
141991
Previous Proprietors:
LABORATORIOS VITA S.A.
New Proprietors:
VITA CIENTIFICA, S.L.
:‫מס' פטנט‬
:‫הבעלים הקודמים‬
No. of Patent:
147701
Previous Proprietors:
KOSLOW TECHNOLOGIES
CORPORATION
New Proprietors:
KX INDUSTRIES, L.P.
:‫מס' פטנט‬
:‫הבעלים הקודמים‬
No. of Patent:
156186
Previous Proprietors:
KOSLOW TECHNOLOGIES
CORPORATION
New Proprietors:
KX INDUSTRIES, L.P.
:‫מס' פטנט‬
:‫הבעלים הקודמים‬
July 24, 2007– ‫ט' באב התשס"ז‬
:‫הבעלים החדשים‬
:‫הבעלים החדשים‬
:‫הבעלים החדשים‬
:‫הבעלים החדשים‬
2132
No. of Patent:
158362
Previous Proprietors:
KOSLOW TECHNOLOGIES
CORPORATION
New Proprietors:
KX INDUSTRIES, L.P.
:‫מס' פטנט‬
:‫הבעלים הקודמים‬
No. of Patent:
163057
Previous Proprietors:
KOSLOW TECHNOLOGIES
CORPORATION
New Proprietors:
KX INDUSTRIES, L.P.
:‫מס' פטנט‬
:‫הבעלים הקודמים‬
No. of Patent:
163159
Previous Proprietors:
KOSLOW TECHNOLOGIES
CORPORATION
New Proprietors:
KX INDUSTRIES, L.P.
:‫מס' פטנט‬
:‫הבעלים הקודמים‬
No. of Patent:
165739
Previous Proprietors:
KOSLOW TECHNOLOGIES
CORPORATION
New Proprietors:
KX INDUSTRIES, L.P.
:‫מס' פטנט‬
:‫הבעלים הקודמים‬
2133
:‫הבעלים החדשים‬
:‫הבעלים החדשים‬
:‫הבעלים החדשים‬
:‫הבעלים החדשים‬
July 24, 2007– ‫ט' באב התשס"ז‬
No. of Patent:
165740
Previous Proprietors:
KOSLOW TECHNOLOGIES
CORPORATION
New Proprietors:
KX INDUSTRIES, L.P.
:‫מס' פטנט‬
:‫הבעלים הקודמים‬
No. of Patent:
165741
Previous Proprietors:
KOSLOW TECHNOLOGIES
CORPORATION
New Proprietors:
KX INDUSTRIES, L.P.
:‫מס' פטנט‬
:‫הבעלים הקודמים‬
No. of Patent:
165742
Previous Proprietors:
KOSLOW TECHNOLOGIES
CORPORATION
New Proprietors:
KX INDUSTRIES, L.P.
:‫מס' פטנט‬
:‫הבעלים הקודמים‬
July 24, 2007– ‫ט' באב התשס"ז‬
:‫הבעלים החדשים‬
:‫הבעלים החדשים‬
:‫הבעלים החדשים‬
2134
‫תיקוני טעויות‬
CORRIGENDA
Journal
11/2005
P. 4667 Patent application No. 118235
Correct address for service toINTERPHARM LABORATORIES LTD.
KIRYAT WEIZMANN
NES ZIONA 76110
‫יומן‬
118235 '‫ בקשת פטנט מס‬4667 '‫ע‬
:‫תקן המען למסירת‬
‫אינטרפארם מעבדות בע"מ‬
‫ פארק לתעשיות עתירות ידע‬,‫קרית ויצמן‬
76100 ‫נס ציונה‬
Journal
11/2006
P. 4359 Notice under section 35 of the law
Concerning patent application No. 101769
Delete the notice under section 35.
The notice was published by mistake
‫יומן‬
‫ לחוק‬35 ‫ הודעה לפי סעיף‬4359 '‫ע‬
101769 '‫בעניין בקשת פטנט מס‬
‫ההודעה פורסמה בטעות‬
Journal
9/2006
‫יומן‬
P. 3455 Patent application No. 122942
122942 '‫ בקשת פטנט מס‬3455 '‫ע‬
GB 25.7.1995
9515279.9
WO 1997/05154
Correct priority claim
‫תקן דין קדימה‬
Correct international publication no. to
‫תקן את מספר הפרסום הבינלאומי ל‬
2135
July 24, 2007– ‫ט' באב התשס"ז‬
‫קודים למדינת המופיעים ביומן‬
COUNTRY CODES APPEARING IN THIS JOURNAL
Code
AR
AT
AU
BA
BE
BR
CA
CH
CN
CU
CZ
DE
DK
EC
EP
ES
FI
FR
GB
GE
GR
GT
HR
HU
IE
IL
IN
IT
JP
KR
LK
LU
LV
MX
Country or Organization
Argentina
Austria
Australia
Herzegovina
Belgium
Brazil
Canada
Switzerland
China
Cuba
Czech Republic
Germany
Denmark
Ecuador
European Patent Office
Spain
Finland
France
United Kingdom
Georgia
Greece
Guatemala
Croatia
Hungary
Ireland
Israel
India
Italy
Japan
Republic of Korea
Sri Lanka
Luxembourg
Latvia
Mexico
July 24, 2007– ‫ט' באב התשס"ז‬
2136
MY
NL
NO
NZ
PL
PT
RU
SE
SG
SI
SK
TH
TR
TW
UA
US
UY
UZ
WO
ZA
2137
Malaysia
The Netherlands
Norway
New Zealand
Poland
Portugal
Russian Federation
Sweden
Singapore
Slovenia
Slovakia
Thailand
Turkey
Taiwan
Ukraine
United States of America
Uruguay
Uzbekistan
World Intellectual Property Organization (W.I.P.O.)
South Africa
July 24, 2007– ‫ט' באב התשס"ז‬
‫מדגמים‬
DESIGNS
‫מדגמים שנרשמו‬
DESIGNS REGISTERED
Class
38950, 38951, 38952
2(04)
23. 2.2004
‫סוג‬
‫אשר ליאני‬
)‫תאריך אמנה (ארצות הברית‬
‫סוליה‬
ASHER LIEANY
Sole
39711
6(06)
21. 9.2004
Class
WIEDER THE EXPERTS ON BEDS
AND MATTRESSES LTD.
‫סוג‬
‫וידר המומחים למיטות ומזרונים‬
‫בע"מ‬
‫רגליים של ספה‬
Feet of a couch
39798
25(01)
20.10.2004
Class
‫סוג‬
‫בודי משומשים בע"מ‬
BODY MESHUMASHIM LTD.
‫פרופיל‬
Profile
Class
39861, 39862
14(03)
9. 11.2004
‫סוג‬
RESEARCH IN MOTION LTD.
‫התקן תקשורת‬
Communication device
Class
39926, 42710, 42711
14(03)
16.11.2004
‫סוג‬
RESEARCH IN MOTION LTD.
Communication device
July 24, 2007– ‫ט' באב התשס"ז‬
‫מכשיר תקשורת‬
2138
Class
40092, 40093
8(06)
21.12.2004
‫סוג‬
‫אבנרס קולקשיין בע"מ‬
AVNER'S COLLECTION LTD.
‫ידית‬
Handle
Class
40103
21(01)
22.12.2004
‫סוג‬
‫למדע תעשיות קלות בע"מ‬
LEMADA LIGHT INDUSTRIES
LTD.
‫משחק‬
Game
Class
40129
19(02)
29.12.2004
‫סוג‬
‫משה מנור‬
MOSHE MANOR
‫פורט כסף‬
Money changer
Class
40331
8(08)
13. 2.2005
‫סוג‬
‫ אורלי בע"מ‬.‫ב‬.‫ל‬
L.B. ORLY LTD.
‫תפסן‬
Gripper
Class
40424
25(01)
9. 3.2005
‫סוג‬
‫פרס פלסט בע"מ‬
PRESS PLAST LTD.
‫פרופיל‬
Profile
Class
MIGAL ENGINEERING AND
CONSTRUCTION LTD.
Building unit for acoustic wall
2139
40590
25(01)
11. 4.2005
‫סוג‬
‫מיגל חברה להנדסה ובניין בע"מ‬
‫יחידת בניה לקיר אקוסטי‬
July 24, 2007– ‫ט' באב התשס"ז‬
40998
10(02)
12. 7.2005
Class
‫סוג‬
‫אופטו ליין בע"מ‬-‫אחים סגל‬
SEGAL BROS-OPTO LINE LTD.
‫שעון‬
Watch
41107
11(01)
25.7.2005
Class
‫סוג‬
H. STERN COMERCIO E INDUSTRIA S.A.
‫תכשיט‬
Jewel
41119
8(06)
27.7.2005
Class
‫סוג‬
UNION KNOPF GMBH
‫ידית‬
Handle
41204
25(01)
11. 8.2005
Class
‫סוג‬
‫יגאל בלכר‬
IGAL BLECHER
‫פרופיל‬
Profile
41217
28(02)
15.8.2005
Class
‫סוג‬
UNILEVER PLC
Soap bar
3.3.2005
Convention date (United Kingdom)
Class
41240
25(02)
17. 8.2005
ALIAZER GANNY (GARTNER)
Barrier
July 24, 2007– ‫ט' באב התשס"ז‬
‫סבון‬
‫תאריך האמנה (הממלכה‬
)‫המאוחדת‬
‫סוג‬
)‫אליעזר גנני (גרטנר‬
‫מחסום‬
2140
)‫צות הברית‬
41447
6(03)
2. 10.2005
Class
‫סוג‬
‫עמינח תעשית רהיטים ומזרונים‬
‫בע"מ‬
AMINACH BEDDING AND
FURNITURE LTD.
‫שולחנון צד המיטה‬
Bedside table
Class
41450
13(03)
2.10.2005
‫סוג‬
LUTRON ELECTRONICS CO., INC.
‫מתג עמעם‬
)‫הברית‬
)‫הברית‬
‫(ארצות‬
‫(ארצות‬
‫האמנה‬
‫תאריךאמנה‬
‫תאריך‬
Dimmer switch
Convention date (U.S.A.)
Class
4.4.2005
41468, 41469, 41471,
41472, 41473, 41474,
41475, 41476, 41477,
41478, 41479
6(06)
9. 10.2005
WIEDER THE EXPERTS ON BEDS
AND MATTRESSES LTD.
‫סוג‬
‫וידר המומחים למיטות ומזרונים‬
‫בע"מ‬
‫רגליים של ספה‬
Feet for couch
Class
41489, 41491
6(06)
9. 10.2005
WIEDER THE EXPERTS ON BEDS
AND MATTRESSES LTD.
‫סוג‬
‫וידר המומחים למיטות ומזרונים‬
‫בע"מ‬
‫מסעד לספה‬
Support for couch
Class
41495, 41496, 41497,
41498
6(06)
9. 10.2005
WIEDER THE EXPERTS ON BEDS
AND MATTRESSES LTD.
Frame for couch
2141
‫סוג‬
‫וידר המומחים למיטות ומזרונים‬
‫בע"מ‬
‫מסגרת לספה‬
July 24, 2007– ‫ט' באב התשס"ז‬
Class
41502
6(06)
9. 10.2005
WIEDER THE EXPERTS ON BEDS
AND MATTRESSES LTD.
‫סוג‬
‫וידר המומחים למיטות ומזרונים‬
‫בע"מ‬
‫ידית לספה‬
Handle for couch
Class
41599
9(01)
15. 11.2005
‫סוג‬
‫יפאורה תבורי בע"מ‬
JAFORA TABORI LTD.
‫בקבוק‬
Bottle
Class
41684
23(02)
4. 12.2005
‫סוג‬
‫ יציקות בע"מ‬.‫מ‬.‫א‬.‫ר‬
R.A.M. CASTING LTD.
‫מושב למקלחון‬
Seat for shower room
Class
41802
9(07)
27.12.2005
‫סוג‬
PORTOLA PACKAGING LIMITED
Closure for containers
8.7.2005
Convention date (OHIM)
Class
‫סגר עבור מיכלים‬
)‫הברית‬
)‫(אוהיים‬
‫(ארצות‬
‫האמנה‬
‫תאריךאמנה‬
‫תאריך‬
41855, 41856
7(07)
29.12.2004
‫סוג‬
DART INDUSTRIES INC.
Container
Convention date (U.S.A.)
Class
22.7.2004
41908
11(01)
25.1.2006
‫מיכל‬
)‫הברית‬
)‫הברית‬
‫(ארצות‬
‫(ארצות‬
‫האמנה‬
‫תאריךאמנה‬
‫תאריך‬
‫סוג‬
H. STERN COMERCIO E INDUSTRIA S.A.
Jewel
July 24, 2007– ‫ט' באב התשס"ז‬
‫תכשיט‬
2142
41919
25(01)
26. 1.2006
Class
GUMIX LIMITED PARTNERSHIP
‫גומיקס שותפות מוגבלת‬
‫מעבר חציה למוגבלים‬
Crosswalk for handicapped
Class
‫סוג‬
42133, 42135, 42136
10(07)
26.7.2005
‫סוג‬
H. STERN COMERCIO E INDUSTRIA S.A.
Watch dial
Convention date (EUROPE)
Class
28.1.2005
42216
9(03)
22. 3.2006
‫לוח שעון‬
)‫הברית‬
)‫(אירופה‬
‫(ארצות‬
‫האמנה‬
‫תאריךאמנה‬
‫תאריך‬
‫סוג‬
‫) בע"מ‬1990( ‫ווק‬-‫פלסטו‬
PLASTO-VACK (1990) LTD.
‫מיכל‬
Container
Class
42237, 42238
8(06)
26. 3.2006
‫סוג‬
‫אבנרס קולקשיין בע"מ‬
AVNER'S COLLECTION LTD.
‫ידית‬
Handle
Class
SHARON BELGAZAL
Profile
2143
42253
25(01)
30. 3.2006
‫סוג‬
‫שרון בלגזל‬
‫פרופיל‬
July 24, 2007– ‫ט' באב התשס"ז‬
42309
13(03)
2.10.2005
Class
‫סוג‬
LUTRON ELECTRONICS CO., INC.
Dimmer switch
Convention date (U.S.A.)
4.4.2005
42319
7(01)
11. 4.2006
Class
‫מתג עמעם‬
)‫הברית‬
)‫הברית‬
‫(ארצות‬
‫(ארצות‬
‫האמנה‬
‫תאריךאמנה‬
‫תאריך‬
‫סוג‬
‫דורון מרדינגר בע"מ‬
DORON MERDINGER LTD.
‫תחתית לספל‬
Saucer for cup
Class
42329, 43362
25(01)
20. 4.2006
‫סוג‬
‫תמנון הופ בע"מ‬
TAMNUN HOP LTD.
‫פרופיל‬
Profile
Class
42330
20(03)
20. 4.2006
‫סוג‬
‫תמנון הופ בע"מ‬
TAMNUN HOP LTD.
‫התקן תמיכה לרשימת קניות‬
Support for shopping list
Class
42361, 42362
2(04)
25.4.2006
‫סוג‬
CROCS, INC.
Upper
Convention date (U.S.A.)
Class
26.10.2005
42426
19(06)
2.5.2006
‫גפה‬
)‫הברית‬
)‫הברית‬
‫(ארצות‬
‫(ארצות‬
‫האמנה‬
‫תאריךאמנה‬
‫תאריך‬
‫סוג‬
ZEBRA CO. LTD.
Ballpoint pen
Convention date (Japan)
July 24, 2007– ‫ט' באב התשס"ז‬
21.2.2006
‫עט כדורי‬
)‫(ארצות) הברית‬
‫האמנה (יפן‬
‫תאריךאמנה‬
‫תאריך‬
2144
Class
42725
10(02)
11.7.2006
‫סוג‬
CARTIER CREATION STUDIO SA
Wristwatch
Convention date (OHIM(
‫שעון יד‬
)‫הברית‬
)‫(אוהיים‬
‫(ארצות‬
‫האמנה‬
‫תאריךאמנה‬
‫תאריך‬
12.1.2006
Class
42763
6(01)
18.7.2006
‫סוג‬
NICOLETTI S.P.A.
‫ספה‬
)‫הברית‬
)‫(איטליה‬
‫(ארצות‬
‫האמנה‬
‫תאריךאמנה‬
‫תאריך‬
Sofa
19.1.2006
Convention date (Italy)
Class
42849, 42850
7(01)
6.8.2006
‫סוג‬
VILLEROY & BOCH AG
‫צלחת‬
)‫הברית‬
)‫(אוהיים‬
‫(ארצות‬
‫האמנה‬
‫תאריךאמנה‬
‫תאריך‬
Plate
8.2.2006
Convention date (OHIM)
Class
42851
7(01)
6.8.2006
‫סוג‬
VILLEROY & BOCH AG
Set of cup and saucer
Convention date (OHIM)
Class
8.2.2006
42911
13(03)
16. 8.2006
NISKO ELECTRICITY &
ELECTRONICS PRODUCTS )1982)
LTD.
Socket
2145
‫מערכת חפצים ספל ותחתית‬
)‫הברית‬
)‫(אוהיים‬
‫(ארצות‬
‫האמנה‬
‫תאריךאמנה‬
‫תאריך‬
‫סוג‬
‫ניסקו מוצרי חשמל‬
‫) בע"מ‬1982( ‫ואלקטרוניקה‬
‫שקע‬
July 24, 2007– ‫ט' באב התשס"ז‬
Class
42930
9(03)
21. 8.2006
‫סוג‬
‫מנשה רוגוטנר‬
MENASHE ROGOTNER
‫אריזה‬
Packaging
Class
42951
9(01)
28.8.2006
‫סוג‬
BULGARI S.P.A.
Cream jar
Convention date (OHIM)
Class
3.3.2006
43126
6(06)
26. 9.2006
WIEDER THE EXPERTS ON BEDS
AND MATTRESSES LTD.
‫צנצנת למשחה‬
)‫הברית‬
)‫(אוהיים‬
‫(ארצות‬
‫האמנה‬
‫תאריךאמנה‬
‫תאריך‬
‫סוג‬
‫וידר המומחים למיטות ומזרונים‬
‫בע"מ‬
‫רגליים של ספה‬
Feet for couch
Class
43130
6(06)
26. 9.2006
WIEDER THE EXPERTS ON BEDS
AND MATTRESSES LTD.
‫סוג‬
‫וידר המומחים למיטות ומזרונים‬
‫בע"מ‬
‫מסגרת לספה‬
Frame for a couch
Class
43137, 43139
6(01)
26. 9.2006
WIEDER THE EXPERTS ON BEDS
AND MATTRESSES LTD.
‫סוג‬
‫וידר המומחים למיטות ומזרונים‬
‫בע"מ‬
‫משענת גב לספה‬
Back rest for couch
Class
PAPAYA FASHION LTD.
Sole
July 24, 2007– ‫ט' באב התשס"ז‬
43192
2(04)
15. 10.2006
‫סוג‬
‫פאפאיה אופנה בע"מ‬
‫סוליה‬
2146
Class
43212
24(04)
18.10.2006
‫סוג‬
VECTURA GROUP PLC
Inhaler
Convention date (OHIM)
Class
28.4.2006
43224, 43921
11(01)
22.10.2006
‫משאף‬
)‫הברית‬
)‫(אוהיים‬
‫(ארצות‬
‫האמנה‬
‫תאריךאמנה‬
‫תאריך‬
‫סוג‬
H. STERN COMERCIO E INDUSTRIA S.A.
‫תכשיט‬
Jewel
Class
43229
25(01)
22. 10.2006
‫סוג‬
‫שרון בלגזל‬
SHARON BELGAZAL
‫פרופיל‬
Profile
Class
43288
4(02)
6.11.2006
‫סוג‬
GLAXOSMITHKLINE CONSUMER HEALTHCARE GMBH & CO
KG
Toothbrush handle
Convention date (United Kingdom)
Class
R.A.M. CASTING LTD.
Chair
2147
8.5.2006
43298
6(01)
7. 11.2006
‫ידית למברשת שיניים‬
‫תאריך האמנה (הממלכה‬
)‫המאוחדת‬
‫סוג‬
‫ יציקות בע"מ‬.‫מ‬.‫א‬.‫ר‬
‫כסא‬
July 24, 2007– ‫ט' באב התשס"ז‬
)‫ות הברית‬
43321
3(03)
14. 11.2006
Class
‫סוג‬
‫אורית יצחק‬
ORIT YIZHAK
‫מטריה‬
Umbrella
43357
12(15)
22.11.2006
Class
‫סוג‬
BRIDGESTONE CORPORATION
Tire
25.5.2006
Convention date (Japan)
43382
15(07)
30.5.2006
Class
‫צמיג‬
)‫(יפן) הברית‬
‫(ארצות‬
‫האמנה‬
‫תאריךאמנה‬
‫תאריך‬
‫סוג‬
DAF TRUCKS N.V.
‫מקרר‬
Refrigerator
Class
43406
24(04)
29.11.2006
‫סוג‬
NORTON HEALTHCARE LTD.
Inhaler device
Convention date (OHIM)
Class
AVISHY COSMETIC AND
HYGIENE LTD.
16.6.2006
43416
28(03)
30. 11.2005
‫משאף‬
)‫הברית‬
)‫(אוהיים‬
‫(ארצות‬
‫האמנה‬
‫תאריךאמנה‬
‫תאריך‬
‫סוג‬
‫אבישי תמרוקים והיגיינה בע"מ‬
‫בקבוק‬
Bottle
Class
43421
10(07)
3. 12.2006
‫סוג‬
EREZ BARUCH
‫ארז ברוך‬
Hands for watch dial
‫מחוגים של לוח השעון‬
July 24, 2007– ‫ט' באב התשס"ז‬
2148
Class
43426
13(03)
4. 12.2006
UNITRONICS (1989) (R.G.) LTD.
‫סוג‬
‫) (ר"ג) בע"מ‬1989( ‫יוניטרוניקס‬
‫בקר‬
Controller
Class
43449
24(02)
10. 12.2006
‫סוג‬
‫יוסף פלדמן‬
JOSEPH FELDMAN
‫מכשיר טיפולי להקרנות‬
Therapeutic radiation instrument
Class
43463, 43464, 43465
8(06)
12. 12.2006
‫סוג‬
SMILDO S.L.
‫ידית‬
Handle
Class
43466
23(02)
12. 12.2006
DOMICILE IMPORT EXPORT LTD.
‫סוג‬
‫דומיסיל יבוא ויצוא בע"מ‬
‫וו‬
Hook
Class
43468
23(02)
12. 12.2006
DOMICILE IMPORT EXPORT LTD.
‫סוג‬
‫דומיסיל יבוא ויצוא בע"מ‬
‫סבוניה לקיר‬
Wall soap-dish
Class
43469
23(02)
12. 12.2006
DOMICILE IMPORT EXPORT LTD.
Toilet paper holder
2149
‫סוג‬
‫דומיסיל יבוא ויצוא בע"מ‬
‫מחזיק נייר טואלט‬
July 24, 2007– ‫ט' באב התשס"ז‬
Class
43471
23(02)
12. 12.2006
DOMICILE IMPORT EXPORT LTD.
‫סוג‬
‫דומיסיל יבוא ויצוא בע"מ‬
‫מתלה למגבות‬
Towel hanger
Class
43472
23(02)
12. 12.2006
DOMICILE IMPORT EXPORT LTD.
‫סוג‬
‫דומיסיל יבוא ויצוא בע"מ‬
‫מתלה כפול למגבות‬
Double towel hanger
Class
43478
10(04)
13.12.2006
‫סוג‬
THE DIAMOND TRADING COMPANY LTD.
Diamond verification instrument
1.8.2006
Convention date (EUROPE)
Class
43492
28(03)
14.12.2006
‫מכשיר לבדיקת יהלומים‬
)‫הברית‬
)‫(אירופה‬
‫(ארצות‬
‫האמנה‬
‫תאריךאמנה‬
‫תאריך‬
‫סוג‬
CALOR
Depilator
7.7.2006
Convention date (France)
Class
43503
23(04)
14.12.2006
‫מסיר שערות‬
)‫הברית‬
)‫(צרפת‬
‫(ארצות‬
‫האמנה‬
‫תאריךאמנה‬
‫תאריך‬
‫סוג‬
SARA LEE HOUSEHOLD AND BODY CARE NEDERLAND B.V.
Refill bottle for air deodorizing apparatus
Convention date (OHIM)
Class
‫בקבוקון מילוי למכשיר לבישום אוויר‬
26.9.2006
)‫הברית‬
)‫(אוהיים‬
‫(ארצות‬
‫האמנה‬
‫תאריךאמנה‬
‫תאריך‬
43504
23(04)
14.12.2006
‫סוג‬
SARA LEE HOUSEHOLD AND BODY CARE NEDERLAND B.V.
Air deodorizing apparatus
Convention date (OHIM)
July 24, 2007– ‫ט' באב התשס"ז‬
26.9.2006
‫מכשיר לבישום אוויר‬
)‫הברית‬
)‫(אוהיים‬
‫(ארצות‬
‫האמנה‬
‫תאריךאמנה‬
‫תאריך‬
2150
Class
43546
6(09)
26. 12.2006
‫סוג‬
‫אלמוג צחר‬
ALMOG TSACHAR
‫מזרון החתלה לתינוק‬
Baby diaper changing mattress
Class
43661
11(01)
4. 11.2004
‫סוג‬
H. STERN COMERCIO E INDUSTRIA S.A.
‫עגיל‬
Earring
Class
43692
26(03)
29. 1.2007
‫סוג‬
ILAN NAHSON
‫אילן נחשון‬
Lighting fixture
‫התקן תאורה‬
Class
43839
23(01)
2.3.2005
‫סוג‬
STRIX LIMITED
Water filter
Convention date (OHIM)
Class
9.9.2004
43923
11(01)
10. 9.2006
‫מסנן למים‬
)‫הברית‬
)‫(אוהיים‬
‫(ארצות‬
‫האמנה‬
‫תאריךאמנה‬
‫תאריך‬
‫סוג‬
H. STERN COMERCIO E INDUSTRIA S.A.
Jewel
2151
‫תכשיט‬
July 24, 2007– ‫ט' באב התשס"ז‬
‫מדגמים שחודשו‬
‫‪DESIGNS RENEWED‬‬
‫‪27961‬‬
‫‪36370‬‬
‫‪36534‬‬
‫‪37152‬‬
‫‪2152‬‬
‫‪27960‬‬
‫‪36369‬‬
‫‪36505‬‬
‫‪36983‬‬
‫‪27959‬‬
‫‪36304‬‬
‫‪36496‬‬
‫‪36803‬‬
‫‪27957‬‬
‫‪36258‬‬
‫‪36492‬‬
‫‪36689‬‬
‫‪27932‬‬
‫‪28462‬‬
‫‪36491‬‬
‫‪36688‬‬
‫‪27913‬‬
‫‪28241‬‬
‫‪36487‬‬
‫‪36681‬‬
‫‪27846‬‬
‫‪28239‬‬
‫‪36373‬‬
‫‪36610‬‬
‫‪27584‬‬
‫‪27962‬‬
‫‪36372‬‬
‫‪36609‬‬
‫‪37153‬‬
‫ט' באב התשס"ז –‪July 24, 2007‬‬
‫מדגמים שבוטלו‬
DESIGNS VOID
19399
26944
27029
35749
35810
35819
35845
35882
19487
26954
27030
35795
35811
35820
35847
35883
19488
26956
27031
35796
35812
35823
35848
35884
Dr. Meir Noam
Commissioner of Patents,
Designs and Trade Marks
2153
19489
26958
27036
35800
35813
35824
35849
35987
19490
26959
27037
35801
35814
35841
35856
19506
26992
27038
35802
35815
35842
35866
19513
26995
27039
35804
35817
35843
35867
26934
27016
33070
35809
35818
35844
35881
‫ד"ר מאיר נועם‬
‫ המדגמים‬,‫רשם הפטנטים‬
‫וסימני מסחר‬
July 24, 2007– ‫ט' באב התשס"ז‬
‫מפתחות לבקשות שקובלו‬
‫‪INDICES OF APPLICATIONS ACCEPTED‬‬
‫מפתח שמי‬
‫א‪.‬י‪ .‬מעבדות בע"מ ‪159911‬‬
‫אבי דסקלו ‪132625‬‬
‫אבישי מלמד ‪165639‬‬
‫אברהם ניסנקורן ‪146534‬‬
‫אדוארד ג‪.‬שיפרין ‪147954‬‬
‫אדוארד שיפרין ‪147954‬‬
‫אדי קרניאלי ‪137759‬‬
‫אוה ‪ -‬טק מדיקל ‪ 21‬בע"מ ‪147954‬‬
‫אורבוטק בע"מ ‪149588‬‬
‫אורמת תעשיות בע"מ ‪156048‬‬
‫איי אופטימה בע"מ ‪152343‬‬
‫אייל אליאב ‪159990‬‬
‫אילן שר ‪155796‬‬
‫אינולייז ‪ 2002‬בע"מ ‪150094‬‬
‫איתמר מדיקל בע"מ ‪154833‬‬
‫אלי לויס ‪148378‬‬
‫אנקו‪-‬טון בע"מ ‪122023‬‬
‫אפרון רוזן ‪124301‬‬
‫אקספנד נטוורקס בע"מ ‪137199‬‬
‫‪NAME INDEX‬‬
‫טבע תעשיות פרמצבטיות בע"מ ‪,144679‬‬
‫‪149681 ,149308‬‬
‫ידע חברה למחקר ופיתוח בע"מ ‪,112699‬‬
‫‪145299 ,132455 ,126835‬‬
‫יובל זינגר ‪146981‬‬
‫יונתן לביא ‪172637‬‬
‫יישום חברה לפיתוח המחקר של‬
‫האוניברסיטה העברית בירושלים ‪118570‬‬
‫יישום חברה לפיתוח המחקר של‬
‫האוניברסיטה העברית בירושלים ‪,141370‬‬
‫‪142172‬‬
‫יצחק לבטון ‪122023‬‬
‫יראל יאירוב ‪132700‬‬
‫ישקר בע"מ ‪150015 ,150013 ,150012‬‬
‫ישקר בע"מ ‪150015 ,150013 ,150012‬‬
‫כרמלי אדהאן ‪160096‬‬
‫לאון ליפסיקס ‪144581‬‬
‫גדעון רוזנברג ‪157525‬‬
‫ג'ינוטק בע"מ ‪146534‬‬
‫דורון חכימי ‪158726‬‬
‫דיינמיק שלס בע"מ ‪148400‬‬
‫דני לביא ‪159990‬‬
‫הדסית שרותי מחקר רפואי ופתוח בע"מ‬
‫‪142172‬‬
‫הנדסה דנטלית מתקדמת בע''מ ‪149563‬‬
‫זולי החזקות בע"מ ‪142176‬‬
‫טאגרה ביוטכנולוגיות בע"מ ‪149637‬‬
‫‪i‬‬
‫מאיר אבגנים ‪151060‬‬
‫מדדינמיקס בע"מ ‪163061‬‬
‫מדידרמיס בע"מ ‪132625‬‬
‫מדינול בע"מ ‪142176‬‬
‫מוסד הטכניון למחקר ופיתוח בע"מ‬
‫‪122115‬‬
‫מוסד הטכניון למחקר ופיתוח בע"מ‬
‫‪128727‬‬
‫מוסרות בע"מ ‪147685‬‬
‫מור אנרגיה בע"מ ‪156624‬‬
‫מטאו‪-‬טק בע"מ ‪147725‬‬
‫מיג"ל מרכז ידע גליל עליון ‪132666‬‬
‫מרדכי אלדר ‪152089‬‬
‫ט' באב התשס"ז –‪July 24, 2007‬‬
149180 ‫קומברס בע"מ‬
151611 ‫משה שאלתיאל‬
‫אביב בע"מ‬-‫רמות ליד אוניברסיטת תל‬
116416
‫רפא"ל רשות לפיתוח אמצעי לחימה‬
138831 ‫בע"מ‬
‫רפא"ל רשות לפיתוח אמצעי לחימה‬
147370 ‫בע"מ‬
‫רשות לפיתוח אמצעי לחימה‬-‫רפא"ל‬
136566 ‫בע"מ‬
‫) בע"מ‬1975( ‫תעשיות מגופים‬-‫רפאל‬
156797
148566 ‫נובה מכשירי מדידה בע"מ‬
151826 ‫נורה מרקובייקי‬
144581 ‫שמעון פרידמן‬
148926 ‫סלקום ישראל בע"מ‬
‫עמינח תעשית רהיטים ומזרונים בע"מ‬
167402
144040 ‫פאורדסיין בע"מ‬
‫ מערכות חליבה‬-‫ אפיקים‬.‫מ‬.‫ח‬.‫צ‬
162821 ‫ממוחשבות‬
156362 ‫קבוצת גל בע"מ‬
147260 ‫קדנט בע"מ‬
149433 ,147276 ‫קומברס בע"מ‬
A.Y. LABORATORIES LTD. 159911
ABBOTT LABORATORIES 145135
ABRAHAM NISSENKORN 146534
ADVANCED DENTAL ENGINEERING
LTD. 149563
AHLSTROM CORPORATION 159891
AHLSTROM CORPORATION 159891
AHLSTROM RESEARCH AND
SERVICES 159891
AIR-CRAFT BRAKING SYSTEMS
CORPORATION 158541
AKZO NOBEL N.V. 149412
AKZO NOBEL N.V. 153934
ALBANY INTERNATIONAL
TECHNIWEAVE, INC. 143154
ALLELIX BIOPHARMACEUTICALS,
INC. 139320
ALLISON SAMPSON 160153
ALZA CORPORATION 142808
AMINACH BEDDING & FURNITURE
MANUFACTURING LTD. 167402
ANDREY SHUSTOV 151612
ANORMED, INC. 145401
ANTHONY KHOURI 148560
iv
APPLETON PAPERS INC. 156108,
156109
APPLIED RESEARCH SYSTEMS ARS
HOLDING N.V. 130123, 136855
APPLIED RESEARCH SYSTEMS ARS
HOLDING N.V. 133686
ARES TRADING S.A. 152320, 152321
ARJO WIGGINS LIMITED 165464
ASAHI KASEI KABUSHIKI KAISHA
153377
ASK S.A. 155882
ASTRAZENECA AB 145192, 145357,
146187, 151392, 155995
ASTRAZENECA AB 163642
ASTRAZENECA UK LIMITED 151930
ATI PROPERTIES, INC. 161175, 161289
AVENTIS INC. 174850
Aventis Pharma S.A 122991, 134192
AVENTIS PHARMA S.A. 132671
AVENTIS PHARMA S.A. 161841
AVENTIS PHARMACEUTICALS INC.
146729
AVENTIS PHARMACEUTICALS INC.
147495
July 24, 2007– ‫ט' באב התשס"ז‬
AVI DASCXALU 132625
AVISHAI MELAMED 165639
BASF AKTIENGESELLSCHAFT
148464
BASF AKTIENGESELLSCHAFT
150528
BATTELLE MEMORIAL INSTITUTE
149080
BAYER CORPORATION 136738,
136767
BAYER CROPSCIENCE S.A. 153786
BAYER PHARMACEUTICALS
CORPORATION 136738, 136767
BERNARD TECHNOLOGIES, INC.
146440
BIOGEN IDEC INC. 146005
Biogen Idec MA Inc. 127162, 128407
BIOGEN IDEC MA INC. 134593,
145898
BIONICHE LIFE SCIENCES INC.
134371
BIOSENSE, INC. 137322, 144271,
146217
BIOVITRUM AB 155875
BODYMEDIA, INC. 153516
BOEHRINGER INGELHEIM
INTERNATIONAL GMBH 151465
BOEHRINGER INGELHEIM PHARMA
GMBH & CO. KG 144619, 150377,
150621
BPSI HOLDINGS, INC. 150850
BRISTOL-MYERS SQUIBB
COMPANY 144910
BRISTOL-MYERS SQUIBB
COMPANY 149601
BYK GULDEN LOMBERG
CHEMISCHE FABRIK GMBH 141157
CADENT LTD. 147260
CARGILL, INCORPORATED 156017
CARMEL PHARMA AB 153998
CARMELI ADAHAN 160096
CATAVAULT 150728
CELLCOM ISRAEL LIMITED 148926
CENTRE NATIONAL DE LA
RECHERCHE SCIENTIFIQUE (CNRS)
July 24, 2007– ‫ט' באב התשס"ז‬
146396
CENTRO DE INGENIERIA GENETICA
Y BIOTECNOLOGIA 156700
CEPHALON, INC. 155263
CHIRON CORPORATION 123248
CIBA SPECIALTY CHEMICALS
HOLDING INC. 158505
CILAG GMBH INTERNATIONAL
137808
CODENA INC. 151786
COLLATERAL THERAPEUTICS INC.
128727
COMMONWEALTH SCIENTIFIC AND
INDUSTRIAL RESEARCH
ORGANISATION 152087
COMPUTER ASSOCIATES THINK,
INC. 147879
COMVERSE LTD. 147276, 149433
COMVERSE LTD. 149180
COMVERSE, INC. 147137, 149697
CONCEPTO DIAGNOSTICS, INC.
137601
CONNECTIVE TISSUE
IMAGINEERING LLC 138453
DADE BEHRING INC. 160418
DAINIPPON SUMITOMO PHARMA
CO., LTD. 153439
DAINIPPON SUMITOMO PHARMA
CO., LTD. 133512
DANNY LAVIE 159990
DAVID M. ALLEN 156757
DELAVAL HOLDING AB 151990
DENTSPLY INTERNATIONAL INC.
147320
DEPOMED, INC. 149421
DETLEF SCHUPPAN 128042
DISCOVISION ASSOCIATES 139083
DIVERSA CORPORATION 130245
DOMPE PHA.R.MA S.P.A. 137564
DOMPE S.P.A. 137564
DORON HAKIMI 158726
DR. REDDY'S LABORATORIES
LIMITED 123201
DRK-BLUTSPENDEDIENDST
BADEN-WUERTTEMBERG-HESSEN
GEMEINNUTZIGE GMBH 137522
iii
DYNAMIC SHELLS LTD. 148400
E.I. DU PONT DE NEMOURS AND
COMPANY 152087
E.I. DUPONT DE NEMOURS AND
COMPANY 151083, 155409
EADS DEUTSCHLAND GMBH 151466
EDDIE KARNIELI 137759
EDWARD G. SHIFRIN 147954
EDWARD G.SHIFRIN 147954
EFRON ROZAN 124301
ELI LEVIS 148378
EMORY UNIVERSITY 138281
ENCO-TONE LTD. 122023
ESSILOR INTERNATIONAL
(COMPAGNIE GENERALE
D'OPTIQUE) 150234
EURO - CELTIQUE S.A. 139230
EVA - TECH MEDICAL 21 LTD 147954
EVEREADY BATTERY COMPANY,
INC. 157252
EXCEL INDUSTRIES LIMITED 158490
EXPAND NETWORKS LTD. 137199
EYAL ELIAV 159990
F. HOFFMANN-LA ROCHE AG 144055
F. HOFFMANN-LA ROCHE AG 144636
FEDERICO SINGER 146981
FLEXPLAY TECHNOLOGIES, INC.
147543
FORESCOUT TECHNOLOGIES INC.
149594
FRANCO BRUTTI 154335
GE HEALTHCARE AS 155475
GEA ENERGIETECHNIK GMBH
150875
GEM PHARMACEUTICALS, INC.
134494
GENENTECH, INC. 114668, 115792,
128128
GENENTECH, INC. 146005
GENERAL DYNAMICS ADVANCED
INFORMATION SYSTEMS, INC.
157521
GENTIUM SPA 130405
GIDEON ROSENBERG 157525
GLAXO GROUP LIMITED 137403
iv
GLAXOSMITHKLINE S.P.A. 139301
GORE ENTERPRISE HOLDINGS, INC.
157410
GRANDIS BIOTECH GMBH 147253
GREAT CIRCLE TECHNOLOGIES,
INC. 155248
GRUNENTHAL GMBH 149010
GYNOTECH LTD. 146534
H. LUNDBECK A/S 145959, 149994
HADASIT MEDICAL RESEARCH
SERVICES AND DEVELOPMENT
LTD. 142172
HEE-SUNG CHUNG 149205
HEIDELBERGER
DRUCKMASCHINEN AG 166910
HUNTER DOUGLAS INDUSTRIES
B.V. 151766
I OPTIMA LTD 152343
IBM CORPORATION 140141, 153925
IBM UNITED KINGDOM LIMITED
147015
IGOR K. KOTLIAR 152017
IHARA CHEMICAL INDUSTRY CO.,
LTD. 147958
ILAN SHERR 155796
IMAGINATION MEDICAL, INC.
140972
IMMUNEX CORPORATION 137178
IMMUPHARM APS 154144
INDENA S.P.A. 163225
INDIVIDUAL NETWORK, LLC 150474
INEX PHARMACEUTICALS
CORPORATION 153676
INNOVATA BIOMED LIMITED
149623
INOLASE 2002 LTD. 150094
INSTITUT GUSTAVE ROUSSY 130123
INSTITUT NATIONAL DE LA SANTE
ET DE LA RECHERCHE MEDICALE
(INSERM) 130123
INTEGRAGEN, S.A.S. 145141
INTEL CORPORATION 144017, 152798
INTELLIGENT ENGINEERING
(BAHAMAS) LIMITED 154672
INTERDIGITAL TECHNOLOGY
CORPORATION 148412
July 24, 2007– ‫ט' באב התשס"ז‬
INTERNATIONAL BUSINESS
MACHINES CORPORATION 147015,
147630
INTERSENSE, INC. 152359
INTERTEX DATA AB 148700
INTEVAC, INC. 154517
INTRALUMINAL THERAPEUTICS,
INC. 151864
ISAAC J. LABATON 122023
ISCAR LTD. 150012, 150013, 150015
ISCAR LTD. 150012, 150013, 150015
ITAMAR MEDICAL LTD. 154833
JANSSEN PHARMACEUTICA N.V.
138745, 143830
JOHNSON & JOHNSON VISION
CARE, INC. 150234
JOHNSON MATTHEY PUBLIC
LIMITED COMPANY 158439, 158798
KARALEE RESEARCH PTY LTD.
163835
KENNAMETAL INC. 148284
KUMIAI CHEMICAL INDUSTRY CO.,
LTD. 147958
KUNIFUMI KOMIYA 156426
L. MOLTENI & C. DEI FRATELLI
ALITTI SOCIETA' DI ESERCIZIO
S.P.A. 147876
LABORATOIRE MEDIDOM S.A.
150390
LABORATOIRE THERAMEX 149370
LACER, S.A. 142391
LAM RESEARCH CORPORATION
134926
LANCER PARTNERSHIP, LTD. 153538
LATTICE INTELLECTUAL
PROPERTY LIMITED 152499
LEON LIPSICAS 144581
LEONID MIHALJOV 143453
LOCKHEED MARTIN CORPORATION
156143
LOTUS PHARMACEUTICAL CO. LTD.
153205
MACROVISION CORPORATION
July 24, 2007– ‫ט' באב התשס"ז‬
148002
MARA-INSTITUT D.O.O. 155480
MARGA DUMMEN 154938
MASSEY UNIVERSITY 157862
MAUSER-WERKE GMBH & CO. KG
155579
MCCOMAS TECHNOLOGIES AG
156656
MEDDYNAMICS LTD. 163061
Medidermis Ltd. 132625
MEDINOL LTD. 142176
MEDIVIR AB 141161
MEIR AVGANIM 151060
MERIDIAN MEDICAL
TECHNOLOGIES, INC. 151579
METABASIS THERAPEUTICS, INC.
145052, 151248
METEO-TECH LTD. 147725
MFH HYPERTHERMIESYSTEME
GMBH 142409
MICROSOFT CORPORATION 173678
MIGAL GALILEE TECHNOLOGICAL
CENTER 132666
MILBRIDGE INVESTMENTS (PTY)
LTD. 157717
MILOW LTD. 157525
MOBIL OIL CORPORATION 144846
MOLECULAR EXPRESS, INC. 141675
MONA INDUSTRIES, INC. 149196
MORDECHAI ELDAR 152089
MORE ENERGY LTD. 156624
MOSEROTH LTD. 147685
MOSHE SHEALTIEL 151611
N.V. ORGANON 149412, 153934
NABRIVA THERAPEUTICS
FORSCHUNGS GMBH 138477
NAGRAVISION S.A. 149303, 152092
NANOSCALE MATERIALS, INC.
141747
NEKTAR THERAPEUTICS 141562,
142215
NEOTHERMIA CORPORATION
148989
NEST INTERNATIONAL N.V. 151612
NEW YORK UNIVERSITY 146228
NEWMAT, S.A. 148911
v
NOBORU OYAMA 155409
NORA MARKOWIECKI 151826
NOVA MEASURING INSTRUMENTS
LTD. 148566
NOVARTIS AG 143233
NOVARTIS AG 153229
NOVEN PHARMACEUTICALS, INC.
158551
NOVO NORDISK A/S 126463, 149049
NOVOGEN RESEARCH PTY LTD.
128765
NOZOMU SAHASHI 159329
NUG NAHRUNG-UND
GENUSSMITTEL
VERTRIEBSGESELLSCHAFT MBH
162871
NYMPHEA WATER 146846
OBSCHESTVO S OGRANICHENNOI
OTVETSTVENNOSTIJU "KLINIKA
INSTITUTA BIOREGUL YATSII I
GERONTOLOGII" 140412
OCTAPHARMA AG 152173
OMD DEVICES, L.L.C. 132796
ORBOTECH LTD. 149588
ORION CORPORATION 141680
ORMAT INDUSTRIES LTD. 156048
ORMAT TECHNOLOGIES INC. 156048
ORTHOFIX INTERNATIONAL B.V
152563
ORTHOFIX S.R.L. 152563
ORTHOFIX S.R.L. 152563
PANACEA BIOTEC LIMITED 149030
PECHINEY EMBALLAGE FLEXIBLE
EUROPE 154669
PFIZER INC. 134851, 138911
PFIZER ITALIA S.R.L 152537
PFIZER PRODUCTS, INC. 139012,
145946, 157103
PHARMACIA & UPJOHN COMPANY
152537
PHARMACIA CORPORATION 144757,
144761
POWDERJECT RESEARCH LIMITED
144380
POWER MEDICAL INTERVENTIONS,
INC. 147511
vi
POWERDSINE LTD. 144040
PRAECIS PHARMACEUTICALS
INCORPORATED 130309
QPOD SYSTEMS LIMITED 146979
QUADLOGIC CONTROLS
CORPORATION 151406
QUALCOMM INCORPORATED
145652, 147719, 147792, 148069,
148367, 148370
QUALCOMM INCORPORATED
155562
RAFAEL ARMAMENT
DEVELOPMENT AUTHORITY LTD.
147370
RAFAEL-ARMAMENT
DEVELOPMENT AUTHORITY LTD.
136566
RAFAEL-ARMAMENT
DEVELOPMENT AUTHORITY LTD.
138831
RAMOT AT TEL-AVIV UNIVERSITY
LTD. 116416
RAPHAEL VALVES INDUSTRIES
(1975) LTD. 156797
RAVCO INNOVATIONS INC. 151668
REDDY-CHEMINOR, INC. 123201
REIFENHAUSER GMBH & CO.
MASCHINENFABRIK 154630
RHEON AUTOMATIC MACHINERY
CO., LTD. 152240
RHONE-POULENC AGRO 131750
RICHARD SAMPSON 160153
ROHM GMBH & CO. KG 150850
RTP PHARMA INC. 139779, 140276
RUBY HILL LTD. 147954
RVC LLC 139995
S.A.E. AFIKIM- COMPUTERIZED
DAIRY MANAGEMENT SYSTEMS
162821
SAMSUNG ELECTRONICS CO., LTD.
149656
SAMSUNG ELECTRONICS CO., LTD.
152648, 157864
SANDOZ AG 138477, 147253
SANDOZ GMBH 138477
July 24, 2007– ‫ט' באב התשס"ז‬
SANKYO COMPANY LIMITED
132962, 149444
SANOFI AVENTIS 135520, 144181,
153632
SANOFI AVENTIS 147320
SANOFI-AVENTIS DEUTSCHLAND
GMBH 145923
SANOFI-AVENTIS DEUTSCHLAND
GMBH 146731
SAP AG 147105
SCHERING AKTIENGESELLSCHAFT
128691, 133195
SCHERING AKTIENGESELLSCHAFT
154828, 156353
SCHUCO INTERNATIONAL KG
151447
SCHWARZ PHARMA AG 165917
SEB S.A. 155352
SEQUOIA SOFTWARE
CORPORATION 150106
SERONO GENETICS INSTITUTE S.A.
155179
SHIMON FREEDMAN 144581
SILVERBROOK RESEARCH PTY.
LTD. 146606, 146652, 146680, 163486,
163494, 163496, 164953, 165540,
166422, 166723, 166725, 166726,
166874, 166876
SILVERBROOK RESEARCH PTY.
LTD. 160172, 161088, 164691, 166875
SILVERBROOK RESEARCH
PTY.LTD. 164447, 164503
SINON CORPORATION 146027
SIRAP-GEMA S.P.A. 140677
SK TELETECH CO., LTD. 147799
SKELETON TECHNOLOGIES AG
161555
SMITHKLINE BEECHAM
BIOLOGICALS S.A. 139612, 145043
SOCIETE DE CONSEILS DE
RECHERCHES ET D'APPLICATIONS
SCIENTIFIQUES (S.C.R.A.S.) 149177
SOLUTIA INC. 139816
SOLYSTIC 150792
SOUTHWEST RESEARCH INSTITUTE
146440
SPECIAL CARTRIDGE COMPANY
July 24, 2007– ‫ט' באב התשס"ז‬
LIMITED 138823
SPEEDFAM-IPEC CORPORATION
148274
SPINEVISION S.A. 149981
SUN MICROSYSTEMS INC. 150583
SWISSCOM MOBILE AG 147399,
148431
SYNGENTA LIMITED 141066
SYNGENTA LIMITED 141109, 145962
SYNGENTA PARTICIPATIONS AG
132768, 158360
T.J. BROOKS COMPANY-DIVISION
OF HANNA CYLINDERS 157804
TAGRA BIOTECHNOLOGIES LTD.
149637
TECHNION RESEARCH AND
DEVELOPMENT FOUNDATION LTD.
122115
TECHNION RESEARCH AND
DEVELOPMENT FOUNDATION LTD.
128727
TEENESS ASA 164561
TEIJIN TWARON GMBH 156645
TELEDIFFUSION DE FRANCE 149877
TELEFONAKTIEBOLAGET LM
ERICSSON
(PUBL) 179054
TERRAPLAY SYSTEMS AB 179054
TEVA PHARMACEUTICAL
INDUSTRIES LTD. 144679, 149308,
149681
THE BABCOCK & WILCOX
COMPANY 146157
THE BOARD OF TRUSTEES OF THE
UNIVERSITY OF ILLINOIS 138856
THE CHIEF CONTROLLER,
RESEARCH AND DEVELOPMENT
152139
THE CUPRON CORPORATION 149206
THE FACULTY OF MEDICINE OF
THE UNIVERSITY OF GENEVA
128407
THE GENERAL HOSPITAL
CORPORATION 127162
THE GILLETTE COMPANY 150871
THE REGENTS OF THE UNIVERSITY
OF MICHIGAN 153374
vii
THE SCRIPPS RESEARCH INSTITUTE
126843, 136544, 137661
THE TEXAS A&M UNIVERSITY
SYSTEM 151083
THE TEXAS ENGINEERING
EXPERIMENT STATION 151083
THE UNIVERSITY OF BRISTOL
151949
THOMSON LICENSING S.A. 148775
TRANSNEURONIX, INC. 150552
TRISOPLAST INTERNATIONAL B.V.
151803
TRUSTEES OF THE UNIVERSITY OF
PENNSYLVANIA 150617
UNILEVER PLC 146357
UNITED TECHNOLOGIES
CORPORATION 165759
UNIVERSAL PRESERVATION
TECHNOLOGIES, INC. 149778
UNIVERSITE PARIS 7-DENIS
DIDEROT 150839
UNIVERSITY OF PITTSBURGH OF
THE COMMONWEALTH SYSTEM OF
HIGHER EDUCATION 141990
UNIVERSITY OF SOUTHERN
CALIFORNIA 139360
UNIVERSITY OF UTAH RESEARCH
FOUNDATION 133799
WISCONSIN ALUMNI RESEARCH
FOUNDATION 135458
YAREL YAIROV 132700
YEDA RESEARCH AND
DEVELOPMENT CO. LTD. 112699,
126835, 132455, 145299
YEHONATAN LAVEE 172637
YISSUM RESEARCH DEVELOPMENT
COMPANY OF THE HEBREW
UNIVERSITY OF JERUSALEM
118570
YISSUM RESEARCH DEVELOPMENT
COMPANY OF THE HEBREW
UNIVERSITY OF JERUSALEM
141370, 142172
YUVAL SINGER 146981
ZENTARIS GmbH 135103
ZULI HOLDINGS LTD. 142176
VELA PHARMACEUTICALS, INC.
149134
VIASAT, INC. 135786
VICTORY PRODUCTS, S.L. 164992
VLADIMIR DROBKOV 151612
VLADIMIR MELNIKOV 151612
W. RUITENBERG CZN. N.V. 154489
WALBURGA DIETERICH 128042
WALTER REED ARMY INSTITUTE
OF RESEARCH 137449
WARNER-LAMBERT COMPANY LLC
145684
WAVE GROUP LTD. 156362
WESTFALIASURGE GMBH 153580
WILLIAMS INTERNATIONAL CO.,
L.L.C. 145349
viii
July 24, 2007– ‫ט' באב התשס"ז‬
‫מפתח ענייני‬
SUBJECT MATTER INDEX
A01J – 151990
A01K – 141370
A01 N – 141109
A23G – 146357
A23J – 162871
A23L – 159990
A61B – 124301, 144271, 147511,
147954, 148989, 149981,
152343, 152359, 152563,
163061
A61C – 149563
A61F – 142176
A61K – 128765, 130405, 132666,
134371, 136767, 137808,
138453, 139230, 140276,
141562, 141990, 143233,
144757, 145898, 146005,
147253, 149308, 149421,
149994, 150390, 163642,
165917
A61M – 142215, 144380, 149623,
152320
B25B – 152089
B41F – 163486
B41J – 155512, 160172, 161088,
164503, 166725, 166726,
166874, 166875, 166876
B60T – 1585411
B65D – 140677, 146979, 155579,
156108
B01B– 157717, 160153
C02F – 155248
C07C – 128691, 155263, 174850
C07D – 123201, 133195, 135520,
138856, 142391, 143830,
144055, 144761, 144910,
145357, 145401, 145959,
145962, 146027, 147495,
149049, 149177, 153439,
153632, 155995, 158490,
161841
C07F – 142172, 145052, 145299,
153299, 154144
A63H – 164992
C07J – 149412, 153934
B01J – 141066, 158439, 159891
C07K– 138911, 146731, 152173,
157103
B02C – 146157, 153538
B07C – 150792
B23B – 148284
July 24, 2007– ‫ט' באב התשס"ז‬
C08G – 139816, 149196
C08J – 155409
C10L –163835
ix
G01S – 151466
C12N – 114668, 122991, 123248,
126835, 127162, 128407,
130123, 133686, 133799,
136855, 139360, 139612,
149206
G01V – 146846
G02B – 151949
G03B – 139995
C12P – 134494, 136544, 137403,
141161
G06F– 147105, 147630, 149588,
149594, 179054
G06Q– 144846
C12Q – 145141, 146228
G09G –149205
C21D– 161289
G11B – 148002, 165464
C22C – 161175
H01J – 134926, 154517
C23C – 150839
H01M –150617, 156624, 157862
E04B – 155480
H01R – 132700
E04F – 151668
H01S – 132455
F01K – 156048
H03M– 140141
F02C – 165759
H04B – 145652, 149656
F16B – 151060
H04J –147719
F16L –152499
F41G – 136566, 147370
F41H– 156645
H04L – 144040, 148775, 150728,
152648
H04M – 147276, 149180, 149697,
151611
G01C – 138831, 146981
H04N – 150474, 152092, 152798
G01D – 151406
G01N – 155179, 156143
x
H04Q – 147137, 147799, 148926,
149433
July 24, 2007– ‫ט' באב התשס"ז‬
‫ ירושלים‬,‫ משרד המשפטים‬,‫נערך ע"י רשות הפטנטים‬
‫ ירושלים‬,‫הופק והודפס במדפיס הממשלתי‬
EDITED BY THE PATENT OFFICE, MINISTRY OF JUSTICE, JERUSALEM
PRINTED AND PUBLISHED BY THE GOVERNMENT PRINTER